{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "import time\n",
    "start_time = time.time()\n",
    "import pyodbc\n",
    "from flashtext import KeywordProcessor\n",
    "import nltk.data\n",
    "import pandas as pd\n",
    "from nltk import FreqDist"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Server document collection"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "56097\n",
      "56785\n",
      "61021\n",
      "64624\n",
      "64918\n",
      "67495\n",
      "68176\n",
      "71147\n",
      "72656\n",
      "75437\n",
      "75802\n",
      "79178\n",
      "79437\n",
      "82677\n",
      "82945\n",
      "85576\n",
      "86134\n",
      "89827\n",
      "90135\n",
      "93534\n",
      "93874\n",
      "96856\n",
      "97398\n",
      "100497\n",
      "150650\n",
      "150761\n",
      "150799\n",
      "150812\n",
      "150846\n",
      "150946\n",
      "150961\n",
      "151107\n",
      "151230\n",
      "151261\n",
      "151343\n",
      "151382\n",
      "151698\n",
      "152083\n",
      "152489\n",
      "152673\n",
      "153680\n",
      "161057\n",
      "163031\n",
      "163894\n",
      "164216\n",
      "168175\n",
      "171023\n",
      "173379\n",
      "174010\n",
      "174612\n",
      "179771\n",
      "182855\n",
      "184247\n",
      "184917\n",
      "191102\n",
      "193536\n",
      "194444\n",
      "197501\n",
      "203745\n",
      "207320\n",
      "210448\n",
      "212454\n",
      "217084\n",
      "220457\n",
      "257951\n",
      "261508\n",
      "444629\n",
      "446532\n",
      "484580\n",
      "486819\n",
      "491839\n",
      "494512\n",
      "495292\n",
      "495610\n",
      "499548\n",
      "504720\n",
      "505501\n",
      "513358\n",
      "543059\n",
      "625562\n",
      "641434\n",
      "646802\n",
      "677240\n"
     ]
    }
   ],
   "source": [
    "server = '10.8.2.90' \n",
    "database = 'EarningsCalls' \n",
    "username = 'ecuser' \n",
    "password = 'ecuser@121'\n",
    "con = 'Yes'\n",
    "Selectcnxn = pyodbc.connect('DRIVER={SQL Server};SERVER='+server+';DATABASE='+database+';UID='+username+';PWD='+ password+'; MARS_Connection=' + con)\n",
    "Selectcursor = Selectcnxn.cursor()\n",
    "Selectcursor.execute(\"select ecno, tfulltext,link,cdmsid,thtmltext from EC_Transcripts with(nolock) where ecno in (64918,152489,484580,495292,543059,151107,164216,184917,210448,499548,89827,93874,151343,151382,191102,505501,68176,163031,446532,641434,56785,61021,75802,152083,168175,171023,174010,79437,86134,151230,151261,161057,217084,491839,495610,56097,64624,71147,75437,174612,207320,97398,151698,153680,173379,194444,212454,513358,72656,85576,152673,193536,79178,100497,150650,257951,67495,444629,646802,90135,150761,150799,150812,150846,184247,220457,504720,82945,150946,150961,163894,625562,82677,93534,203745,96856,182855,261508,486819,494512,677240,179771,197501)\")\n",
    "\n",
    "sentences=[]\n",
    "links=[]\n",
    "htmls=[]\n",
    "while True:\n",
    "    rows = Selectcursor.fetchmany(1)\n",
    "    if not rows:\n",
    "        break\n",
    "\n",
    "    for row1 in rows:\n",
    "        EC_No = row1[0]\n",
    "        print(EC_No)\n",
    "        link=row1[2]\n",
    "        html=row1[4]\n",
    "        Atext = row1[1]\n",
    "        \n",
    "        #Tokenizing Sentences\n",
    "        htmls.append(html)\n",
    "        sentences.append(Atext)\n",
    "        links.append(link)\n",
    "        \n",
    "#        #Splitting by /n\n",
    "#        for sent in sentences:\n",
    "#            result = sent.splitlines()\n",
    "#            for res in result:\n",
    "#                Sentenceslst.append(res)\n",
    "        \n",
    "        #matching through each sentences\n",
    "        for sent in sentences:\n",
    "            pass\n",
    "            \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('Sentences.txt', 'w') as filehandle:\n",
    "    for listitem in sentences:\n",
    "        filehandle.write('%s\\n' % listitem)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--- 311.7084860801697 seconds ---\n"
     ]
    }
   ],
   "source": [
    "Selectcnxn.close()\n",
    "print(\"--- %s seconds ---\" % (time.time() - start_time))         "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Pfizer Inc. (NYSE:PFE) Q4 2015 Earnings Conference Call February  2, 2016 10:00 AM ET',\n",
       " 'Executives',\n",
       " 'Chuck Triano - SVP, IR',\n",
       " 'Ian Read - Chairman and CEO',\n",
       " \"Frank D'Amelio - CFO\",\n",
       " 'Mikael Dolsten - President of Worldwide Research and Development',\n",
       " 'Albert Bourla - President of Vaccines, Oncology and Consumer',\n",
       " 'Geno Germano - President of Global Innovative Pharma',\n",
       " 'John Young - President of Established Pharma',\n",
       " 'Doug Lankler - General Counsel',\n",
       " 'Analysts',\n",
       " 'Colin Bristow - Bank of America',\n",
       " 'Alex Arfaei - BMO Capital Markets',\n",
       " 'Jami Rubin - Goldman Sachs',\n",
       " 'Andrew Baum - Citi',\n",
       " 'Vamil Divan - Credit Suisse',\n",
       " 'Steve Scala - Cowen',\n",
       " 'Mark Schoenebaum - Evercore ISI',\n",
       " 'Marc Goodman - UBS',\n",
       " 'John Boris - SunTrust',\n",
       " 'Tim Anderson - Bernstein',\n",
       " 'Richard Purkiss - Piper Jaffray',\n",
       " 'Geoff Meacham - Barclays',\n",
       " 'David Risinger - Morgan Stanley',\n",
       " 'Gregg Gilbert - Deutsche Bank',\n",
       " 'Chris Schott - JPMorgan',\n",
       " 'Manoj Garg - HealthCo',\n",
       " 'Operator',\n",
       " \"Good day everyone, and welcome to Pfizer's Fourth Quarter 2015 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Mr. Chuck Triano, Senior Vice President of Investor Relations. Please go ahead, sir.\",\n",
       " 'Chuck Triano',\n",
       " \"Good morning, and thanks for joining us today to review Pfizer's fourth quarter and full year 2015 performance, as well as 2016 financial guidance.\",\n",
       " \"I am joined here today as usual by our Chairman and CEO, Ian Read; Frank D'Amelio, our CFO; Mikael Dolsten, President of Worldwide Research and Development; Albert Bourla, President of Vaccines, Oncology and Consumer; Geno Germano, President of Global Innovative Pharma; John Young, President of Established Pharma; and Doug Lankler, General Counsel.\",\n",
       " 'The slides that will be presented on this call can be viewed on our homepage, pfizer.com by clicking on the link for Pfizer Quarterly Corporate Performance Fourth Quarter 2015, which is located in the For Investors Section in the lower right hand corner of the page.',\n",
       " \"Before we start, I'd like to remind you that our discussion during the call will include forward-looking statements and that actual results could differ materially from those projected in the statements. Factor that could cause actual results to differ are discussed in Pfizer's 2014 Annual Report on Form 10-K, as well as on our reports in Forms 10-Q and 8-K.\",\n",
       " \"Discussions during the call will also include certain financial measures that were not prepared in accordance with Generally Accepted Accounting Principles. Reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in Pfizer's current report on Form 8-K dated today.\",\n",
       " \"Also, today's call is not intended to, and does not constitute an offer to sell or the solicitation of an offer to subscribe for, or buy securities of Pfizer or Allergan.\",\n",
       " \"We will now make prepared remarks and then we will move to a question-and-answer session. With that, I'll now turn the call over to Ian Read. Ian?\",\n",
       " 'Ian Read',\n",
       " 'Thank you Chuck, and good morning everyone. We finished 2015 with strong financial and operational performance. For the full year, we exceeded our 2015 revenue guidance and met the top-end of our adjusted diluted EPS guidance. Excuse me; and we achieved our first year of operational revenue growth in five years.',\n",
       " 'Frank will take you through the numbers. Before he does, I have a few brief comments about what is driving our performance, some thoughts regarding where we expect to see pipeline advancements during the year, and I will close with a few comments about Allergan.',\n",
       " 'Throughout the year and especially in the fourth quarter, our business executed flawlessly despite a challenging operational environment. We ended 2015 with solid momentum in both developed and emerging markets.',\n",
       " 'Specifically in developed markets, during the year we gained incremental market penetration driven by continued success of products that are early in their life cycles, including Prevnar 13 adults, Ibrance, Eliquis, Xeljanz, and we still saw steady growth from key inline products in 2015, specifically Lyrica in markets where it remains patent protected.',\n",
       " '',\n",
       " 'And during the year in emerging markets we saw operational revenue growth primarily due to the performance of Prevnar, Lipitor, and Enbrel, as well as from the addition of legacy Hospira products. The integration of the Hospira business into Pfizer Global Established pharma businesses is on track, and we look forward to this business being an attractive potential growth driver. This acquisition is indeed proving to be an excellent strategic fit, and we are seeing the expected value contribution to our GAAP business that we anticipated.',\n",
       " 'Frank will speak to our 2016 guidance in a moment. We expect to deliver operational revenue growth in 2016. Our key growth drivers will continue to be Ibrance, Eliquis, and Xeljanz. And we believe that Prevnar adult global revenues will be comparable to the strong results we achieved in 2015. Additionally, we believe our near-term pipeline will help accelerate this ongoing growth forward.',\n",
       " \"In looking at the year ahead, we expect our businesses will continue to execute well. They are competitively positioned to win their markets and are performing strongly against their competitors' set.\",\n",
       " 'Regarding the pipeline, we anticipate advancing many of our Phase III programs during the year. For Bococizumab, we reported today that the first of our six Phase III efficacy studies achieved its primary endpoint, and we expect readouts of the remaining five Bococizumab lipid-lowering studies [technical difficulty] during 2016.',\n",
       " 'For [indiscernible], this year, we and our partners Merck will begin to deliver results from our comprehensive Phase III clinical program. In 2016, the alliance expects to submit applications to regulatory approval in the U.S. for both monotherapy and two fixed dose combination tablets using data from eight clinical trials.',\n",
       " \"For Dacomitinib, we expect results in the second half of the year for a Phase III study in first-line EGFR mutant non-small-cell lung cancer, and we'll discuss our regulatory strategy with the FDA. So Xeljanz in the first half of this year we expect top line results for our Phase III program in psoriatic arthritis. We believe Xeljanz can potentially fill a significant unmet need in the psoriatic arthritis when non-biologic DMARDS do not have proven success, and where there are currently few alternatives for patients who have inadequate responses to anti-TNF therapy.\",\n",
       " 'In addition, in the first half of the year we anticipate the decisions from the FDA for a once-a-day daily Xeljanz formulation for rheumatoid arthritis, and we remain on track to re-file our application for RA in the EU.',\n",
       " 'For Ibrance, we expect to see the top line PALOMA-2 study results in first-line advanced breast cancer in combination with letrozole, and we have an April PDUFA date for second and third-line treatment for advanced breast cancer based on the PALOMA-3 data. We could also see a regulatory decision for Ibrance in the E.U. by year end.',\n",
       " 'Additionally, in the oncology business, we have a PDUFA date this year in the U.S. with Xalkori in ROS 1 non-small-cell lung cancer, and we expect to file for approval of Inotuzumab for acute lymphoblastic leukemia in the U.S. And in immuno-oncology we now have a broad portfolio of compounds that we believe has the potential to support the development of a strong, deep competitive market position. We now have five immuno-oncology assets in the clinic, and expect to have up to 10 in the clinic by the end of 2016. As a result of our partnership with Merck KGaA, as of the end of 2015, we had 28 ongoing clinical development programs for Avelumab, with seven of them being pivotal registrational studies.',\n",
       " \"We anticipate some of these studies will give us potential registrations in areas like Merkel cell, ovarian, bladder, gastric, and lung cancer. Of these seven studies, we expect to present data in Merkel cell this year, and to see data from the other tumor types in the following two years. And we continue to believe that the winners in this space will be those that have a breadth of portfolio assets to support rational combinations. We have a range of assets to combine with Avelumab when compared to other companies' assets, and we have already initiated six combination studies with Avelumab.\",\n",
       " '',\n",
       " 'In 2016, we expect to see data from 4-1BB in combination with Keytruda and in combination with Avelumab in various tumors, 4-1BB in combination with Rituximab in lymphoma, a combination of Lorlatinib, our next generation ALK inhibitor with Avelumab and ALK-positive non-small-cell lung cancer, and data from [indiscernible] with Avelumab in renal cell carcinoma. Finally, we may see data from OX40 as a single agent this year. Taking of all of this into account, we believe we are well on our way to being a leading player in this space.',\n",
       " \"And now a few comments about our proposed combination with Allergan. We're excited about bringing two great companies together that have a strong strategic fit. The transaction is about acceleration growth potential in our innovative businesses and strengthening our established business, and more efficiently allocating our capital around the world. We are confident that we are taking appropriate steps so that we can achieve the key milestones needed to complete the transaction and continue to expect close in the second half of 2016.\",\n",
       " \"Since the announcement, we have been working closely with Brent Saunders and his team at Allergan, and have been delighted by the engagement and rapport that is occurring. We see a number of potential opportunities after closing as we continue to learn more about each other's portfolio. For example, we see complementarity in information in gastroenterology, and we have a -- when we will have a broader presence in cardiovascular disease with Eliquis and Bystolic.\",\n",
       " \"In neuroscience, Allergan's work in Alzheimer's, schizophrenia, and major depressive orders will be highly complementary to Pfizer's promising early work in such areas as Parkinson's, Alzheimer's, and Duchenne muscular dystrophy.\",\n",
       " \"When you look at over the next few years we expect both companies will continue -- contribute, sorry, several potential new drugs to launch. We'll also continue to be excited about the international potential. And by coming together, we are enhancing category leadership throughout our complementary inline portfolio, and a combined pipeline with great late-stage and mid-stage assets across each of our key therapeutic areas. Both companies bring a great deal of scientific and product expertise to the provost combination and a shared philosophy in our approach to research and development.\",\n",
       " \"Upon the close of the transaction, the combined company will be an influential player in the industry with a competitive product portfolio with several leadership positions, robust pipeline, compelling capital structure, and financial position, and aligned cultures that are based on ownership and entrepreneurial spirit creating shareholder value and meeting patients' needs. This combination is about investing in our business. It's about accelerating our existing strategy, while preserving our options as putting the company into an innovative business and an established business. If we determine that is the best way to unlock the most value for our shareholders.\",\n",
       " \"By the end of the current quarter our integration teams will be fully engaged, and we anticipate announcing post-closing leadership positions. Throughout the year we will continue to keep you updated on our progress. In summary, we're looking at a year ahead we have a sound strategy, and a strong business. Our outlook and financial guidance for the year takes into the account the benefit of anticipated positive organic growth from key products, as well as the impact from foreign exchange. We have a solid portfolio of market-leading inline products, a healthy pipeline. We expect to further strengthen the growth potential of the business with the pending addition of Allergan. We will continue to have the means by which we can create value for our shareholders and bring innovative medicines to patients by producing expected top line growth, progressing key pipeline assets, pursuing strategic business development, and returning capital to shareholders through dividends and buybacks.\",\n",
       " '',\n",
       " \"Now I'll turn it over to Frank for additional details on the quarter and our 2016 financial guidance.\",\n",
       " \"Frank D'Amelio\",\n",
       " \"Thanks, Ian. Good day everyone. As always, the charts that we're viewing today are included in our webcast. As a reminder, because we completed the acquisition of Hospira on September 3, 2015, Pfizer's full year financial results for the year ended December 31, 2015 include four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations.\",\n",
       " 'Financial results for the fourth quarter 2015 include three months of legacy Hospira Global operations. By comparison, financial results for full year and fourth quarter 2014 do not include any contribution from legacy Hospira operations.',\n",
       " 'Now, moving on to the financials; fourth quarter 2015 reported revenues were approximately $14 billion, and reflect year-over-year operational growth of 1.9 billion or 14%, mainly driven by the addition of legacy Hospira operations. The continued strong performance of products that are early in their lifecycles such as Prevnar 13 adult, Ibrance, Eliquis, and Xeljanz, Lyrica primarily in the U.S. and 5% operational growth in emerging markets, mainly from legacy Hospira operations, Prevnar 13, and certain other products.',\n",
       " 'Reported revenues continued to be unfavorably impacted by foreign exchange of 934 million or 7%. Excluding the inclusion of legacy Hospira operations of 1.2 billion, the negative impact of foreign exchange and to a much lesser extent the inclusion of 35 million of revenues associated with vaccines acquired from Baxter, Pfizer-standalone achieved operational growth of 646 million or 5% while at the same time absorbing a 720 million negative operational impact from product losses of exclusivity.',\n",
       " 'Fourth quarter adjusted diluted EPS was $0.53 versus $0.54 in the year ago quarter. The decrease is primarily due to an aggregate operational increase and adjusted cost of sales, adjusted SI&A expenses, and adjusted R&D expenses or 1.8 billion or 21%, $0.07 due to foreign exchange and the continued product losses of exclusivity in certain geographies. These were partially offset by revenue growth of certain new, in-line, and acquired products, lower effective tax rate, and few diluted weighted average shares outstanding which declined by 125 million shares versus the year ago quarter due to our share repurchase program which includes the impact of $5 billion accelerated share repurchase agreement executed in February 2015 and completed in July.',\n",
       " 'Reported diluted EPS was $0.10 compared with $0.19 in the year ago quarter due to the previously mentioned factors and the unfavorable impact of foreign currency losses related to Venezuela, increased purchase accounting adjustments, acquisition related cost, restructuring charges, and asset impairment charges versus the prior year quarter, and non-recurring charges related to pension settlements, which were partially offset by the non-recurrence of a charge associated with the global strategic alliance formed with Merck KGaA in November 2014 to jointly develop and commercialize Avelumab, lower charges for certain legal matters, and a lower effective tax rate.',\n",
       " 'Foreign exchange negatively impacted fourth quarter reported revenues by approximately $934 million or 7% and positively impacted adjusted cost of sales, adjusted SI&A expenses and adjusted R&D expenses in the aggregate by $435 million or 5%. As a result, foreign exchange negatively impacted fourth quarter adjusted diluted EPS by approximately $0.07 compared with the year ago quarter.',\n",
       " 'Now, moving on to the financial highlights of our business segments; in the fourth quarter, Global Innovative Pharmaceutical revenues increased 10% operational year-over-year due to the strong performance of recently launched products including Eliquis globally and Xeljanz in the U.S. and the strong performance of Lyrica in the U.S. and Japan.',\n",
       " '',\n",
       " 'Income before taxes increased 17% operationally due to the increase of revenues and a 5% operational decrease in cost of sales. Cost of sales as a percentage of revenue decreased 1.7 percentage points operationally because of low royalty expenses and increased alliance revenues with no associated cost of sales.',\n",
       " 'IBT was unfavorably impacted by a 4% operational increase and SI&A expenses as a result of additional investment in Eliquis, Xeljanz, and Chantix, and 11% operational increase in R&D reflecting investments in our late-stage pipeline primarily for Bococizumab and Tanezumab.',\n",
       " 'Fourth quarter VOC revenues increased 38% operationally, reflecting operational revenue growth in each business. Global vaccine revenues grew 53% operationally driven by 102% increase of Prevnar 13 U.S. revenues to the strong uptake among adults.',\n",
       " 'Global oncology revenues grew 61% operationally driven by Ibrance in the U.S. and to a lesser extent by Sutent and Xalkori globally. And consumer healthcare revenues grew 4% operationally due to Nexium 24HR in the U.S.',\n",
       " 'Income before taxes increased 33% operationally, mainly due to increased revenues and associated improvement in gross margin, which were partially offset by a 66% operational increase and SI&A expenses as a result of higher promotional expenses in the U.S. for newly launched consumer healthcare products, Ibrance, and Prevnar 13 adult. And the 46% operational increase in R&D expenses due to increased cost associated with oncology oncology programs, primarily our alliance with Merck KGaA and Ibrance.',\n",
       " 'Fourth quarter, Global Established Pharmaceutical revenues increased 5% operationally, mainly due to the previously mentioned inclusion of legacy Hospira revenues contributing $1.2 billion, which was partially offset by loss of exclusivity and generic competition for Celebrex in the U.S. and certain other developed markets, Lyrica in most developed markets in Europe and Zyvox in the U.S.',\n",
       " 'Emerging market revenues were flat operationally, which reflected the positive impact of the inclusion of legacy Hospira operations and continued strong growth in China offset by declines in certain markets in the Middle East.',\n",
       " 'Income before taxes declined 12% operationally reflecting the unfavorable impact of a 4.7 percentage point operational increase in cost of sales as a percentage of revenues due to the inclusion of Hospira operations and the impact of losses of exclusivity, a 24% operational increase in SI&A expenses driven in part by the addition of Hospira operations and the 53% operational increase in R&D expenses due to increased legacy Hospira development programs.',\n",
       " 'We exceeded the top of our guidance range of expectations for 2015 reported revenues by approximately $400 million. Adjusted cost of sales as a percentage of revenues was 18.5% versus 18.7% at the low-end of our guidance range due to increased Alliance revenues and sales volumes, and we exceeded our expectation for our effective tax rate on adjusted income as a result of the favorable change in our jurisdictional mix of earnings.',\n",
       " 'We met our expectations for adjusted R&D expenses and achieved the top-end of our adjusted diluted EPS. Adjusted SI&A expenses are $14.3 billion, or higher than our guidance range due to increased expenses for recently launched products such as Prevnar 13 adult and Ibrance, other inline products, and certain Consumer Healthcare brands.',\n",
       " 'We recorded adjusted other income of $409 million versus our expectation of approximately $500 million. Finally, reported diluted EPS was a $1.24 versus our expected range of a $1.37 to a $1.43, mainly as a result of increased purchase accounting adjustments, acquisition-related costs and restructuring charges primarily related to the acquisition of Hospira, the negative impact of foreign currency losses related to Venezuela, and non-recurring charges related to pension settlements.',\n",
       " '',\n",
       " \"Now I'd like to walk you through the 2016 guidance ranges for reported revenues, reported diluted EPS, and adjusted diluted EPS relative to our 2015 actual results. First, it's important to note that our 2016 financial guidance excludes the impact of our pending combination with Allergan.\",\n",
       " 'Our 2016 reported revenue guidance range reflects anticipated strong growth of certain new inline and acquired product that is partially offset by an anticipated $2.3 billion negative impact due to continuing product losses of exclusivity. I want to point out that that would be in this range and consistent with our previous comments we expect full year Prevnar 13 adult global revenues to be comparable with its full year 2015 global revenue level.',\n",
       " 'We expect adverse changes in foreign exchange based on mid-January 2016 rates relative to the U.S. dollar compared with actual foreign exchange rates in 2015 to have an additional $2.3 billion negative impact on the reported revenues, including an estimated $800 million negative currency impact related to Venezuela. Consequently, we expect 2016 reported revenues to be in the range of $49 billion to $51 billion.',\n",
       " 'Reported diluted EPS and adjusted diluted EPS guidance also include the negative impact from product losses of exclusivity, as well as an expected $0.09 negative impact from foreign exchange rates and the $0.07 negative currency impact related to Venezuela. As a result, we expect reported diluted EPS to be in the range of a $1.54 to a $1.67, and adjusted diluted EPS to be in the range $2.20 to $2.30.',\n",
       " 'In addition, I want to remind everyone that guidance ranges for both reported and adjusted diluted EPS incorporate $5 billion of anticipated share repurchases in 2016, which consists of our previously announced intention to execute a $5 billion accelerated share repurchase program in the first half of 2016. These repurchases are expected to more than offset the potential dilution related to employee compensation programs.',\n",
       " 'In summary, to exclude anticipated foreign exchange impacts, including the negative currency impact related to Venezuela, full year 2016 revenue and adjusted EPS guidance midpoints are 7% and 10% greater than actual full year 2015 levels respectively. The remaining elements of our 2016 financial guidance are set forth on this chart.',\n",
       " 'Now moving on to key takeaways, we had a very strong financial performance in 2015 and we achieved operational revenue growth every quarter, including 14% operational growth in the fourth quarter. For the full year 2015, we achieved 6% operational revenue growth that was mainly driven by new products that are early in their lifecycles and we achieved this growth despite a 3.2 billion negative impact from product losses of exclusivity.',\n",
       " 'Our full year 2016 reported revenue guidance range of 49 billion to 51 billion absorbs a 4.6 billion combined negative impact of product losses of exclusivity, adverse changes in foreign exchange rates, and the negative currency impact related to Venezuela. And the adjusted diluted EPS guidance range includes an anticipated $0.16 negative impact from foreign exchange, including Venezuela.',\n",
       " 'We announced our proposed combination with Allergan, and continue to expect the transaction to close the second half of 2016. And we continue to create shareholder value through prudent capital allocation. In 2015, we returned $13.1 billion to our shareholders through dividends and share repurchases. And we expect to execute a $5 billion accelerated share repurchase program in the first half of 2016. Finally, we remain committed to delivering attractive shareholder returns in 2016, and beyond.',\n",
       " \"Now I'll turn it back to Chuck.\",\n",
       " 'Chuck Triano',\n",
       " 'Thanks, Ian and Frank. Operator, can we please poll for questions?',\n",
       " '',\n",
       " 'Question-and-Answer Session',\n",
       " 'Operator',\n",
       " '[Operator Instructions] Your first question comes from Colin Bristow from Bank of America.',\n",
       " 'Colin Bristow',\n",
       " \"Good morning, and congrats on the solid finish for the year. So a couple of product-specific questions if I may, on the Prevnar franchise, you've posted strong 4Q numbers. Could you just talk about your expectations for the trajectory going forward? On Ibrance there's been a lot of discussion around [indiscernible], and the potential there for a threat to Ibrance. What's your view here?\",\n",
       " 'And then just lastly on Biosimilars, can you update us on the status of your Biosimilar candidates, and when we should expect any data readouts? Thanks.',\n",
       " 'Ian Read',\n",
       " \"Thank you, Colin. I'll ask Albert to manage the Prevnar and Ibrance, and then pass it over to John for Biosimilars.\",\n",
       " 'Albert Bourla',\n",
       " 'Thank you very much for the question, Colin. Let me provide some insight to help you understand the situation moving forward. In the U.S., obviously we have done an excellent job with the catch-up opportunity. We have achieved 86% markets there, 92% at retailers. We have 90% awareness of the recommendation at healthcare practitioner. And as a result, over the 45 million adults eligible at the time of recommendation for vaccination, we have already captured about a third [ph] of them.',\n",
       " 'Now while many adults remain, this cohort is more difficult to capture, as the low-hanging fruit is gone. It will require more innovative strategies that we all have in place, but even if we assume a similar or higher penetration rate this year, it will be on a much smaller pool of adults. However, we expect this will be mitigated by Europe, which has a very different growth profile. Even with prices lower than U.S., the demographics are very favorable, with much larger eligible population, and who have already received pneumonia in our label in 2015, and we are working to obtain broad recommendations, and following that reimbursement from the authorities.',\n",
       " 'Now this will be phased likely over a two-years window period, because in Europe this is done country-by-country, and sometimes region-by-region within the same country. But all in all, we expect very strong growth in Europe next year.',\n",
       " \"Now let me move on Ibrance, and your question about competition or particularly [indiscernible] drug. Look, [indiscernible] drug, while in the same class, is for any [ph] indication. The refractory patient population, what we have received breakthrough designation, is a very small population with few options available. In fact the average refractory patient undergoes seven lines of treatment. So it's -- they are in high-mid.\",\n",
       " \"Now speaking generally on competition, there is only limited clinical data on the public domain, and we need to see more efficacy and safety data to make comparisons. What I can tell you is about our strategic position. We are the only company with a registered product in U.S., and six other countries, and an accepted filing in Europe, where we may obtain registration as early as next year. We have very good clinical experience with the product. Ibrance has been prescribed by 5,000 physicians in more than 20,000 patients. And so far feedback is very positive, particularly on patients' quality of life.\",\n",
       " 'We are having a very heavy clinical program. We have two pivotal studies in first-line metastatic breast cancer, two studies in recurrent metastatic breast cancer, and three in early breast cancer, PENELOPE-B, PALLAS, and PEARL [ph]. Ibrance is part of 88 investigational initiated trials, approximately 50 in breast cancer and 38 in other tumor types. So as you can see, we are investing heavily to stay ahead of the competition.',\n",
       " 'Ian Read',\n",
       " 'Thank you, Albert. I think just on Ibrance, you mentioned next year for Europe, you meant this year, late this year we may be able to get registrationâ€¦',\n",
       " '',\n",
       " 'Albert Bourla',\n",
       " \"Correct in '16, I mean. Sorry. I apologize.\",\n",
       " 'Ian Read',\n",
       " 'Yes, thank you. Go ahead.',\n",
       " 'John Young',\n",
       " \"Okay. So thanks for the question on Biosimilars, Colin. So I think we're obviously very excited to being able to bring together the combination of Hospira's current inline biosimiliars which are already in the market. So we have three assets, as you know, which are already in the market in Europe, Nivestim, Retacrit, and Inflectra. And to bring that together along with the legacy Pfizer monoclonal antibody pipeline, plus some additional assets that Hospira have. So in total, when you look at the pipeline, we have nine distinct biosimilar molecules in different stages of development. Infliximab, outside of the E.U., Adalimumab, Trastuzumab, Bevacizumab, Rituximab, Pegfilgrastim, Ranibizumab, Denosumab, and Ustekinumab.\",\n",
       " \"So overall we have a very strong pipeline. A number of those assets are in Phase III, late-phase development. And the first dataset there you'd be seeing from our Phase III studies would come from the legacy Pfizer Infliximab program where we would expect to produce data from our Phase III towards the end of this year.\",\n",
       " 'Ian Read',\n",
       " 'Thank you, John.',\n",
       " \"Frank D'Amelio\",\n",
       " 'Thanks, John.',\n",
       " 'Chuck Triano',\n",
       " 'Operator, can we please move to the next question.',\n",
       " 'Operator',\n",
       " 'Your next question comes from Jami Rubin from Goldman Sachs.',\n",
       " 'Chuck Triano',\n",
       " \"Jami? Okay, Jami. We may come back to Jami if she's -- if we can correct the technical issues. If not, let's go to Alex.\",\n",
       " 'Operator',\n",
       " 'Your next question comes from Alex Arfaei from BMO Capital Markets.',\n",
       " 'Alex Arfaei',\n",
       " \"Good morning and thank you for taking the questions. Frank, your gross margin for 2016 is better than we expected, considering you're integrating a lower margin business in Hospira and losing exclusivity on some high-margin products. Can you help us understand what's driving that, and how we should think about -- and should we expect traditional margin expansion going forward, given that your Innovative business is growing at a faster rate?\",\n",
       " \"And then on Hospira's contribution this quarter, it doesn't seem to reflect much revenue synergies. Obviously it's too early, but how should we think about Hospira's contribution next year and possible revenue synergies going forward? Thank you.\",\n",
       " \"Frank D'Amelio\",\n",
       " \"So Alex, on the gross margin, let me run the numbers and then I'll answer the question. So we ended the full year at 18.5% in terms of cost of sale. So I'll do the cost of sale. The reciprocal obviously is gross margin. We got it for next year across the sales number of 21% to 22%. So if you take the midpoint of that 21 to 22, just to make the math easy, that's 21.5% from our 18.5%. That's a 3%, 300 basis point increase in our cost of sales as a percentage of revenues. By the way, that's being driven by a few factors, but one of which clearly is Hospira.\",\n",
       " \"In terms of -- I think your question, which was why wasn't even more, I think the answer is our ongoing productivity and cost reduction initiatives. When you think about our factories, our manufacturing capabilities, we really manage that from a cost perspective. First of all, we focus that on quality, service, and cost. If you think about that as a triangle, quality is at the top of the triangle. But there's four major buckets, right? There's the number of facilities, there's the numerous quality initiatives we have within each facility. There's the purchasing that we can get from a leverage perspective, and then finally, there's the center cost that resides outside of the factories. We manage all four of those very aggressively to basically -- to manage our cost structure in manufacturing, but that gives you a feel for what the numbers were, and why they are what they are.\",\n",
       " 'Ian Read',\n",
       " 'Please, John.',\n",
       " 'John Young',\n",
       " \"So thanks, Alex. So obviously, again, we are very excited by the opportunities afforded us by the combination of our two businesses. And I think I've talked about biosimilars already, and the opportunities we see in that marketplace. So let me just touch briefly on sterile injectables. Obviously it's a very -- it's a large, it's a growing market. It's somewhere between $50 billion to $70 billion currently globally, and one of the sort of features of that market is it's very concentrated, particularly in the U.S., but also in a few ex-U.S. markets, such as Western Europe, and particularly China.\",\n",
       " '',\n",
       " \"So, one of the things that we are very focused on is going to be revenue synergy. We obviously have a strong commercial presence in China, and also in the hospital segment in developed Europe and emerging Europe. So essentially the lag time since September when we closed this transaction we've been focused really on making sure that we have our blocking and tackling in place to be very systematic with our highest value molecules that really sort of meet market needs most appropriately. To be very focused on registering and brining those molecules to market.\",\n",
       " \"So in the biggest opportunity that we have in China, that is going to take time, as you are very well aware. Drug lag in China is a significant issue, but we're very encouraged by the progress that the CFDA are making to accelerate access to important new medicines in China. But that will take time. But we do see opportunities both in the short-term, as well as medium and long-term to deliver significant growth ex-U.S. through the sterile injectable business and the combination of Hospira's portfolio into our commercial footprint.\",\n",
       " 'Chuck Triano',\n",
       " 'Thanks, John. And operator, see if we can get Jami Rubin back.',\n",
       " 'Operator',\n",
       " 'The next question comes from Jami Rubin from Goldman Sachs.',\n",
       " 'Jami Rubin',\n",
       " \"Thank you. Sorry about that. Don't really know what happened on my end, but anyway, just a few questions. Frank, can you tell us what the Venezuela revenues are? I guess we are in consensus, we're surprised by the size of the hit; can you all hear me?\",\n",
       " \"Frank D'Amelio\",\n",
       " \"Yes, we can hear you. You're a little static, but we can hear you.\",\n",
       " 'Jami Rubin',\n",
       " 'Okay, sorry about that. Anyway, so Frank, if you could just provide more color on Venezuela? And why such a big hit?',\n",
       " 'And then Ian, just a couple of questions for you, just back on this whole breakup thesis and the timing, I think investors initially were disappointed by the timing that you laid out at the time that you were announcing Allergan deal. I think you said you would make a decision by the end of 2018. I just want to put out there that the stock has pulled back quite a bit since you announced the Allergan deal, and I would think despite clearly the market is excited about this, but I would think that that would -- that the difference in -- even growing gap in valuation between where your stock is in an SOTP should help you to accelerate your decision to move in that direction, and if you could just comment on that please.',\n",
       " \"And then just, thirdly, on revenue growth. I mean, clearly there have been tons of pushes and pulls in your numbers, mostly currency, and patent expirations. Can you remind us when you expect, and this excludes the acquisition from Allergan, but when you expect your reported revenue growth -- or just talk about operationally revenue growth, when we should start to see a positive inflection point, because it has, when I look at my models, revenues have been in decline for many years and some of that's divestitures, and spins, but really since 2013, we've had revenues sort of flat to down. When is that going to change, and what's going to drive that change, just talking from Pfizer's standpoint? Thanks very much.\",\n",
       " \"Frank D'Amelio\",\n",
       " \"Let me just do the revenue growth first. Well, you know, as I said, '15 was the first year when we saw revenue growth; '16, we expect it to be around operationally narrow. We expect it to be Hospira and Allergan, we expect it to be flat and that's because we had a huge growth from adult vaccine in '15, and we'll hold that franchise. We won't grow it again. We'll have good growth from our inline products and our newly launched products, but we'll still deal with a couple of billion of LOEs. So I think you can begin to see, as we launch -- as we begin to get more traction with more clinical trial in Ibrance as we begin to see the launch, as we begin to see our next wave of products get approved, you'll see us returning to a very robust growth. But obviously, Jami, one of the reasons for doing the Allergan deal was in fact to ensure that we had robust growth in our innovative business. So we're aware of that issue.\",\n",
       " '',\n",
       " \"Now this is the breakup timing. Number one, I point out that while the stock is down, I don't think it's specifically down more than a DRG. In fact I think it's roughly the same as a DRG, and in fact, given the our pressure that one would expect in a stock, I'm actually -- well, never like to see the stock go down. It certainly was expected to come under pressure from the odd community.\",\n",
       " \"Now the breakup timing is an issue of -- we are focused on integrating this company and the two companies together, and we have laid out the full questions that we need to answer. And I think shareholder would want those questions answered. So, can we run the businesses successfully insider Pfizer? And we bought Hospira. You are seeing the sterile injectables. You have got the Biosimilars. You're beginning to see if you strip out the LOEs and stabilization of the core business, which we expect to return to growth, but that being said, we can run it well inside Pfizer. Can it be run better outside Pfizer? Is there trade value and can we unlock trade value in tax efficient manner? And these are the very serious questions. These are very large companies. And I think that by innovating we will be well positioned to make that decision in the best interest of our shareholders. And frankly, don't particularly see a way of short-circuiting that just because of the amount of work that has to be done and integration and getting the transaction of Allergan right. I do understand your wish for more speedy decision, but I think we are taking the right approach for shareholder value here.\",\n",
       " 'Ian Read',\n",
       " 'Venezuela?',\n",
       " \"Frank D'Amelio\",\n",
       " 'Yes.',\n",
       " 'Ian Read',\n",
       " \"So, Jami, the Venezuela revenues for -- I'll call it initially projected for 2016 were about $800 million, roughly the same size as 2015. If you look at the adjustments, we took -- we changed the exchange rate from 6.3 Bolivar to a dollar to 200 Bolivar to dollar. We went to the SIMADI rate for Venezuela. That change in the translation is what causes the adjustment that we made for 2016, and we thought that the timing of that adjustment was appropriate, given oil prices, given what's going on in Venezuela economically, given the dollars that are coming out of Venezuela, we thought the timing for this was appropriate. But it's really the 6.3 to 200 to the dollar conversion that's really causing the adjustment to 2016.\",\n",
       " \"Frank D'Amelio\",\n",
       " 'Now, Jami, ongoing, when Venezuela passes through this crisis and they re-establish a normal economy, we would expect Venezuela to grow back to be in the -- between 200 and 400 million a year. So the actual delta medium-term is for the 400 million between what was an overvalued currency.',\n",
       " 'Jami Rubin',\n",
       " 'Thank you.',\n",
       " 'Chuck Triano',\n",
       " 'Thanks, Ian and Frank. Can we move to the next question please?',\n",
       " 'Operator',\n",
       " 'Your next question comes from Andrew Baum from Citi.',\n",
       " 'Andrew Baum',\n",
       " 'Hi. Three questions please, two of them of very short. Firstly, perhaps you could just outline sequential growth for China, say, [technical difficulty] last quarter? Second, do you anticipate extra notice from Treasury on conversion, and obviously [technical difficulty] how restricted do you see any measures to impact the Allergan transaction? And then finally, just returning to [indiscernible], the patients in the ongoing Phase 2 trial, which accelerates approval that have not seen Palbociclib in early line of therapy, is that an approval possessing given the design of that trial, given the fact you are approved for indication or does that include any regulatory approval for the drug? Thank you.',\n",
       " 'Ian Read',\n",
       " \"Okay. I am going to do the notice first. We at the moment understand that the Treasury are working on formalizing and regulating the first two notices they issued, which are not in many ways applicable to our transaction as we're at the below 50% ownership.\",\n",
       " '',\n",
       " \"I really can't speculate if there is going to be a third notice or not. We feel confident the transaction is fully within the U.S. law and fully within accepted interpretation of that law and expect the transaction to close in the second half of next year.\",\n",
       " \"With that, I'll go to growth to Frank, and I would ask Mikael to talk about Palbociclib.\",\n",
       " 'Andrew Baum',\n",
       " 'And with China.',\n",
       " \"Frank D'Amelio\",\n",
       " 'On China, for the quarter, China grew 10%. Full year, China grew about 10%. Nice numbers. Somewhat moderated from 2014. In 2014, China grew to about 15%. So, we saw some moderation in the growth in China.',\n",
       " 'That said, Andrew, we remain very bullish on China. Has an increasing population, increasing personal wealth, government is committed to healthcare. We see increased spending in the government and the GDP rate is still very healthy. Not as high as it has been the past, but still quite healthy. So, we remain very bullish on the China market on going forward basis.',\n",
       " 'Ian Read',\n",
       " 'Mikael?',\n",
       " 'Mikael Dolsten',\n",
       " \"Yes. Thank you, Andrew, for a good question here. Two things; first, I want to just to point out that Abemaciclib is somewhat different from Palbo and Novartis drug in that it seems to be less selective and has a different resident profile likely due to hitting multiple CDKs particularly been reported significant GI issues. So it's a different profile, and we, as Albert very well pointed out, have been extremely pleased with the favorable profile that allow patients to benefit from Ibrance with very good reliability.\",\n",
       " 'Now you asked about this late stage population studies Abema [ph], and how that population in the future will evolve. We anticipate as Ibrance is having a very nice uptake in the marketplace in first line metastatic and some also more advanced lines, and hopefully with Prevnar 3 approval, Ibrance is likely to be used in multiple lines.',\n",
       " \"Hence, monotherapy with another CDK will of course have the potential to face patient population that have seen CDK inhibitor, and that's why we are developing a strategy for how we can see patients benefit from drug like Ibrance at various stages with different anti-hormonals. And we are also now studying Ibrance in triple therapy. So I think you can see that multiple drugs is likely to be the preferred as patients become more advanced.\",\n",
       " 'Andrew Baum',\n",
       " 'Thank you, Mikael.',\n",
       " 'Chuck Triano',\n",
       " 'Thank you. Next question please.',\n",
       " 'Operator',\n",
       " 'Your next question comes from Vamil Divan from Credit Suisse.',\n",
       " 'Vamil Divan',\n",
       " 'Great. Good morning everyone. Thanks for taking the questions. Soâ€¦',\n",
       " 'Ian Read',\n",
       " 'Good morning.',\n",
       " 'Vamil Divan',\n",
       " 'Hi, good morning. Just again on Biosimilars front, I know there has been a couple of questions, but just a couple of more if I could. One is specifically on Enbrel, and if you can discuss in terms of 2016 how you are viewing the impact of Biosimiliars to your performance for that product?',\n",
       " 'And then second, now that Hospira has closed, I am just wondering, I guess this is a question for John or whoever wants to jump in, in terms of the value having a Biosimilar business under the same broad umbrella as your innovative business so you can leverage that commercial infrastructure areas like oncology and autoimmune disorders. Is there any way sort of maybe make more sense than to keep Pfizer as a single entity as opposed to splitting up and then needing to rebuild the commercial infrastructure for your Biosimilars in those similar areas where you do have innovative products? Thanks.',\n",
       " 'Ian Read',\n",
       " \"Vamil, I'll ask Geno to talk about Enbrel and the impact of Biosimilars in Europe.\",\n",
       " 'Geno Germano',\n",
       " \"Sure. So, the first Biosimilar for Etanercept has been approved in Europe. And we've watching the situation very closely and evaluating adoption of Biosimilars across each of the countries throughout Europe for awhile now.\",\n",
       " 'Our overall expectation is that there will be somewhat modest impact in 2016. The Biosimilar landscape is clearly still developing. There are different approaches taken by different countries. And we have a very clear detailed roadmap for how to address each of the dynamics that exist in these different countries.',\n",
       " '',\n",
       " 'So we are fairly confident that we are going to continue to have a strong Enbrel business throughout Europe. We think that the new patients would be probably most at risk of being exposed to the Biosimilars and hope that the availability of lower cost biologics will expand the market. So overall, we see this as again a modest impact to our business in the initial period of time.',\n",
       " 'Ian Read',\n",
       " 'And Vamil, maybe a very interesting question on the connectivity between the Biosimilars and the other space. I would say that that would be taken into account if there was any such linkage that was positive in our TSAs, the setup the separate companies to ensure that that as overall we maximize value of that between both companies in the contracts we would sign if we decided to split. Thank you.',\n",
       " 'Vamil Divan',\n",
       " 'Thanks, Ian.',\n",
       " 'Chuck Triano',\n",
       " 'Next question please.',\n",
       " 'Operator',\n",
       " 'Your next question comes from Steve Scala from Cowen.',\n",
       " 'Steve Scala',\n",
       " 'Couple of questions. First, apologizes if I missed the explanation, but the 2016 guidance includes roughly an incremental 4 billion in revenue and $0.08 in earnings from Hospira implying down to significantly down underlying sales for the legacy Pfizer and flattish to down EPS, and it seems that generic exposure in currency cannot be the explanation because the predicted 4.6 billion hurdle in 2016 from these factors is well less than the 6 billion plus predicted in 2015 at this time last year.',\n",
       " 'So actually the comparison on generic exposure in currency is improving and more than offsets the year-over-year increase in Prevnar. So, any thoughts on that would be appreciated.',\n",
       " 'And one more, how should we think about the long-term outlook for Sutent particularly given the competition from immuno-oncology agent. You think Sutent will soon become a defining asset or do you see growth in the future? Thanks.',\n",
       " 'Ian Read',\n",
       " \"I'll ask Albert to talk about Sutent and its possible combinations and the other studies we have already had on Sutent. And then, I'll ask Frank to come back on your questions about growth rates.\",\n",
       " 'Albert Bourla',\n",
       " 'We remain very confident in our position in the RCC space and that includes both, Sutent and Inlyta, because they are very well known by physicians and other stakeholders. The recent approval in RCC for immunotherapy but this does not affect Sutent. It is in the second line. Sutent is used primarily in first line. And s we have previously disclosed we are studying Inlyta, and Inlyta plus other PD-1 inhibitors pretty aggressively so that we can achieve better result in monotherapy in RCC second line.',\n",
       " 'Ian Read',\n",
       " 'Frank?',\n",
       " \"Frank D'Amelio\",\n",
       " \"Yes. Let's see if I can answer the question. Just first, we don't give a specific number for Hospira revenues for 2016. But that said, I believe I could still answer the question. So, the way I think about this is if you enter the midpoint of the guidance prior to foreign exchange in Venezuela, which is part of the basis of your question, the midpoint for guidance would be 52.3 just to use midpoint. We take 50.3 compare that to the 48.9 that we printed in 2015 are all now at the same foreign exchange, so, clearly operational. That's an increase of about $3.5 billion. We said -- Ian said when he answered Jami's question that revenue excluding Hospira on a year-over-year basis was essentially flat operationally while absorbing 2.3 billion in LOEs for 2016.\",\n",
       " \"The other data point I think to help you answer the question is, remember, we did 1.5 billion in Hospira sales this year. So, when we say that the bulk of the growth is from Hospira, you understand it's incremental growth on top of the 1.5 billion that we printed in 2015. So that's how I think -- that's how you get to numbers we said and why we said operationally the numbers were essentially flat if you left Hospira out of the equation.\",\n",
       " '',\n",
       " 'Steve Scala',\n",
       " 'Thank you, Frank.',\n",
       " 'Chuck Triano',\n",
       " 'Thanks, Frank. Next question please.',\n",
       " 'Operator',\n",
       " 'Your next question is from Mark Schoenebaum from Evercore ISI.',\n",
       " 'Mark Schoenebaum',\n",
       " \"Hey, guys. How are you doing? Thanks for being so clear on the communications in the quarter. I have one question that's been danced around but maybe let me just ask you it again and hope so I won't annoy you, but I'll try again.\",\n",
       " 'So first is do you believe that there is anything, Ian, under the current U.S. statute that would allow treasury to block and/or materially delay the closing of the AGN deal? So I am asking you if there will be third proposed notice. I am asking you under the current law, are you very -- do you remain I guess very comfortable there is nothing that treasury legally could do to block the deal or to materially delay it like in the 2017 when there will be a new a congress and a new president.',\n",
       " \"And then I would also just for Frank perhaps just like you talked a little about your leverage ratio, if my math is right, the leverage ratio of the combined company the NewCo should closer to be around 1? By my math, you could take that to maybe 3 without affecting credit ratings in a big way, I would like to hear -- that's my math and I am not very good at math, so I would love to hear your general thoughts around leverage ratio of the NewCo where you might be willing to take that should the deal close. Thank you.\",\n",
       " 'Ian Read',\n",
       " \"Thank you, Mark. And thank you for the compliment on the clarity to communications. We strive to make them clear. So on your question which I don't think on the current law, I do not believe there is any reason why this deal will not close; full stop.\",\n",
       " \"Frank D'Amelio\",\n",
       " \"Mark, let me run some numbers. So on leverage let me run the Pfizer numbers based on third quarter. We haven't issued a balance sheet yet for the fourth quarter. We will do that when we file the K. We had about 37 billion of cash in investments. We had about 39 billion of debt, short and long term debt. So to your point call that one to one essentially, and what we said when we announced the Allergan deal, what I said was we could take the leverage ratio at yield point up to about 2.5 to 3.\",\n",
       " \"And then, obviously, once took it there, we would want to see what kind of rhythm that created relative to the company, the operation supporting the company in that we take it there, but that we still want access to commercial paper. We would be willing take a one notch downgrade but we would still want to have access to commercial paper. But in terms of your math and your calculation 2.5 to 3, that's right. That's basically what I talked about when we announced the Allergan deal. So, your math was good.\",\n",
       " 'Chuck Triano',\n",
       " 'Thanks, Frank. Next question please.',\n",
       " 'Operator',\n",
       " 'Our next question comes from Marc Goodman from UBS.',\n",
       " 'Marc Goodman',\n",
       " 'Yes, few things. One is can you tell us what the key products are in Venezuela, if there are any massive ones that we need to be hitting the model on? Second, Frank, maybe you can go through some of the push-pulls on SG&A and how you are thinking about the spending this year? And then, third, can you just give us an update on the IL-6? Thanks.',\n",
       " 'Ian Read',\n",
       " \"So key products, I don't think there's any outstanding product, but the Enbrel is the biggest product that contributes. John, would you want to add anything to that?\",\n",
       " 'John Young',\n",
       " 'Yes, I think the Enbrel is the biggest product. I think in addition to that we have a portfolio of matured established product, Lipitor and Norvasc would be other key products for us in Venezuela. So really just think about the basket of established products and the fit in that marketplace.',\n",
       " 'Ian Read',\n",
       " 'Okay. The SG&A? Yes.',\n",
       " \"Frank D'Amelio\",\n",
       " \"So, Marc, on SG&A, let me just talk to the quarter and then I'll talk to the rhythm of the numbers. So if you look at the quarter, we had a big spend in SG&A. It's 4.6 billion all in. Three major factors there, right, one, obviously the inclusion of Hospira, which added a couple of hundred million. Two, sequentially, if you think about the fourth quarter compared to the third quarter, we had a lot more selling days in the quarter. So, internationally, we had six more selling days. Domestically, we had two more selling days.\",\n",
       " '',\n",
       " \"So, sequentially, Q3 of '15 to Q4 of '15, we had more selling days. So obviously it helps revenue, but also increases the spend on our line items. And then, we had obviously I alluded to in my comments increased promotional spend in many areas of the business.\",\n",
       " \"Now, if you take that 4.6 and you annualize it, times 2 is what? 9.2 times 2 is 18.4. If you look at the guidance we gave for next year on SI&A, it's 13.2 to 14.2 billion. So you can't take that Q4 number and annualize it. You get to a number that's nothing close to what our guidance is for 2016, which is a combination of Hospira numbers, the selling days, and then the increased spend in the quarter. But we look at it for next year, we get a number that our annual basis is significantly lower than what that annualized number would be.\",\n",
       " 'Ian Read',\n",
       " 'And, Mikael, do you want to discuss IL-6?',\n",
       " 'Mikael Dolsten',\n",
       " 'Yes. Thank you for your question. So we tested IL-6 antibody in Lupus and [indiscernible], and while antibody did show some activity, we found that overall profile did not compete as well as many other real interesting immunology agents and other opportunities we have in our very rich pipeline of 90 clinical programs. So this is part of prudent portfolio prioritization within Pfizer.',\n",
       " 'Marc Goodman',\n",
       " 'Thank you, Mikael.',\n",
       " 'Chuck Triano',\n",
       " 'Can we move to the next question please?',\n",
       " 'Operator',\n",
       " 'Your next question comes from John Boris from SunTrust.',\n",
       " 'John Boris',\n",
       " \"Thanks for taking the questions and for all the clarity that you've given on the '16 guidance. Ian, first question on the timing around the breakup, I think you've indicated that integration of Allergan is very important. You've also indicated that you had time to look even deeper into the Allergan portfolio.\",\n",
       " \"As you think about integration, can you give us some more commentary around how you are thinking about mapping out integration? Some look at Wyeth and look at the massive amount of synergies that you are able to extract out of Wyeth transaction and are somewhat puzzled as to why you can't do that here. So, any commentary around that?\",\n",
       " \"Two additional questions; one on CDK 4/6, this one is for Mikael. Mikael, when you look at preclinical models, is there any argument or hypothesis around a drug that has to be given intermittently that it might have less efficacy than one that's given on a continuous dosing? And is that supported by any preclinical models?\",\n",
       " 'And then, the last question just has to do with Xeljanz. Obviously, a very important asset for you not only in the U.S. but on the EU timing for filing, I think you indicated you wanted to have that filed before the end of the year. Just any update on what Europe is looking for within that filing to secure approval in Europe?',\n",
       " 'And then, on psoriasis in the U.S., any developments there on the modified release from a regulatory standpoint and then obviously with Enbrel seeing generic competition what have you done with your infrastructure in Europe to still keep some infrastructure in place to support Xeljanz if and when it gets approved?',\n",
       " 'Ian Read',\n",
       " 'Okay. So let me just -- quickly the last one first, we still have very strong expectations from Enbrel in Europe as Geno was discussing. We are not removing our support from Enbrel. So we expect to have full support for Xeljanz when it launches in Europe. There was a somewhat of a slippage from -- as you say, the end of the year to the beginning of this year on the Xeljanz application in Europe. We wanted to get it right and make sure that it was in the best shape we could, and these things happened. So there was a slight slippage on time on that. Mikael, do you want to deal with this hypothetical on CDK 4/6?',\n",
       " 'Mikael Dolsten',\n",
       " \"Yes, thank you for the questions. Of course, always we would caution you can speculate on things that haven't been studied in humans in comparative aspects, but you know, we think it's important to hit CDK 4/6 hard for breast cancer, and when you do that with high doses you will get efficacy on the tumor, but also see some neutropenia and that's we why chose the intermittent schedules. Particularly it seems very effective for combination therapy with multiple agents such as [indiscernible] in breast cancer.\",\n",
       " '',\n",
       " 'For other tumor types, we may explore various schedules for various combination of drugs, but for breast cancer we think to show some schedule with the combinations we have studied is very effective and works well.',\n",
       " 'Ian Read',\n",
       " 'Thank you. Geno, you want to deal with the other questions that John asked on Xeljanz?',\n",
       " 'Geno Germano',\n",
       " \"Yes. John, I think the question -- as Ian had already alluded to, we are now expecting our filing to be in the first quarter of this year. We're actually meeting with [indiscernible] at this point. We did generate additional data on immune function as a result of the discussions that we had with the regulators in the first submission. So we feel that we have a strong package that we have responded to the information requests that they had, and we're just tidying up the kind of last few details and expect to put that filing in imminently.\",\n",
       " 'Ian Read',\n",
       " 'And psoriasis and -- so, question on psoriasis? In the U.Sâ€¦',\n",
       " 'Geno Germano',\n",
       " \"So psoriasis -- well, as you probably know we have a -- we received a complete response letter from the FDA on psoriasis. We have provided a backgrounder to the FDA, and we expect to meet with them also this quarter to follow-up on the components of the complete response letter, and once we know in more detail what their issues and concerns are, then we'll determine best way forward from there.\",\n",
       " 'Ian Read',\n",
       " 'Thank you. Frank, do you want to deal with theâ€¦',\n",
       " \"Frank D'Amelio\",\n",
       " 'Synergy number?',\n",
       " 'Ian Read',\n",
       " 'Yes.',\n",
       " \"Frank D'Amelio\",\n",
       " \"Yes. So we have certainly announced the deal more than $2 billion. We gave you the timing in terms of when we would get that. A couple of comments, John, to your question, I think first why more than $2 billion, why not a higher number? I think these are two companies that have done a lot on the cost reduction front; significant reductions at both companies, I think efficiently run companies. Two, not a lot of therapeutic area overlap, which is always seeing a kind of a trigger for synergy opportunities. Third, if you look at the Allergan cost of goods sold, two-thirds of that from my perspective, from a synergy perspective was unaddressable. It's their end of business and then royalties. So really not a lot we could do there, but all that said and done, we're working now with the Allergan teams with Brent, with Bob Steward, with Tessa. Ian and myself, our leadership team here at Pfizer, we've already launched a couple of operational teams, and we're starting to dig into this in much more detail. If there is more there, please know we're going to get it, and we'll tell you about it. So I think on a synergy front just more to come.\",\n",
       " 'Ian Read',\n",
       " 'Yes. And you know, John, the process from this deal was not huge cost synergies, it was about driving revenue growth in the innovative business, driving reasonably young portfolios, taking the products internationally, and then getting excellent capital allocation over the world. So we will get the synergies we can get, but our focus is on growth, and a lot of the questions on the call have been about growth. So this is part of the solution to that, and also really a good capital allocation.',\n",
       " \"Frank D'Amelio\",\n",
       " 'Thank you for the questions.',\n",
       " 'John Boris',\n",
       " 'Thanks, Ian.',\n",
       " 'Chuck Triano',\n",
       " 'Next question please.',\n",
       " 'Operator',\n",
       " 'Your next question comes from Tim Anderson from Bernstein.',\n",
       " 'Tim Anderson',\n",
       " \"Thank you. If I could go back to the revenue guidance, the midpoint is about $2.5 billion below consensus, you flagged FX was a major headwind. I know that we spend a lot of time trying to incorporate FX, and I imagine consensus does too, yet that's still a very big delta. So my question on this is when you look at analyst models, are there particular revenue line items for products or divisions where you think consensus is too high unrelated to foreign exchange?\",\n",
       " \"Second question, you mentioned the 4-1BB with Merck, and I'm showing foundation data with Keytruda. That's Phase I data, so as such I'm blinded -- I'm wondering if you can give us a preview of the tumor types here you think are most promising and also any preliminary safety findings?\",\n",
       " '',\n",
       " \"And then last pipeline question, last year you mentioned having an oral PCSK9 approaching human development, and I'm wondering if that is now in the clinic when I look at your pipeline chart I see a new compound has been advanced on the Phase I?\",\n",
       " 'Ian Read',\n",
       " 'Okay. Frank, if you could deal with the first question, and Mikael will have remaining two.',\n",
       " \"Frank D'Amelio\",\n",
       " \"Sure. So Tim, let me run the numbers in, then I'll answer the questions. So your numbers are right. So consensus numbers give or take on revenue for 2016 about 52.4 billion the midpoint of all guidance $50 billion, the net there is roughly 2.5 billion that you alluded to, just to kind of nail the numbers.\",\n",
       " \"I think two major pieces in terms of the GAAP; one is, clearly the Venezuela adjustment we made in 2016 wouldn't have been at the 52.4. So that's an $800 million adjustment. That would take a 52.4 to 51.6, and then I think when you look at the line items, I think the big difference [technical difficulty] if you ask me to point out one single place, it's Prevnar 13. Significant results, and the growth expectations in Prevnar 13 -- '16 versus our modeling for '16 where I said in my comments, and Albert punctuated in some of his detailed remarks about we're expecting that to be essentially comparable to 2015 levels. Those are the two things that I would point out that will make up the majority big piece of the difference in terms of your 2.5 billion.\",\n",
       " 'Ian Read',\n",
       " 'Thank you. Mikael?',\n",
       " 'Mikael Dolsten',\n",
       " 'So thank you for asking about 4-1BB, and as you know, we believe that the combination therapy moved immuno-oncology feel to the next level. We are very pleased with the 4-1BB, one of tumor antibody that we have. We have started eating combination with Rituximab in lymphoma and with PD-1 Keytruda in a small study across various tumor types, and have also initiated combination study with Avelumab.',\n",
       " \"The 4-1BB antibody, the Pfizer antibody shows very good tolerability when combined with other biological agents, and it's clinical performance suggest also very interesting favorable clinical activity on top of other biologicals, such as Rituximab and PD-1 Keytruda. We will share the date from this first cohort this year likely at ASCO. We are quite excited about 4-1BB and also OX40 that's in our pipeline, and you will see 4-1BB Avelumab data likely late this year as well OX40 monodata, and early next year several doublets and triplets, which makes me very enthusiastic as I look forward how we advanced the strategy of combinations therapy.\",\n",
       " \"We have an oral PCSK9 in Phase I. It's too early to have any definitive interpretation of that data, and we also have a PCSK9 vaccine in late preclinical development.\",\n",
       " 'Chuck Triano',\n",
       " 'Thanks, Mikael. Next question please.',\n",
       " 'Operator',\n",
       " 'Your next question comes from Richard Purkiss from Piper Jaffray.',\n",
       " 'Richard Purkiss',\n",
       " 'Oh, thanks. I have a couple of questions for Mikael, just on Ibrance, can you flag any upcoming data for tumor types outside of breast cancer that we should look out for? Also, can you update on how well the Adjuvant breast cancer studies are enrolling? Thanks.',\n",
       " 'Ian Read',\n",
       " 'Mikae, would you like toâ€¦',\n",
       " 'Mikeal Dolsten',\n",
       " \"Yes. I could say a few words, so as Albert alluded to, there is a large number of Ibrance study, the great majority by investing in initiative research. So we will have to see as these studies result report emerging. I can say that we also have sponsor-led studies outside breasts, that includes pancreatic cancer, and head and neck, and we're also looking at triple therapy in breast cancer. I remain optimistic and excited about Ibrance performance, and think we will see interesting datasets coming from several of these new tumor types.\",\n",
       " 'Ian Read',\n",
       " \"Enrollment? It's going well?\",\n",
       " 'Albert Bourla',\n",
       " 'Yes, actually I can only add here. But likely the Mantel cell lymphoma, and the neck we may see data even this year. And then many of the areas that Mikael discussed, including small-cell-lung, we may see next year.',\n",
       " '',\n",
       " 'Chuck Triano',\n",
       " 'Okay, thanks Albert and Mikael. Next question please.',\n",
       " 'Operator',\n",
       " 'Your next question comes from Geoff Meacham from Barclays.',\n",
       " 'Geoff Meacham',\n",
       " \"Good morning guys. And thanks for taking my question, just a couple of quick ones. On Bevacizumab, given Pfizer's experience in cardiovascular I was just curious what your thoughts on the demand trends were, looking peripherally at the PCSK9 class today. I know a lot looking forward depends on outcomes data, but just curious about whether there's a tipping point, and the position adoption.\",\n",
       " \"And then just on Biosimilars in the U.S., just wanted to get you guys to view on where you think the FDA is with respect to extrapolation when we're looking at the upcoming senior panel next week. Thanks.\",\n",
       " 'Ian Read',\n",
       " 'Geno, any comments on that?',\n",
       " 'Geno Germano',\n",
       " \"Yes, I mean I think I would just reinforce the comment that you made. I mean, it's been our contention all along that this class becomes a real class in managing these patients with the cardiovascular outcome data, that we'll be seeing either late this year or starting next year. Our program is advancing nicely. We have, as you know, two cardiovascular trials. And the SPIRE-2 trial, which is in the high-risk patient population, we've now reached the point where we've discontinued screening. We're almost completely enrolled. And that trial is moving along very rapidly. And the SPIRE-1 trial will be completely enrolled by the end of this year or early next year.\",\n",
       " \"So we're looking forward to these data, and the impact that we think they're going to have on the marketplace.\",\n",
       " 'John Young',\n",
       " \"So, on the Inflectra AdCom, as you know it's scheduled for February 9, next week. I think it would probably be premature to speculate on the view that the FDA will take. We certainly think that this will be extremely informative as to the FDA's views and perspectives on extrapolation. I think obviously their product is being filed by Xeljanz. So specific questions about the AdCom really should be directed to Xeljanz, but I would say is that while we obviously await the resolution of the advisory committee and certain other factors. We're certainly moving ahead with the preparation for launch plans in 2016.\",\n",
       " 'Chuck Triano',\n",
       " 'Thanks Geno, and John. Next question please.',\n",
       " 'Operator',\n",
       " 'Your next question comes from David Risinger from Morgan Stanley.',\n",
       " 'David Risinger',\n",
       " \"Yes, thanks very much. I have three questions. First, Ian, besides the likelihood of closing, what do think investors most under-appreciate about the Allergan merger? Second, I guess these are two financial questions. One is with respect to Enbrel ex-U.S. Could you just give us a sense for the percentage of revenue that is in countries where Biosimilars are launching in 2016, so that we have a sense for the percentage of Enbrel revenue that's exposed to Biosimilar threat?\",\n",
       " 'And then finally, Frank, if you could just run through the cash flow outlook for 2016, the operating cash flow, and then the planned use of funds. Thank you.',\n",
       " 'Ian Read',\n",
       " \"David, again on your question on Allergan, our interactions with the shareholders, both sell side and buy side have been very positive. I don't think in reality there's anything underappreciated, other than the Street's perception of risk around the close. I would direct you back of course to the excitement I have about the products that Allergan have that they just launched, about their phase III products, both in depression, and in diabetic gastroparesis. And they just got breakthrough status, so -- and the combination of our information knowledge and RTAs with Xeljanz around their area. Our jacks around their expertise net area. I think perhaps the Street is just -- is right now hung up on this close issue. So bio, John?\",\n",
       " 'John Young',\n",
       " \"Yes, David on the question regarding percentage of Enbrel business potentially exposed to Biosimilar competition, I don't have a figure on the top of my head. I would say more than 50% of the ex-U.S. business would be in the European Union, where we expect to see biosimilars. We won't -- we're not expecting to see it in Japan, Australia, and several of the Latin American countries. But I would say it's more than 50% of the business.\",\n",
       " '',\n",
       " \"Frank D'Amelio\",\n",
       " \"And then the last question was on '16 operating cash flow. The way I'll answer this David, is if you look at our operating cash flow through three quarters, it was about $10 billion. We expect the fourth quarter to be healthy in terms of the operating cash flow for the year. And then obviously 2016, we expect -- we want to obviously continue to grow that operating cash flow number. And then in terms of the uses, from my perspective, the uses of how we deploy our capital haven't changed, obviously investing in our business, returning capital to shareholders. I mentioned in my remarks we returned 13.1 billion to our shareholders in 2015 through a combination of dividends and share buybacks, and obviously looking at some bolt-on acquisitions if those make sense. So -- but no change. It would be how I'd answer the question on capital allocation.\",\n",
       " 'Chuck Triano',\n",
       " 'Thanks, Frank. Next question please.',\n",
       " 'Operator',\n",
       " 'Your next question comes from Gregg Gilbert from Deutsche Bank.',\n",
       " 'Gregg Gilbert',\n",
       " \"Thanks, also a three-parter. First Frank, what level of detail should we expect in the proxy in terms of your long-term projections, similar to the Pfizer Wyeth documents or any difference and any caveats you'd like to order to let us know about before folks start slapping accretion percentages on those numbers?\",\n",
       " \"Secondly, going back to something you said earlier. Taking your leverage to two-and-a-half to three times for Newco, and if you were to apply that capital to buybacks that would create EPS accretion that's far beyond what you've suggested. So just would like your thoughts on what you'd be doing with that leverage or is that just kind of a hypothetical.\",\n",
       " 'And third, for John, do you still see the benefit of the Hospira device business alongside the drug business as you originally thought? Thank you.',\n",
       " 'Ian Read',\n",
       " 'Okay, John, could you deal with Hospira first please?',\n",
       " 'John Young',\n",
       " 'Yes, sure. I think we would say that in the Hospira infusion systems business, which comprises pumps, consumables, large volume solutions. We believe we acquired a very valuable asset. It provides novel capabilities in an adjacent area. And that adds significant value to customers, and their patients. And we are committed to ensuring its success in the short, medium, and longer term.',\n",
       " 'Ian Read',\n",
       " 'Okay, Frank, on the leverage and then the loan level of detail.',\n",
       " \"Frank D'Amelio\",\n",
       " 'Level of detail, and the proxy.',\n",
       " 'Ian Read',\n",
       " 'Yes.',\n",
       " \"Frank D'Amelio\",\n",
       " \"So I think on level of detail, we'll be providing revenue details, EPS details. It would be directed out, I believe, it's several years, five years. So there'll be information out there relative to projections on the company; on the leverage number, the 2.5 to 3, in my mind that's what's possible. In terms of what we did on buybacks, we tried to provide information when we announced the deal to give you all the data you needed. So that when you connected the dots you could model what at buyback numbers would be, right.\",\n",
       " \"So we started out with the accretion dilution. We said neutral in year one, modestly accretive in year one, more than 10% in year three, and then high teens in year four. We gave what the beginning share count number of the combined company would be. It was 10.6 billion shares. We said we'd have 5.5 billion, and Allergan would have 4.7 billion. And then we gave the tax rate, which was 17% to 18%. So with those data points, we felt we provided the information that you needed in order to model what the buybacks would be. And then just to the two-and-a-half to three, now clearly there could be some extra juice if we took the leverage ratio up to that level.\",\n",
       " 'Chuck Triano',\n",
       " 'Thanks, Frank. Next question please.',\n",
       " 'Operator',\n",
       " 'Your next question comes from Chris Schott from JPMorgan.',\n",
       " 'Chris Schott',\n",
       " \"Great, thanks, just two quick ones here. First, just more broadly on emerging markets, can you talk about the growth outlook here maybe beyond China, just given the current economic environment we're seeing? Has there been any change in your growth expectations there?\",\n",
       " '',\n",
       " \"And then the second question for Ian. I know you've obviously had a very large deal pending right now. But how are you thinking of business development given the recent volatility and kind of valuation reset we see in the market. I guess what's the size and scope of assets that you could be interested at this point, given the upcoming Allergan transaction. And maybe how quickly post the Allergan transaction could this company start considering larger deals if there was an attractive opportunity in the market.\",\n",
       " 'Ian Read',\n",
       " 'Thank you. John, you want to talk about China?',\n",
       " 'John Young',\n",
       " \"Yes, sure. So I mean, I think as we always say, Chris, on the emerging markets. We're always going to see courses and course of volatility. But at the same time we continue to expect to see growth numbers in the mid-single digit mid to high single-digit range. Frank's already talked about China. We continue to be very positive about the prospects in the short, medium, and longer term in China. It's obviously not just the world's largest country, with 1.3, 1.4 billion population, but we continue to see a strong government commitment to expanding access to to quality healthcare. We are very encouraged by steps that we see the government taking in the regulatory environment to really enhance quality standards in the marketplace.\",\n",
       " 'And whilst there are few headwinds, GDP growth is slowly but still positive, still mid single-digit percentage. We are seeing some pressure on pricing. But overall when you put all of those factors together, we can continue to see China being a very positive growth driver.',\n",
       " 'Ian Read',\n",
       " \"Thank you, John. On BD, Chris, we see we would be more focused to smaller deals than larger deals right now. But once we close, we'll look at the opportunities. And we know we still have substantial flexibility and of course it will be measured against the alternative usage of that cash which right now are scheduled for buybacks and the accretion equation. So we'll make the decisions that we believe are best for shareholders and we will take it into account the -- what the asset priced at the time when we close.\",\n",
       " \"Frank D'Amelio\",\n",
       " 'And Chris, the only thing I would add is we, Pfizer-standalone today generate a lot of operating cash flow. The combine new company we said by 2018 would be generating in excess of $25 billion a year in operating cash flow. So, new company will generate significant amounts of operating cash flow. Thank you.',\n",
       " 'Chris Schott',\n",
       " 'All right.',\n",
       " 'Chuck Triano',\n",
       " 'And can we take our last question please, operator?',\n",
       " 'Operator',\n",
       " 'Your final question comes from Manoj Garg from HealthCo.',\n",
       " 'Manoj Garg',\n",
       " \"Hi, it's Manoj. Thanks for taking the question. A couple on the pending Allergan transaction and one on next Tuesday, on Allergan, one, I guess if maybe just if you can highlight, what are some of the levers that would dictate whether the deal would close in early second half of '16 versus later in the second half?\",\n",
       " \"Two is, for Frank, on the $2 billion synergy number if you can just quantify as we fine-tune our pro forma model, if that's a gross number or an net number?\",\n",
       " 'Ian Read',\n",
       " 'Okay. On the lever, Doug Lankler, would you indicate what you see the levers are for the close?',\n",
       " 'Doug Lankler',\n",
       " \"Sure. So, Manoj, we're working closely with regulators. We are pleased with the profits that we are making. We like the standpoint from the complementary nature of the businesses. And as a result, we continue to expect to close the transaction during the second half.\",\n",
       " 'Manoj Garg',\n",
       " 'Thank you.',\n",
       " 'Doug Lankler',\n",
       " \"It's a net number.\",\n",
       " 'Manoj Garg',\n",
       " 'Synergy number is a net number?',\n",
       " 'Doug Lankler',\n",
       " \"Right. Yes, you asked whether it was gross or net. And the answer is it's a net number.\",\n",
       " 'Manoj Garg',\n",
       " 'Okay.',\n",
       " 'Ian Read',\n",
       " 'That should do it.',\n",
       " 'Chuck Triano',\n",
       " 'That should do it. Thank you very much for your questions.',\n",
       " 'Ian Read',\n",
       " '',\n",
       " 'Thanks for your time everybody.',\n",
       " 'Operator',\n",
       " \"Ladies and gentlemen, this does conclude today's fourth quarter 2015 earnings conference call. Thank you for participating. You may now disconnect.\"]"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sentences[0].split('\\n')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [],
   "source": [
    "x=[]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [],
   "source": [
    "for j in range(len(sentences)):\n",
    "    x.append(''.join([i  for i in sentences[j].split('\\n') if len(i)>85]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [],
   "source": [
    "df=pd.DataFrame(columns=['Documents'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [],
   "source": [
    "df['Documents']=x"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 133,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"Good day everyone, and welcome to Pfizer's Fourth Quarter 2015 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Mr. Chuck Triano, Senior Vice President of Investor Relations. Please go ahead, sir.Good morning, and thanks for joining us today to review Pfizer's fourth quarter and full year 2015 performance, as well as 2016 financial guidance.I am joined here today as usual by our Chairman and CEO, Ian Read; Frank D'Amelio, our CFO; Mikael Dolsten, President of Worldwide Research and Development; Albert Bourla, President of Vaccines, Oncology and Consumer; Geno Germano, President of Global Innovative Pharma; John Young, President of Established Pharma; and Doug Lankler, General Counsel.The slides that will be presented on this call can be viewed on our homepage, pfizer.com by clicking on the link for Pfizer Quarterly Corporate Performance Fourth Quarter 2015, which is located in the For Investors Section in the lower right hand corner of the page.Before we start, I'd like to remind you that our discussion during the call will include forward-looking statements and that actual results could differ materially from those projected in the statements. Factor that could cause actual results to differ are discussed in Pfizer's 2014 Annual Report on Form 10-K, as well as on our reports in Forms 10-Q and 8-K.Discussions during the call will also include certain financial measures that were not prepared in accordance with Generally Accepted Accounting Principles. Reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in Pfizer's current report on Form 8-K dated today.Also, today's call is not intended to, and does not constitute an offer to sell or the solicitation of an offer to subscribe for, or buy securities of Pfizer or Allergan.We will now make prepared remarks and then we will move to a question-and-answer session. With that, I'll now turn the call over to Ian Read. Ian?Thank you Chuck, and good morning everyone. We finished 2015 with strong financial and operational performance. For the full year, we exceeded our 2015 revenue guidance and met the top-end of our adjusted diluted EPS guidance. Excuse me; and we achieved our first year of operational revenue growth in five years.Frank will take you through the numbers. Before he does, I have a few brief comments about what is driving our performance, some thoughts regarding where we expect to see pipeline advancements during the year, and I will close with a few comments about Allergan.Throughout the year and especially in the fourth quarter, our business executed flawlessly despite a challenging operational environment. We ended 2015 with solid momentum in both developed and emerging markets.Specifically in developed markets, during the year we gained incremental market penetration driven by continued success of products that are early in their life cycles, including Prevnar 13 adults, Ibrance, Eliquis, Xeljanz, and we still saw steady growth from key inline products in 2015, specifically Lyrica in markets where it remains patent protected.And during the year in emerging markets we saw operational revenue growth primarily due to the performance of Prevnar, Lipitor, and Enbrel, as well as from the addition of legacy Hospira products. The integration of the Hospira business into Pfizer Global Established pharma businesses is on track, and we look forward to this business being an attractive potential growth driver. This acquisition is indeed proving to be an excellent strategic fit, and we are seeing the expected value contribution to our GAAP business that we anticipated.Frank will speak to our 2016 guidance in a moment. We expect to deliver operational revenue growth in 2016. Our key growth drivers will continue to be Ibrance, Eliquis, and Xeljanz. And we believe that Prevnar adult global revenues will be comparable to the strong results we achieved in 2015. Additionally, we believe our near-term pipeline will help accelerate this ongoing growth forward.In looking at the year ahead, we expect our businesses will continue to execute well. They are competitively positioned to win their markets and are performing strongly against their competitors' set.Regarding the pipeline, we anticipate advancing many of our Phase III programs during the year. For Bococizumab, we reported today that the first of our six Phase III efficacy studies achieved its primary endpoint, and we expect readouts of the remaining five Bococizumab lipid-lowering studies [technical difficulty] during 2016.For [indiscernible], this year, we and our partners Merck will begin to deliver results from our comprehensive Phase III clinical program. In 2016, the alliance expects to submit applications to regulatory approval in the U.S. for both monotherapy and two fixed dose combination tablets using data from eight clinical trials.For Dacomitinib, we expect results in the second half of the year for a Phase III study in first-line EGFR mutant non-small-cell lung cancer, and we'll discuss our regulatory strategy with the FDA. So Xeljanz in the first half of this year we expect top line results for our Phase III program in psoriatic arthritis. We believe Xeljanz can potentially fill a significant unmet need in the psoriatic arthritis when non-biologic DMARDS do not have proven success, and where there are currently few alternatives for patients who have inadequate responses to anti-TNF therapy.In addition, in the first half of the year we anticipate the decisions from the FDA for a once-a-day daily Xeljanz formulation for rheumatoid arthritis, and we remain on track to re-file our application for RA in the EU.For Ibrance, we expect to see the top line PALOMA-2 study results in first-line advanced breast cancer in combination with letrozole, and we have an April PDUFA date for second and third-line treatment for advanced breast cancer based on the PALOMA-3 data. We could also see a regulatory decision for Ibrance in the E.U. by year end.Additionally, in the oncology business, we have a PDUFA date this year in the U.S. with Xalkori in ROS 1 non-small-cell lung cancer, and we expect to file for approval of Inotuzumab for acute lymphoblastic leukemia in the U.S. And in immuno-oncology we now have a broad portfolio of compounds that we believe has the potential to support the development of a strong, deep competitive market position. We now have five immuno-oncology assets in the clinic, and expect to have up to 10 in the clinic by the end of 2016. As a result of our partnership with Merck KGaA, as of the end of 2015, we had 28 ongoing clinical development programs for Avelumab, with seven of them being pivotal registrational studies.We anticipate some of these studies will give us potential registrations in areas like Merkel cell, ovarian, bladder, gastric, and lung cancer. Of these seven studies, we expect to present data in Merkel cell this year, and to see data from the other tumor types in the following two years. And we continue to believe that the winners in this space will be those that have a breadth of portfolio assets to support rational combinations. We have a range of assets to combine with Avelumab when compared to other companies' assets, and we have already initiated six combination studies with Avelumab.In 2016, we expect to see data from 4-1BB in combination with Keytruda and in combination with Avelumab in various tumors, 4-1BB in combination with Rituximab in lymphoma, a combination of Lorlatinib, our next generation ALK inhibitor with Avelumab and ALK-positive non-small-cell lung cancer, and data from [indiscernible] with Avelumab in renal cell carcinoma. Finally, we may see data from OX40 as a single agent this year. Taking of all of this into account, we believe we are well on our way to being a leading player in this space.And now a few comments about our proposed combination with Allergan. We're excited about bringing two great companies together that have a strong strategic fit. The transaction is about acceleration growth potential in our innovative businesses and strengthening our established business, and more efficiently allocating our capital around the world. We are confident that we are taking appropriate steps so that we can achieve the key milestones needed to complete the transaction and continue to expect close in the second half of 2016.Since the announcement, we have been working closely with Brent Saunders and his team at Allergan, and have been delighted by the engagement and rapport that is occurring. We see a number of potential opportunities after closing as we continue to learn more about each other's portfolio. For example, we see complementarity in information in gastroenterology, and we have a -- when we will have a broader presence in cardiovascular disease with Eliquis and Bystolic.In neuroscience, Allergan's work in Alzheimer's, schizophrenia, and major depressive orders will be highly complementary to Pfizer's promising early work in such areas as Parkinson's, Alzheimer's, and Duchenne muscular dystrophy.When you look at over the next few years we expect both companies will continue -- contribute, sorry, several potential new drugs to launch. We'll also continue to be excited about the international potential. And by coming together, we are enhancing category leadership throughout our complementary inline portfolio, and a combined pipeline with great late-stage and mid-stage assets across each of our key therapeutic areas. Both companies bring a great deal of scientific and product expertise to the provost combination and a shared philosophy in our approach to research and development.Upon the close of the transaction, the combined company will be an influential player in the industry with a competitive product portfolio with several leadership positions, robust pipeline, compelling capital structure, and financial position, and aligned cultures that are based on ownership and entrepreneurial spirit creating shareholder value and meeting patients' needs. This combination is about investing in our business. It's about accelerating our existing strategy, while preserving our options as putting the company into an innovative business and an established business. If we determine that is the best way to unlock the most value for our shareholders.By the end of the current quarter our integration teams will be fully engaged, and we anticipate announcing post-closing leadership positions. Throughout the year we will continue to keep you updated on our progress. In summary, we're looking at a year ahead we have a sound strategy, and a strong business. Our outlook and financial guidance for the year takes into the account the benefit of anticipated positive organic growth from key products, as well as the impact from foreign exchange. We have a solid portfolio of market-leading inline products, a healthy pipeline. We expect to further strengthen the growth potential of the business with the pending addition of Allergan. We will continue to have the means by which we can create value for our shareholders and bring innovative medicines to patients by producing expected top line growth, progressing key pipeline assets, pursuing strategic business development, and returning capital to shareholders through dividends and buybacks.Now I'll turn it over to Frank for additional details on the quarter and our 2016 financial guidance.Thanks, Ian. Good day everyone. As always, the charts that we're viewing today are included in our webcast. As a reminder, because we completed the acquisition of Hospira on September 3, 2015, Pfizer's full year financial results for the year ended December 31, 2015 include four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations.Financial results for the fourth quarter 2015 include three months of legacy Hospira Global operations. By comparison, financial results for full year and fourth quarter 2014 do not include any contribution from legacy Hospira operations.Now, moving on to the financials; fourth quarter 2015 reported revenues were approximately $14 billion, and reflect year-over-year operational growth of 1.9 billion or 14%, mainly driven by the addition of legacy Hospira operations. The continued strong performance of products that are early in their lifecycles such as Prevnar 13 adult, Ibrance, Eliquis, and Xeljanz, Lyrica primarily in the U.S. and 5% operational growth in emerging markets, mainly from legacy Hospira operations, Prevnar 13, and certain other products.Reported revenues continued to be unfavorably impacted by foreign exchange of 934 million or 7%. Excluding the inclusion of legacy Hospira operations of 1.2 billion, the negative impact of foreign exchange and to a much lesser extent the inclusion of 35 million of revenues associated with vaccines acquired from Baxter, Pfizer-standalone achieved operational growth of 646 million or 5% while at the same time absorbing a 720 million negative operational impact from product losses of exclusivity.Fourth quarter adjusted diluted EPS was $0.53 versus $0.54 in the year ago quarter. The decrease is primarily due to an aggregate operational increase and adjusted cost of sales, adjusted SI&A expenses, and adjusted R&D expenses or 1.8 billion or 21%, $0.07 due to foreign exchange and the continued product losses of exclusivity in certain geographies. These were partially offset by revenue growth of certain new, in-line, and acquired products, lower effective tax rate, and few diluted weighted average shares outstanding which declined by 125 million shares versus the year ago quarter due to our share repurchase program which includes the impact of $5 billion accelerated share repurchase agreement executed in February 2015 and completed in July.Reported diluted EPS was $0.10 compared with $0.19 in the year ago quarter due to the previously mentioned factors and the unfavorable impact of foreign currency losses related to Venezuela, increased purchase accounting adjustments, acquisition related cost, restructuring charges, and asset impairment charges versus the prior year quarter, and non-recurring charges related to pension settlements, which were partially offset by the non-recurrence of a charge associated with the global strategic alliance formed with Merck KGaA in November 2014 to jointly develop and commercialize Avelumab, lower charges for certain legal matters, and a lower effective tax rate.Foreign exchange negatively impacted fourth quarter reported revenues by approximately $934 million or 7% and positively impacted adjusted cost of sales, adjusted SI&A expenses and adjusted R&D expenses in the aggregate by $435 million or 5%. As a result, foreign exchange negatively impacted fourth quarter adjusted diluted EPS by approximately $0.07 compared with the year ago quarter.Now, moving on to the financial highlights of our business segments; in the fourth quarter, Global Innovative Pharmaceutical revenues increased 10% operational year-over-year due to the strong performance of recently launched products including Eliquis globally and Xeljanz in the U.S. and the strong performance of Lyrica in the U.S. and Japan.Income before taxes increased 17% operationally due to the increase of revenues and a 5% operational decrease in cost of sales. Cost of sales as a percentage of revenue decreased 1.7 percentage points operationally because of low royalty expenses and increased alliance revenues with no associated cost of sales.IBT was unfavorably impacted by a 4% operational increase and SI&A expenses as a result of additional investment in Eliquis, Xeljanz, and Chantix, and 11% operational increase in R&D reflecting investments in our late-stage pipeline primarily for Bococizumab and Tanezumab.Fourth quarter VOC revenues increased 38% operationally, reflecting operational revenue growth in each business. Global vaccine revenues grew 53% operationally driven by 102% increase of Prevnar 13 U.S. revenues to the strong uptake among adults.Global oncology revenues grew 61% operationally driven by Ibrance in the U.S. and to a lesser extent by Sutent and Xalkori globally. And consumer healthcare revenues grew 4% operationally due to Nexium 24HR in the U.S.Income before taxes increased 33% operationally, mainly due to increased revenues and associated improvement in gross margin, which were partially offset by a 66% operational increase and SI&A expenses as a result of higher promotional expenses in the U.S. for newly launched consumer healthcare products, Ibrance, and Prevnar 13 adult. And the 46% operational increase in R&D expenses due to increased cost associated with oncology oncology programs, primarily our alliance with Merck KGaA and Ibrance.Fourth quarter, Global Established Pharmaceutical revenues increased 5% operationally, mainly due to the previously mentioned inclusion of legacy Hospira revenues contributing $1.2 billion, which was partially offset by loss of exclusivity and generic competition for Celebrex in the U.S. and certain other developed markets, Lyrica in most developed markets in Europe and Zyvox in the U.S.Emerging market revenues were flat operationally, which reflected the positive impact of the inclusion of legacy Hospira operations and continued strong growth in China offset by declines in certain markets in the Middle East.Income before taxes declined 12% operationally reflecting the unfavorable impact of a 4.7 percentage point operational increase in cost of sales as a percentage of revenues due to the inclusion of Hospira operations and the impact of losses of exclusivity, a 24% operational increase in SI&A expenses driven in part by the addition of Hospira operations and the 53% operational increase in R&D expenses due to increased legacy Hospira development programs.We exceeded the top of our guidance range of expectations for 2015 reported revenues by approximately $400 million. Adjusted cost of sales as a percentage of revenues was 18.5% versus 18.7% at the low-end of our guidance range due to increased Alliance revenues and sales volumes, and we exceeded our expectation for our effective tax rate on adjusted income as a result of the favorable change in our jurisdictional mix of earnings.We met our expectations for adjusted R&D expenses and achieved the top-end of our adjusted diluted EPS. Adjusted SI&A expenses are $14.3 billion, or higher than our guidance range due to increased expenses for recently launched products such as Prevnar 13 adult and Ibrance, other inline products, and certain Consumer Healthcare brands.We recorded adjusted other income of $409 million versus our expectation of approximately $500 million. Finally, reported diluted EPS was a $1.24 versus our expected range of a $1.37 to a $1.43, mainly as a result of increased purchase accounting adjustments, acquisition-related costs and restructuring charges primarily related to the acquisition of Hospira, the negative impact of foreign currency losses related to Venezuela, and non-recurring charges related to pension settlements.Now I'd like to walk you through the 2016 guidance ranges for reported revenues, reported diluted EPS, and adjusted diluted EPS relative to our 2015 actual results. First, it's important to note that our 2016 financial guidance excludes the impact of our pending combination with Allergan.Our 2016 reported revenue guidance range reflects anticipated strong growth of certain new inline and acquired product that is partially offset by an anticipated $2.3 billion negative impact due to continuing product losses of exclusivity. I want to point out that that would be in this range and consistent with our previous comments we expect full year Prevnar 13 adult global revenues to be comparable with its full year 2015 global revenue level.We expect adverse changes in foreign exchange based on mid-January 2016 rates relative to the U.S. dollar compared with actual foreign exchange rates in 2015 to have an additional $2.3 billion negative impact on the reported revenues, including an estimated $800 million negative currency impact related to Venezuela. Consequently, we expect 2016 reported revenues to be in the range of $49 billion to $51 billion.Reported diluted EPS and adjusted diluted EPS guidance also include the negative impact from product losses of exclusivity, as well as an expected $0.09 negative impact from foreign exchange rates and the $0.07 negative currency impact related to Venezuela. As a result, we expect reported diluted EPS to be in the range of a $1.54 to a $1.67, and adjusted diluted EPS to be in the range $2.20 to $2.30.In addition, I want to remind everyone that guidance ranges for both reported and adjusted diluted EPS incorporate $5 billion of anticipated share repurchases in 2016, which consists of our previously announced intention to execute a $5 billion accelerated share repurchase program in the first half of 2016. These repurchases are expected to more than offset the potential dilution related to employee compensation programs.In summary, to exclude anticipated foreign exchange impacts, including the negative currency impact related to Venezuela, full year 2016 revenue and adjusted EPS guidance midpoints are 7% and 10% greater than actual full year 2015 levels respectively. The remaining elements of our 2016 financial guidance are set forth on this chart.Now moving on to key takeaways, we had a very strong financial performance in 2015 and we achieved operational revenue growth every quarter, including 14% operational growth in the fourth quarter. For the full year 2015, we achieved 6% operational revenue growth that was mainly driven by new products that are early in their lifecycles and we achieved this growth despite a 3.2 billion negative impact from product losses of exclusivity.Our full year 2016 reported revenue guidance range of 49 billion to 51 billion absorbs a 4.6 billion combined negative impact of product losses of exclusivity, adverse changes in foreign exchange rates, and the negative currency impact related to Venezuela. And the adjusted diluted EPS guidance range includes an anticipated $0.16 negative impact from foreign exchange, including Venezuela.We announced our proposed combination with Allergan, and continue to expect the transaction to close the second half of 2016. And we continue to create shareholder value through prudent capital allocation. In 2015, we returned $13.1 billion to our shareholders through dividends and share repurchases. And we expect to execute a $5 billion accelerated share repurchase program in the first half of 2016. Finally, we remain committed to delivering attractive shareholder returns in 2016, and beyond.[Operator Instructions] Your first question comes from Colin Bristow from Bank of America.Good morning, and congrats on the solid finish for the year. So a couple of product-specific questions if I may, on the Prevnar franchise, you've posted strong 4Q numbers. Could you just talk about your expectations for the trajectory going forward? On Ibrance there's been a lot of discussion around [indiscernible], and the potential there for a threat to Ibrance. What's your view here?And then just lastly on Biosimilars, can you update us on the status of your Biosimilar candidates, and when we should expect any data readouts? Thanks.Thank you, Colin. I'll ask Albert to manage the Prevnar and Ibrance, and then pass it over to John for Biosimilars.Thank you very much for the question, Colin. Let me provide some insight to help you understand the situation moving forward. In the U.S., obviously we have done an excellent job with the catch-up opportunity. We have achieved 86% markets there, 92% at retailers. We have 90% awareness of the recommendation at healthcare practitioner. And as a result, over the 45 million adults eligible at the time of recommendation for vaccination, we have already captured about a third [ph] of them.Now while many adults remain, this cohort is more difficult to capture, as the low-hanging fruit is gone. It will require more innovative strategies that we all have in place, but even if we assume a similar or higher penetration rate this year, it will be on a much smaller pool of adults. However, we expect this will be mitigated by Europe, which has a very different growth profile. Even with prices lower than U.S., the demographics are very favorable, with much larger eligible population, and who have already received pneumonia in our label in 2015, and we are working to obtain broad recommendations, and following that reimbursement from the authorities.Now this will be phased likely over a two-years window period, because in Europe this is done country-by-country, and sometimes region-by-region within the same country. But all in all, we expect very strong growth in Europe next year.Now let me move on Ibrance, and your question about competition or particularly [indiscernible] drug. Look, [indiscernible] drug, while in the same class, is for any [ph] indication. The refractory patient population, what we have received breakthrough designation, is a very small population with few options available. In fact the average refractory patient undergoes seven lines of treatment. So it's -- they are in high-mid.Now speaking generally on competition, there is only limited clinical data on the public domain, and we need to see more efficacy and safety data to make comparisons. What I can tell you is about our strategic position. We are the only company with a registered product in U.S., and six other countries, and an accepted filing in Europe, where we may obtain registration as early as next year. We have very good clinical experience with the product. Ibrance has been prescribed by 5,000 physicians in more than 20,000 patients. And so far feedback is very positive, particularly on patients' quality of life.We are having a very heavy clinical program. We have two pivotal studies in first-line metastatic breast cancer, two studies in recurrent metastatic breast cancer, and three in early breast cancer, PENELOPE-B, PALLAS, and PEARL [ph]. Ibrance is part of 88 investigational initiated trials, approximately 50 in breast cancer and 38 in other tumor types. So as you can see, we are investing heavily to stay ahead of the competition.Thank you, Albert. I think just on Ibrance, you mentioned next year for Europe, you meant this year, late this year we may be able to get registrationâ€¦Okay. So thanks for the question on Biosimilars, Colin. So I think we're obviously very excited to being able to bring together the combination of Hospira's current inline biosimiliars which are already in the market. So we have three assets, as you know, which are already in the market in Europe, Nivestim, Retacrit, and Inflectra. And to bring that together along with the legacy Pfizer monoclonal antibody pipeline, plus some additional assets that Hospira have. So in total, when you look at the pipeline, we have nine distinct biosimilar molecules in different stages of development. Infliximab, outside of the E.U., Adalimumab, Trastuzumab, Bevacizumab, Rituximab, Pegfilgrastim, Ranibizumab, Denosumab, and Ustekinumab.So overall we have a very strong pipeline. A number of those assets are in Phase III, late-phase development. And the first dataset there you'd be seeing from our Phase III studies would come from the legacy Pfizer Infliximab program where we would expect to produce data from our Phase III towards the end of this year.Jami? Okay, Jami. We may come back to Jami if she's -- if we can correct the technical issues. If not, let's go to Alex.Good morning and thank you for taking the questions. Frank, your gross margin for 2016 is better than we expected, considering you're integrating a lower margin business in Hospira and losing exclusivity on some high-margin products. Can you help us understand what's driving that, and how we should think about -- and should we expect traditional margin expansion going forward, given that your Innovative business is growing at a faster rate?And then on Hospira's contribution this quarter, it doesn't seem to reflect much revenue synergies. Obviously it's too early, but how should we think about Hospira's contribution next year and possible revenue synergies going forward? Thank you.So Alex, on the gross margin, let me run the numbers and then I'll answer the question. So we ended the full year at 18.5% in terms of cost of sale. So I'll do the cost of sale. The reciprocal obviously is gross margin. We got it for next year across the sales number of 21% to 22%. So if you take the midpoint of that 21 to 22, just to make the math easy, that's 21.5% from our 18.5%. That's a 3%, 300 basis point increase in our cost of sales as a percentage of revenues. By the way, that's being driven by a few factors, but one of which clearly is Hospira.In terms of -- I think your question, which was why wasn't even more, I think the answer is our ongoing productivity and cost reduction initiatives. When you think about our factories, our manufacturing capabilities, we really manage that from a cost perspective. First of all, we focus that on quality, service, and cost. If you think about that as a triangle, quality is at the top of the triangle. But there's four major buckets, right? There's the number of facilities, there's the numerous quality initiatives we have within each facility. There's the purchasing that we can get from a leverage perspective, and then finally, there's the center cost that resides outside of the factories. We manage all four of those very aggressively to basically -- to manage our cost structure in manufacturing, but that gives you a feel for what the numbers were, and why they are what they are.So thanks, Alex. So obviously, again, we are very excited by the opportunities afforded us by the combination of our two businesses. And I think I've talked about biosimilars already, and the opportunities we see in that marketplace. So let me just touch briefly on sterile injectables. Obviously it's a very -- it's a large, it's a growing market. It's somewhere between $50 billion to $70 billion currently globally, and one of the sort of features of that market is it's very concentrated, particularly in the U.S., but also in a few ex-U.S. markets, such as Western Europe, and particularly China.So, one of the things that we are very focused on is going to be revenue synergy. We obviously have a strong commercial presence in China, and also in the hospital segment in developed Europe and emerging Europe. So essentially the lag time since September when we closed this transaction we've been focused really on making sure that we have our blocking and tackling in place to be very systematic with our highest value molecules that really sort of meet market needs most appropriately. To be very focused on registering and brining those molecules to market.So in the biggest opportunity that we have in China, that is going to take time, as you are very well aware. Drug lag in China is a significant issue, but we're very encouraged by the progress that the CFDA are making to accelerate access to important new medicines in China. But that will take time. But we do see opportunities both in the short-term, as well as medium and long-term to deliver significant growth ex-U.S. through the sterile injectable business and the combination of Hospira's portfolio into our commercial footprint.Thank you. Sorry about that. Don't really know what happened on my end, but anyway, just a few questions. Frank, can you tell us what the Venezuela revenues are? I guess we are in consensus, we're surprised by the size of the hit; can you all hear me?Okay, sorry about that. Anyway, so Frank, if you could just provide more color on Venezuela? And why such a big hit?And then Ian, just a couple of questions for you, just back on this whole breakup thesis and the timing, I think investors initially were disappointed by the timing that you laid out at the time that you were announcing Allergan deal. I think you said you would make a decision by the end of 2018. I just want to put out there that the stock has pulled back quite a bit since you announced the Allergan deal, and I would think despite clearly the market is excited about this, but I would think that that would -- that the difference in -- even growing gap in valuation between where your stock is in an SOTP should help you to accelerate your decision to move in that direction, and if you could just comment on that please.And then just, thirdly, on revenue growth. I mean, clearly there have been tons of pushes and pulls in your numbers, mostly currency, and patent expirations. Can you remind us when you expect, and this excludes the acquisition from Allergan, but when you expect your reported revenue growth -- or just talk about operationally revenue growth, when we should start to see a positive inflection point, because it has, when I look at my models, revenues have been in decline for many years and some of that's divestitures, and spins, but really since 2013, we've had revenues sort of flat to down. When is that going to change, and what's going to drive that change, just talking from Pfizer's standpoint? Thanks very much.Let me just do the revenue growth first. Well, you know, as I said, '15 was the first year when we saw revenue growth; '16, we expect it to be around operationally narrow. We expect it to be Hospira and Allergan, we expect it to be flat and that's because we had a huge growth from adult vaccine in '15, and we'll hold that franchise. We won't grow it again. We'll have good growth from our inline products and our newly launched products, but we'll still deal with a couple of billion of LOEs. So I think you can begin to see, as we launch -- as we begin to get more traction with more clinical trial in Ibrance as we begin to see the launch, as we begin to see our next wave of products get approved, you'll see us returning to a very robust growth. But obviously, Jami, one of the reasons for doing the Allergan deal was in fact to ensure that we had robust growth in our innovative business. So we're aware of that issue.Now this is the breakup timing. Number one, I point out that while the stock is down, I don't think it's specifically down more than a DRG. In fact I think it's roughly the same as a DRG, and in fact, given the our pressure that one would expect in a stock, I'm actually -- well, never like to see the stock go down. It certainly was expected to come under pressure from the odd community.Now the breakup timing is an issue of -- we are focused on integrating this company and the two companies together, and we have laid out the full questions that we need to answer. And I think shareholder would want those questions answered. So, can we run the businesses successfully insider Pfizer? And we bought Hospira. You are seeing the sterile injectables. You have got the Biosimilars. You're beginning to see if you strip out the LOEs and stabilization of the core business, which we expect to return to growth, but that being said, we can run it well inside Pfizer. Can it be run better outside Pfizer? Is there trade value and can we unlock trade value in tax efficient manner? And these are the very serious questions. These are very large companies. And I think that by innovating we will be well positioned to make that decision in the best interest of our shareholders. And frankly, don't particularly see a way of short-circuiting that just because of the amount of work that has to be done and integration and getting the transaction of Allergan right. I do understand your wish for more speedy decision, but I think we are taking the right approach for shareholder value here.So, Jami, the Venezuela revenues for -- I'll call it initially projected for 2016 were about $800 million, roughly the same size as 2015. If you look at the adjustments, we took -- we changed the exchange rate from 6.3 Bolivar to a dollar to 200 Bolivar to dollar. We went to the SIMADI rate for Venezuela. That change in the translation is what causes the adjustment that we made for 2016, and we thought that the timing of that adjustment was appropriate, given oil prices, given what's going on in Venezuela economically, given the dollars that are coming out of Venezuela, we thought the timing for this was appropriate. But it's really the 6.3 to 200 to the dollar conversion that's really causing the adjustment to 2016.Now, Jami, ongoing, when Venezuela passes through this crisis and they re-establish a normal economy, we would expect Venezuela to grow back to be in the -- between 200 and 400 million a year. So the actual delta medium-term is for the 400 million between what was an overvalued currency.Hi. Three questions please, two of them of very short. Firstly, perhaps you could just outline sequential growth for China, say, [technical difficulty] last quarter? Second, do you anticipate extra notice from Treasury on conversion, and obviously [technical difficulty] how restricted do you see any measures to impact the Allergan transaction? And then finally, just returning to [indiscernible], the patients in the ongoing Phase 2 trial, which accelerates approval that have not seen Palbociclib in early line of therapy, is that an approval possessing given the design of that trial, given the fact you are approved for indication or does that include any regulatory approval for the drug? Thank you.Okay. I am going to do the notice first. We at the moment understand that the Treasury are working on formalizing and regulating the first two notices they issued, which are not in many ways applicable to our transaction as we're at the below 50% ownership.I really can't speculate if there is going to be a third notice or not. We feel confident the transaction is fully within the U.S. law and fully within accepted interpretation of that law and expect the transaction to close in the second half of next year.With that, I'll go to growth to Frank, and I would ask Mikael to talk about Palbociclib.On China, for the quarter, China grew 10%. Full year, China grew about 10%. Nice numbers. Somewhat moderated from 2014. In 2014, China grew to about 15%. So, we saw some moderation in the growth in China.That said, Andrew, we remain very bullish on China. Has an increasing population, increasing personal wealth, government is committed to healthcare. We see increased spending in the government and the GDP rate is still very healthy. Not as high as it has been the past, but still quite healthy. So, we remain very bullish on the China market on going forward basis.Yes. Thank you, Andrew, for a good question here. Two things; first, I want to just to point out that Abemaciclib is somewhat different from Palbo and Novartis drug in that it seems to be less selective and has a different resident profile likely due to hitting multiple CDKs particularly been reported significant GI issues. So it's a different profile, and we, as Albert very well pointed out, have been extremely pleased with the favorable profile that allow patients to benefit from Ibrance with very good reliability.Now you asked about this late stage population studies Abema [ph], and how that population in the future will evolve. We anticipate as Ibrance is having a very nice uptake in the marketplace in first line metastatic and some also more advanced lines, and hopefully with Prevnar 3 approval, Ibrance is likely to be used in multiple lines.Hence, monotherapy with another CDK will of course have the potential to face patient population that have seen CDK inhibitor, and that's why we are developing a strategy for how we can see patients benefit from drug like Ibrance at various stages with different anti-hormonals. And we are also now studying Ibrance in triple therapy. So I think you can see that multiple drugs is likely to be the preferred as patients become more advanced.Hi, good morning. Just again on Biosimilars front, I know there has been a couple of questions, but just a couple of more if I could. One is specifically on Enbrel, and if you can discuss in terms of 2016 how you are viewing the impact of Biosimiliars to your performance for that product?And then second, now that Hospira has closed, I am just wondering, I guess this is a question for John or whoever wants to jump in, in terms of the value having a Biosimilar business under the same broad umbrella as your innovative business so you can leverage that commercial infrastructure areas like oncology and autoimmune disorders. Is there any way sort of maybe make more sense than to keep Pfizer as a single entity as opposed to splitting up and then needing to rebuild the commercial infrastructure for your Biosimilars in those similar areas where you do have innovative products? Thanks.Sure. So, the first Biosimilar for Etanercept has been approved in Europe. And we've watching the situation very closely and evaluating adoption of Biosimilars across each of the countries throughout Europe for awhile now.Our overall expectation is that there will be somewhat modest impact in 2016. The Biosimilar landscape is clearly still developing. There are different approaches taken by different countries. And we have a very clear detailed roadmap for how to address each of the dynamics that exist in these different countries.So we are fairly confident that we are going to continue to have a strong Enbrel business throughout Europe. We think that the new patients would be probably most at risk of being exposed to the Biosimilars and hope that the availability of lower cost biologics will expand the market. So overall, we see this as again a modest impact to our business in the initial period of time.And Vamil, maybe a very interesting question on the connectivity between the Biosimilars and the other space. I would say that that would be taken into account if there was any such linkage that was positive in our TSAs, the setup the separate companies to ensure that that as overall we maximize value of that between both companies in the contracts we would sign if we decided to split. Thank you.Couple of questions. First, apologizes if I missed the explanation, but the 2016 guidance includes roughly an incremental 4 billion in revenue and $0.08 in earnings from Hospira implying down to significantly down underlying sales for the legacy Pfizer and flattish to down EPS, and it seems that generic exposure in currency cannot be the explanation because the predicted 4.6 billion hurdle in 2016 from these factors is well less than the 6 billion plus predicted in 2015 at this time last year.So actually the comparison on generic exposure in currency is improving and more than offsets the year-over-year increase in Prevnar. So, any thoughts on that would be appreciated.And one more, how should we think about the long-term outlook for Sutent particularly given the competition from immuno-oncology agent. You think Sutent will soon become a defining asset or do you see growth in the future? Thanks.I'll ask Albert to talk about Sutent and its possible combinations and the other studies we have already had on Sutent. And then, I'll ask Frank to come back on your questions about growth rates.We remain very confident in our position in the RCC space and that includes both, Sutent and Inlyta, because they are very well known by physicians and other stakeholders. The recent approval in RCC for immunotherapy but this does not affect Sutent. It is in the second line. Sutent is used primarily in first line. And s we have previously disclosed we are studying Inlyta, and Inlyta plus other PD-1 inhibitors pretty aggressively so that we can achieve better result in monotherapy in RCC second line.Yes. Let's see if I can answer the question. Just first, we don't give a specific number for Hospira revenues for 2016. But that said, I believe I could still answer the question. So, the way I think about this is if you enter the midpoint of the guidance prior to foreign exchange in Venezuela, which is part of the basis of your question, the midpoint for guidance would be 52.3 just to use midpoint. We take 50.3 compare that to the 48.9 that we printed in 2015 are all now at the same foreign exchange, so, clearly operational. That's an increase of about $3.5 billion. We said -- Ian said when he answered Jami's question that revenue excluding Hospira on a year-over-year basis was essentially flat operationally while absorbing 2.3 billion in LOEs for 2016.The other data point I think to help you answer the question is, remember, we did 1.5 billion in Hospira sales this year. So, when we say that the bulk of the growth is from Hospira, you understand it's incremental growth on top of the 1.5 billion that we printed in 2015. So that's how I think -- that's how you get to numbers we said and why we said operationally the numbers were essentially flat if you left Hospira out of the equation.Hey, guys. How are you doing? Thanks for being so clear on the communications in the quarter. I have one question that's been danced around but maybe let me just ask you it again and hope so I won't annoy you, but I'll try again.So first is do you believe that there is anything, Ian, under the current U.S. statute that would allow treasury to block and/or materially delay the closing of the AGN deal? So I am asking you if there will be third proposed notice. I am asking you under the current law, are you very -- do you remain I guess very comfortable there is nothing that treasury legally could do to block the deal or to materially delay it like in the 2017 when there will be a new a congress and a new president.And then I would also just for Frank perhaps just like you talked a little about your leverage ratio, if my math is right, the leverage ratio of the combined company the NewCo should closer to be around 1? By my math, you could take that to maybe 3 without affecting credit ratings in a big way, I would like to hear -- that's my math and I am not very good at math, so I would love to hear your general thoughts around leverage ratio of the NewCo where you might be willing to take that should the deal close. Thank you.Thank you, Mark. And thank you for the compliment on the clarity to communications. We strive to make them clear. So on your question which I don't think on the current law, I do not believe there is any reason why this deal will not close; full stop.Mark, let me run some numbers. So on leverage let me run the Pfizer numbers based on third quarter. We haven't issued a balance sheet yet for the fourth quarter. We will do that when we file the K. We had about 37 billion of cash in investments. We had about 39 billion of debt, short and long term debt. So to your point call that one to one essentially, and what we said when we announced the Allergan deal, what I said was we could take the leverage ratio at yield point up to about 2.5 to 3.And then, obviously, once took it there, we would want to see what kind of rhythm that created relative to the company, the operation supporting the company in that we take it there, but that we still want access to commercial paper. We would be willing take a one notch downgrade but we would still want to have access to commercial paper. But in terms of your math and your calculation 2.5 to 3, that's right. That's basically what I talked about when we announced the Allergan deal. So, your math was good.Yes, few things. One is can you tell us what the key products are in Venezuela, if there are any massive ones that we need to be hitting the model on? Second, Frank, maybe you can go through some of the push-pulls on SG&A and how you are thinking about the spending this year? And then, third, can you just give us an update on the IL-6? Thanks.So key products, I don't think there's any outstanding product, but the Enbrel is the biggest product that contributes. John, would you want to add anything to that?Yes, I think the Enbrel is the biggest product. I think in addition to that we have a portfolio of matured established product, Lipitor and Norvasc would be other key products for us in Venezuela. So really just think about the basket of established products and the fit in that marketplace.So, Marc, on SG&A, let me just talk to the quarter and then I'll talk to the rhythm of the numbers. So if you look at the quarter, we had a big spend in SG&A. It's 4.6 billion all in. Three major factors there, right, one, obviously the inclusion of Hospira, which added a couple of hundred million. Two, sequentially, if you think about the fourth quarter compared to the third quarter, we had a lot more selling days in the quarter. So, internationally, we had six more selling days. Domestically, we had two more selling days.So, sequentially, Q3 of '15 to Q4 of '15, we had more selling days. So obviously it helps revenue, but also increases the spend on our line items. And then, we had obviously I alluded to in my comments increased promotional spend in many areas of the business.Now, if you take that 4.6 and you annualize it, times 2 is what? 9.2 times 2 is 18.4. If you look at the guidance we gave for next year on SI&A, it's 13.2 to 14.2 billion. So you can't take that Q4 number and annualize it. You get to a number that's nothing close to what our guidance is for 2016, which is a combination of Hospira numbers, the selling days, and then the increased spend in the quarter. But we look at it for next year, we get a number that our annual basis is significantly lower than what that annualized number would be.Yes. Thank you for your question. So we tested IL-6 antibody in Lupus and [indiscernible], and while antibody did show some activity, we found that overall profile did not compete as well as many other real interesting immunology agents and other opportunities we have in our very rich pipeline of 90 clinical programs. So this is part of prudent portfolio prioritization within Pfizer.Thanks for taking the questions and for all the clarity that you've given on the '16 guidance. Ian, first question on the timing around the breakup, I think you've indicated that integration of Allergan is very important. You've also indicated that you had time to look even deeper into the Allergan portfolio.As you think about integration, can you give us some more commentary around how you are thinking about mapping out integration? Some look at Wyeth and look at the massive amount of synergies that you are able to extract out of Wyeth transaction and are somewhat puzzled as to why you can't do that here. So, any commentary around that?Two additional questions; one on CDK 4/6, this one is for Mikael. Mikael, when you look at preclinical models, is there any argument or hypothesis around a drug that has to be given intermittently that it might have less efficacy than one that's given on a continuous dosing? And is that supported by any preclinical models?And then, the last question just has to do with Xeljanz. Obviously, a very important asset for you not only in the U.S. but on the EU timing for filing, I think you indicated you wanted to have that filed before the end of the year. Just any update on what Europe is looking for within that filing to secure approval in Europe?And then, on psoriasis in the U.S., any developments there on the modified release from a regulatory standpoint and then obviously with Enbrel seeing generic competition what have you done with your infrastructure in Europe to still keep some infrastructure in place to support Xeljanz if and when it gets approved?Okay. So let me just -- quickly the last one first, we still have very strong expectations from Enbrel in Europe as Geno was discussing. We are not removing our support from Enbrel. So we expect to have full support for Xeljanz when it launches in Europe. There was a somewhat of a slippage from -- as you say, the end of the year to the beginning of this year on the Xeljanz application in Europe. We wanted to get it right and make sure that it was in the best shape we could, and these things happened. So there was a slight slippage on time on that. Mikael, do you want to deal with this hypothetical on CDK 4/6?Yes, thank you for the questions. Of course, always we would caution you can speculate on things that haven't been studied in humans in comparative aspects, but you know, we think it's important to hit CDK 4/6 hard for breast cancer, and when you do that with high doses you will get efficacy on the tumor, but also see some neutropenia and that's we why chose the intermittent schedules. Particularly it seems very effective for combination therapy with multiple agents such as [indiscernible] in breast cancer.For other tumor types, we may explore various schedules for various combination of drugs, but for breast cancer we think to show some schedule with the combinations we have studied is very effective and works well.Thank you. Geno, you want to deal with the other questions that John asked on Xeljanz?Yes. John, I think the question -- as Ian had already alluded to, we are now expecting our filing to be in the first quarter of this year. We're actually meeting with [indiscernible] at this point. We did generate additional data on immune function as a result of the discussions that we had with the regulators in the first submission. So we feel that we have a strong package that we have responded to the information requests that they had, and we're just tidying up the kind of last few details and expect to put that filing in imminently.So psoriasis -- well, as you probably know we have a -- we received a complete response letter from the FDA on psoriasis. We have provided a backgrounder to the FDA, and we expect to meet with them also this quarter to follow-up on the components of the complete response letter, and once we know in more detail what their issues and concerns are, then we'll determine best way forward from there.Yes. So we have certainly announced the deal more than $2 billion. We gave you the timing in terms of when we would get that. A couple of comments, John, to your question, I think first why more than $2 billion, why not a higher number? I think these are two companies that have done a lot on the cost reduction front; significant reductions at both companies, I think efficiently run companies. Two, not a lot of therapeutic area overlap, which is always seeing a kind of a trigger for synergy opportunities. Third, if you look at the Allergan cost of goods sold, two-thirds of that from my perspective, from a synergy perspective was unaddressable. It's their end of business and then royalties. So really not a lot we could do there, but all that said and done, we're working now with the Allergan teams with Brent, with Bob Steward, with Tessa. Ian and myself, our leadership team here at Pfizer, we've already launched a couple of operational teams, and we're starting to dig into this in much more detail. If there is more there, please know we're going to get it, and we'll tell you about it. So I think on a synergy front just more to come.Yes. And you know, John, the process from this deal was not huge cost synergies, it was about driving revenue growth in the innovative business, driving reasonably young portfolios, taking the products internationally, and then getting excellent capital allocation over the world. So we will get the synergies we can get, but our focus is on growth, and a lot of the questions on the call have been about growth. So this is part of the solution to that, and also really a good capital allocation.Thank you. If I could go back to the revenue guidance, the midpoint is about $2.5 billion below consensus, you flagged FX was a major headwind. I know that we spend a lot of time trying to incorporate FX, and I imagine consensus does too, yet that's still a very big delta. So my question on this is when you look at analyst models, are there particular revenue line items for products or divisions where you think consensus is too high unrelated to foreign exchange?Second question, you mentioned the 4-1BB with Merck, and I'm showing foundation data with Keytruda. That's Phase I data, so as such I'm blinded -- I'm wondering if you can give us a preview of the tumor types here you think are most promising and also any preliminary safety findings?And then last pipeline question, last year you mentioned having an oral PCSK9 approaching human development, and I'm wondering if that is now in the clinic when I look at your pipeline chart I see a new compound has been advanced on the Phase I?Okay. Frank, if you could deal with the first question, and Mikael will have remaining two.Sure. So Tim, let me run the numbers in, then I'll answer the questions. So your numbers are right. So consensus numbers give or take on revenue for 2016 about 52.4 billion the midpoint of all guidance $50 billion, the net there is roughly 2.5 billion that you alluded to, just to kind of nail the numbers.I think two major pieces in terms of the GAAP; one is, clearly the Venezuela adjustment we made in 2016 wouldn't have been at the 52.4. So that's an $800 million adjustment. That would take a 52.4 to 51.6, and then I think when you look at the line items, I think the big difference [technical difficulty] if you ask me to point out one single place, it's Prevnar 13. Significant results, and the growth expectations in Prevnar 13 -- '16 versus our modeling for '16 where I said in my comments, and Albert punctuated in some of his detailed remarks about we're expecting that to be essentially comparable to 2015 levels. Those are the two things that I would point out that will make up the majority big piece of the difference in terms of your 2.5 billion.So thank you for asking about 4-1BB, and as you know, we believe that the combination therapy moved immuno-oncology feel to the next level. We are very pleased with the 4-1BB, one of tumor antibody that we have. We have started eating combination with Rituximab in lymphoma and with PD-1 Keytruda in a small study across various tumor types, and have also initiated combination study with Avelumab.The 4-1BB antibody, the Pfizer antibody shows very good tolerability when combined with other biological agents, and it's clinical performance suggest also very interesting favorable clinical activity on top of other biologicals, such as Rituximab and PD-1 Keytruda. We will share the date from this first cohort this year likely at ASCO. We are quite excited about 4-1BB and also OX40 that's in our pipeline, and you will see 4-1BB Avelumab data likely late this year as well OX40 monodata, and early next year several doublets and triplets, which makes me very enthusiastic as I look forward how we advanced the strategy of combinations therapy.We have an oral PCSK9 in Phase I. It's too early to have any definitive interpretation of that data, and we also have a PCSK9 vaccine in late preclinical development.Oh, thanks. I have a couple of questions for Mikael, just on Ibrance, can you flag any upcoming data for tumor types outside of breast cancer that we should look out for? Also, can you update on how well the Adjuvant breast cancer studies are enrolling? Thanks.Yes. I could say a few words, so as Albert alluded to, there is a large number of Ibrance study, the great majority by investing in initiative research. So we will have to see as these studies result report emerging. I can say that we also have sponsor-led studies outside breasts, that includes pancreatic cancer, and head and neck, and we're also looking at triple therapy in breast cancer. I remain optimistic and excited about Ibrance performance, and think we will see interesting datasets coming from several of these new tumor types.Yes, actually I can only add here. But likely the Mantel cell lymphoma, and the neck we may see data even this year. And then many of the areas that Mikael discussed, including small-cell-lung, we may see next year.Good morning guys. And thanks for taking my question, just a couple of quick ones. On Bevacizumab, given Pfizer's experience in cardiovascular I was just curious what your thoughts on the demand trends were, looking peripherally at the PCSK9 class today. I know a lot looking forward depends on outcomes data, but just curious about whether there's a tipping point, and the position adoption.And then just on Biosimilars in the U.S., just wanted to get you guys to view on where you think the FDA is with respect to extrapolation when we're looking at the upcoming senior panel next week. Thanks.Yes, I mean I think I would just reinforce the comment that you made. I mean, it's been our contention all along that this class becomes a real class in managing these patients with the cardiovascular outcome data, that we'll be seeing either late this year or starting next year. Our program is advancing nicely. We have, as you know, two cardiovascular trials. And the SPIRE-2 trial, which is in the high-risk patient population, we've now reached the point where we've discontinued screening. We're almost completely enrolled. And that trial is moving along very rapidly. And the SPIRE-1 trial will be completely enrolled by the end of this year or early next year.So we're looking forward to these data, and the impact that we think they're going to have on the marketplace.So, on the Inflectra AdCom, as you know it's scheduled for February 9, next week. I think it would probably be premature to speculate on the view that the FDA will take. We certainly think that this will be extremely informative as to the FDA's views and perspectives on extrapolation. I think obviously their product is being filed by Xeljanz. So specific questions about the AdCom really should be directed to Xeljanz, but I would say is that while we obviously await the resolution of the advisory committee and certain other factors. We're certainly moving ahead with the preparation for launch plans in 2016.Yes, thanks very much. I have three questions. First, Ian, besides the likelihood of closing, what do think investors most under-appreciate about the Allergan merger? Second, I guess these are two financial questions. One is with respect to Enbrel ex-U.S. Could you just give us a sense for the percentage of revenue that is in countries where Biosimilars are launching in 2016, so that we have a sense for the percentage of Enbrel revenue that's exposed to Biosimilar threat?And then finally, Frank, if you could just run through the cash flow outlook for 2016, the operating cash flow, and then the planned use of funds. Thank you.David, again on your question on Allergan, our interactions with the shareholders, both sell side and buy side have been very positive. I don't think in reality there's anything underappreciated, other than the Street's perception of risk around the close. I would direct you back of course to the excitement I have about the products that Allergan have that they just launched, about their phase III products, both in depression, and in diabetic gastroparesis. And they just got breakthrough status, so -- and the combination of our information knowledge and RTAs with Xeljanz around their area. Our jacks around their expertise net area. I think perhaps the Street is just -- is right now hung up on this close issue. So bio, John?Yes, David on the question regarding percentage of Enbrel business potentially exposed to Biosimilar competition, I don't have a figure on the top of my head. I would say more than 50% of the ex-U.S. business would be in the European Union, where we expect to see biosimilars. We won't -- we're not expecting to see it in Japan, Australia, and several of the Latin American countries. But I would say it's more than 50% of the business.And then the last question was on '16 operating cash flow. The way I'll answer this David, is if you look at our operating cash flow through three quarters, it was about $10 billion. We expect the fourth quarter to be healthy in terms of the operating cash flow for the year. And then obviously 2016, we expect -- we want to obviously continue to grow that operating cash flow number. And then in terms of the uses, from my perspective, the uses of how we deploy our capital haven't changed, obviously investing in our business, returning capital to shareholders. I mentioned in my remarks we returned 13.1 billion to our shareholders in 2015 through a combination of dividends and share buybacks, and obviously looking at some bolt-on acquisitions if those make sense. So -- but no change. It would be how I'd answer the question on capital allocation.Thanks, also a three-parter. First Frank, what level of detail should we expect in the proxy in terms of your long-term projections, similar to the Pfizer Wyeth documents or any difference and any caveats you'd like to order to let us know about before folks start slapping accretion percentages on those numbers?Secondly, going back to something you said earlier. Taking your leverage to two-and-a-half to three times for Newco, and if you were to apply that capital to buybacks that would create EPS accretion that's far beyond what you've suggested. So just would like your thoughts on what you'd be doing with that leverage or is that just kind of a hypothetical.And third, for John, do you still see the benefit of the Hospira device business alongside the drug business as you originally thought? Thank you.Yes, sure. I think we would say that in the Hospira infusion systems business, which comprises pumps, consumables, large volume solutions. We believe we acquired a very valuable asset. It provides novel capabilities in an adjacent area. And that adds significant value to customers, and their patients. And we are committed to ensuring its success in the short, medium, and longer term.So I think on level of detail, we'll be providing revenue details, EPS details. It would be directed out, I believe, it's several years, five years. So there'll be information out there relative to projections on the company; on the leverage number, the 2.5 to 3, in my mind that's what's possible. In terms of what we did on buybacks, we tried to provide information when we announced the deal to give you all the data you needed. So that when you connected the dots you could model what at buyback numbers would be, right.So we started out with the accretion dilution. We said neutral in year one, modestly accretive in year one, more than 10% in year three, and then high teens in year four. We gave what the beginning share count number of the combined company would be. It was 10.6 billion shares. We said we'd have 5.5 billion, and Allergan would have 4.7 billion. And then we gave the tax rate, which was 17% to 18%. So with those data points, we felt we provided the information that you needed in order to model what the buybacks would be. And then just to the two-and-a-half to three, now clearly there could be some extra juice if we took the leverage ratio up to that level.Great, thanks, just two quick ones here. First, just more broadly on emerging markets, can you talk about the growth outlook here maybe beyond China, just given the current economic environment we're seeing? Has there been any change in your growth expectations there?And then the second question for Ian. I know you've obviously had a very large deal pending right now. But how are you thinking of business development given the recent volatility and kind of valuation reset we see in the market. I guess what's the size and scope of assets that you could be interested at this point, given the upcoming Allergan transaction. And maybe how quickly post the Allergan transaction could this company start considering larger deals if there was an attractive opportunity in the market.Yes, sure. So I mean, I think as we always say, Chris, on the emerging markets. We're always going to see courses and course of volatility. But at the same time we continue to expect to see growth numbers in the mid-single digit mid to high single-digit range. Frank's already talked about China. We continue to be very positive about the prospects in the short, medium, and longer term in China. It's obviously not just the world's largest country, with 1.3, 1.4 billion population, but we continue to see a strong government commitment to expanding access to to quality healthcare. We are very encouraged by steps that we see the government taking in the regulatory environment to really enhance quality standards in the marketplace.And whilst there are few headwinds, GDP growth is slowly but still positive, still mid single-digit percentage. We are seeing some pressure on pricing. But overall when you put all of those factors together, we can continue to see China being a very positive growth driver.Thank you, John. On BD, Chris, we see we would be more focused to smaller deals than larger deals right now. But once we close, we'll look at the opportunities. And we know we still have substantial flexibility and of course it will be measured against the alternative usage of that cash which right now are scheduled for buybacks and the accretion equation. So we'll make the decisions that we believe are best for shareholders and we will take it into account the -- what the asset priced at the time when we close.And Chris, the only thing I would add is we, Pfizer-standalone today generate a lot of operating cash flow. The combine new company we said by 2018 would be generating in excess of $25 billion a year in operating cash flow. So, new company will generate significant amounts of operating cash flow. Thank you.Hi, it's Manoj. Thanks for taking the question. A couple on the pending Allergan transaction and one on next Tuesday, on Allergan, one, I guess if maybe just if you can highlight, what are some of the levers that would dictate whether the deal would close in early second half of '16 versus later in the second half?Two is, for Frank, on the $2 billion synergy number if you can just quantify as we fine-tune our pro forma model, if that's a gross number or an net number?Okay. On the lever, Doug Lankler, would you indicate what you see the levers are for the close?Sure. So, Manoj, we're working closely with regulators. We are pleased with the profits that we are making. We like the standpoint from the complementary nature of the businesses. And as a result, we continue to expect to close the transaction during the second half.Right. Yes, you asked whether it was gross or net. And the answer is it's a net number.Ladies and gentlemen, this does conclude today's fourth quarter 2015 earnings conference call. Thank you for participating. You may now disconnect.\""
      ]
     },
     "execution_count": 133,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['Documents'].iloc[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 136,
   "metadata": {},
   "outputs": [],
   "source": [
    "import summarize"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 140,
   "metadata": {},
   "outputs": [],
   "source": [
    "ss=summarize.SimpleSummarizer()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "ss.summarize('Hi I am sandeeep',2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 148,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "We believe Xeljanz can potentially fill a significant unmet need in the psoriatic arthritis when non-biologic DMARDS do not have proven success, and where there are currently few alternatives for patients who have inadequate responses to anti-TNF therapy.In addition, in the first half of the year we anticipate the decisions from the FDA for a once-a-day daily Xeljanz formulation for rheumatoid arthritis, and we remain on track to re-file our application for RA in the EU.For Ibrance, we expect to see the top line PALOMA-2 study results in first-line advanced breast cancer in combination with letrozole, and we have an April PDUFA date for second and third-line treatment for advanced breast cancer based on the PALOMA-3 data.\n",
      "Of course, always we would caution you can speculate on things that haven't been studied in humans in comparative aspects, but you know, we think it's important to hit CDK 4/6 hard for breast cancer, and when you do that with high doses you will get efficacy on the tumor, but also see some neutropenia and that's we why chose the intermittent schedules.\n",
      "First Frank, what level of detail should we expect in the proxy in terms of your long-term projections, similar to the Pfizer Wyeth documents or any difference and any caveats you'd like to order to let us know about before folks start slapping accretion percentages on those numbers?Secondly, going back to something you said earlier.\n"
     ]
    }
   ],
   "source": [
    "from __future__ import absolute_import\n",
    "from __future__ import division, print_function, unicode_literals\n",
    "\n",
    "from sumy.parsers.html import HtmlParser\n",
    "from sumy.parsers.plaintext import PlaintextParser\n",
    "from sumy.nlp.tokenizers import Tokenizer\n",
    "from sumy.summarizers.lsa import LsaSummarizer as Summarizer\n",
    "from sumy.nlp.stemmers import Stemmer\n",
    "from sumy.utils import get_stop_words\n",
    "\n",
    "\n",
    "LANGUAGE = \"english\"\n",
    "SENTENCES_COUNT = 3\n",
    "\n",
    "\n",
    "if __name__ == \"__main__\":\n",
    "    url = \"https://en.wikipedia.org/wiki/Automatic_summarization\"\n",
    "    #parser = HtmlParser.from_url(url, Tokenizer(LANGUAGE))\n",
    "    # or for plain text files\n",
    "    # parser = PlaintextParser.from_file(\"document.txt\", Tokenizer(LANGUAGE))\n",
    "    parser = PlaintextParser.from_string(x[0], Tokenizer(LANGUAGE))\n",
    "    stemmer = Stemmer(LANGUAGE)\n",
    "\n",
    "    summarizer = Summarizer(stemmer)\n",
    "    summarizer.stop_words = get_stop_words(LANGUAGE)\n",
    "\n",
    "    for sentence in summarizer(parser.document, SENTENCES_COUNT):\n",
    "        print(sentence)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "for token in doc:\n",
    "    print(nlp.vocab.morphology.tag_map[token.tag_])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package averaged_perceptron_tagger to\n",
      "[nltk_data]     C:\\Users\\kasandeep\\AppData\\Roaming\\nltk_data...\n",
      "[nltk_data]   Unzipping taggers\\averaged_perceptron_tagger.zip.\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 102,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import nltk\n",
    "nltk.download('averaged_perceptron_tagger')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 109,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('would', 'MD')\n",
      "('will', 'MD')\n",
      "('can', 'MD')\n",
      "(\"'d\", 'MD')\n",
      "('will', 'MD')\n",
      "('could', 'MD')\n",
      "('could', 'MD')\n",
      "('will', 'MD')\n",
      "('can', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('can', 'MD')\n",
      "('could', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('may', 'MD')\n",
      "('can', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('can', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "(\"'d\", 'MD')\n",
      "('would', 'MD')\n",
      "('may', 'MD')\n",
      "('can', 'MD')\n",
      "('should', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('can', 'MD')\n",
      "('may', 'MD')\n",
      "('can', 'MD')\n",
      "('may', 'MD')\n",
      "(\"'d\", 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('may', 'MD')\n",
      "('can', 'MD')\n",
      "('Can', 'MD')\n",
      "('should', 'MD')\n",
      "('should', 'MD')\n",
      "('should', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('can', 'MD')\n",
      "('will', 'MD')\n",
      "('can', 'MD')\n",
      "('can', 'MD')\n",
      "('could', 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('should', 'MD')\n",
      "('could', 'MD')\n",
      "('Can', 'MD')\n",
      "('should', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('wo', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('can', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('can', 'MD')\n",
      "('can', 'MD')\n",
      "('can', 'MD')\n",
      "('will', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('would', 'MD')\n",
      "('could', 'MD')\n",
      "('ca', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('would', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('can', 'MD')\n",
      "('can', 'MD')\n",
      "('could', 'MD')\n",
      "('can', 'MD')\n",
      "('can', 'MD')\n",
      "('will', 'MD')\n",
      "('would', 'MD')\n",
      "('will', 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('can', 'MD')\n",
      "('would', 'MD')\n",
      "('should', 'MD')\n",
      "('will', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('can', 'MD')\n",
      "('can', 'MD')\n",
      "('could', 'MD')\n",
      "('would', 'MD')\n",
      "('wo', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('would', 'MD')\n",
      "('will', 'MD')\n",
      "('could', 'MD')\n",
      "('will', 'MD')\n",
      "('would', 'MD')\n",
      "('should', 'MD')\n",
      "('could', 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('might', 'MD')\n",
      "('should', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('could', 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('can', 'MD')\n",
      "('can', 'MD')\n",
      "('can', 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('ca', 'MD')\n",
      "('would', 'MD')\n",
      "('can', 'MD')\n",
      "('ca', 'MD')\n",
      "('might', 'MD')\n",
      "('could', 'MD')\n",
      "('would', 'MD')\n",
      "('can', 'MD')\n",
      "('will', 'MD')\n",
      "('may', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('would', 'MD')\n",
      "('could', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('will', 'MD')\n",
      "('can', 'MD')\n",
      "('could', 'MD')\n",
      "('can', 'MD')\n",
      "('could', 'MD')\n",
      "('will', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('can', 'MD')\n",
      "('should', 'MD')\n",
      "('can', 'MD')\n",
      "('could', 'MD')\n",
      "('will', 'MD')\n",
      "('can', 'MD')\n",
      "('will', 'MD')\n",
      "('can', 'MD')\n",
      "('may', 'MD')\n",
      "('may', 'MD')\n",
      "('would', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('will', 'MD')\n",
      "('would', 'MD')\n",
      "('will', 'MD')\n",
      "('will', 'MD')\n",
      "('should', 'MD')\n",
      "('would', 'MD')\n",
      "('could', 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('wo', 'MD')\n",
      "('would', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('would', 'MD')\n",
      "(\"'d\", 'MD')\n",
      "('should', 'MD')\n",
      "(\"'d\", 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "(\"'d\", 'MD')\n",
      "('would', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('would', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('could', 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "(\"'d\", 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('could', 'MD')\n",
      "('can', 'MD')\n",
      "('could', 'MD')\n",
      "('could', 'MD')\n",
      "('can', 'MD')\n",
      "('would', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('will', 'MD')\n",
      "(\"'ll\", 'MD')\n",
      "('will', 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('will', 'MD')\n",
      "('can', 'MD')\n",
      "('would', 'MD')\n",
      "('would', 'MD')\n",
      "('can', 'MD')\n",
      "('would', 'MD')\n",
      "('may', 'MD')\n"
     ]
    }
   ],
   "source": [
    "text=nltk.word_tokenize(x[0])\n",
    "for i in nltk.pos_tag(text):\n",
    "    if i[1]=='MD':\n",
    "        print(i)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "metadata": {},
   "outputs": [],
   "source": [
    "import spacy\n",
    "from gensim.summarization.summarizer import summarize \n",
    "from gensim.summarization import keywords \n",
    "nlp =spacy.load('en_core_web_sm')\n",
    "doc = nlp(x[0]) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 120,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Word count summary\n",
      "Please go ahead, sir.Good morning, and thanks for joining us today to review Pfizer's fourth quarter and full year 2015 performance, as well as 2016 financial guidance.I am joined here today as usual by our Chairman and CEO, Ian Read; Frank D'Amelio, our CFO; Mikael Dolsten, President of Worldwide Research and Development; Albert Bourla, President of Vaccines, Oncology and Consumer; Geno Germano, President of Global Innovative Pharma; John Young, President of Established Pharma; and Doug Lankler, General Counsel.The slides that will be presented on this call can be viewed on our homepage, pfizer.com by clicking on the link for Pfizer Quarterly Corporate Performance Fourth Quarter 2015, which is located in the For Investors Section in the lower right hand corner of the page.Before we start, I'd like to remind you that our discussion during the call will include forward-looking statements and that actual results could differ materially from those projected in the statements.\n",
      "We will continue to have the means by which we can create value for our shareholders and bring innovative medicines to patients by producing expected top line growth, progressing key pipeline assets, pursuing strategic business development, and returning capital to shareholders through dividends and buybacks.Now I'll turn it over to Frank for additional details on the quarter and our 2016 financial guidance.Thanks, Ian. Good day everyone.\n"
     ]
    }
   ],
   "source": [
    "summ_words = summarize(x[0], word_count = 200) \n",
    "print(\"Word count summary\") \n",
    "print(summ_words) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [],
   "source": [
    "df=pd.read_csv('Future_text.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [],
   "source": [
    "x=df['Documents']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "from summarizer import Summarizer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "model = Summarizer()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Good day everyone, and welcome to Pfizer's Fourth Quarter 2015 Earnings Conference Call. At this time, I would like to turn the call over to Mr. Chuck Triano, Senior Vice President of Investor Relations. We will now make prepared remarks and then we will move to a question-and-answer session. We finished 2015 with strong financial and operational performance. And we believe that Prevnar adult global revenues will be comparable to the strong results we achieved in 2015. They are competitively positioned to win their markets and are performing strongly against their competitors' set. We believe Xeljanz can potentially fill a significant unmet need in the psoriatic arthritis when non-biologic DMARDS do not have proven success, and where there are currently few alternatives for patients who have inadequate responses to anti-TNF therapy. In addition, in the first half of the year we anticipate the decisions from the FDA for a once-a-day daily Xeljanz formulation for rheumatoid arthritis, and we remain on track to re-file our application for RA in the EU.For Ibrance, we expect to see the top line PALOMA-2 study results in first-line advanced breast cancer in combination with letrozole, and we have an April PDUFA date for second and third-line treatment for advanced breast cancer based on the PALOMA-3 data. We anticipate some of these studies will give us potential registrations in areas like Merkel cell, ovarian, bladder, gastric, and lung cancer. And now a few comments about our proposed combination with Allergan. we're excited about bringing two great companies together that have a strong strategic fit. We see a number of potential opportunities after closing as we continue to learn more about each other's portfolio. we'll also continue to be excited about the international potential. Upon the close of the transaction, the combined company will be an influential player in the industry with a competitive product portfolio with several leadership positions, robust pipeline, compelling capital structure, and financial position, and aligned cultures that are based on ownership and entrepreneurial spirit creating shareholder value and meeting patients' needs. By the end of the current quarter our integration teams will be fully engaged, and we anticipate announcing post-closing leadership positions. We have a solid portfolio of market-leading inline products, a healthy pipeline. Now I'll turn it over to Frank for additional details on the quarter and our 2016 financial guidance. By comparison, financial results for full year and fourth quarter 2014 do not include any contribution from legacy Hospira operations. Reported revenues continued to be unfavorably impacted by foreign exchange of 934 million or 7%. These were partially offset by revenue growth of certain new, in-line, and acquired products, lower effective tax rate, and few diluted weighted average shares outstanding which declined by 125 million shares versus the year ago quarter due to our share repurchase program which includes the impact of $5 billion accelerated share repurchase agreement executed in February 2015 and completed in July. Adjusted cost of sales as a percentage of revenues was 18.5% versus 18.7% at the low-end of our guidance range due to increased Alliance revenues and sales volumes, and we exceeded our expectation for our effective tax rate on adjusted income as a result of the favorable change in our jurisdictional mix of earnings. Reported diluted EPS and adjusted diluted EPS guidance also include the negative impact from product losses of exclusivity, as well as an expected $0.09 negative impact from foreign exchange rates and the $0.07 negative currency impact related to Venezuela. These repurchases are expected to more than offset the potential dilution related to employee compensation programs. Now moving on to key takeaways, we had a very strong financial performance in 2015 and we achieved operational revenue growth every quarter, including 14% operational growth in the fourth quarter. And we continue to create shareholder value through prudent capital allocation. Let me provide some insight to help you understand the situation moving forward. And as a result, over the 45 million adults eligible at the time of recommendation for vaccination, we have already captured about a third [ph] of them. But all in all, we expect very strong growth in Europe next year. Now let me move on Ibrance, and your question about competition or particularly [indiscernible] drug. Ibrance has been prescribed by 5,000 physicians in more than 20,000 patients. I think just on Ibrance, you mentioned next year for Europe, you meant this year, late this year we may be able to get registrationâ€¦Okay. We may come back to Jami if she's -- if we can correct the technical issues. So Alex, on the gross margin, let me run the numbers and then I'll answer the question. If you think about that as a triangle, quality is at the top of the triangle. So obviously, again, we are very excited by the opportunities afforded us by the combination of our two businesses. Obviously it's a very -- it's a large, it's a growing market. To be very focused on registering and brining those molecules to market. Don't really know what happened on my end, but anyway, just a few questions. Anyway, so Frank, if you could just provide more color on Venezuela? And why such a big hit?And then Ian, just a couple of questions for you, just back on this whole breakup thesis and the timing, I think investors initially were disappointed by the timing that you laid out at the time that you were announcing Allergan deal. Number one, I point out that while the stock is down, I don't think it's specifically down more than a DRG. Now the breakup timing is an issue of -- we are focused on integrating this company and the two companies together, and we have laid out the full questions that we need to answer. Is there trade value and can we unlock trade value in tax efficient manner? And I think that by innovating we will be well positioned to make that decision in the best interest of our shareholders. And then finally, just returning to [indiscernible], the patients in the ongoing Phase 2 trial, which accelerates approval that have not seen Palbociclib in early line of therapy, is that an approval possessing given the design of that trial, given the fact you are approved for indication or does that include any regulatory approval for the drug? Has an increasing population, increasing personal wealth, government is committed to healthcare. We see increased spending in the government and the GDP rate is still very healthy. Not as high as it has been the past, but still quite healthy. Two things; first, I want to just to point out that Abemaciclib is somewhat different from Palbo and Novartis drug in that it seems to be less selective and has a different resident profile likely due to hitting multiple CDKs particularly been reported significant GI issues. Just again on Biosimilars front, I know there has been a couple of questions, but just a couple of more if I could. Our overall expectation is that there will be somewhat modest impact in 2016. So we are fairly confident that we are going to continue to have a strong Enbrel business throughout Europe. So overall, we see this as again a modest impact to our business in the initial period of time. You think Sutent will soon become a defining asset or do you see growth in the future? We remain very confident in our position in the RCC space and that includes both, Sutent and Inlyta, because they are very well known by physicians and other stakeholders. So, the way I think about this is if you enter the midpoint of the guidance prior to foreign exchange in Venezuela, which is part of the basis of your question, the midpoint for guidance would be 52.3 just to use midpoint. We said -- Ian said when he answered Jami's question that revenue excluding Hospira on a year-over-year basis was essentially flat operationally while absorbing 2.3 billion in LOEs for 2016.The other data point I think to help you answer the question is, remember, we did 1.5 billion in Hospira sales this year. And thank you for the compliment on the clarity to communications. We would be willing take a one notch downgrade but we would still want to have access to commercial paper. So, Marc, on SG&A, let me just talk to the quarter and then I'll talk to the rhythm of the numbers. And then, we had obviously I alluded to in my comments increased promotional spend in many areas of the business. Now, if you take that 4.6 and you annualize it, times 2 is what? So this is part of prudent portfolio prioritization within Pfizer. Ian, first question on the timing around the breakup, I think you've indicated that integration of Allergan is very important. As you think about integration, can you give us some more commentary around how you are thinking about mapping out integration? Mikael, do you want to deal with this hypothetical on CDK 4/6?Yes, thank you for the questions. A couple of comments, John, to your question, I think first why more than $2 billion, why not a higher number? That's Phase I data, so as such I'm blinded -- I'm wondering if you can give us a preview of the tumor types here you think are most promising and also any preliminary safety findings?And then last pipeline question, last year you mentioned having an oral PCSK9 approaching human development, and I'm wondering if that is now in the clinic when I look at your pipeline chart I see a new compound has been advanced on the Phase I?Okay. Yes, I mean I think I would just reinforce the comment that you made. So We're looking forward to these data, and the impact that we think they're going to have on the marketplace. So, on the Inflectra AdCom, as you know it's scheduled for February 9, next week. David, again on your question on Allergan, our interactions with the shareholders, both sell side and buy side have been very positive. I think perhaps the Street is just -- is right now hung up on this close issue. It would be how I'd answer the question on capital allocation. First Frank, what level of detail should we expect in the proxy in terms of your long-term projections, similar to the Pfizer Wyeth documents or any difference and any caveats you'd like to order to let us know about before folks start slapping accretion percentages on those numbers?Secondly, going back to something you said earlier. I think we would say that in the Hospira infusion systems business, which comprises pumps, consumables, large volume solutions. We gave what the beginning share count number of the combined company would be. So with those data points, we felt we provided the information that you needed in order to model what the buybacks would be. First, just more broadly on emerging markets, can you talk about the growth outlook here maybe beyond China, just given the current economic environment we're seeing? Has there been any change in your growth expectations there?And then the second question for Ian. On BD, Chris, we see we would be more focused to smaller deals than larger deals right now. So, new company will generate significant amounts of operating cash flow. A couple on the pending Allergan transaction and one on next Tuesday, on Allergan, one, I guess if maybe just if you can highlight, what are some of the levers that would dictate whether the deal would close in early second half of '16 versus later in the second half?Two is, for Frank, on the $2 billion synergy number if you can just quantify as we fine-tune our pro forma model, if that's a gross number or an net number?Okay."
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "result = model(x[0], min_length=60)\n",
    "full = ''.join(result)\n",
    "print(full)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#Text Blob POS Tags"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Good JJ\n",
      "day NN\n",
      "everyone NN\n",
      "and CC\n",
      "welcome VB\n",
      "to TO\n",
      "Pfizer NNP\n",
      "'s POS\n",
      "Fourth NNP\n",
      "Quarter NNP\n",
      "2015 CD\n",
      "Earnings NNP\n",
      "Conference NNP\n",
      "Call NNP\n",
      "Today NN\n",
      "'s POS\n",
      "call NN\n",
      "is VBZ\n",
      "being VBG\n",
      "recorded VBN\n",
      "At IN\n",
      "this DT\n",
      "time NN\n",
      "I PRP\n",
      "would MD\n",
      "like VB\n",
      "to TO\n",
      "turn VB\n",
      "the DT\n",
      "call NN\n",
      "over IN\n",
      "to TO\n",
      "Mr. NNP\n",
      "Chuck NNP\n",
      "Triano NNP\n",
      "Senior NNP\n",
      "Vice NNP\n",
      "President NNP\n",
      "of IN\n",
      "Investor NNP\n",
      "Relations NNP\n",
      "Please NNP\n",
      "go VB\n",
      "ahead RB\n",
      "sir.Good VBD\n",
      "morning NN\n",
      "and CC\n",
      "thanks NNS\n",
      "for IN\n",
      "joining VBG\n",
      "us PRP\n",
      "today NN\n",
      "to TO\n",
      "review VB\n",
      "Pfizer NNP\n",
      "'s POS\n",
      "fourth JJ\n",
      "quarter NN\n",
      "and CC\n",
      "full JJ\n",
      "year NN\n",
      "2015 CD\n",
      "performance NN\n",
      "as RB\n",
      "well RB\n",
      "as IN\n",
      "2016 CD\n",
      "financial JJ\n",
      "guidance.I NN\n",
      "am VBP\n",
      "joined VBN\n",
      "here RB\n",
      "today NN\n",
      "as IN\n",
      "usual JJ\n",
      "by IN\n",
      "our PRP$\n",
      "Chairman NNP\n",
      "and CC\n",
      "CEO NNP\n",
      "Ian NNP\n",
      "Read NNP\n",
      "Frank NNP\n",
      "D'Amelio NNP\n",
      "our PRP$\n",
      "CFO NNP\n",
      "Mikael NNP\n",
      "Dolsten NNP\n",
      "President NNP\n",
      "of IN\n",
      "Worldwide NNP\n",
      "Research NNP\n",
      "and CC\n",
      "Development NNP\n",
      "Albert NNP\n",
      "Bourla NNP\n",
      "President NNP\n",
      "of IN\n",
      "Vaccines NNP\n",
      "Oncology NNP\n",
      "and CC\n",
      "Consumer NNP\n",
      "Geno NNP\n",
      "Germano NNP\n",
      "President NNP\n",
      "of IN\n",
      "Global NNP\n",
      "Innovative NNP\n",
      "Pharma NNP\n",
      "John NNP\n",
      "Young NNP\n",
      "President NNP\n",
      "of IN\n",
      "Established NNP\n",
      "Pharma NNP\n",
      "and CC\n",
      "Doug NNP\n",
      "Lankler NNP\n",
      "General NNP\n",
      "Counsel.The NNP\n",
      "slides VBZ\n",
      "that WDT\n",
      "will MD\n",
      "be VB\n",
      "presented VBN\n",
      "on IN\n",
      "this DT\n",
      "call NN\n",
      "can MD\n",
      "be VB\n",
      "viewed VBN\n",
      "on IN\n",
      "our PRP$\n",
      "homepage NN\n",
      "pfizer.com NN\n",
      "by IN\n",
      "clicking VBG\n",
      "on IN\n",
      "the DT\n",
      "link NN\n",
      "for IN\n",
      "Pfizer NNP\n",
      "Quarterly NNP\n",
      "Corporate NNP\n",
      "Performance NNP\n",
      "Fourth NNP\n",
      "Quarter NNP\n",
      "2015 CD\n",
      "which WDT\n",
      "is VBZ\n",
      "located VBN\n",
      "in IN\n",
      "the DT\n",
      "For IN\n",
      "Investors NNPS\n",
      "Section NNP\n",
      "in IN\n",
      "the DT\n",
      "lower JJR\n",
      "right JJ\n",
      "hand NN\n",
      "corner NN\n",
      "of IN\n",
      "the DT\n",
      "page.Before NN\n",
      "we PRP\n",
      "start VBP\n",
      "I PRP\n",
      "'d MD\n",
      "like VB\n",
      "to TO\n",
      "remind VB\n",
      "you PRP\n",
      "that IN\n",
      "our PRP$\n",
      "discussion NN\n",
      "during IN\n",
      "the DT\n",
      "call NN\n",
      "will MD\n",
      "include VB\n",
      "forward-looking JJ\n",
      "statements NNS\n",
      "and CC\n",
      "that DT\n",
      "actual JJ\n",
      "results NNS\n",
      "could MD\n",
      "differ VB\n",
      "materially RB\n",
      "from IN\n",
      "those DT\n",
      "projected VBN\n",
      "in IN\n",
      "the DT\n",
      "statements NNS\n",
      "Factor NN\n",
      "that WDT\n",
      "could MD\n",
      "cause VB\n",
      "actual JJ\n",
      "results NNS\n",
      "to TO\n",
      "differ VB\n",
      "are VBP\n",
      "discussed VBN\n",
      "in IN\n",
      "Pfizer NNP\n",
      "'s POS\n",
      "2014 CD\n",
      "Annual NNP\n",
      "Report NNP\n",
      "on IN\n",
      "Form NNP\n",
      "10-K JJ\n",
      "as RB\n",
      "well RB\n",
      "as IN\n",
      "on IN\n",
      "our PRP$\n",
      "reports NNS\n",
      "in IN\n",
      "Forms NNP\n",
      "10-Q JJ\n",
      "and CC\n",
      "8-K.Discussions NNS\n",
      "during IN\n",
      "the DT\n",
      "call NN\n",
      "will MD\n",
      "also RB\n",
      "include VB\n",
      "certain JJ\n",
      "financial JJ\n",
      "measures NNS\n",
      "that WDT\n",
      "were VBD\n",
      "not RB\n",
      "prepared VBN\n",
      "in IN\n",
      "accordance NN\n",
      "with IN\n",
      "Generally NNP\n",
      "Accepted NNP\n",
      "Accounting NNP\n",
      "Principles NNP\n",
      "Reconciliation NN\n",
      "of IN\n",
      "the DT\n",
      "non-GAAP JJ\n",
      "financial JJ\n",
      "measures NNS\n",
      "to TO\n",
      "the DT\n",
      "most RBS\n",
      "directly RB\n",
      "comparable JJ\n",
      "GAAP NNP\n",
      "financial JJ\n",
      "measures NNS\n",
      "can MD\n",
      "be VB\n",
      "found VBN\n",
      "in IN\n",
      "Pfizer NNP\n",
      "'s POS\n",
      "current JJ\n",
      "report NN\n",
      "on IN\n",
      "Form NNP\n",
      "8-K JJ\n",
      "dated VBD\n",
      "today.Also NN\n",
      "today NN\n",
      "'s POS\n",
      "call NN\n",
      "is VBZ\n",
      "not RB\n",
      "intended VBN\n",
      "to TO\n",
      "and CC\n",
      "does VBZ\n",
      "not RB\n",
      "constitute VB\n",
      "an DT\n",
      "offer NN\n",
      "to TO\n",
      "sell VB\n",
      "or CC\n",
      "the DT\n",
      "solicitation NN\n",
      "of IN\n",
      "an DT\n",
      "offer NN\n",
      "to TO\n",
      "subscribe VB\n",
      "for IN\n",
      "or CC\n",
      "buy VB\n",
      "securities NNS\n",
      "of IN\n",
      "Pfizer NNP\n",
      "or CC\n",
      "Allergan.We NNP\n",
      "will MD\n",
      "now RB\n",
      "make VB\n",
      "prepared JJ\n",
      "remarks NNS\n",
      "and CC\n",
      "then RB\n",
      "we PRP\n",
      "will MD\n",
      "move VB\n",
      "to TO\n",
      "a DT\n",
      "question-and-answer JJ\n",
      "session NN\n",
      "With IN\n",
      "that DT\n",
      "I PRP\n",
      "'ll MD\n",
      "now RB\n",
      "turn VB\n",
      "the DT\n",
      "call NN\n",
      "over IN\n",
      "to TO\n",
      "Ian NNP\n",
      "Read NNP\n",
      "Ian NNP\n",
      "Thank NNP\n",
      "you PRP\n",
      "Chuck NNP\n",
      "and CC\n",
      "good JJ\n",
      "morning NN\n",
      "everyone NN\n",
      "We PRP\n",
      "finished VBD\n",
      "2015 CD\n",
      "with IN\n",
      "strong JJ\n",
      "financial JJ\n",
      "and CC\n",
      "operational JJ\n",
      "performance NN\n",
      "For IN\n",
      "the DT\n",
      "full JJ\n",
      "year NN\n",
      "we PRP\n",
      "exceeded VBD\n",
      "our PRP$\n",
      "2015 CD\n",
      "revenue NN\n",
      "guidance NN\n",
      "and CC\n",
      "met VBD\n",
      "the DT\n",
      "top-end NN\n",
      "of IN\n",
      "our PRP$\n",
      "adjusted VBN\n",
      "diluted VBN\n",
      "EPS NNP\n",
      "guidance NN\n",
      "Excuse IN\n",
      "me PRP\n",
      "and CC\n",
      "we PRP\n",
      "achieved VBD\n",
      "our PRP$\n",
      "first JJ\n",
      "year NN\n",
      "of IN\n",
      "operational JJ\n",
      "revenue NN\n",
      "growth NN\n",
      "in IN\n",
      "five CD\n",
      "years.Frank NN\n",
      "will MD\n",
      "take VB\n",
      "you PRP\n",
      "through IN\n",
      "the DT\n",
      "numbers NNS\n",
      "Before IN\n",
      "he PRP\n",
      "does VBZ\n",
      "I PRP\n",
      "have VBP\n",
      "a DT\n",
      "few JJ\n",
      "brief NN\n",
      "comments NNS\n",
      "about IN\n",
      "what WP\n",
      "is VBZ\n",
      "driving VBG\n",
      "our PRP$\n",
      "performance NN\n",
      "some DT\n",
      "thoughts NNS\n",
      "regarding VBG\n",
      "where WRB\n",
      "we PRP\n",
      "expect VBP\n",
      "to TO\n",
      "see VB\n",
      "pipeline NN\n",
      "advancements NNS\n",
      "during IN\n",
      "the DT\n",
      "year NN\n",
      "and CC\n",
      "I PRP\n",
      "will MD\n",
      "close VB\n",
      "with IN\n",
      "a DT\n",
      "few JJ\n",
      "comments NNS\n",
      "about IN\n",
      "Allergan.Throughout IN\n",
      "the DT\n",
      "year NN\n",
      "and CC\n",
      "especially RB\n",
      "in IN\n",
      "the DT\n",
      "fourth JJ\n",
      "quarter NN\n",
      "our PRP$\n",
      "business NN\n",
      "executed VBD\n",
      "flawlessly RB\n",
      "despite IN\n",
      "a DT\n",
      "challenging JJ\n",
      "operational JJ\n",
      "environment NN\n",
      "We PRP\n",
      "ended VBD\n",
      "2015 CD\n",
      "with IN\n",
      "solid JJ\n",
      "momentum NN\n",
      "in IN\n",
      "both DT\n",
      "developed JJ\n",
      "and CC\n",
      "emerging VBG\n",
      "markets.Specifically RB\n",
      "in IN\n",
      "developed JJ\n",
      "markets NNS\n",
      "during IN\n",
      "the DT\n",
      "year NN\n",
      "we PRP\n",
      "gained VBD\n",
      "incremental JJ\n",
      "market NN\n",
      "penetration NN\n",
      "driven VBN\n",
      "by IN\n",
      "continued JJ\n",
      "success NN\n",
      "of IN\n",
      "products NNS\n",
      "that WDT\n",
      "are VBP\n",
      "early RB\n",
      "in IN\n",
      "their PRP$\n",
      "life NN\n",
      "cycles NNS\n",
      "including VBG\n",
      "Prevnar NNP\n",
      "13 CD\n",
      "adults NNS\n",
      "Ibrance NNP\n",
      "Eliquis NNP\n",
      "Xeljanz NNP\n",
      "and CC\n",
      "we PRP\n",
      "still RB\n",
      "saw VBD\n",
      "steady JJ\n",
      "growth NN\n",
      "from IN\n",
      "key JJ\n",
      "inline NN\n",
      "products NNS\n",
      "in IN\n",
      "2015 CD\n",
      "specifically RB\n",
      "Lyrica NNP\n",
      "in IN\n",
      "markets NNS\n",
      "where WRB\n",
      "it PRP\n",
      "remains VBZ\n",
      "patent JJ\n",
      "protected.And NN\n",
      "during IN\n",
      "the DT\n",
      "year NN\n",
      "in IN\n",
      "emerging VBG\n",
      "markets NNS\n",
      "we PRP\n",
      "saw VBD\n",
      "operational JJ\n",
      "revenue NN\n",
      "growth NN\n",
      "primarily RB\n",
      "due JJ\n",
      "to TO\n",
      "the DT\n",
      "performance NN\n",
      "of IN\n",
      "Prevnar NNP\n",
      "Lipitor NNP\n",
      "and CC\n",
      "Enbrel NNP\n",
      "as RB\n",
      "well RB\n",
      "as IN\n",
      "from IN\n",
      "the DT\n",
      "addition NN\n",
      "of IN\n",
      "legacy NN\n",
      "Hospira NNP\n",
      "products NNS\n",
      "The DT\n",
      "integration NN\n",
      "of IN\n",
      "the DT\n",
      "Hospira NNP\n",
      "business NN\n",
      "into IN\n",
      "Pfizer NNP\n",
      "Global NNP\n",
      "Established NNP\n",
      "pharma NN\n",
      "businesses NNS\n",
      "is VBZ\n",
      "on IN\n",
      "track NN\n",
      "and CC\n",
      "we PRP\n",
      "look VBP\n",
      "forward RB\n",
      "to TO\n",
      "this DT\n",
      "business NN\n",
      "being VBG\n",
      "an DT\n",
      "attractive JJ\n",
      "potential JJ\n",
      "growth NN\n",
      "driver NN\n",
      "This DT\n",
      "acquisition NN\n",
      "is VBZ\n",
      "indeed RB\n",
      "proving VBG\n",
      "to TO\n",
      "be VB\n",
      "an DT\n",
      "excellent JJ\n",
      "strategic JJ\n",
      "fit NN\n",
      "and CC\n",
      "we PRP\n",
      "are VBP\n",
      "seeing VBG\n",
      "the DT\n",
      "expected VBN\n",
      "value NN\n",
      "contribution NN\n",
      "to TO\n",
      "our PRP$\n",
      "GAAP NNP\n",
      "business NN\n",
      "that IN\n",
      "we PRP\n",
      "anticipated.Frank VBP\n",
      "will MD\n",
      "speak VB\n",
      "to TO\n",
      "our PRP$\n",
      "2016 CD\n",
      "guidance NN\n",
      "in IN\n",
      "a DT\n",
      "moment NN\n",
      "We PRP\n",
      "expect VBP\n",
      "to TO\n",
      "deliver VB\n",
      "operational JJ\n",
      "revenue NN\n",
      "growth NN\n",
      "in IN\n",
      "2016 CD\n",
      "Our PRP$\n",
      "key JJ\n",
      "growth NN\n",
      "drivers NNS\n",
      "will MD\n",
      "continue VB\n",
      "to TO\n",
      "be VB\n",
      "Ibrance NNP\n",
      "Eliquis NNP\n",
      "and CC\n",
      "Xeljanz NNP\n",
      "And CC\n",
      "we PRP\n",
      "believe VBP\n",
      "that IN\n",
      "Prevnar NNP\n",
      "adult NN\n",
      "global JJ\n",
      "revenues NNS\n",
      "will MD\n",
      "be VB\n",
      "comparable JJ\n",
      "to TO\n",
      "the DT\n",
      "strong JJ\n",
      "results NNS\n",
      "we PRP\n",
      "achieved VBD\n",
      "in IN\n",
      "2015 CD\n",
      "Additionally RB\n",
      "we PRP\n",
      "believe VBP\n",
      "our PRP$\n",
      "near-term JJ\n",
      "pipeline NN\n",
      "will MD\n",
      "help VB\n",
      "accelerate VB\n",
      "this DT\n",
      "ongoing JJ\n",
      "growth NN\n",
      "forward.In NN\n",
      "looking VBG\n",
      "at IN\n",
      "the DT\n",
      "year NN\n",
      "ahead RB\n",
      "we PRP\n",
      "expect VBP\n",
      "our PRP$\n",
      "businesses NNS\n",
      "will MD\n",
      "continue VB\n",
      "to TO\n",
      "execute VB\n",
      "well RB\n",
      "They PRP\n",
      "are VBP\n",
      "competitively RB\n",
      "positioned VBN\n",
      "to TO\n",
      "win VB\n",
      "their PRP$\n",
      "markets NNS\n",
      "and CC\n",
      "are VBP\n",
      "performing VBG\n",
      "strongly RB\n",
      "against IN\n",
      "their PRP$\n",
      "competitors NNS\n",
      "' POS\n",
      "set.Regarding VBG\n",
      "the DT\n",
      "pipeline NN\n",
      "we PRP\n",
      "anticipate VBP\n",
      "advancing VBG\n",
      "many JJ\n",
      "of IN\n",
      "our PRP$\n",
      "Phase NNP\n",
      "III NNP\n",
      "programs NNS\n",
      "during IN\n",
      "the DT\n",
      "year NN\n",
      "For IN\n",
      "Bococizumab NNP\n",
      "we PRP\n",
      "reported VBD\n",
      "today NN\n",
      "that IN\n",
      "the DT\n",
      "first JJ\n",
      "of IN\n",
      "our PRP$\n",
      "six CD\n",
      "Phase NNP\n",
      "III NNP\n",
      "efficacy NN\n",
      "studies NNS\n",
      "achieved VBD\n",
      "its PRP$\n",
      "primary JJ\n",
      "endpoint NN\n",
      "and CC\n",
      "we PRP\n",
      "expect VBP\n",
      "readouts NNS\n",
      "of IN\n",
      "the DT\n",
      "remaining VBG\n",
      "five CD\n",
      "Bococizumab NNP\n",
      "lipid-lowering JJ\n",
      "studies NNS\n",
      "[ VBP\n",
      "technical JJ\n",
      "difficulty NN\n",
      "] NN\n",
      "during IN\n",
      "2016.For CD\n",
      "[ NNS\n",
      "indiscernible JJ\n",
      "] NN\n",
      "this DT\n",
      "year NN\n",
      "we PRP\n",
      "and CC\n",
      "our PRP$\n",
      "partners NNS\n",
      "Merck NNP\n",
      "will MD\n",
      "begin VB\n",
      "to TO\n",
      "deliver VB\n",
      "results NNS\n",
      "from IN\n",
      "our PRP$\n",
      "comprehensive JJ\n",
      "Phase NNP\n",
      "III NNP\n",
      "clinical JJ\n",
      "program NN\n",
      "In IN\n",
      "2016 CD\n",
      "the DT\n",
      "alliance NN\n",
      "expects VBZ\n",
      "to TO\n",
      "submit VB\n",
      "applications NNS\n",
      "to TO\n",
      "regulatory JJ\n",
      "approval NN\n",
      "in IN\n",
      "the DT\n",
      "U.S. NNP\n",
      "for IN\n",
      "both DT\n",
      "monotherapy NNS\n",
      "and CC\n",
      "two CD\n",
      "fixed VBN\n",
      "dose JJ\n",
      "combination NN\n",
      "tablets NNS\n",
      "using VBG\n",
      "data NNS\n",
      "from IN\n",
      "eight CD\n",
      "clinical JJ\n",
      "trials.For NN\n",
      "Dacomitinib NNP\n",
      "we PRP\n",
      "expect VBP\n",
      "results NNS\n",
      "in IN\n",
      "the DT\n",
      "second JJ\n",
      "half NN\n",
      "of IN\n",
      "the DT\n",
      "year NN\n",
      "for IN\n",
      "a DT\n",
      "Phase NNP\n",
      "III NNP\n",
      "study NN\n",
      "in IN\n",
      "first-line JJ\n",
      "EGFR NNP\n",
      "mutant NN\n",
      "non-small-cell NN\n",
      "lung NN\n",
      "cancer NN\n",
      "and CC\n",
      "we PRP\n",
      "'ll MD\n",
      "discuss VB\n",
      "our PRP$\n",
      "regulatory JJ\n",
      "strategy NN\n",
      "with IN\n",
      "the DT\n",
      "FDA NNP\n",
      "So RB\n",
      "Xeljanz RB\n",
      "in IN\n",
      "the DT\n",
      "first JJ\n",
      "half NN\n",
      "of IN\n",
      "this DT\n",
      "year NN\n",
      "we PRP\n",
      "expect VBP\n",
      "top JJ\n",
      "line NN\n",
      "results NNS\n",
      "for IN\n",
      "our PRP$\n",
      "Phase NNP\n",
      "III NNP\n",
      "program NN\n",
      "in IN\n",
      "psoriatic JJ\n",
      "arthritis NN\n",
      "We PRP\n",
      "believe VBP\n",
      "Xeljanz TO\n",
      "can MD\n",
      "potentially RB\n",
      "fill VB\n",
      "a DT\n",
      "significant JJ\n",
      "unmet JJ\n",
      "need NN\n",
      "in IN\n",
      "the DT\n",
      "psoriatic JJ\n",
      "arthritis NN\n",
      "when WRB\n",
      "non-biologic JJ\n",
      "DMARDS NNP\n",
      "do VBP\n",
      "not RB\n",
      "have VB\n",
      "proven VBN\n",
      "success NN\n",
      "and CC\n",
      "where WRB\n",
      "there EX\n",
      "are VBP\n",
      "currently RB\n",
      "few JJ\n",
      "alternatives NNS\n",
      "for IN\n",
      "patients NNS\n",
      "who WP\n",
      "have VBP\n",
      "inadequate JJ\n",
      "responses NNS\n",
      "to TO\n",
      "anti-TNF JJ\n",
      "therapy.In NN\n",
      "addition NN\n",
      "in IN\n",
      "the DT\n",
      "first JJ\n",
      "half NN\n",
      "of IN\n",
      "the DT\n",
      "year NN\n",
      "we PRP\n",
      "anticipate VBP\n",
      "the DT\n",
      "decisions NNS\n",
      "from IN\n",
      "the DT\n",
      "FDA NNP\n",
      "for IN\n",
      "a DT\n",
      "once-a-day JJ\n",
      "daily JJ\n",
      "Xeljanz NNP\n",
      "formulation NN\n",
      "for IN\n",
      "rheumatoid NN\n",
      "arthritis NN\n",
      "and CC\n",
      "we PRP\n",
      "remain VBP\n",
      "on IN\n",
      "track NN\n",
      "to TO\n",
      "re-file VB\n",
      "our PRP$\n",
      "application NN\n",
      "for IN\n",
      "RA NNP\n",
      "in IN\n",
      "the DT\n",
      "EU.For NNP\n",
      "Ibrance NNP\n",
      "we PRP\n",
      "expect VBP\n",
      "to TO\n",
      "see VB\n",
      "the DT\n",
      "top JJ\n",
      "line NN\n",
      "PALOMA-2 NNP\n",
      "study NN\n",
      "results NNS\n",
      "in IN\n",
      "first-line JJ\n",
      "advanced JJ\n",
      "breast NN\n",
      "cancer NN\n",
      "in IN\n",
      "combination NN\n",
      "with IN\n",
      "letrozole JJ\n",
      "and CC\n",
      "we PRP\n",
      "have VBP\n",
      "an DT\n",
      "April NNP\n",
      "PDUFA NNP\n",
      "date NN\n",
      "for IN\n",
      "second JJ\n",
      "and CC\n",
      "third-line JJ\n",
      "treatment NN\n",
      "for IN\n",
      "advanced JJ\n",
      "breast NN\n",
      "cancer NN\n",
      "based VBN\n",
      "on IN\n",
      "the DT\n",
      "PALOMA-3 NNP\n",
      "data NNS\n",
      "We PRP\n",
      "could MD\n",
      "also RB\n",
      "see VB\n",
      "a DT\n",
      "regulatory JJ\n",
      "decision NN\n",
      "for IN\n",
      "Ibrance NNP\n",
      "in IN\n",
      "the DT\n",
      "E.U NNP\n",
      "by IN\n",
      "year NN\n",
      "end.Additionally RB\n",
      "in IN\n",
      "the DT\n",
      "oncology NN\n",
      "business NN\n",
      "we PRP\n",
      "have VBP\n",
      "a DT\n",
      "PDUFA NNP\n",
      "date NN\n",
      "this DT\n",
      "year NN\n",
      "in IN\n",
      "the DT\n",
      "U.S. NNP\n",
      "with IN\n",
      "Xalkori NNP\n",
      "in IN\n",
      "ROS NNP\n",
      "1 CD\n",
      "non-small-cell JJ\n",
      "lung NN\n",
      "cancer NN\n",
      "and CC\n",
      "we PRP\n",
      "expect VBP\n",
      "to TO\n",
      "file VB\n",
      "for IN\n",
      "approval NN\n",
      "of IN\n",
      "Inotuzumab NNP\n",
      "for IN\n",
      "acute JJ\n",
      "lymphoblastic JJ\n",
      "leukemia NN\n",
      "in IN\n",
      "the DT\n",
      "U.S. NNP\n",
      "And CC\n",
      "in IN\n",
      "immuno-oncology NN\n",
      "we PRP\n",
      "now RB\n",
      "have VBP\n",
      "a DT\n",
      "broad JJ\n",
      "portfolio NN\n",
      "of IN\n",
      "compounds NNS\n",
      "that IN\n",
      "we PRP\n",
      "believe VBP\n",
      "has VBZ\n",
      "the DT\n",
      "potential NN\n",
      "to TO\n",
      "support VB\n",
      "the DT\n",
      "development NN\n",
      "of IN\n",
      "a DT\n",
      "strong JJ\n",
      "deep JJ\n",
      "competitive JJ\n",
      "market NN\n",
      "position NN\n",
      "We PRP\n",
      "now RB\n",
      "have VBP\n",
      "five CD\n",
      "immuno-oncology JJ\n",
      "assets NNS\n",
      "in IN\n",
      "the DT\n",
      "clinic NN\n",
      "and CC\n",
      "expect VBP\n",
      "to TO\n",
      "have VB\n",
      "up RP\n",
      "to TO\n",
      "10 CD\n",
      "in IN\n",
      "the DT\n",
      "clinic NN\n",
      "by IN\n",
      "the DT\n",
      "end NN\n",
      "of IN\n",
      "2016 CD\n",
      "As IN\n",
      "a DT\n",
      "result NN\n",
      "of IN\n",
      "our PRP$\n",
      "partnership NN\n",
      "with IN\n",
      "Merck NNP\n",
      "KGaA NNP\n",
      "as IN\n",
      "of IN\n",
      "the DT\n",
      "end NN\n",
      "of IN\n",
      "2015 CD\n",
      "we PRP\n",
      "had VBD\n",
      "28 CD\n",
      "ongoing JJ\n",
      "clinical JJ\n",
      "development NN\n",
      "programs NNS\n",
      "for IN\n",
      "Avelumab NNP\n",
      "with IN\n",
      "seven CD\n",
      "of IN\n",
      "them PRP\n",
      "being VBG\n",
      "pivotal JJ\n",
      "registrational JJ\n",
      "studies.We NN\n",
      "anticipate VBP\n",
      "some DT\n",
      "of IN\n",
      "these DT\n",
      "studies NNS\n",
      "will MD\n",
      "give VB\n",
      "us PRP\n",
      "potential JJ\n",
      "registrations NNS\n",
      "in IN\n",
      "areas NNS\n",
      "like IN\n",
      "Merkel NNP\n",
      "cell NN\n",
      "ovarian JJ\n",
      "bladder NN\n",
      "gastric NN\n",
      "and CC\n",
      "lung NN\n",
      "cancer NN\n",
      "Of IN\n",
      "these DT\n",
      "seven CD\n",
      "studies NNS\n",
      "we PRP\n",
      "expect VBP\n",
      "to TO\n",
      "present VB\n",
      "data NNS\n",
      "in IN\n",
      "Merkel NNP\n",
      "cell NN\n",
      "this DT\n",
      "year NN\n",
      "and CC\n",
      "to TO\n",
      "see VB\n",
      "data NNS\n",
      "from IN\n",
      "the DT\n",
      "other JJ\n",
      "tumor NN\n",
      "types NNS\n",
      "in IN\n",
      "the DT\n",
      "following JJ\n",
      "two CD\n",
      "years NNS\n",
      "And CC\n",
      "we PRP\n",
      "continue VBP\n",
      "to TO\n",
      "believe VB\n",
      "that IN\n",
      "the DT\n",
      "winners NNS\n",
      "in IN\n",
      "this DT\n",
      "space NN\n",
      "will MD\n",
      "be VB\n",
      "those DT\n",
      "that WDT\n",
      "have VBP\n",
      "a DT\n",
      "breadth NN\n",
      "of IN\n",
      "portfolio NN\n",
      "assets NNS\n",
      "to TO\n",
      "support VB\n",
      "rational JJ\n",
      "combinations NNS\n",
      "We PRP\n",
      "have VBP\n",
      "a DT\n",
      "range NN\n",
      "of IN\n",
      "assets NNS\n",
      "to TO\n",
      "combine VB\n",
      "with IN\n",
      "Avelumab NNP\n",
      "when WRB\n",
      "compared VBN\n",
      "to TO\n",
      "other JJ\n",
      "companies NNS\n",
      "' POS\n",
      "assets NNS\n",
      "and CC\n",
      "we PRP\n",
      "have VBP\n",
      "already RB\n",
      "initiated VBN\n",
      "six CD\n",
      "combination NN\n",
      "studies NNS\n",
      "with IN\n",
      "Avelumab.In NNP\n",
      "2016 CD\n",
      "we PRP\n",
      "expect VBP\n",
      "to TO\n",
      "see VB\n",
      "data NNS\n",
      "from IN\n",
      "4-1BB JJ\n",
      "in IN\n",
      "combination NN\n",
      "with IN\n",
      "Keytruda NNP\n",
      "and CC\n",
      "in IN\n",
      "combination NN\n",
      "with IN\n",
      "Avelumab NNP\n",
      "in IN\n",
      "various JJ\n",
      "tumors NNS\n",
      "4-1BB JJ\n",
      "in IN\n",
      "combination NN\n",
      "with IN\n",
      "Rituximab NNP\n",
      "in IN\n",
      "lymphoma NN\n",
      "a DT\n",
      "combination NN\n",
      "of IN\n",
      "Lorlatinib NNP\n",
      "our PRP$\n",
      "next JJ\n",
      "generation NN\n",
      "ALK NNP\n",
      "inhibitor NN\n",
      "with IN\n",
      "Avelumab NNP\n",
      "and CC\n",
      "ALK-positive JJ\n",
      "non-small-cell JJ\n",
      "lung NN\n",
      "cancer NN\n",
      "and CC\n",
      "data NNS\n",
      "from IN\n",
      "[ NNP\n",
      "indiscernible JJ\n",
      "] NN\n",
      "with IN\n",
      "Avelumab NNP\n",
      "in IN\n",
      "renal JJ\n",
      "cell NN\n",
      "carcinoma NN\n",
      "Finally RB\n",
      "we PRP\n",
      "may MD\n",
      "see VB\n",
      "data NNS\n",
      "from IN\n",
      "OX40 NNP\n",
      "as IN\n",
      "a DT\n",
      "single JJ\n",
      "agent NN\n",
      "this DT\n",
      "year NN\n",
      "Taking VBG\n",
      "of IN\n",
      "all DT\n",
      "of IN\n",
      "this DT\n",
      "into IN\n",
      "account NN\n",
      "we PRP\n",
      "believe VBP\n",
      "we PRP\n",
      "are VBP\n",
      "well RB\n",
      "on IN\n",
      "our PRP$\n",
      "way NN\n",
      "to TO\n",
      "being VBG\n",
      "a DT\n",
      "leading VBG\n",
      "player NN\n",
      "in IN\n",
      "this DT\n",
      "space.And NN\n",
      "now RB\n",
      "a DT\n",
      "few JJ\n",
      "comments NNS\n",
      "about IN\n",
      "our PRP$\n",
      "proposed VBN\n",
      "combination NN\n",
      "with IN\n",
      "Allergan NNP\n",
      "We PRP\n",
      "'re VBP\n",
      "excited VBN\n",
      "about IN\n",
      "bringing VBG\n",
      "two CD\n",
      "great JJ\n",
      "companies NNS\n",
      "together RB\n",
      "that WDT\n",
      "have VBP\n",
      "a DT\n",
      "strong JJ\n",
      "strategic JJ\n",
      "fit NN\n",
      "The DT\n",
      "transaction NN\n",
      "is VBZ\n",
      "about IN\n",
      "acceleration NN\n",
      "growth NN\n",
      "potential NN\n",
      "in IN\n",
      "our PRP$\n",
      "innovative JJ\n",
      "businesses NNS\n",
      "and CC\n",
      "strengthening VBG\n",
      "our PRP$\n",
      "established VBN\n",
      "business NN\n",
      "and CC\n",
      "more RBR\n",
      "efficiently RB\n",
      "allocating VBG\n",
      "our PRP$\n",
      "capital NN\n",
      "around IN\n",
      "the DT\n",
      "world NN\n",
      "We PRP\n",
      "are VBP\n",
      "confident JJ\n",
      "that IN\n",
      "we PRP\n",
      "are VBP\n",
      "taking VBG\n",
      "appropriate JJ\n",
      "steps NNS\n",
      "so RB\n",
      "that IN\n",
      "we PRP\n",
      "can MD\n",
      "achieve VB\n",
      "the DT\n",
      "key JJ\n",
      "milestones NNS\n",
      "needed VBN\n",
      "to TO\n",
      "complete VB\n",
      "the DT\n",
      "transaction NN\n",
      "and CC\n",
      "continue NN\n",
      "to TO\n",
      "expect VB\n",
      "close RB\n",
      "in IN\n",
      "the DT\n",
      "second JJ\n",
      "half NN\n",
      "of IN\n",
      "2016.Since CD\n",
      "the DT\n",
      "announcement NN\n",
      "we PRP\n",
      "have VBP\n",
      "been VBN\n",
      "working VBG\n",
      "closely RB\n",
      "with IN\n",
      "Brent NNP\n",
      "Saunders NNPS\n",
      "and CC\n",
      "his PRP$\n",
      "team NN\n",
      "at IN\n",
      "Allergan NNP\n",
      "and CC\n",
      "have VBP\n",
      "been VBN\n",
      "delighted VBN\n",
      "by IN\n",
      "the DT\n",
      "engagement NN\n",
      "and CC\n",
      "rapport NN\n",
      "that WDT\n",
      "is VBZ\n",
      "occurring VBG\n",
      "We PRP\n",
      "see VBP\n",
      "a DT\n",
      "number NN\n",
      "of IN\n",
      "potential JJ\n",
      "opportunities NNS\n",
      "after IN\n",
      "closing VBG\n",
      "as IN\n",
      "we PRP\n",
      "continue VBP\n",
      "to TO\n",
      "learn VB\n",
      "more JJR\n",
      "about IN\n",
      "each DT\n",
      "other JJ\n",
      "'s POS\n",
      "portfolio NN\n",
      "For IN\n",
      "example NN\n",
      "we PRP\n",
      "see VBP\n",
      "complementarity NN\n",
      "in IN\n",
      "information NN\n",
      "in IN\n",
      "gastroenterology NN\n",
      "and CC\n",
      "we PRP\n",
      "have VBP\n",
      "a DT\n",
      "when WRB\n",
      "we PRP\n",
      "will MD\n",
      "have VB\n",
      "a DT\n",
      "broader JJR\n",
      "presence NN\n",
      "in IN\n",
      "cardiovascular JJ\n",
      "disease NN\n",
      "with IN\n",
      "Eliquis NNP\n",
      "and CC\n",
      "Bystolic.In NNP\n",
      "neuroscience NN\n",
      "Allergan NNP\n",
      "'s POS\n",
      "work NN\n",
      "in IN\n",
      "Alzheimer NNP\n",
      "'s POS\n",
      "schizophrenia NN\n",
      "and CC\n",
      "major JJ\n",
      "depressive JJ\n",
      "orders NNS\n",
      "will MD\n",
      "be VB\n",
      "highly RB\n",
      "complementary JJ\n",
      "to TO\n",
      "Pfizer NNP\n",
      "'s POS\n",
      "promising VBG\n",
      "early JJ\n",
      "work NN\n",
      "in IN\n",
      "such JJ\n",
      "areas NNS\n",
      "as IN\n",
      "Parkinson NNP\n",
      "'s POS\n",
      "Alzheimer NNP\n",
      "'s POS\n",
      "and CC\n",
      "Duchenne NNP\n",
      "muscular VBP\n",
      "dystrophy.When NN\n",
      "you PRP\n",
      "look VBP\n",
      "at IN\n",
      "over IN\n",
      "the DT\n",
      "next JJ\n",
      "few JJ\n",
      "years NNS\n",
      "we PRP\n",
      "expect VBP\n",
      "both DT\n",
      "companies NNS\n",
      "will MD\n",
      "continue VB\n",
      "contribute NN\n",
      "sorry NN\n",
      "several JJ\n",
      "potential JJ\n",
      "new JJ\n",
      "drugs NNS\n",
      "to TO\n",
      "launch NN\n",
      "We PRP\n",
      "'ll MD\n",
      "also RB\n",
      "continue VB\n",
      "to TO\n",
      "be VB\n",
      "excited VBN\n",
      "about IN\n",
      "the DT\n",
      "international JJ\n",
      "potential NN\n",
      "And CC\n",
      "by IN\n",
      "coming VBG\n",
      "together RB\n",
      "we PRP\n",
      "are VBP\n",
      "enhancing VBG\n",
      "category NN\n",
      "leadership NN\n",
      "throughout IN\n",
      "our PRP$\n",
      "complementary JJ\n",
      "inline NN\n",
      "portfolio NN\n",
      "and CC\n",
      "a DT\n",
      "combined JJ\n",
      "pipeline NN\n",
      "with IN\n",
      "great JJ\n",
      "late-stage JJ\n",
      "and CC\n",
      "mid-stage JJ\n",
      "assets NNS\n",
      "across IN\n",
      "each DT\n",
      "of IN\n",
      "our PRP$\n",
      "key JJ\n",
      "therapeutic JJ\n",
      "areas NNS\n",
      "Both DT\n",
      "companies NNS\n",
      "bring VBP\n",
      "a DT\n",
      "great JJ\n",
      "deal NN\n",
      "of IN\n",
      "scientific JJ\n",
      "and CC\n",
      "product NN\n",
      "expertise NN\n",
      "to TO\n",
      "the DT\n",
      "provost NN\n",
      "combination NN\n",
      "and CC\n",
      "a DT\n",
      "shared VBN\n",
      "philosophy NN\n",
      "in IN\n",
      "our PRP$\n",
      "approach NN\n",
      "to TO\n",
      "research NN\n",
      "and CC\n",
      "development.Upon VBZ\n",
      "the DT\n",
      "close NN\n",
      "of IN\n",
      "the DT\n",
      "transaction NN\n",
      "the DT\n",
      "combined VBN\n",
      "company NN\n",
      "will MD\n",
      "be VB\n",
      "an DT\n",
      "influential JJ\n",
      "player NN\n",
      "in IN\n",
      "the DT\n",
      "industry NN\n",
      "with IN\n",
      "a DT\n",
      "competitive JJ\n",
      "product NN\n",
      "portfolio NN\n",
      "with IN\n",
      "several JJ\n",
      "leadership NN\n",
      "positions NNS\n",
      "robust JJ\n",
      "pipeline NN\n",
      "compelling VBG\n",
      "capital NN\n",
      "structure NN\n",
      "and CC\n",
      "financial JJ\n",
      "position NN\n",
      "and CC\n",
      "aligned VBD\n",
      "cultures NNS\n",
      "that WDT\n",
      "are VBP\n",
      "based VBN\n",
      "on IN\n",
      "ownership NN\n",
      "and CC\n",
      "entrepreneurial JJ\n",
      "spirit NN\n",
      "creating VBG\n",
      "shareholder NN\n",
      "value NN\n",
      "and CC\n",
      "meeting VBG\n",
      "patients NNS\n",
      "' POS\n",
      "needs NNS\n",
      "This DT\n",
      "combination NN\n",
      "is VBZ\n",
      "about IN\n",
      "investing VBG\n",
      "in IN\n",
      "our PRP$\n",
      "business NN\n",
      "It PRP\n",
      "'s VBZ\n",
      "about IN\n",
      "accelerating VBG\n",
      "our PRP$\n",
      "existing VBG\n",
      "strategy NN\n",
      "while IN\n",
      "preserving VBG\n",
      "our PRP$\n",
      "options NNS\n",
      "as IN\n",
      "putting VBG\n",
      "the DT\n",
      "company NN\n",
      "into IN\n",
      "an DT\n",
      "innovative JJ\n",
      "business NN\n",
      "and CC\n",
      "an DT\n",
      "established JJ\n",
      "business NN\n",
      "If IN\n",
      "we PRP\n",
      "determine VBP\n",
      "that DT\n",
      "is VBZ\n",
      "the DT\n",
      "best JJS\n",
      "way NN\n",
      "to TO\n",
      "unlock VB\n",
      "the DT\n",
      "most RBS\n",
      "value NN\n",
      "for IN\n",
      "our PRP$\n",
      "shareholders.By NN\n",
      "the DT\n",
      "end NN\n",
      "of IN\n",
      "the DT\n",
      "current JJ\n",
      "quarter NN\n",
      "our PRP$\n",
      "integration NN\n",
      "teams NNS\n",
      "will MD\n",
      "be VB\n",
      "fully RB\n",
      "engaged VBN\n",
      "and CC\n",
      "we PRP\n",
      "anticipate VBP\n",
      "announcing VBG\n",
      "post-closing JJ\n",
      "leadership NN\n",
      "positions NNS\n",
      "Throughout IN\n",
      "the DT\n",
      "year NN\n",
      "we PRP\n",
      "will MD\n",
      "continue VB\n",
      "to TO\n",
      "keep VB\n",
      "you PRP\n",
      "updated VBN\n",
      "on IN\n",
      "our PRP$\n",
      "progress NN\n",
      "In IN\n",
      "summary JJ\n",
      "we PRP\n",
      "'re VBP\n",
      "looking VBG\n",
      "at IN\n",
      "a DT\n",
      "year NN\n",
      "ahead RB\n",
      "we PRP\n",
      "have VBP\n",
      "a DT\n",
      "sound NN\n",
      "strategy NN\n",
      "and CC\n",
      "a DT\n",
      "strong JJ\n",
      "business NN\n",
      "Our PRP$\n",
      "outlook NN\n",
      "and CC\n",
      "financial JJ\n",
      "guidance NN\n",
      "for IN\n",
      "the DT\n",
      "year NN\n",
      "takes VBZ\n",
      "into IN\n",
      "the DT\n",
      "account NN\n",
      "the DT\n",
      "benefit NN\n",
      "of IN\n",
      "anticipated JJ\n",
      "positive JJ\n",
      "organic JJ\n",
      "growth NN\n",
      "from IN\n",
      "key JJ\n",
      "products NNS\n",
      "as RB\n",
      "well RB\n",
      "as IN\n",
      "the DT\n",
      "impact NN\n",
      "from IN\n",
      "foreign JJ\n",
      "exchange NN\n",
      "We PRP\n",
      "have VBP\n",
      "a DT\n",
      "solid JJ\n",
      "portfolio NN\n",
      "of IN\n",
      "market-leading JJ\n",
      "inline NN\n",
      "products NNS\n",
      "a DT\n",
      "healthy JJ\n",
      "pipeline NN\n",
      "We PRP\n",
      "expect VBP\n",
      "to TO\n",
      "further RBR\n",
      "strengthen VB\n",
      "the DT\n",
      "growth NN\n",
      "potential NN\n",
      "of IN\n",
      "the DT\n",
      "business NN\n",
      "with IN\n",
      "the DT\n",
      "pending VBG\n",
      "addition NN\n",
      "of IN\n",
      "Allergan NNP\n",
      "We PRP\n",
      "will MD\n",
      "continue VB\n",
      "to TO\n",
      "have VB\n",
      "the DT\n",
      "means NNS\n",
      "by IN\n",
      "which WDT\n",
      "we PRP\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "can MD\n",
      "create VB\n",
      "value NN\n",
      "for IN\n",
      "our PRP$\n",
      "shareholders NNS\n",
      "and CC\n",
      "bring VB\n",
      "innovative JJ\n",
      "medicines NNS\n",
      "to TO\n",
      "patients NNS\n",
      "by IN\n",
      "producing VBG\n",
      "expected VBN\n",
      "top JJ\n",
      "line NN\n",
      "growth NN\n",
      "progressing VBG\n",
      "key JJ\n",
      "pipeline NN\n",
      "assets NNS\n",
      "pursuing VBG\n",
      "strategic JJ\n",
      "business NN\n",
      "development NN\n",
      "and CC\n",
      "returning VBG\n",
      "capital NN\n",
      "to TO\n",
      "shareholders NNS\n",
      "through IN\n",
      "dividends NNS\n",
      "and CC\n",
      "buybacks.Now NN\n",
      "I PRP\n",
      "'ll MD\n",
      "turn VB\n",
      "it PRP\n",
      "over IN\n",
      "to TO\n",
      "Frank NNP\n",
      "for IN\n",
      "additional JJ\n",
      "details NNS\n",
      "on IN\n",
      "the DT\n",
      "quarter NN\n",
      "and CC\n",
      "our PRP$\n",
      "2016 CD\n",
      "financial JJ\n",
      "guidance.Thanks NNS\n",
      "Ian NNP\n",
      "Good JJ\n",
      "day NN\n",
      "everyone NN\n",
      "As IN\n",
      "always RB\n",
      "the DT\n",
      "charts NNS\n",
      "that IN\n",
      "we PRP\n",
      "'re VBP\n",
      "viewing VBG\n",
      "today NN\n",
      "are VBP\n",
      "included VBN\n",
      "in IN\n",
      "our PRP$\n",
      "webcast NN\n",
      "As IN\n",
      "a DT\n",
      "reminder NN\n",
      "because IN\n",
      "we PRP\n",
      "completed VBD\n",
      "the DT\n",
      "acquisition NN\n",
      "of IN\n",
      "Hospira NNP\n",
      "on IN\n",
      "September NNP\n",
      "3 CD\n",
      "2015 CD\n",
      "Pfizer NNP\n",
      "'s POS\n",
      "full JJ\n",
      "year NN\n",
      "financial JJ\n",
      "results NNS\n",
      "for IN\n",
      "the DT\n",
      "year NN\n",
      "ended VBD\n",
      "December NNP\n",
      "31 CD\n",
      "2015 CD\n",
      "include VBP\n",
      "four CD\n",
      "months NNS\n",
      "of IN\n",
      "legacy NN\n",
      "Hospira NNP\n",
      "U.S. NNP\n",
      "operations NNS\n",
      "and CC\n",
      "three CD\n",
      "months NNS\n",
      "of IN\n",
      "legacy NN\n",
      "Hospira NNP\n",
      "international JJ\n",
      "operations.Financial JJ\n",
      "results NNS\n",
      "for IN\n",
      "the DT\n",
      "fourth JJ\n",
      "quarter NN\n",
      "2015 CD\n",
      "include VBP\n",
      "three CD\n",
      "months NNS\n",
      "of IN\n",
      "legacy NN\n",
      "Hospira NNP\n",
      "Global NNP\n",
      "operations NNS\n",
      "By IN\n",
      "comparison NN\n",
      "financial JJ\n",
      "results NNS\n",
      "for IN\n",
      "full JJ\n",
      "year NN\n",
      "and CC\n",
      "fourth JJ\n",
      "quarter NN\n",
      "2014 CD\n",
      "do VBP\n",
      "not RB\n",
      "include VB\n",
      "any DT\n",
      "contribution NN\n",
      "from IN\n",
      "legacy NN\n",
      "Hospira NNP\n",
      "operations.Now NN\n",
      "moving VBG\n",
      "on IN\n",
      "to TO\n",
      "the DT\n",
      "financials NNS\n",
      "fourth JJ\n",
      "quarter NN\n",
      "2015 CD\n",
      "reported VBD\n",
      "revenues NNS\n",
      "were VBD\n",
      "approximately RB\n",
      "14 CD\n",
      "billion CD\n",
      "and CC\n",
      "reflect VB\n",
      "year-over-year JJ\n",
      "operational JJ\n",
      "growth NN\n",
      "of IN\n",
      "1.9 CD\n",
      "billion CD\n",
      "or CC\n",
      "14 CD\n",
      "% NN\n",
      "mainly RB\n",
      "driven VBN\n",
      "by IN\n",
      "the DT\n",
      "addition NN\n",
      "of IN\n",
      "legacy NN\n",
      "Hospira NNP\n",
      "operations NNS\n",
      "The DT\n",
      "continued VBN\n",
      "strong JJ\n",
      "performance NN\n",
      "of IN\n",
      "products NNS\n",
      "that WDT\n",
      "are VBP\n",
      "early RB\n",
      "in IN\n",
      "their PRP$\n",
      "lifecycles NNS\n",
      "such JJ\n",
      "as IN\n",
      "Prevnar NNP\n",
      "13 CD\n",
      "adult NN\n",
      "Ibrance NNP\n",
      "Eliquis NNP\n",
      "and CC\n",
      "Xeljanz NNP\n",
      "Lyrica NNP\n",
      "primarily RB\n",
      "in IN\n",
      "the DT\n",
      "U.S. NNP\n",
      "and CC\n",
      "5 CD\n",
      "% NN\n",
      "operational JJ\n",
      "growth NN\n",
      "in IN\n",
      "emerging VBG\n",
      "markets NNS\n",
      "mainly RB\n",
      "from IN\n",
      "legacy NN\n",
      "Hospira NNP\n",
      "operations NNS\n",
      "Prevnar NNP\n",
      "13 CD\n",
      "and CC\n",
      "certain JJ\n",
      "other JJ\n",
      "products.Reported VBD\n",
      "revenues NNS\n",
      "continued VBN\n",
      "to TO\n",
      "be VB\n",
      "unfavorably RB\n",
      "impacted VBN\n",
      "by IN\n",
      "foreign JJ\n",
      "exchange NN\n",
      "of IN\n",
      "934 CD\n",
      "million CD\n",
      "or CC\n",
      "7 CD\n",
      "% NN\n",
      "Excluding VBG\n",
      "the DT\n",
      "inclusion NN\n",
      "of IN\n",
      "legacy NN\n",
      "Hospira NNP\n",
      "operations NNS\n",
      "of IN\n",
      "1.2 CD\n",
      "billion CD\n",
      "the DT\n",
      "negative JJ\n",
      "impact NN\n",
      "of IN\n",
      "foreign JJ\n",
      "exchange NN\n",
      "and CC\n",
      "to TO\n",
      "a DT\n",
      "much RB\n",
      "lesser JJR\n",
      "extent NN\n",
      "the DT\n",
      "inclusion NN\n",
      "of IN\n",
      "35 CD\n",
      "million CD\n",
      "of IN\n",
      "revenues NNS\n",
      "associated VBN\n",
      "with IN\n",
      "vaccines NNS\n",
      "acquired VBN\n",
      "from IN\n",
      "Baxter NNP\n",
      "Pfizer-standalone NNP\n",
      "achieved VBD\n",
      "operational JJ\n",
      "growth NN\n",
      "of IN\n",
      "646 CD\n",
      "million CD\n",
      "or CC\n",
      "5 CD\n",
      "% NN\n",
      "while IN\n",
      "at IN\n",
      "the DT\n",
      "same JJ\n",
      "time NN\n",
      "absorbing VBG\n",
      "a DT\n",
      "720 CD\n",
      "million CD\n",
      "negative JJ\n",
      "operational JJ\n",
      "impact NN\n",
      "from IN\n",
      "product NN\n",
      "losses NNS\n",
      "of IN\n",
      "exclusivity.Fourth JJ\n",
      "quarter NN\n",
      "adjusted VBN\n",
      "diluted VBD\n",
      "EPS NNP\n",
      "was VBD\n",
      "0.53 CD\n",
      "versus IN\n",
      "0.54 CD\n",
      "in IN\n",
      "the DT\n",
      "year NN\n",
      "ago RB\n",
      "quarter NN\n",
      "The DT\n",
      "decrease NN\n",
      "is VBZ\n",
      "primarily RB\n",
      "due JJ\n",
      "to TO\n",
      "an DT\n",
      "aggregate JJ\n",
      "operational JJ\n",
      "increase NN\n",
      "and CC\n",
      "adjusted VBD\n",
      "cost NN\n",
      "of IN\n",
      "sales NNS\n",
      "adjusted VBD\n",
      "SI NNP\n",
      "& CC\n",
      "A NNP\n",
      "expenses NNS\n",
      "and CC\n",
      "adjusted VBD\n",
      "R NNP\n",
      "& CC\n",
      "D NNP\n",
      "expenses NNS\n",
      "or CC\n",
      "1.8 CD\n",
      "billion CD\n",
      "or CC\n",
      "21 CD\n",
      "% NN\n",
      "0.07 CD\n",
      "due JJ\n",
      "to TO\n",
      "foreign JJ\n",
      "exchange NN\n",
      "and CC\n",
      "the DT\n",
      "continued JJ\n",
      "product NN\n",
      "losses NNS\n",
      "of IN\n",
      "exclusivity NN\n",
      "in IN\n",
      "certain JJ\n",
      "geographies NNS\n",
      "These DT\n",
      "were VBD\n",
      "partially RB\n",
      "offset VBN\n",
      "by IN\n",
      "revenue NN\n",
      "growth NN\n",
      "of IN\n",
      "certain JJ\n",
      "new JJ\n",
      "in-line JJ\n",
      "and CC\n",
      "acquired VBD\n",
      "products NNS\n",
      "lower JJR\n",
      "effective JJ\n",
      "tax NN\n",
      "rate NN\n",
      "and CC\n",
      "few JJ\n",
      "diluted VBN\n",
      "weighted JJ\n",
      "average JJ\n",
      "shares NNS\n",
      "outstanding JJ\n",
      "which WDT\n",
      "declined VBD\n",
      "by IN\n",
      "125 CD\n",
      "million CD\n",
      "shares NNS\n",
      "versus IN\n",
      "the DT\n",
      "year NN\n",
      "ago RB\n",
      "quarter NN\n",
      "due JJ\n",
      "to TO\n",
      "our PRP$\n",
      "share NN\n",
      "repurchase NN\n",
      "program NN\n",
      "which WDT\n",
      "includes VBZ\n",
      "the DT\n",
      "impact NN\n",
      "of IN\n",
      "5 CD\n",
      "billion CD\n",
      "accelerated VBN\n",
      "share NN\n",
      "repurchase JJ\n",
      "agreement NN\n",
      "executed VBN\n",
      "in IN\n",
      "February NNP\n",
      "2015 CD\n",
      "and CC\n",
      "completed VBN\n",
      "in IN\n",
      "July.Reported NNP\n",
      "diluted VBD\n",
      "EPS NNP\n",
      "was VBD\n",
      "0.10 CD\n",
      "compared VBN\n",
      "with IN\n",
      "0.19 CD\n",
      "in IN\n",
      "the DT\n",
      "year NN\n",
      "ago RB\n",
      "quarter NN\n",
      "due JJ\n",
      "to TO\n",
      "the DT\n",
      "previously RB\n",
      "mentioned VBN\n",
      "factors NNS\n",
      "and CC\n",
      "the DT\n",
      "unfavorable JJ\n",
      "impact NN\n",
      "of IN\n",
      "foreign JJ\n",
      "currency NN\n",
      "losses NNS\n",
      "related VBN\n",
      "to TO\n",
      "Venezuela NNP\n",
      "increased VBD\n",
      "purchase NN\n",
      "accounting NN\n",
      "adjustments NNS\n",
      "acquisition NN\n",
      "related VBD\n",
      "cost NN\n",
      "restructuring NN\n",
      "charges NNS\n",
      "and CC\n",
      "asset NN\n",
      "impairment NN\n",
      "charges NNS\n",
      "versus VBP\n",
      "the DT\n",
      "prior JJ\n",
      "year NN\n",
      "quarter NN\n",
      "and CC\n",
      "non-recurring JJ\n",
      "charges NNS\n",
      "related VBN\n",
      "to TO\n",
      "pension NN\n",
      "settlements NNS\n",
      "which WDT\n",
      "were VBD\n",
      "partially RB\n",
      "offset VBN\n",
      "by IN\n",
      "the DT\n",
      "non-recurrence NN\n",
      "of IN\n",
      "a DT\n",
      "charge NN\n",
      "associated VBN\n",
      "with IN\n",
      "the DT\n",
      "global JJ\n",
      "strategic JJ\n",
      "alliance NN\n",
      "formed VBN\n",
      "with IN\n",
      "Merck NNP\n",
      "KGaA NNP\n",
      "in IN\n",
      "November NNP\n",
      "2014 CD\n",
      "to TO\n",
      "jointly RB\n",
      "develop VB\n",
      "and CC\n",
      "commercialize VB\n",
      "Avelumab NNP\n",
      "lower JJR\n",
      "charges NNS\n",
      "for IN\n",
      "certain JJ\n",
      "legal JJ\n",
      "matters NNS\n",
      "and CC\n",
      "a DT\n",
      "lower JJR\n",
      "effective JJ\n",
      "tax NN\n",
      "rate.Foreign NN\n",
      "exchange NN\n",
      "negatively RB\n",
      "impacted JJ\n",
      "fourth JJ\n",
      "quarter NN\n",
      "reported VBD\n",
      "revenues NNS\n",
      "by IN\n",
      "approximately RB\n",
      "934 CD\n",
      "million CD\n",
      "or CC\n",
      "7 CD\n",
      "% NN\n",
      "and CC\n",
      "positively RB\n",
      "impacted VBN\n",
      "adjusted JJ\n",
      "cost NN\n",
      "of IN\n",
      "sales NNS\n",
      "adjusted VBD\n",
      "SI NNP\n",
      "& CC\n",
      "A NNP\n",
      "expenses NNS\n",
      "and CC\n",
      "adjusted VBN\n",
      "R NNP\n",
      "& CC\n",
      "D NNP\n",
      "expenses NNS\n",
      "in IN\n",
      "the DT\n",
      "aggregate NN\n",
      "by IN\n",
      "435 CD\n",
      "million CD\n",
      "or CC\n",
      "5 CD\n",
      "% NN\n",
      "As IN\n",
      "a DT\n",
      "result NN\n",
      "foreign JJ\n",
      "exchange NN\n",
      "negatively RB\n",
      "impacted JJ\n",
      "fourth JJ\n",
      "quarter NN\n",
      "adjusted VBD\n",
      "diluted VBN\n",
      "EPS NNP\n",
      "by IN\n",
      "approximately RB\n",
      "0.07 CD\n",
      "compared VBN\n",
      "with IN\n",
      "the DT\n",
      "year NN\n",
      "ago RB\n",
      "quarter.Now NN\n",
      "moving VBG\n",
      "on IN\n",
      "to TO\n",
      "the DT\n",
      "financial JJ\n",
      "highlights NNS\n",
      "of IN\n",
      "our PRP$\n",
      "business NN\n",
      "segments NNS\n",
      "in IN\n",
      "the DT\n",
      "fourth JJ\n",
      "quarter NN\n",
      "Global NNP\n",
      "Innovative NNP\n",
      "Pharmaceutical NNP\n",
      "revenues NNS\n",
      "increased VBD\n",
      "10 CD\n",
      "% NN\n",
      "operational JJ\n",
      "year-over-year JJ\n",
      "due JJ\n",
      "to TO\n",
      "the DT\n",
      "strong JJ\n",
      "performance NN\n",
      "of IN\n",
      "recently RB\n",
      "launched VBN\n",
      "products NNS\n",
      "including VBG\n",
      "Eliquis NNP\n",
      "globally RB\n",
      "and CC\n",
      "Xeljanz NNP\n",
      "in IN\n",
      "the DT\n",
      "U.S. NNP\n",
      "and CC\n",
      "the DT\n",
      "strong JJ\n",
      "performance NN\n",
      "of IN\n",
      "Lyrica NNP\n",
      "in IN\n",
      "the DT\n",
      "U.S. NNP\n",
      "and CC\n",
      "Japan.Income NNP\n",
      "before IN\n",
      "taxes NNS\n",
      "increased VBD\n",
      "17 CD\n",
      "% NN\n",
      "operationally RB\n",
      "due JJ\n",
      "to TO\n",
      "the DT\n",
      "increase NN\n",
      "of IN\n",
      "revenues NNS\n",
      "and CC\n",
      "a DT\n",
      "5 CD\n",
      "% NN\n",
      "operational JJ\n",
      "decrease NN\n",
      "in IN\n",
      "cost NN\n",
      "of IN\n",
      "sales NNS\n",
      "Cost NN\n",
      "of IN\n",
      "sales NNS\n",
      "as IN\n",
      "a DT\n",
      "percentage NN\n",
      "of IN\n",
      "revenue NN\n",
      "decreased VBD\n",
      "1.7 CD\n",
      "percentage NN\n",
      "points NNS\n",
      "operationally RB\n",
      "because IN\n",
      "of IN\n",
      "low JJ\n",
      "royalty NN\n",
      "expenses NNS\n",
      "and CC\n",
      "increased JJ\n",
      "alliance NN\n",
      "revenues NNS\n",
      "with IN\n",
      "no DT\n",
      "associated JJ\n",
      "cost NN\n",
      "of IN\n",
      "sales.IBT NN\n",
      "was VBD\n",
      "unfavorably RB\n",
      "impacted VBN\n",
      "by IN\n",
      "a DT\n",
      "4 CD\n",
      "% NN\n",
      "operational JJ\n",
      "increase NN\n",
      "and CC\n",
      "SI NNP\n",
      "& CC\n",
      "A NNP\n",
      "expenses NNS\n",
      "as IN\n",
      "a DT\n",
      "result NN\n",
      "of IN\n",
      "additional JJ\n",
      "investment NN\n",
      "in IN\n",
      "Eliquis NNP\n",
      "Xeljanz NNP\n",
      "and CC\n",
      "Chantix NNP\n",
      "and CC\n",
      "11 CD\n",
      "% NN\n",
      "operational JJ\n",
      "increase NN\n",
      "in IN\n",
      "R NNP\n",
      "& CC\n",
      "D NNP\n",
      "reflecting VBG\n",
      "investments NNS\n",
      "in IN\n",
      "our PRP$\n",
      "late-stage JJ\n",
      "pipeline NN\n",
      "primarily RB\n",
      "for IN\n",
      "Bococizumab NNP\n",
      "and CC\n",
      "Tanezumab.Fourth NNP\n",
      "quarter NN\n",
      "VOC NNP\n",
      "revenues NNS\n",
      "increased VBD\n",
      "38 CD\n",
      "% NN\n",
      "operationally RB\n",
      "reflecting VBG\n",
      "operational JJ\n",
      "revenue NN\n",
      "growth NN\n",
      "in IN\n",
      "each DT\n",
      "business NN\n",
      "Global JJ\n",
      "vaccine NN\n",
      "revenues NNS\n",
      "grew VBD\n",
      "53 CD\n",
      "% NN\n",
      "operationally RB\n",
      "driven VBN\n",
      "by IN\n",
      "102 CD\n",
      "% NN\n",
      "increase NN\n",
      "of IN\n",
      "Prevnar NNP\n",
      "13 CD\n",
      "U.S. NNP\n",
      "revenues NNS\n",
      "to TO\n",
      "the DT\n",
      "strong JJ\n",
      "uptake NN\n",
      "among IN\n",
      "adults.Global JJ\n",
      "oncology NN\n",
      "revenues NNS\n",
      "grew VBD\n",
      "61 CD\n",
      "% NN\n",
      "operationally RB\n",
      "driven VBN\n",
      "by IN\n",
      "Ibrance NNP\n",
      "in IN\n",
      "the DT\n",
      "U.S. NNP\n",
      "and CC\n",
      "to TO\n",
      "a DT\n",
      "lesser JJR\n",
      "extent NN\n",
      "by IN\n",
      "Sutent NNP\n",
      "and CC\n",
      "Xalkori NNP\n",
      "globally RB\n",
      "And CC\n",
      "consumer NN\n",
      "healthcare NN\n",
      "revenues NNS\n",
      "grew VBD\n",
      "4 CD\n",
      "% NN\n",
      "operationally RB\n",
      "due JJ\n",
      "to TO\n",
      "Nexium NNP\n",
      "24HR CD\n",
      "in IN\n",
      "the DT\n",
      "U.S.Income NNP\n",
      "before IN\n",
      "taxes NNS\n",
      "increased VBD\n",
      "33 CD\n",
      "% NN\n",
      "operationally RB\n",
      "mainly RB\n",
      "due JJ\n",
      "to TO\n",
      "increased VBN\n",
      "revenues NNS\n",
      "and CC\n",
      "associated JJ\n",
      "improvement NN\n",
      "in IN\n",
      "gross JJ\n",
      "margin NN\n",
      "which WDT\n",
      "were VBD\n",
      "partially RB\n",
      "offset VBN\n",
      "by IN\n",
      "a DT\n",
      "66 CD\n",
      "% NN\n",
      "operational JJ\n",
      "increase NN\n",
      "and CC\n",
      "SI NNP\n",
      "& CC\n",
      "A NNP\n",
      "expenses NNS\n",
      "as IN\n",
      "a DT\n",
      "result NN\n",
      "of IN\n",
      "higher JJR\n",
      "promotional NN\n",
      "expenses NNS\n",
      "in IN\n",
      "the DT\n",
      "U.S. NNP\n",
      "for IN\n",
      "newly RB\n",
      "launched VBN\n",
      "consumer NN\n",
      "healthcare NN\n",
      "products NNS\n",
      "Ibrance NNP\n",
      "and CC\n",
      "Prevnar NNP\n",
      "13 CD\n",
      "adult NN\n",
      "And CC\n",
      "the DT\n",
      "46 CD\n",
      "% NN\n",
      "operational JJ\n",
      "increase NN\n",
      "in IN\n",
      "R NNP\n",
      "& CC\n",
      "D NNP\n",
      "expenses NNS\n",
      "due JJ\n",
      "to TO\n",
      "increased VBN\n",
      "cost NN\n",
      "associated VBN\n",
      "with IN\n",
      "oncology NN\n",
      "oncology NN\n",
      "programs NNS\n",
      "primarily RB\n",
      "our PRP$\n",
      "alliance NN\n",
      "with IN\n",
      "Merck NNP\n",
      "KGaA NNP\n",
      "and CC\n",
      "Ibrance.Fourth NNP\n",
      "quarter NN\n",
      "Global NNP\n",
      "Established NNP\n",
      "Pharmaceutical NNP\n",
      "revenues NNS\n",
      "increased VBD\n",
      "5 CD\n",
      "% NN\n",
      "operationally RB\n",
      "mainly RB\n",
      "due JJ\n",
      "to TO\n",
      "the DT\n",
      "previously RB\n",
      "mentioned VBN\n",
      "inclusion NN\n",
      "of IN\n",
      "legacy NN\n",
      "Hospira NNP\n",
      "revenues NNS\n",
      "contributing VBG\n",
      "1.2 CD\n",
      "billion CD\n",
      "which WDT\n",
      "was VBD\n",
      "partially RB\n",
      "offset VBN\n",
      "by IN\n",
      "loss NN\n",
      "of IN\n",
      "exclusivity NN\n",
      "and CC\n",
      "generic JJ\n",
      "competition NN\n",
      "for IN\n",
      "Celebrex NNP\n",
      "in IN\n",
      "the DT\n",
      "U.S. NNP\n",
      "and CC\n",
      "certain JJ\n",
      "other JJ\n",
      "developed VBN\n",
      "markets NNS\n",
      "Lyrica NNP\n",
      "in IN\n",
      "most JJS\n",
      "developed JJ\n",
      "markets NNS\n",
      "in IN\n",
      "Europe NNP\n",
      "and CC\n",
      "Zyvox NNP\n",
      "in IN\n",
      "the DT\n",
      "U.S.Emerging VBG\n",
      "market NN\n",
      "revenues NNS\n",
      "were VBD\n",
      "flat JJ\n",
      "operationally RB\n",
      "which WDT\n",
      "reflected VBD\n",
      "the DT\n",
      "positive JJ\n",
      "impact NN\n",
      "of IN\n",
      "the DT\n",
      "inclusion NN\n",
      "of IN\n",
      "legacy NN\n",
      "Hospira NNP\n",
      "operations NNS\n",
      "and CC\n",
      "continued VBN\n",
      "strong JJ\n",
      "growth NN\n",
      "in IN\n",
      "China NNP\n",
      "offset NN\n",
      "by IN\n",
      "declines NNS\n",
      "in IN\n",
      "certain JJ\n",
      "markets NNS\n",
      "in IN\n",
      "the DT\n",
      "Middle NNP\n",
      "East.Income NNP\n",
      "before IN\n",
      "taxes NNS\n",
      "declined VBD\n",
      "12 CD\n",
      "% NN\n",
      "operationally RB\n",
      "reflecting VBG\n",
      "the DT\n",
      "unfavorable JJ\n",
      "impact NN\n",
      "of IN\n",
      "a DT\n",
      "4.7 CD\n",
      "percentage NN\n",
      "point NN\n",
      "operational JJ\n",
      "increase NN\n",
      "in IN\n",
      "cost NN\n",
      "of IN\n",
      "sales NNS\n",
      "as IN\n",
      "a DT\n",
      "percentage NN\n",
      "of IN\n",
      "revenues NNS\n",
      "due JJ\n",
      "to TO\n",
      "the DT\n",
      "inclusion NN\n",
      "of IN\n",
      "Hospira NNP\n",
      "operations NNS\n",
      "and CC\n",
      "the DT\n",
      "impact NN\n",
      "of IN\n",
      "losses NNS\n",
      "of IN\n",
      "exclusivity NN\n",
      "a DT\n",
      "24 CD\n",
      "% NN\n",
      "operational JJ\n",
      "increase NN\n",
      "in IN\n",
      "SI NNP\n",
      "& CC\n",
      "A NNP\n",
      "expenses NNS\n",
      "driven VBN\n",
      "in IN\n",
      "part NN\n",
      "by IN\n",
      "the DT\n",
      "addition NN\n",
      "of IN\n",
      "Hospira NNP\n",
      "operations NNS\n",
      "and CC\n",
      "the DT\n",
      "53 CD\n",
      "% NN\n",
      "operational JJ\n",
      "increase NN\n",
      "in IN\n",
      "R NNP\n",
      "& CC\n",
      "D NNP\n",
      "expenses NNS\n",
      "due JJ\n",
      "to TO\n",
      "increased VBN\n",
      "legacy NN\n",
      "Hospira NNP\n",
      "development NN\n",
      "programs.We NN\n",
      "exceeded VBD\n",
      "the DT\n",
      "top NN\n",
      "of IN\n",
      "our PRP$\n",
      "guidance NN\n",
      "range NN\n",
      "of IN\n",
      "expectations NNS\n",
      "for IN\n",
      "2015 CD\n",
      "reported VBD\n",
      "revenues NNS\n",
      "by IN\n",
      "approximately RB\n",
      "400 CD\n",
      "million CD\n",
      "Adjusted VBN\n",
      "cost NN\n",
      "of IN\n",
      "sales NNS\n",
      "as IN\n",
      "a DT\n",
      "percentage NN\n",
      "of IN\n",
      "revenues NNS\n",
      "was VBD\n",
      "18.5 CD\n",
      "% NN\n",
      "versus IN\n",
      "18.7 CD\n",
      "% NN\n",
      "at IN\n",
      "the DT\n",
      "low-end NN\n",
      "of IN\n",
      "our PRP$\n",
      "guidance NN\n",
      "range NN\n",
      "due JJ\n",
      "to TO\n",
      "increased JJ\n",
      "Alliance NNP\n",
      "revenues NNS\n",
      "and CC\n",
      "sales NNS\n",
      "volumes NNS\n",
      "and CC\n",
      "we PRP\n",
      "exceeded VBD\n",
      "our PRP$\n",
      "expectation NN\n",
      "for IN\n",
      "our PRP$\n",
      "effective JJ\n",
      "tax NN\n",
      "rate NN\n",
      "on IN\n",
      "adjusted JJ\n",
      "income NN\n",
      "as IN\n",
      "a DT\n",
      "result NN\n",
      "of IN\n",
      "the DT\n",
      "favorable JJ\n",
      "change NN\n",
      "in IN\n",
      "our PRP$\n",
      "jurisdictional JJ\n",
      "mix NN\n",
      "of IN\n",
      "earnings.We NN\n",
      "met VBD\n",
      "our PRP$\n",
      "expectations NNS\n",
      "for IN\n",
      "adjusted VBN\n",
      "R NNP\n",
      "& CC\n",
      "D NNP\n",
      "expenses NNS\n",
      "and CC\n",
      "achieved VBD\n",
      "the DT\n",
      "top-end NN\n",
      "of IN\n",
      "our PRP$\n",
      "adjusted VBN\n",
      "diluted VBN\n",
      "EPS NNP\n",
      "Adjusted NNP\n",
      "SI NNP\n",
      "& CC\n",
      "A NNP\n",
      "expenses NNS\n",
      "are VBP\n",
      "14.3 CD\n",
      "billion CD\n",
      "or CC\n",
      "higher JJR\n",
      "than IN\n",
      "our PRP$\n",
      "guidance NN\n",
      "range NN\n",
      "due JJ\n",
      "to TO\n",
      "increased VBN\n",
      "expenses NNS\n",
      "for IN\n",
      "recently RB\n",
      "launched VBN\n",
      "products NNS\n",
      "such JJ\n",
      "as IN\n",
      "Prevnar NNP\n",
      "13 CD\n",
      "adult NN\n",
      "and CC\n",
      "Ibrance NNP\n",
      "other JJ\n",
      "inline NN\n",
      "products NNS\n",
      "and CC\n",
      "certain JJ\n",
      "Consumer NNP\n",
      "Healthcare NNP\n",
      "brands.We NN\n",
      "recorded VBN\n",
      "adjusted VBD\n",
      "other JJ\n",
      "income NN\n",
      "of IN\n",
      "409 CD\n",
      "million CD\n",
      "versus IN\n",
      "our PRP$\n",
      "expectation NN\n",
      "of IN\n",
      "approximately RB\n",
      "500 CD\n",
      "million CD\n",
      "Finally RB\n",
      "reported VBD\n",
      "diluted JJ\n",
      "EPS NNP\n",
      "was VBD\n",
      "a DT\n",
      "1.24 CD\n",
      "versus IN\n",
      "our PRP$\n",
      "expected JJ\n",
      "range NN\n",
      "of IN\n",
      "a DT\n",
      "1.37 CD\n",
      "to TO\n",
      "a DT\n",
      "1.43 CD\n",
      "mainly RB\n",
      "as IN\n",
      "a DT\n",
      "result NN\n",
      "of IN\n",
      "increased JJ\n",
      "purchase NN\n",
      "accounting NN\n",
      "adjustments NNS\n",
      "acquisition-related JJ\n",
      "costs NNS\n",
      "and CC\n",
      "restructuring NN\n",
      "charges NNS\n",
      "primarily RB\n",
      "related VBN\n",
      "to TO\n",
      "the DT\n",
      "acquisition NN\n",
      "of IN\n",
      "Hospira NNP\n",
      "the DT\n",
      "negative JJ\n",
      "impact NN\n",
      "of IN\n",
      "foreign JJ\n",
      "currency NN\n",
      "losses NNS\n",
      "related VBN\n",
      "to TO\n",
      "Venezuela NNP\n",
      "and CC\n",
      "non-recurring JJ\n",
      "charges NNS\n",
      "related VBN\n",
      "to TO\n",
      "pension NN\n",
      "settlements.Now NN\n",
      "I PRP\n",
      "'d MD\n",
      "like VB\n",
      "to TO\n",
      "walk VB\n",
      "you PRP\n",
      "through IN\n",
      "the DT\n",
      "2016 CD\n",
      "guidance NN\n",
      "ranges VBZ\n",
      "for IN\n",
      "reported VBN\n",
      "revenues NNS\n",
      "reported VBD\n",
      "diluted JJ\n",
      "EPS NNP\n",
      "and CC\n",
      "adjusted VBD\n",
      "diluted VBN\n",
      "EPS NNP\n",
      "relative JJ\n",
      "to TO\n",
      "our PRP$\n",
      "2015 CD\n",
      "actual JJ\n",
      "results NNS\n",
      "First RB\n",
      "it PRP\n",
      "'s VBZ\n",
      "important JJ\n",
      "to TO\n",
      "note VB\n",
      "that IN\n",
      "our PRP$\n",
      "2016 CD\n",
      "financial JJ\n",
      "guidance NN\n",
      "excludes VBZ\n",
      "the DT\n",
      "impact NN\n",
      "of IN\n",
      "our PRP$\n",
      "pending VBG\n",
      "combination NN\n",
      "with IN\n",
      "Allergan.Our NNP\n",
      "2016 CD\n",
      "reported VBD\n",
      "revenue NN\n",
      "guidance NN\n",
      "range NN\n",
      "reflects VBZ\n",
      "anticipated VBN\n",
      "strong JJ\n",
      "growth NN\n",
      "of IN\n",
      "certain JJ\n",
      "new JJ\n",
      "inline NN\n",
      "and CC\n",
      "acquired VBD\n",
      "product NN\n",
      "that WDT\n",
      "is VBZ\n",
      "partially RB\n",
      "offset VBN\n",
      "by IN\n",
      "an DT\n",
      "anticipated JJ\n",
      "2.3 CD\n",
      "billion CD\n",
      "negative JJ\n",
      "impact NN\n",
      "due JJ\n",
      "to TO\n",
      "continuing VBG\n",
      "product NN\n",
      "losses NNS\n",
      "of IN\n",
      "exclusivity NN\n",
      "I PRP\n",
      "want VBP\n",
      "to TO\n",
      "point VB\n",
      "out RP\n",
      "that IN\n",
      "that DT\n",
      "would MD\n",
      "be VB\n",
      "in IN\n",
      "this DT\n",
      "range NN\n",
      "and CC\n",
      "consistent NN\n",
      "with IN\n",
      "our PRP$\n",
      "previous JJ\n",
      "comments NNS\n",
      "we PRP\n",
      "expect VBP\n",
      "full JJ\n",
      "year NN\n",
      "Prevnar NNP\n",
      "13 CD\n",
      "adult NN\n",
      "global JJ\n",
      "revenues NNS\n",
      "to TO\n",
      "be VB\n",
      "comparable JJ\n",
      "with IN\n",
      "its PRP$\n",
      "full JJ\n",
      "year NN\n",
      "2015 CD\n",
      "global JJ\n",
      "revenue NN\n",
      "level.We NN\n",
      "expect VBP\n",
      "adverse JJ\n",
      "changes NNS\n",
      "in IN\n",
      "foreign JJ\n",
      "exchange NN\n",
      "based VBN\n",
      "on IN\n",
      "mid-January JJ\n",
      "2016 CD\n",
      "rates NNS\n",
      "relative VBP\n",
      "to TO\n",
      "the DT\n",
      "U.S. NNP\n",
      "dollar NN\n",
      "compared VBN\n",
      "with IN\n",
      "actual JJ\n",
      "foreign JJ\n",
      "exchange NN\n",
      "rates NNS\n",
      "in IN\n",
      "2015 CD\n",
      "to TO\n",
      "have VB\n",
      "an DT\n",
      "additional JJ\n",
      "2.3 CD\n",
      "billion CD\n",
      "negative JJ\n",
      "impact NN\n",
      "on IN\n",
      "the DT\n",
      "reported VBN\n",
      "revenues NNS\n",
      "including VBG\n",
      "an DT\n",
      "estimated JJ\n",
      "800 CD\n",
      "million CD\n",
      "negative JJ\n",
      "currency NN\n",
      "impact NN\n",
      "related VBN\n",
      "to TO\n",
      "Venezuela NNP\n",
      "Consequently RB\n",
      "we PRP\n",
      "expect VBP\n",
      "2016 CD\n",
      "reported VBD\n",
      "revenues NNS\n",
      "to TO\n",
      "be VB\n",
      "in IN\n",
      "the DT\n",
      "range NN\n",
      "of IN\n",
      "49 CD\n",
      "billion CD\n",
      "to TO\n",
      "51 CD\n",
      "billion.Reported VBN\n",
      "diluted JJ\n",
      "EPS NNP\n",
      "and CC\n",
      "adjusted VBN\n",
      "diluted JJ\n",
      "EPS NNP\n",
      "guidance NN\n",
      "also RB\n",
      "include VBP\n",
      "the DT\n",
      "negative JJ\n",
      "impact NN\n",
      "from IN\n",
      "product NN\n",
      "losses NNS\n",
      "of IN\n",
      "exclusivity NN\n",
      "as RB\n",
      "well RB\n",
      "as IN\n",
      "an DT\n",
      "expected JJ\n",
      "0.09 CD\n",
      "negative JJ\n",
      "impact NN\n",
      "from IN\n",
      "foreign JJ\n",
      "exchange NN\n",
      "rates NNS\n",
      "and CC\n",
      "the DT\n",
      "0.07 CD\n",
      "negative JJ\n",
      "currency NN\n",
      "impact NN\n",
      "related VBN\n",
      "to TO\n",
      "Venezuela NNP\n",
      "As IN\n",
      "a DT\n",
      "result NN\n",
      "we PRP\n",
      "expect VBP\n",
      "reported VBN\n",
      "diluted JJ\n",
      "EPS NNP\n",
      "to TO\n",
      "be VB\n",
      "in IN\n",
      "the DT\n",
      "range NN\n",
      "of IN\n",
      "a DT\n",
      "1.54 CD\n",
      "to TO\n",
      "a DT\n",
      "1.67 CD\n",
      "and CC\n",
      "adjusted VBD\n",
      "diluted VBN\n",
      "EPS NNP\n",
      "to TO\n",
      "be VB\n",
      "in IN\n",
      "the DT\n",
      "range NN\n",
      "2.20 CD\n",
      "to TO\n",
      "2.30.In CD\n",
      "addition NN\n",
      "I PRP\n",
      "want VBP\n",
      "to TO\n",
      "remind VB\n",
      "everyone NN\n",
      "that WDT\n",
      "guidance NN\n",
      "ranges VBZ\n",
      "for IN\n",
      "both DT\n",
      "reported VBN\n",
      "and CC\n",
      "adjusted VBN\n",
      "diluted JJ\n",
      "EPS NNP\n",
      "incorporate VB\n",
      "5 CD\n",
      "billion CD\n",
      "of IN\n",
      "anticipated JJ\n",
      "share NN\n",
      "repurchases VBZ\n",
      "in IN\n",
      "2016 CD\n",
      "which WDT\n",
      "consists VBZ\n",
      "of IN\n",
      "our PRP$\n",
      "previously RB\n",
      "announced VBN\n",
      "intention NN\n",
      "to TO\n",
      "execute VB\n",
      "a DT\n",
      "5 CD\n",
      "billion CD\n",
      "accelerated VBN\n",
      "share NN\n",
      "repurchase JJ\n",
      "program NN\n",
      "in IN\n",
      "the DT\n",
      "first JJ\n",
      "half NN\n",
      "of IN\n",
      "2016 CD\n",
      "These DT\n",
      "repurchases NNS\n",
      "are VBP\n",
      "expected VBN\n",
      "to TO\n",
      "more RBR\n",
      "than IN\n",
      "offset VB\n",
      "the DT\n",
      "potential JJ\n",
      "dilution NN\n",
      "related VBN\n",
      "to TO\n",
      "employee NN\n",
      "compensation NN\n",
      "programs.In NN\n",
      "summary NN\n",
      "to TO\n",
      "exclude VB\n",
      "anticipated JJ\n",
      "foreign JJ\n",
      "exchange NN\n",
      "impacts NNS\n",
      "including VBG\n",
      "the DT\n",
      "negative JJ\n",
      "currency NN\n",
      "impact NN\n",
      "related VBN\n",
      "to TO\n",
      "Venezuela NNP\n",
      "full JJ\n",
      "year NN\n",
      "2016 CD\n",
      "revenue NN\n",
      "and CC\n",
      "adjusted JJ\n",
      "EPS NNP\n",
      "guidance NN\n",
      "midpoints NNS\n",
      "are VBP\n",
      "7 CD\n",
      "% NN\n",
      "and CC\n",
      "10 CD\n",
      "% NN\n",
      "greater JJR\n",
      "than IN\n",
      "actual JJ\n",
      "full JJ\n",
      "year NN\n",
      "2015 CD\n",
      "levels NNS\n",
      "respectively RB\n",
      "The DT\n",
      "remaining VBG\n",
      "elements NNS\n",
      "of IN\n",
      "our PRP$\n",
      "2016 CD\n",
      "financial JJ\n",
      "guidance NN\n",
      "are VBP\n",
      "set VBN\n",
      "forth NN\n",
      "on IN\n",
      "this DT\n",
      "chart.Now NN\n",
      "moving VBG\n",
      "on IN\n",
      "to TO\n",
      "key VB\n",
      "takeaways NNS\n",
      "we PRP\n",
      "had VBD\n",
      "a DT\n",
      "very RB\n",
      "strong JJ\n",
      "financial JJ\n",
      "performance NN\n",
      "in IN\n",
      "2015 CD\n",
      "and CC\n",
      "we PRP\n",
      "achieved VBD\n",
      "operational JJ\n",
      "revenue NN\n",
      "growth NN\n",
      "every DT\n",
      "quarter NN\n",
      "including VBG\n",
      "14 CD\n",
      "% NN\n",
      "operational JJ\n",
      "growth NN\n",
      "in IN\n",
      "the DT\n",
      "fourth JJ\n",
      "quarter NN\n",
      "For IN\n",
      "the DT\n",
      "full JJ\n",
      "year NN\n",
      "2015 CD\n",
      "we PRP\n",
      "achieved VBD\n",
      "6 CD\n",
      "% NN\n",
      "operational JJ\n",
      "revenue NN\n",
      "growth NN\n",
      "that WDT\n",
      "was VBD\n",
      "mainly RB\n",
      "driven VBN\n",
      "by IN\n",
      "new JJ\n",
      "products NNS\n",
      "that WDT\n",
      "are VBP\n",
      "early RB\n",
      "in IN\n",
      "their PRP$\n",
      "lifecycles NNS\n",
      "and CC\n",
      "we PRP\n",
      "achieved VBD\n",
      "this DT\n",
      "growth NN\n",
      "despite IN\n",
      "a DT\n",
      "3.2 CD\n",
      "billion CD\n",
      "negative JJ\n",
      "impact NN\n",
      "from IN\n",
      "product NN\n",
      "losses NNS\n",
      "of IN\n",
      "exclusivity.Our NN\n",
      "full JJ\n",
      "year NN\n",
      "2016 CD\n",
      "reported VBD\n",
      "revenue NN\n",
      "guidance NN\n",
      "range NN\n",
      "of IN\n",
      "49 CD\n",
      "billion CD\n",
      "to TO\n",
      "51 CD\n",
      "billion CD\n",
      "absorbs NNS\n",
      "a DT\n",
      "4.6 CD\n",
      "billion CD\n",
      "combined VBN\n",
      "negative JJ\n",
      "impact NN\n",
      "of IN\n",
      "product NN\n",
      "losses NNS\n",
      "of IN\n",
      "exclusivity NN\n",
      "adverse JJ\n",
      "changes NNS\n",
      "in IN\n",
      "foreign JJ\n",
      "exchange NN\n",
      "rates NNS\n",
      "and CC\n",
      "the DT\n",
      "negative JJ\n",
      "currency NN\n",
      "impact NN\n",
      "related VBN\n",
      "to TO\n",
      "Venezuela NNP\n",
      "And CC\n",
      "the DT\n",
      "adjusted VBN\n",
      "diluted JJ\n",
      "EPS NNP\n",
      "guidance NN\n",
      "range NN\n",
      "includes VBZ\n",
      "an DT\n",
      "anticipated JJ\n",
      "0.16 CD\n",
      "negative JJ\n",
      "impact NN\n",
      "from IN\n",
      "foreign JJ\n",
      "exchange NN\n",
      "including VBG\n",
      "Venezuela.We NNP\n",
      "announced VBD\n",
      "our PRP$\n",
      "proposed VBN\n",
      "combination NN\n",
      "with IN\n",
      "Allergan NNP\n",
      "and CC\n",
      "continue VBP\n",
      "to TO\n",
      "expect VB\n",
      "the DT\n",
      "transaction NN\n",
      "to TO\n",
      "close VB\n",
      "the DT\n",
      "second JJ\n",
      "half NN\n",
      "of IN\n",
      "2016 CD\n",
      "And CC\n",
      "we PRP\n",
      "continue VBP\n",
      "to TO\n",
      "create VB\n",
      "shareholder NN\n",
      "value NN\n",
      "through IN\n",
      "prudent JJ\n",
      "capital NN\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "allocation NN\n",
      "In IN\n",
      "2015 CD\n",
      "we PRP\n",
      "returned VBD\n",
      "13.1 CD\n",
      "billion CD\n",
      "to TO\n",
      "our PRP$\n",
      "shareholders NNS\n",
      "through IN\n",
      "dividends NNS\n",
      "and CC\n",
      "share NN\n",
      "repurchases NNS\n",
      "And CC\n",
      "we PRP\n",
      "expect VBP\n",
      "to TO\n",
      "execute VB\n",
      "a DT\n",
      "5 CD\n",
      "billion CD\n",
      "accelerated VBN\n",
      "share NN\n",
      "repurchase JJ\n",
      "program NN\n",
      "in IN\n",
      "the DT\n",
      "first JJ\n",
      "half NN\n",
      "of IN\n",
      "2016 CD\n",
      "Finally RB\n",
      "we PRP\n",
      "remain VBP\n",
      "committed JJ\n",
      "to TO\n",
      "delivering VBG\n",
      "attractive JJ\n",
      "shareholder NN\n",
      "returns NNS\n",
      "in IN\n",
      "2016 CD\n",
      "and CC\n",
      "beyond IN\n",
      "[ NN\n",
      "Operator NNP\n",
      "Instructions NNP\n",
      "] NNP\n",
      "Your NNP\n",
      "first JJ\n",
      "question NN\n",
      "comes VBZ\n",
      "from IN\n",
      "Colin NNP\n",
      "Bristow NNP\n",
      "from IN\n",
      "Bank NNP\n",
      "of IN\n",
      "America.Good NNP\n",
      "morning NN\n",
      "and CC\n",
      "congrats NNS\n",
      "on IN\n",
      "the DT\n",
      "solid JJ\n",
      "finish NN\n",
      "for IN\n",
      "the DT\n",
      "year NN\n",
      "So RB\n",
      "a DT\n",
      "couple NN\n",
      "of IN\n",
      "product-specific JJ\n",
      "questions NNS\n",
      "if IN\n",
      "I PRP\n",
      "may MD\n",
      "on IN\n",
      "the DT\n",
      "Prevnar NNP\n",
      "franchise NN\n",
      "you PRP\n",
      "'ve VBP\n",
      "posted VBN\n",
      "strong JJ\n",
      "4Q CD\n",
      "numbers NNS\n",
      "Could NNP\n",
      "you PRP\n",
      "just RB\n",
      "talk VB\n",
      "about IN\n",
      "your PRP$\n",
      "expectations NNS\n",
      "for IN\n",
      "the DT\n",
      "trajectory NN\n",
      "going VBG\n",
      "forward RB\n",
      "On IN\n",
      "Ibrance NNP\n",
      "there EX\n",
      "'s VBZ\n",
      "been VBN\n",
      "a DT\n",
      "lot NN\n",
      "of IN\n",
      "discussion NN\n",
      "around IN\n",
      "[ NNP\n",
      "indiscernible JJ\n",
      "] NN\n",
      "and CC\n",
      "the DT\n",
      "potential NN\n",
      "there RB\n",
      "for IN\n",
      "a DT\n",
      "threat NN\n",
      "to TO\n",
      "Ibrance NNP\n",
      "What WP\n",
      "'s VBZ\n",
      "your PRP$\n",
      "view NN\n",
      "here RB\n",
      "And CC\n",
      "then RB\n",
      "just RB\n",
      "lastly RB\n",
      "on IN\n",
      "Biosimilars NNP\n",
      "can MD\n",
      "you PRP\n",
      "update VB\n",
      "us PRP\n",
      "on IN\n",
      "the DT\n",
      "status NN\n",
      "of IN\n",
      "your PRP$\n",
      "Biosimilar NNP\n",
      "candidates NNS\n",
      "and CC\n",
      "when WRB\n",
      "we PRP\n",
      "should MD\n",
      "expect VB\n",
      "any DT\n",
      "data NN\n",
      "readouts NNS\n",
      "Thanks.Thank NNP\n",
      "you PRP\n",
      "Colin NNP\n",
      "I PRP\n",
      "'ll MD\n",
      "ask VB\n",
      "Albert NNP\n",
      "to TO\n",
      "manage VB\n",
      "the DT\n",
      "Prevnar NNP\n",
      "and CC\n",
      "Ibrance NNP\n",
      "and CC\n",
      "then RB\n",
      "pass VB\n",
      "it PRP\n",
      "over RP\n",
      "to TO\n",
      "John NNP\n",
      "for IN\n",
      "Biosimilars.Thank NNP\n",
      "you PRP\n",
      "very RB\n",
      "much RB\n",
      "for IN\n",
      "the DT\n",
      "question NN\n",
      "Colin NNP\n",
      "Let VB\n",
      "me PRP\n",
      "provide VB\n",
      "some DT\n",
      "insight NN\n",
      "to TO\n",
      "help VB\n",
      "you PRP\n",
      "understand VB\n",
      "the DT\n",
      "situation NN\n",
      "moving VBG\n",
      "forward RB\n",
      "In IN\n",
      "the DT\n",
      "U.S. NNP\n",
      "obviously RB\n",
      "we PRP\n",
      "have VBP\n",
      "done VBN\n",
      "an DT\n",
      "excellent JJ\n",
      "job NN\n",
      "with IN\n",
      "the DT\n",
      "catch-up JJ\n",
      "opportunity NN\n",
      "We PRP\n",
      "have VBP\n",
      "achieved VBN\n",
      "86 CD\n",
      "% NN\n",
      "markets NNS\n",
      "there RB\n",
      "92 CD\n",
      "% NN\n",
      "at IN\n",
      "retailers NNS\n",
      "We PRP\n",
      "have VBP\n",
      "90 CD\n",
      "% NN\n",
      "awareness NN\n",
      "of IN\n",
      "the DT\n",
      "recommendation NN\n",
      "at IN\n",
      "healthcare NN\n",
      "practitioner NN\n",
      "And CC\n",
      "as IN\n",
      "a DT\n",
      "result NN\n",
      "over IN\n",
      "the DT\n",
      "45 CD\n",
      "million CD\n",
      "adults NNS\n",
      "eligible JJ\n",
      "at IN\n",
      "the DT\n",
      "time NN\n",
      "of IN\n",
      "recommendation NN\n",
      "for IN\n",
      "vaccination NN\n",
      "we PRP\n",
      "have VBP\n",
      "already RB\n",
      "captured VBN\n",
      "about IN\n",
      "a DT\n",
      "third JJ\n",
      "[ NNP\n",
      "ph NN\n",
      "] NN\n",
      "of IN\n",
      "them.Now NN\n",
      "while IN\n",
      "many JJ\n",
      "adults NNS\n",
      "remain VBP\n",
      "this DT\n",
      "cohort NN\n",
      "is VBZ\n",
      "more RBR\n",
      "difficult JJ\n",
      "to TO\n",
      "capture VB\n",
      "as IN\n",
      "the DT\n",
      "low-hanging JJ\n",
      "fruit NN\n",
      "is VBZ\n",
      "gone VBN\n",
      "It PRP\n",
      "will MD\n",
      "require VB\n",
      "more RBR\n",
      "innovative JJ\n",
      "strategies NNS\n",
      "that IN\n",
      "we PRP\n",
      "all DT\n",
      "have VBP\n",
      "in IN\n",
      "place NN\n",
      "but CC\n",
      "even RB\n",
      "if IN\n",
      "we PRP\n",
      "assume VBP\n",
      "a DT\n",
      "similar JJ\n",
      "or CC\n",
      "higher JJR\n",
      "penetration NN\n",
      "rate NN\n",
      "this DT\n",
      "year NN\n",
      "it PRP\n",
      "will MD\n",
      "be VB\n",
      "on IN\n",
      "a DT\n",
      "much RB\n",
      "smaller JJR\n",
      "pool NN\n",
      "of IN\n",
      "adults NNS\n",
      "However RB\n",
      "we PRP\n",
      "expect VBP\n",
      "this DT\n",
      "will MD\n",
      "be VB\n",
      "mitigated VBN\n",
      "by IN\n",
      "Europe NNP\n",
      "which WDT\n",
      "has VBZ\n",
      "a DT\n",
      "very RB\n",
      "different JJ\n",
      "growth NN\n",
      "profile NN\n",
      "Even RB\n",
      "with IN\n",
      "prices NNS\n",
      "lower JJR\n",
      "than IN\n",
      "U.S. NNP\n",
      "the DT\n",
      "demographics NNS\n",
      "are VBP\n",
      "very RB\n",
      "favorable JJ\n",
      "with IN\n",
      "much JJ\n",
      "larger JJR\n",
      "eligible JJ\n",
      "population NN\n",
      "and CC\n",
      "who WP\n",
      "have VBP\n",
      "already RB\n",
      "received VBN\n",
      "pneumonia NN\n",
      "in IN\n",
      "our PRP$\n",
      "label NN\n",
      "in IN\n",
      "2015 CD\n",
      "and CC\n",
      "we PRP\n",
      "are VBP\n",
      "working VBG\n",
      "to TO\n",
      "obtain VB\n",
      "broad JJ\n",
      "recommendations NNS\n",
      "and CC\n",
      "following VBG\n",
      "that DT\n",
      "reimbursement NN\n",
      "from IN\n",
      "the DT\n",
      "authorities.Now NN\n",
      "this DT\n",
      "will MD\n",
      "be VB\n",
      "phased VBN\n",
      "likely RB\n",
      "over IN\n",
      "a DT\n",
      "two-years JJ\n",
      "window NN\n",
      "period NN\n",
      "because IN\n",
      "in IN\n",
      "Europe NNP\n",
      "this DT\n",
      "is VBZ\n",
      "done VBN\n",
      "country-by-country NN\n",
      "and CC\n",
      "sometimes RB\n",
      "region-by-region NN\n",
      "within IN\n",
      "the DT\n",
      "same JJ\n",
      "country NN\n",
      "But CC\n",
      "all DT\n",
      "in IN\n",
      "all DT\n",
      "we PRP\n",
      "expect VBP\n",
      "very RB\n",
      "strong JJ\n",
      "growth NN\n",
      "in IN\n",
      "Europe NNP\n",
      "next RB\n",
      "year.Now NN\n",
      "let VB\n",
      "me PRP\n",
      "move VB\n",
      "on IN\n",
      "Ibrance NNP\n",
      "and CC\n",
      "your PRP$\n",
      "question NN\n",
      "about IN\n",
      "competition NN\n",
      "or CC\n",
      "particularly RB\n",
      "[ JJ\n",
      "indiscernible JJ\n",
      "] JJ\n",
      "drug NN\n",
      "Look NNP\n",
      "[ NNP\n",
      "indiscernible JJ\n",
      "] JJ\n",
      "drug NN\n",
      "while IN\n",
      "in IN\n",
      "the DT\n",
      "same JJ\n",
      "class NN\n",
      "is VBZ\n",
      "for IN\n",
      "any DT\n",
      "[ NNP\n",
      "ph NN\n",
      "] NNP\n",
      "indication NN\n",
      "The DT\n",
      "refractory NN\n",
      "patient JJ\n",
      "population NN\n",
      "what WP\n",
      "we PRP\n",
      "have VBP\n",
      "received VBN\n",
      "breakthrough IN\n",
      "designation NN\n",
      "is VBZ\n",
      "a DT\n",
      "very RB\n",
      "small JJ\n",
      "population NN\n",
      "with IN\n",
      "few JJ\n",
      "options NNS\n",
      "available JJ\n",
      "In IN\n",
      "fact NN\n",
      "the DT\n",
      "average JJ\n",
      "refractory JJ\n",
      "patient NN\n",
      "undergoes NNS\n",
      "seven CD\n",
      "lines NNS\n",
      "of IN\n",
      "treatment NN\n",
      "So IN\n",
      "it PRP\n",
      "'s VBZ\n",
      "they PRP\n",
      "are VBP\n",
      "in IN\n",
      "high-mid.Now JJ\n",
      "speaking NN\n",
      "generally RB\n",
      "on IN\n",
      "competition NN\n",
      "there EX\n",
      "is VBZ\n",
      "only RB\n",
      "limited JJ\n",
      "clinical JJ\n",
      "data NNS\n",
      "on IN\n",
      "the DT\n",
      "public JJ\n",
      "domain NN\n",
      "and CC\n",
      "we PRP\n",
      "need VBP\n",
      "to TO\n",
      "see VB\n",
      "more JJR\n",
      "efficacy NN\n",
      "and CC\n",
      "safety NN\n",
      "data NNS\n",
      "to TO\n",
      "make VB\n",
      "comparisons NNS\n",
      "What WP\n",
      "I PRP\n",
      "can MD\n",
      "tell VB\n",
      "you PRP\n",
      "is VBZ\n",
      "about IN\n",
      "our PRP$\n",
      "strategic JJ\n",
      "position NN\n",
      "We PRP\n",
      "are VBP\n",
      "the DT\n",
      "only JJ\n",
      "company NN\n",
      "with IN\n",
      "a DT\n",
      "registered JJ\n",
      "product NN\n",
      "in IN\n",
      "U.S. NNP\n",
      "and CC\n",
      "six CD\n",
      "other JJ\n",
      "countries NNS\n",
      "and CC\n",
      "an DT\n",
      "accepted JJ\n",
      "filing NN\n",
      "in IN\n",
      "Europe NNP\n",
      "where WRB\n",
      "we PRP\n",
      "may MD\n",
      "obtain VB\n",
      "registration NN\n",
      "as RB\n",
      "early RB\n",
      "as IN\n",
      "next JJ\n",
      "year NN\n",
      "We PRP\n",
      "have VBP\n",
      "very RB\n",
      "good JJ\n",
      "clinical JJ\n",
      "experience NN\n",
      "with IN\n",
      "the DT\n",
      "product NN\n",
      "Ibrance NN\n",
      "has VBZ\n",
      "been VBN\n",
      "prescribed VBN\n",
      "by IN\n",
      "5,000 CD\n",
      "physicians NNS\n",
      "in IN\n",
      "more JJR\n",
      "than IN\n",
      "20,000 CD\n",
      "patients NNS\n",
      "And CC\n",
      "so RB\n",
      "far RB\n",
      "feedback NN\n",
      "is VBZ\n",
      "very RB\n",
      "positive JJ\n",
      "particularly RB\n",
      "on IN\n",
      "patients NNS\n",
      "' POS\n",
      "quality NN\n",
      "of IN\n",
      "life.We NN\n",
      "are VBP\n",
      "having VBG\n",
      "a DT\n",
      "very RB\n",
      "heavy JJ\n",
      "clinical JJ\n",
      "program NN\n",
      "We PRP\n",
      "have VBP\n",
      "two CD\n",
      "pivotal JJ\n",
      "studies NNS\n",
      "in IN\n",
      "first-line JJ\n",
      "metastatic JJ\n",
      "breast NN\n",
      "cancer NN\n",
      "two CD\n",
      "studies NNS\n",
      "in IN\n",
      "recurrent NN\n",
      "metastatic JJ\n",
      "breast NN\n",
      "cancer NN\n",
      "and CC\n",
      "three CD\n",
      "in IN\n",
      "early JJ\n",
      "breast NN\n",
      "cancer NN\n",
      "PENELOPE-B NNP\n",
      "PALLAS NNP\n",
      "and CC\n",
      "PEARL NNP\n",
      "[ NNP\n",
      "ph NN\n",
      "] NN\n",
      "Ibrance NN\n",
      "is VBZ\n",
      "part NN\n",
      "of IN\n",
      "88 CD\n",
      "investigational JJ\n",
      "initiated VBN\n",
      "trials NNS\n",
      "approximately RB\n",
      "50 CD\n",
      "in IN\n",
      "breast NN\n",
      "cancer NN\n",
      "and CC\n",
      "38 CD\n",
      "in IN\n",
      "other JJ\n",
      "tumor NN\n",
      "types NNS\n",
      "So RB\n",
      "as IN\n",
      "you PRP\n",
      "can MD\n",
      "see VB\n",
      "we PRP\n",
      "are VBP\n",
      "investing VBG\n",
      "heavily RB\n",
      "to TO\n",
      "stay VB\n",
      "ahead RB\n",
      "of IN\n",
      "the DT\n",
      "competition.Thank NN\n",
      "you PRP\n",
      "Albert NNP\n",
      "I PRP\n",
      "think VBP\n",
      "just RB\n",
      "on IN\n",
      "Ibrance NNP\n",
      "you PRP\n",
      "mentioned VBD\n",
      "next JJ\n",
      "year NN\n",
      "for IN\n",
      "Europe NNP\n",
      "you PRP\n",
      "meant VBP\n",
      "this DT\n",
      "year NN\n",
      "late RB\n",
      "this DT\n",
      "year NN\n",
      "we PRP\n",
      "may MD\n",
      "be VB\n",
      "able JJ\n",
      "to TO\n",
      "get VB\n",
      "registrationâ€¦Okay NN\n",
      "So RB\n",
      "thanks NNS\n",
      "for IN\n",
      "the DT\n",
      "question NN\n",
      "on IN\n",
      "Biosimilars NNP\n",
      "Colin NNP\n",
      "So RB\n",
      "I PRP\n",
      "think VBP\n",
      "we PRP\n",
      "'re VBP\n",
      "obviously RB\n",
      "very RB\n",
      "excited JJ\n",
      "to TO\n",
      "being VBG\n",
      "able JJ\n",
      "to TO\n",
      "bring VB\n",
      "together RB\n",
      "the DT\n",
      "combination NN\n",
      "of IN\n",
      "Hospira NNP\n",
      "'s POS\n",
      "current JJ\n",
      "inline NN\n",
      "biosimiliars NNS\n",
      "which WDT\n",
      "are VBP\n",
      "already RB\n",
      "in IN\n",
      "the DT\n",
      "market NN\n",
      "So IN\n",
      "we PRP\n",
      "have VBP\n",
      "three CD\n",
      "assets NNS\n",
      "as IN\n",
      "you PRP\n",
      "know VBP\n",
      "which WDT\n",
      "are VBP\n",
      "already RB\n",
      "in IN\n",
      "the DT\n",
      "market NN\n",
      "in IN\n",
      "Europe NNP\n",
      "Nivestim NNP\n",
      "Retacrit NNP\n",
      "and CC\n",
      "Inflectra NNP\n",
      "And CC\n",
      "to TO\n",
      "bring VB\n",
      "that DT\n",
      "together RB\n",
      "along IN\n",
      "with IN\n",
      "the DT\n",
      "legacy NN\n",
      "Pfizer NNP\n",
      "monoclonal JJ\n",
      "antibody NN\n",
      "pipeline NN\n",
      "plus CC\n",
      "some DT\n",
      "additional JJ\n",
      "assets NNS\n",
      "that WDT\n",
      "Hospira NNP\n",
      "have VBP\n",
      "So RB\n",
      "in IN\n",
      "total JJ\n",
      "when WRB\n",
      "you PRP\n",
      "look VBP\n",
      "at IN\n",
      "the DT\n",
      "pipeline NN\n",
      "we PRP\n",
      "have VBP\n",
      "nine CD\n",
      "distinct JJ\n",
      "biosimilar JJ\n",
      "molecules NNS\n",
      "in IN\n",
      "different JJ\n",
      "stages NNS\n",
      "of IN\n",
      "development NN\n",
      "Infliximab NNP\n",
      "outside IN\n",
      "of IN\n",
      "the DT\n",
      "E.U. NNP\n",
      "Adalimumab NNP\n",
      "Trastuzumab NNP\n",
      "Bevacizumab NNP\n",
      "Rituximab NNP\n",
      "Pegfilgrastim NNP\n",
      "Ranibizumab NNP\n",
      "Denosumab NNP\n",
      "and CC\n",
      "Ustekinumab.So NNP\n",
      "overall VBP\n",
      "we PRP\n",
      "have VBP\n",
      "a DT\n",
      "very RB\n",
      "strong JJ\n",
      "pipeline NN\n",
      "A DT\n",
      "number NN\n",
      "of IN\n",
      "those DT\n",
      "assets NNS\n",
      "are VBP\n",
      "in IN\n",
      "Phase NNP\n",
      "III NNP\n",
      "late-phase JJ\n",
      "development NN\n",
      "And CC\n",
      "the DT\n",
      "first JJ\n",
      "dataset NN\n",
      "there EX\n",
      "you PRP\n",
      "'d MD\n",
      "be VB\n",
      "seeing VBG\n",
      "from IN\n",
      "our PRP$\n",
      "Phase NNP\n",
      "III NNP\n",
      "studies NNS\n",
      "would MD\n",
      "come VB\n",
      "from IN\n",
      "the DT\n",
      "legacy NN\n",
      "Pfizer NNP\n",
      "Infliximab NNP\n",
      "program NN\n",
      "where WRB\n",
      "we PRP\n",
      "would MD\n",
      "expect VB\n",
      "to TO\n",
      "produce VB\n",
      "data NNS\n",
      "from IN\n",
      "our PRP$\n",
      "Phase NNP\n",
      "III NNP\n",
      "towards IN\n",
      "the DT\n",
      "end NN\n",
      "of IN\n",
      "this DT\n",
      "year.Jami NN\n",
      "Okay NNP\n",
      "Jami NNP\n",
      "We PRP\n",
      "may MD\n",
      "come VB\n",
      "back RB\n",
      "to TO\n",
      "Jami NNP\n",
      "if IN\n",
      "she PRP\n",
      "'s VBZ\n",
      "if IN\n",
      "we PRP\n",
      "can MD\n",
      "correct VB\n",
      "the DT\n",
      "technical JJ\n",
      "issues NNS\n",
      "If IN\n",
      "not RB\n",
      "let VB\n",
      "'s POS\n",
      "go VB\n",
      "to TO\n",
      "Alex.Good NNP\n",
      "morning NN\n",
      "and CC\n",
      "thank NN\n",
      "you PRP\n",
      "for IN\n",
      "taking VBG\n",
      "the DT\n",
      "questions NNS\n",
      "Frank NNP\n",
      "your PRP$\n",
      "gross JJ\n",
      "margin NN\n",
      "for IN\n",
      "2016 CD\n",
      "is VBZ\n",
      "better JJR\n",
      "than IN\n",
      "we PRP\n",
      "expected VBD\n",
      "considering VBG\n",
      "you PRP\n",
      "'re VBP\n",
      "integrating VBG\n",
      "a DT\n",
      "lower JJR\n",
      "margin NN\n",
      "business NN\n",
      "in IN\n",
      "Hospira NNP\n",
      "and CC\n",
      "losing VBG\n",
      "exclusivity NN\n",
      "on IN\n",
      "some DT\n",
      "high-margin JJ\n",
      "products NNS\n",
      "Can MD\n",
      "you PRP\n",
      "help VB\n",
      "us PRP\n",
      "understand VB\n",
      "what WP\n",
      "'s VBZ\n",
      "driving VBG\n",
      "that IN\n",
      "and CC\n",
      "how WRB\n",
      "we PRP\n",
      "should MD\n",
      "think VB\n",
      "about IN\n",
      "and CC\n",
      "should MD\n",
      "we PRP\n",
      "expect VB\n",
      "traditional JJ\n",
      "margin NN\n",
      "expansion NN\n",
      "going VBG\n",
      "forward RB\n",
      "given VBN\n",
      "that IN\n",
      "your PRP$\n",
      "Innovative JJ\n",
      "business NN\n",
      "is VBZ\n",
      "growing VBG\n",
      "at IN\n",
      "a DT\n",
      "faster NN\n",
      "rate NN\n",
      "And CC\n",
      "then RB\n",
      "on IN\n",
      "Hospira NNP\n",
      "'s POS\n",
      "contribution NN\n",
      "this DT\n",
      "quarter NN\n",
      "it PRP\n",
      "does VBZ\n",
      "n't RB\n",
      "seem VB\n",
      "to TO\n",
      "reflect VB\n",
      "much JJ\n",
      "revenue NN\n",
      "synergies NNS\n",
      "Obviously IN\n",
      "it PRP\n",
      "'s VBZ\n",
      "too RB\n",
      "early JJ\n",
      "but CC\n",
      "how WRB\n",
      "should MD\n",
      "we PRP\n",
      "think VB\n",
      "about IN\n",
      "Hospira NNP\n",
      "'s POS\n",
      "contribution NN\n",
      "next IN\n",
      "year NN\n",
      "and CC\n",
      "possible JJ\n",
      "revenue NN\n",
      "synergies NNS\n",
      "going VBG\n",
      "forward RB\n",
      "Thank NNP\n",
      "you.So NN\n",
      "Alex NNP\n",
      "on IN\n",
      "the DT\n",
      "gross JJ\n",
      "margin NN\n",
      "let VB\n",
      "me PRP\n",
      "run VB\n",
      "the DT\n",
      "numbers NNS\n",
      "and CC\n",
      "then RB\n",
      "I PRP\n",
      "'ll MD\n",
      "answer VB\n",
      "the DT\n",
      "question NN\n",
      "So IN\n",
      "we PRP\n",
      "ended VBD\n",
      "the DT\n",
      "full JJ\n",
      "year NN\n",
      "at IN\n",
      "18.5 CD\n",
      "% NN\n",
      "in IN\n",
      "terms NNS\n",
      "of IN\n",
      "cost NN\n",
      "of IN\n",
      "sale NN\n",
      "So RB\n",
      "I PRP\n",
      "'ll MD\n",
      "do VB\n",
      "the DT\n",
      "cost NN\n",
      "of IN\n",
      "sale NN\n",
      "The DT\n",
      "reciprocal JJ\n",
      "obviously RB\n",
      "is VBZ\n",
      "gross JJ\n",
      "margin NN\n",
      "We PRP\n",
      "got VBD\n",
      "it PRP\n",
      "for IN\n",
      "next JJ\n",
      "year NN\n",
      "across IN\n",
      "the DT\n",
      "sales NNS\n",
      "number NN\n",
      "of IN\n",
      "21 CD\n",
      "% NN\n",
      "to TO\n",
      "22 CD\n",
      "% NN\n",
      "So RB\n",
      "if IN\n",
      "you PRP\n",
      "take VBP\n",
      "the DT\n",
      "midpoint NN\n",
      "of IN\n",
      "that DT\n",
      "21 CD\n",
      "to TO\n",
      "22 CD\n",
      "just RB\n",
      "to TO\n",
      "make VB\n",
      "the DT\n",
      "math NN\n",
      "easy NN\n",
      "that WDT\n",
      "'s VBZ\n",
      "21.5 CD\n",
      "% NN\n",
      "from IN\n",
      "our PRP$\n",
      "18.5 CD\n",
      "% NN\n",
      "That DT\n",
      "'s VBZ\n",
      "a DT\n",
      "3 CD\n",
      "% NN\n",
      "300 CD\n",
      "basis NN\n",
      "point NN\n",
      "increase NN\n",
      "in IN\n",
      "our PRP$\n",
      "cost NN\n",
      "of IN\n",
      "sales NNS\n",
      "as IN\n",
      "a DT\n",
      "percentage NN\n",
      "of IN\n",
      "revenues NNS\n",
      "By IN\n",
      "the DT\n",
      "way NN\n",
      "that WDT\n",
      "'s VBZ\n",
      "being VBG\n",
      "driven VBN\n",
      "by IN\n",
      "a DT\n",
      "few JJ\n",
      "factors NNS\n",
      "but CC\n",
      "one CD\n",
      "of IN\n",
      "which WDT\n",
      "clearly RB\n",
      "is VBZ\n",
      "Hospira.In NNP\n",
      "terms NNS\n",
      "of IN\n",
      "I PRP\n",
      "think VBP\n",
      "your PRP$\n",
      "question NN\n",
      "which WDT\n",
      "was VBD\n",
      "why WRB\n",
      "was VBD\n",
      "n't RB\n",
      "even RB\n",
      "more RBR\n",
      "I PRP\n",
      "think VBP\n",
      "the DT\n",
      "answer NN\n",
      "is VBZ\n",
      "our PRP$\n",
      "ongoing JJ\n",
      "productivity NN\n",
      "and CC\n",
      "cost NN\n",
      "reduction NN\n",
      "initiatives NNS\n",
      "When WRB\n",
      "you PRP\n",
      "think VBP\n",
      "about IN\n",
      "our PRP$\n",
      "factories NNS\n",
      "our PRP$\n",
      "manufacturing NN\n",
      "capabilities NNS\n",
      "we PRP\n",
      "really RB\n",
      "manage VB\n",
      "that IN\n",
      "from IN\n",
      "a DT\n",
      "cost NN\n",
      "perspective NN\n",
      "First NNP\n",
      "of IN\n",
      "all RB\n",
      "we PRP\n",
      "focus VBP\n",
      "that IN\n",
      "on IN\n",
      "quality NN\n",
      "service NN\n",
      "and CC\n",
      "cost NN\n",
      "If IN\n",
      "you PRP\n",
      "think VBP\n",
      "about RB\n",
      "that RB\n",
      "as IN\n",
      "a DT\n",
      "triangle NN\n",
      "quality NN\n",
      "is VBZ\n",
      "at IN\n",
      "the DT\n",
      "top NN\n",
      "of IN\n",
      "the DT\n",
      "triangle NN\n",
      "But CC\n",
      "there EX\n",
      "'s VBZ\n",
      "four CD\n",
      "major JJ\n",
      "buckets NNS\n",
      "right RB\n",
      "There EX\n",
      "'s VBZ\n",
      "the DT\n",
      "number NN\n",
      "of IN\n",
      "facilities NNS\n",
      "there EX\n",
      "'s VBZ\n",
      "the DT\n",
      "numerous JJ\n",
      "quality NN\n",
      "initiatives NNS\n",
      "we PRP\n",
      "have VBP\n",
      "within IN\n",
      "each DT\n",
      "facility NN\n",
      "There EX\n",
      "'s VBZ\n",
      "the DT\n",
      "purchasing NN\n",
      "that IN\n",
      "we PRP\n",
      "can MD\n",
      "get VB\n",
      "from IN\n",
      "a DT\n",
      "leverage NN\n",
      "perspective NN\n",
      "and CC\n",
      "then RB\n",
      "finally RB\n",
      "there EX\n",
      "'s VBZ\n",
      "the DT\n",
      "center NN\n",
      "cost NN\n",
      "that WDT\n",
      "resides VBZ\n",
      "outside IN\n",
      "of IN\n",
      "the DT\n",
      "factories NNS\n",
      "We PRP\n",
      "manage VBP\n",
      "all DT\n",
      "four CD\n",
      "of IN\n",
      "those DT\n",
      "very RB\n",
      "aggressively RB\n",
      "to TO\n",
      "basically RB\n",
      "to TO\n",
      "manage VB\n",
      "our PRP$\n",
      "cost NN\n",
      "structure NN\n",
      "in IN\n",
      "manufacturing NN\n",
      "but CC\n",
      "that IN\n",
      "gives VBZ\n",
      "you PRP\n",
      "a DT\n",
      "feel NN\n",
      "for IN\n",
      "what WP\n",
      "the DT\n",
      "numbers NNS\n",
      "were VBD\n",
      "and CC\n",
      "why WRB\n",
      "they PRP\n",
      "are VBP\n",
      "what WP\n",
      "they PRP\n",
      "are.So VBP\n",
      "thanks NNS\n",
      "Alex NNP\n",
      "So RB\n",
      "obviously RB\n",
      "again RB\n",
      "we PRP\n",
      "are VBP\n",
      "very RB\n",
      "excited VBN\n",
      "by IN\n",
      "the DT\n",
      "opportunities NNS\n",
      "afforded VBD\n",
      "us PRP\n",
      "by IN\n",
      "the DT\n",
      "combination NN\n",
      "of IN\n",
      "our PRP$\n",
      "two CD\n",
      "businesses NNS\n",
      "And CC\n",
      "I PRP\n",
      "think VBP\n",
      "I PRP\n",
      "'ve VBP\n",
      "talked VBN\n",
      "about IN\n",
      "biosimilars NNS\n",
      "already RB\n",
      "and CC\n",
      "the DT\n",
      "opportunities NNS\n",
      "we PRP\n",
      "see VBP\n",
      "in IN\n",
      "that DT\n",
      "marketplace NN\n",
      "So RB\n",
      "let VB\n",
      "me PRP\n",
      "just RB\n",
      "touch VB\n",
      "briefly NN\n",
      "on IN\n",
      "sterile JJ\n",
      "injectables NNS\n",
      "Obviously IN\n",
      "it PRP\n",
      "'s VBZ\n",
      "a DT\n",
      "very RB\n",
      "it PRP\n",
      "'s VBZ\n",
      "a DT\n",
      "large JJ\n",
      "it PRP\n",
      "'s VBZ\n",
      "a DT\n",
      "growing VBG\n",
      "market NN\n",
      "It PRP\n",
      "'s VBZ\n",
      "somewhere RB\n",
      "between IN\n",
      "50 CD\n",
      "billion CD\n",
      "to TO\n",
      "70 CD\n",
      "billion CD\n",
      "currently RB\n",
      "globally RB\n",
      "and CC\n",
      "one CD\n",
      "of IN\n",
      "the DT\n",
      "sort NN\n",
      "of IN\n",
      "features NNS\n",
      "of IN\n",
      "that DT\n",
      "market NN\n",
      "is VBZ\n",
      "it PRP\n",
      "'s VBZ\n",
      "very RB\n",
      "concentrated JJ\n",
      "particularly RB\n",
      "in IN\n",
      "the DT\n",
      "U.S. NNP\n",
      "but CC\n",
      "also RB\n",
      "in IN\n",
      "a DT\n",
      "few JJ\n",
      "ex-U.S. JJ\n",
      "markets NNS\n",
      "such JJ\n",
      "as IN\n",
      "Western NNP\n",
      "Europe NNP\n",
      "and CC\n",
      "particularly RB\n",
      "China.So NNP\n",
      "one CD\n",
      "of IN\n",
      "the DT\n",
      "things NNS\n",
      "that IN\n",
      "we PRP\n",
      "are VBP\n",
      "very RB\n",
      "focused JJ\n",
      "on IN\n",
      "is VBZ\n",
      "going VBG\n",
      "to TO\n",
      "be VB\n",
      "revenue NN\n",
      "synergy NN\n",
      "We PRP\n",
      "obviously RB\n",
      "have VBP\n",
      "a DT\n",
      "strong JJ\n",
      "commercial JJ\n",
      "presence NN\n",
      "in IN\n",
      "China NNP\n",
      "and CC\n",
      "also RB\n",
      "in IN\n",
      "the DT\n",
      "hospital NN\n",
      "segment NN\n",
      "in IN\n",
      "developed VBN\n",
      "Europe NNP\n",
      "and CC\n",
      "emerging VBG\n",
      "Europe NNP\n",
      "So RB\n",
      "essentially RB\n",
      "the DT\n",
      "lag NN\n",
      "time NN\n",
      "since IN\n",
      "September NNP\n",
      "when WRB\n",
      "we PRP\n",
      "closed VBD\n",
      "this DT\n",
      "transaction NN\n",
      "we PRP\n",
      "'ve VBP\n",
      "been VBN\n",
      "focused VBN\n",
      "really RB\n",
      "on IN\n",
      "making VBG\n",
      "sure JJ\n",
      "that IN\n",
      "we PRP\n",
      "have VBP\n",
      "our PRP$\n",
      "blocking NN\n",
      "and CC\n",
      "tackling VBG\n",
      "in IN\n",
      "place NN\n",
      "to TO\n",
      "be VB\n",
      "very RB\n",
      "systematic JJ\n",
      "with IN\n",
      "our PRP$\n",
      "highest JJS\n",
      "value NN\n",
      "molecules VBZ\n",
      "that IN\n",
      "really RB\n",
      "sort VB\n",
      "of IN\n",
      "meet NN\n",
      "market NN\n",
      "needs VBZ\n",
      "most RBS\n",
      "appropriately RB\n",
      "To TO\n",
      "be VB\n",
      "very RB\n",
      "focused JJ\n",
      "on IN\n",
      "registering VBG\n",
      "and CC\n",
      "brining VBG\n",
      "those DT\n",
      "molecules NNS\n",
      "to TO\n",
      "market.So VB\n",
      "in IN\n",
      "the DT\n",
      "biggest JJS\n",
      "opportunity NN\n",
      "that IN\n",
      "we PRP\n",
      "have VBP\n",
      "in IN\n",
      "China NNP\n",
      "that WDT\n",
      "is VBZ\n",
      "going VBG\n",
      "to TO\n",
      "take VB\n",
      "time NN\n",
      "as IN\n",
      "you PRP\n",
      "are VBP\n",
      "very RB\n",
      "well RB\n",
      "aware JJ\n",
      "Drug NNP\n",
      "lag NN\n",
      "in IN\n",
      "China NNP\n",
      "is VBZ\n",
      "a DT\n",
      "significant JJ\n",
      "issue NN\n",
      "but CC\n",
      "we PRP\n",
      "'re VBP\n",
      "very RB\n",
      "encouraged VBN\n",
      "by IN\n",
      "the DT\n",
      "progress NN\n",
      "that IN\n",
      "the DT\n",
      "CFDA NNP\n",
      "are VBP\n",
      "making VBG\n",
      "to TO\n",
      "accelerate VB\n",
      "access NN\n",
      "to TO\n",
      "important JJ\n",
      "new JJ\n",
      "medicines NNS\n",
      "in IN\n",
      "China NNP\n",
      "But CC\n",
      "that DT\n",
      "will MD\n",
      "take VB\n",
      "time NN\n",
      "But CC\n",
      "we PRP\n",
      "do VBP\n",
      "see VB\n",
      "opportunities NNS\n",
      "both DT\n",
      "in IN\n",
      "the DT\n",
      "short-term JJ\n",
      "as RB\n",
      "well RB\n",
      "as IN\n",
      "medium NN\n",
      "and CC\n",
      "long-term JJ\n",
      "to TO\n",
      "deliver VB\n",
      "significant JJ\n",
      "growth NN\n",
      "ex-U.S. JJ\n",
      "through IN\n",
      "the DT\n",
      "sterile JJ\n",
      "injectable JJ\n",
      "business NN\n",
      "and CC\n",
      "the DT\n",
      "combination NN\n",
      "of IN\n",
      "Hospira NNP\n",
      "'s POS\n",
      "portfolio NN\n",
      "into IN\n",
      "our PRP$\n",
      "commercial JJ\n",
      "footprint.Thank NN\n",
      "you PRP\n",
      "Sorry NN\n",
      "about IN\n",
      "that DT\n",
      "Do VBP\n",
      "n't RB\n",
      "really RB\n",
      "know VB\n",
      "what WP\n",
      "happened VBD\n",
      "on IN\n",
      "my PRP$\n",
      "end NN\n",
      "but CC\n",
      "anyway RB\n",
      "just RB\n",
      "a DT\n",
      "few JJ\n",
      "questions NNS\n",
      "Frank NNP\n",
      "can MD\n",
      "you PRP\n",
      "tell VB\n",
      "us PRP\n",
      "what WP\n",
      "the DT\n",
      "Venezuela NNP\n",
      "revenues NNS\n",
      "are VBP\n",
      "I PRP\n",
      "guess VBP\n",
      "we PRP\n",
      "are VBP\n",
      "in IN\n",
      "consensus NN\n",
      "we PRP\n",
      "'re VBP\n",
      "surprised VBN\n",
      "by IN\n",
      "the DT\n",
      "size NN\n",
      "of IN\n",
      "the DT\n",
      "hit NN\n",
      "can MD\n",
      "you PRP\n",
      "all DT\n",
      "hear VBP\n",
      "me PRP\n",
      "Okay NNP\n",
      "sorry VBP\n",
      "about IN\n",
      "that DT\n",
      "Anyway RB\n",
      "so RB\n",
      "Frank NNP\n",
      "if IN\n",
      "you PRP\n",
      "could MD\n",
      "just RB\n",
      "provide VB\n",
      "more JJR\n",
      "color NN\n",
      "on IN\n",
      "Venezuela NNP\n",
      "And CC\n",
      "why WRB\n",
      "such PDT\n",
      "a DT\n",
      "big JJ\n",
      "hit NN\n",
      "And CC\n",
      "then RB\n",
      "Ian NNP\n",
      "just RB\n",
      "a DT\n",
      "couple NN\n",
      "of IN\n",
      "questions NNS\n",
      "for IN\n",
      "you PRP\n",
      "just RB\n",
      "back RB\n",
      "on IN\n",
      "this DT\n",
      "whole JJ\n",
      "breakup NN\n",
      "thesis NN\n",
      "and CC\n",
      "the DT\n",
      "timing NN\n",
      "I PRP\n",
      "think VBP\n",
      "investors NNS\n",
      "initially RB\n",
      "were VBD\n",
      "disappointed VBN\n",
      "by IN\n",
      "the DT\n",
      "timing NN\n",
      "that IN\n",
      "you PRP\n",
      "laid VBD\n",
      "out RP\n",
      "at IN\n",
      "the DT\n",
      "time NN\n",
      "that IN\n",
      "you PRP\n",
      "were VBD\n",
      "announcing VBG\n",
      "Allergan NNP\n",
      "deal NN\n",
      "I PRP\n",
      "think VBP\n",
      "you PRP\n",
      "said VBD\n",
      "you PRP\n",
      "would MD\n",
      "make VB\n",
      "a DT\n",
      "decision NN\n",
      "by IN\n",
      "the DT\n",
      "end NN\n",
      "of IN\n",
      "2018 CD\n",
      "I PRP\n",
      "just RB\n",
      "want VBP\n",
      "to TO\n",
      "put VB\n",
      "out RP\n",
      "there RB\n",
      "that IN\n",
      "the DT\n",
      "stock NN\n",
      "has VBZ\n",
      "pulled VBN\n",
      "back RP\n",
      "quite RB\n",
      "a DT\n",
      "bit NN\n",
      "since IN\n",
      "you PRP\n",
      "announced VBD\n",
      "the DT\n",
      "Allergan NNP\n",
      "deal NN\n",
      "and CC\n",
      "I PRP\n",
      "would MD\n",
      "think VB\n",
      "despite IN\n",
      "clearly RB\n",
      "the DT\n",
      "market NN\n",
      "is VBZ\n",
      "excited VBN\n",
      "about IN\n",
      "this DT\n",
      "but CC\n",
      "I PRP\n",
      "would MD\n",
      "think VB\n",
      "that IN\n",
      "that DT\n",
      "would MD\n",
      "that IN\n",
      "the DT\n",
      "difference NN\n",
      "in IN\n",
      "even RB\n",
      "growing VBG\n",
      "gap NN\n",
      "in IN\n",
      "valuation NN\n",
      "between IN\n",
      "where WRB\n",
      "your PRP$\n",
      "stock NN\n",
      "is VBZ\n",
      "in IN\n",
      "an DT\n",
      "SOTP NNP\n",
      "should MD\n",
      "help VB\n",
      "you PRP\n",
      "to TO\n",
      "accelerate VB\n",
      "your PRP$\n",
      "decision NN\n",
      "to TO\n",
      "move VB\n",
      "in IN\n",
      "that DT\n",
      "direction NN\n",
      "and CC\n",
      "if IN\n",
      "you PRP\n",
      "could MD\n",
      "just RB\n",
      "comment VB\n",
      "on IN\n",
      "that DT\n",
      "please.And NN\n",
      "then RB\n",
      "just RB\n",
      "thirdly RB\n",
      "on IN\n",
      "revenue NN\n",
      "growth NN\n",
      "I PRP\n",
      "mean VBP\n",
      "clearly RB\n",
      "there EX\n",
      "have VBP\n",
      "been VBN\n",
      "tons NNS\n",
      "of IN\n",
      "pushes NNS\n",
      "and CC\n",
      "pulls NNS\n",
      "in IN\n",
      "your PRP$\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "numbers NNS\n",
      "mostly RB\n",
      "currency NN\n",
      "and CC\n",
      "patent NN\n",
      "expirations NNS\n",
      "Can MD\n",
      "you PRP\n",
      "remind VB\n",
      "us PRP\n",
      "when WRB\n",
      "you PRP\n",
      "expect VBP\n",
      "and CC\n",
      "this DT\n",
      "excludes VBZ\n",
      "the DT\n",
      "acquisition NN\n",
      "from IN\n",
      "Allergan NNP\n",
      "but CC\n",
      "when WRB\n",
      "you PRP\n",
      "expect VBP\n",
      "your PRP$\n",
      "reported JJ\n",
      "revenue NN\n",
      "growth NN\n",
      "or CC\n",
      "just RB\n",
      "talk VB\n",
      "about IN\n",
      "operationally RB\n",
      "revenue NN\n",
      "growth NN\n",
      "when WRB\n",
      "we PRP\n",
      "should MD\n",
      "start VB\n",
      "to TO\n",
      "see VB\n",
      "a DT\n",
      "positive JJ\n",
      "inflection NN\n",
      "point NN\n",
      "because IN\n",
      "it PRP\n",
      "has VBZ\n",
      "when WRB\n",
      "I PRP\n",
      "look VBP\n",
      "at IN\n",
      "my PRP$\n",
      "models NNS\n",
      "revenues NNS\n",
      "have VBP\n",
      "been VBN\n",
      "in IN\n",
      "decline NN\n",
      "for IN\n",
      "many JJ\n",
      "years NNS\n",
      "and CC\n",
      "some DT\n",
      "of IN\n",
      "that DT\n",
      "'s VBZ\n",
      "divestitures NNS\n",
      "and CC\n",
      "spins NNS\n",
      "but CC\n",
      "really RB\n",
      "since IN\n",
      "2013 CD\n",
      "we PRP\n",
      "'ve VBP\n",
      "had VBD\n",
      "revenues NNS\n",
      "sort NN\n",
      "of IN\n",
      "flat JJ\n",
      "to TO\n",
      "down RB\n",
      "When WRB\n",
      "is VBZ\n",
      "that IN\n",
      "going VBG\n",
      "to TO\n",
      "change VB\n",
      "and CC\n",
      "what WP\n",
      "'s VBZ\n",
      "going VBG\n",
      "to TO\n",
      "drive VB\n",
      "that IN\n",
      "change NN\n",
      "just RB\n",
      "talking VBG\n",
      "from IN\n",
      "Pfizer NNP\n",
      "'s POS\n",
      "standpoint NN\n",
      "Thanks NNS\n",
      "very RB\n",
      "much.Let VB\n",
      "me PRP\n",
      "just RB\n",
      "do VBP\n",
      "the DT\n",
      "revenue NN\n",
      "growth NN\n",
      "first RB\n",
      "Well RB\n",
      "you PRP\n",
      "know VBP\n",
      "as IN\n",
      "I PRP\n",
      "said VBD\n",
      "was VBD\n",
      "the DT\n",
      "first JJ\n",
      "year NN\n",
      "when WRB\n",
      "we PRP\n",
      "saw VBD\n",
      "revenue NN\n",
      "growth NN\n",
      "'16 CC\n",
      "we PRP\n",
      "expect VBP\n",
      "it PRP\n",
      "to TO\n",
      "be VB\n",
      "around IN\n",
      "operationally RB\n",
      "narrow JJ\n",
      "We PRP\n",
      "expect VBP\n",
      "it PRP\n",
      "to TO\n",
      "be VB\n",
      "Hospira NNP\n",
      "and CC\n",
      "Allergan NNP\n",
      "we PRP\n",
      "expect VBP\n",
      "it PRP\n",
      "to TO\n",
      "be VB\n",
      "flat JJ\n",
      "and CC\n",
      "that DT\n",
      "'s VBZ\n",
      "because IN\n",
      "we PRP\n",
      "had VBD\n",
      "a DT\n",
      "huge JJ\n",
      "growth NN\n",
      "from IN\n",
      "adult NN\n",
      "vaccine NN\n",
      "in IN\n",
      "'15 NNP\n",
      "and CC\n",
      "we PRP\n",
      "'ll MD\n",
      "hold VB\n",
      "that IN\n",
      "franchise NN\n",
      "We PRP\n",
      "wo MD\n",
      "n't RB\n",
      "grow VB\n",
      "it PRP\n",
      "again RB\n",
      "We PRP\n",
      "'ll MD\n",
      "have VB\n",
      "good JJ\n",
      "growth NN\n",
      "from IN\n",
      "our PRP$\n",
      "inline NN\n",
      "products NNS\n",
      "and CC\n",
      "our PRP$\n",
      "newly RB\n",
      "launched VBN\n",
      "products NNS\n",
      "but CC\n",
      "we PRP\n",
      "'ll MD\n",
      "still RB\n",
      "deal VB\n",
      "with IN\n",
      "a DT\n",
      "couple NN\n",
      "of IN\n",
      "billion CD\n",
      "of IN\n",
      "LOEs NNP\n",
      "So RB\n",
      "I PRP\n",
      "think VBP\n",
      "you PRP\n",
      "can MD\n",
      "begin VB\n",
      "to TO\n",
      "see VB\n",
      "as IN\n",
      "we PRP\n",
      "launch VBP\n",
      "as IN\n",
      "we PRP\n",
      "begin VBP\n",
      "to TO\n",
      "get VB\n",
      "more JJR\n",
      "traction NN\n",
      "with IN\n",
      "more RBR\n",
      "clinical JJ\n",
      "trial NN\n",
      "in IN\n",
      "Ibrance NNP\n",
      "as IN\n",
      "we PRP\n",
      "begin VBP\n",
      "to TO\n",
      "see VB\n",
      "the DT\n",
      "launch NN\n",
      "as IN\n",
      "we PRP\n",
      "begin VBP\n",
      "to TO\n",
      "see VB\n",
      "our PRP$\n",
      "next JJ\n",
      "wave NN\n",
      "of IN\n",
      "products NNS\n",
      "get VBP\n",
      "approved VBN\n",
      "you PRP\n",
      "'ll MD\n",
      "see VB\n",
      "us PRP\n",
      "returning VBG\n",
      "to TO\n",
      "a DT\n",
      "very RB\n",
      "robust JJ\n",
      "growth NN\n",
      "But CC\n",
      "obviously RB\n",
      "Jami NNP\n",
      "one CD\n",
      "of IN\n",
      "the DT\n",
      "reasons NNS\n",
      "for IN\n",
      "doing VBG\n",
      "the DT\n",
      "Allergan NNP\n",
      "deal NN\n",
      "was VBD\n",
      "in IN\n",
      "fact NN\n",
      "to TO\n",
      "ensure VB\n",
      "that IN\n",
      "we PRP\n",
      "had VBD\n",
      "robust JJ\n",
      "growth NN\n",
      "in IN\n",
      "our PRP$\n",
      "innovative JJ\n",
      "business NN\n",
      "So IN\n",
      "we PRP\n",
      "'re VBP\n",
      "aware JJ\n",
      "of IN\n",
      "that DT\n",
      "issue.Now NN\n",
      "this DT\n",
      "is VBZ\n",
      "the DT\n",
      "breakup NN\n",
      "timing NN\n",
      "Number NNP\n",
      "one CD\n",
      "I PRP\n",
      "point VBP\n",
      "out RP\n",
      "that IN\n",
      "while IN\n",
      "the DT\n",
      "stock NN\n",
      "is VBZ\n",
      "down RB\n",
      "I PRP\n",
      "do VBP\n",
      "n't RB\n",
      "think VB\n",
      "it PRP\n",
      "'s VBZ\n",
      "specifically RB\n",
      "down RB\n",
      "more RBR\n",
      "than IN\n",
      "a DT\n",
      "DRG NNP\n",
      "In IN\n",
      "fact NN\n",
      "I PRP\n",
      "think VBP\n",
      "it PRP\n",
      "'s VBZ\n",
      "roughly RB\n",
      "the DT\n",
      "same JJ\n",
      "as IN\n",
      "a DT\n",
      "DRG NNP\n",
      "and CC\n",
      "in IN\n",
      "fact NN\n",
      "given VBN\n",
      "the DT\n",
      "our PRP$\n",
      "pressure NN\n",
      "that IN\n",
      "one CD\n",
      "would MD\n",
      "expect VB\n",
      "in IN\n",
      "a DT\n",
      "stock NN\n",
      "I PRP\n",
      "'m VBP\n",
      "actually RB\n",
      "well RB\n",
      "never RB\n",
      "like IN\n",
      "to TO\n",
      "see VB\n",
      "the DT\n",
      "stock NN\n",
      "go VBP\n",
      "down RB\n",
      "It PRP\n",
      "certainly RB\n",
      "was VBD\n",
      "expected VBN\n",
      "to TO\n",
      "come VB\n",
      "under IN\n",
      "pressure NN\n",
      "from IN\n",
      "the DT\n",
      "odd NN\n",
      "community.Now VBZ\n",
      "the DT\n",
      "breakup NN\n",
      "timing NN\n",
      "is VBZ\n",
      "an DT\n",
      "issue NN\n",
      "of IN\n",
      "we PRP\n",
      "are VBP\n",
      "focused VBN\n",
      "on IN\n",
      "integrating VBG\n",
      "this DT\n",
      "company NN\n",
      "and CC\n",
      "the DT\n",
      "two CD\n",
      "companies NNS\n",
      "together RB\n",
      "and CC\n",
      "we PRP\n",
      "have VBP\n",
      "laid VBN\n",
      "out RP\n",
      "the DT\n",
      "full JJ\n",
      "questions NNS\n",
      "that IN\n",
      "we PRP\n",
      "need VBP\n",
      "to TO\n",
      "answer VB\n",
      "And CC\n",
      "I PRP\n",
      "think VBP\n",
      "shareholder NN\n",
      "would MD\n",
      "want VB\n",
      "those DT\n",
      "questions NNS\n",
      "answered VBD\n",
      "So RB\n",
      "can MD\n",
      "we PRP\n",
      "run VB\n",
      "the DT\n",
      "businesses NNS\n",
      "successfully RB\n",
      "insider VBP\n",
      "Pfizer NNP\n",
      "And CC\n",
      "we PRP\n",
      "bought VBD\n",
      "Hospira NNP\n",
      "You PRP\n",
      "are VBP\n",
      "seeing VBG\n",
      "the DT\n",
      "sterile JJ\n",
      "injectables NNS\n",
      "You PRP\n",
      "have VBP\n",
      "got VBN\n",
      "the DT\n",
      "Biosimilars NNP\n",
      "You PRP\n",
      "'re VBP\n",
      "beginning VBG\n",
      "to TO\n",
      "see VB\n",
      "if IN\n",
      "you PRP\n",
      "strip VBP\n",
      "out RP\n",
      "the DT\n",
      "LOEs NNP\n",
      "and CC\n",
      "stabilization NN\n",
      "of IN\n",
      "the DT\n",
      "core NN\n",
      "business NN\n",
      "which WDT\n",
      "we PRP\n",
      "expect VBP\n",
      "to TO\n",
      "return VB\n",
      "to TO\n",
      "growth NN\n",
      "but CC\n",
      "that IN\n",
      "being VBG\n",
      "said VBD\n",
      "we PRP\n",
      "can MD\n",
      "run VB\n",
      "it PRP\n",
      "well RB\n",
      "inside IN\n",
      "Pfizer NNP\n",
      "Can MD\n",
      "it PRP\n",
      "be VB\n",
      "run VBN\n",
      "better RBR\n",
      "outside JJ\n",
      "Pfizer NNP\n",
      "Is VBZ\n",
      "there EX\n",
      "trade NN\n",
      "value NN\n",
      "and CC\n",
      "can MD\n",
      "we PRP\n",
      "unlock VB\n",
      "trade NN\n",
      "value NN\n",
      "in IN\n",
      "tax NN\n",
      "efficient NN\n",
      "manner NN\n",
      "And CC\n",
      "these DT\n",
      "are VBP\n",
      "the DT\n",
      "very RB\n",
      "serious JJ\n",
      "questions NNS\n",
      "These DT\n",
      "are VBP\n",
      "very RB\n",
      "large JJ\n",
      "companies NNS\n",
      "And CC\n",
      "I PRP\n",
      "think VBP\n",
      "that IN\n",
      "by IN\n",
      "innovating VBG\n",
      "we PRP\n",
      "will MD\n",
      "be VB\n",
      "well RB\n",
      "positioned VBN\n",
      "to TO\n",
      "make VB\n",
      "that DT\n",
      "decision NN\n",
      "in IN\n",
      "the DT\n",
      "best JJS\n",
      "interest NN\n",
      "of IN\n",
      "our PRP$\n",
      "shareholders NNS\n",
      "And CC\n",
      "frankly RB\n",
      "do VBP\n",
      "n't RB\n",
      "particularly RB\n",
      "see VB\n",
      "a DT\n",
      "way NN\n",
      "of IN\n",
      "short-circuiting NN\n",
      "that WDT\n",
      "just RB\n",
      "because IN\n",
      "of IN\n",
      "the DT\n",
      "amount NN\n",
      "of IN\n",
      "work NN\n",
      "that WDT\n",
      "has VBZ\n",
      "to TO\n",
      "be VB\n",
      "done VBN\n",
      "and CC\n",
      "integration NN\n",
      "and CC\n",
      "getting VBG\n",
      "the DT\n",
      "transaction NN\n",
      "of IN\n",
      "Allergan NNP\n",
      "right NN\n",
      "I PRP\n",
      "do VBP\n",
      "understand VB\n",
      "your PRP$\n",
      "wish NN\n",
      "for IN\n",
      "more JJR\n",
      "speedy JJ\n",
      "decision NN\n",
      "but CC\n",
      "I PRP\n",
      "think VBP\n",
      "we PRP\n",
      "are VBP\n",
      "taking VBG\n",
      "the DT\n",
      "right JJ\n",
      "approach NN\n",
      "for IN\n",
      "shareholder NN\n",
      "value NN\n",
      "here.So NN\n",
      "Jami NNP\n",
      "the DT\n",
      "Venezuela NNP\n",
      "revenues NNS\n",
      "for IN\n",
      "I PRP\n",
      "'ll MD\n",
      "call VB\n",
      "it PRP\n",
      "initially RB\n",
      "projected VBD\n",
      "for IN\n",
      "2016 CD\n",
      "were VBD\n",
      "about IN\n",
      "800 CD\n",
      "million CD\n",
      "roughly RB\n",
      "the DT\n",
      "same JJ\n",
      "size NN\n",
      "as IN\n",
      "2015 CD\n",
      "If IN\n",
      "you PRP\n",
      "look VBP\n",
      "at IN\n",
      "the DT\n",
      "adjustments NNS\n",
      "we PRP\n",
      "took VBD\n",
      "we PRP\n",
      "changed VBD\n",
      "the DT\n",
      "exchange NN\n",
      "rate NN\n",
      "from IN\n",
      "6.3 CD\n",
      "Bolivar NNP\n",
      "to TO\n",
      "a DT\n",
      "dollar NN\n",
      "to TO\n",
      "200 CD\n",
      "Bolivar NNP\n",
      "to TO\n",
      "dollar NN\n",
      "We PRP\n",
      "went VBD\n",
      "to TO\n",
      "the DT\n",
      "SIMADI NNP\n",
      "rate NN\n",
      "for IN\n",
      "Venezuela NNP\n",
      "That DT\n",
      "change NN\n",
      "in IN\n",
      "the DT\n",
      "translation NN\n",
      "is VBZ\n",
      "what WP\n",
      "causes VBZ\n",
      "the DT\n",
      "adjustment NN\n",
      "that IN\n",
      "we PRP\n",
      "made VBD\n",
      "for IN\n",
      "2016 CD\n",
      "and CC\n",
      "we PRP\n",
      "thought VBD\n",
      "that IN\n",
      "the DT\n",
      "timing NN\n",
      "of IN\n",
      "that DT\n",
      "adjustment NN\n",
      "was VBD\n",
      "appropriate JJ\n",
      "given VBN\n",
      "oil NN\n",
      "prices NNS\n",
      "given VBN\n",
      "what WP\n",
      "'s VBZ\n",
      "going VBG\n",
      "on IN\n",
      "in IN\n",
      "Venezuela NNP\n",
      "economically RB\n",
      "given VBN\n",
      "the DT\n",
      "dollars NNS\n",
      "that WDT\n",
      "are VBP\n",
      "coming VBG\n",
      "out IN\n",
      "of IN\n",
      "Venezuela NNP\n",
      "we PRP\n",
      "thought VBD\n",
      "the DT\n",
      "timing NN\n",
      "for IN\n",
      "this DT\n",
      "was VBD\n",
      "appropriate JJ\n",
      "But CC\n",
      "it PRP\n",
      "'s VBZ\n",
      "really RB\n",
      "the DT\n",
      "6.3 CD\n",
      "to TO\n",
      "200 CD\n",
      "to TO\n",
      "the DT\n",
      "dollar NN\n",
      "conversion NN\n",
      "that WDT\n",
      "'s VBZ\n",
      "really RB\n",
      "causing VBG\n",
      "the DT\n",
      "adjustment NN\n",
      "to TO\n",
      "2016.Now CD\n",
      "Jami NNP\n",
      "ongoing VBG\n",
      "when WRB\n",
      "Venezuela NNP\n",
      "passes VBZ\n",
      "through IN\n",
      "this DT\n",
      "crisis NN\n",
      "and CC\n",
      "they PRP\n",
      "re-establish VBP\n",
      "a DT\n",
      "normal JJ\n",
      "economy NN\n",
      "we PRP\n",
      "would MD\n",
      "expect VB\n",
      "Venezuela NNP\n",
      "to TO\n",
      "grow VB\n",
      "back RB\n",
      "to TO\n",
      "be VB\n",
      "in IN\n",
      "the DT\n",
      "between IN\n",
      "200 CD\n",
      "and CC\n",
      "400 CD\n",
      "million CD\n",
      "a DT\n",
      "year NN\n",
      "So IN\n",
      "the DT\n",
      "actual JJ\n",
      "delta NN\n",
      "medium-term NN\n",
      "is VBZ\n",
      "for IN\n",
      "the DT\n",
      "400 CD\n",
      "million CD\n",
      "between IN\n",
      "what WDT\n",
      "was VBD\n",
      "an DT\n",
      "overvalued JJ\n",
      "currency.Hi NN\n",
      "Three CD\n",
      "questions NNS\n",
      "please VBP\n",
      "two CD\n",
      "of IN\n",
      "them PRP\n",
      "of IN\n",
      "very RB\n",
      "short JJ\n",
      "Firstly RB\n",
      "perhaps RB\n",
      "you PRP\n",
      "could MD\n",
      "just RB\n",
      "outline VB\n",
      "sequential JJ\n",
      "growth NN\n",
      "for IN\n",
      "China NNP\n",
      "say VBP\n",
      "[ JJ\n",
      "technical JJ\n",
      "difficulty NN\n",
      "] NN\n",
      "last JJ\n",
      "quarter NN\n",
      "Second NNP\n",
      "do VBP\n",
      "you PRP\n",
      "anticipate VB\n",
      "extra JJ\n",
      "notice NN\n",
      "from IN\n",
      "Treasury NNP\n",
      "on IN\n",
      "conversion NN\n",
      "and CC\n",
      "obviously RB\n",
      "[ JJ\n",
      "technical JJ\n",
      "difficulty NN\n",
      "] NNP\n",
      "how WRB\n",
      "restricted JJ\n",
      "do VBP\n",
      "you PRP\n",
      "see VB\n",
      "any DT\n",
      "measures NNS\n",
      "to TO\n",
      "impact VB\n",
      "the DT\n",
      "Allergan NNP\n",
      "transaction NN\n",
      "And CC\n",
      "then RB\n",
      "finally RB\n",
      "just RB\n",
      "returning VBG\n",
      "to TO\n",
      "[ VB\n",
      "indiscernible JJ\n",
      "] NN\n",
      "the DT\n",
      "patients NNS\n",
      "in IN\n",
      "the DT\n",
      "ongoing JJ\n",
      "Phase NNP\n",
      "2 CD\n",
      "trial NN\n",
      "which WDT\n",
      "accelerates VBZ\n",
      "approval NN\n",
      "that WDT\n",
      "have VBP\n",
      "not RB\n",
      "seen VBN\n",
      "Palbociclib NNP\n",
      "in IN\n",
      "early JJ\n",
      "line NN\n",
      "of IN\n",
      "therapy NN\n",
      "is VBZ\n",
      "that IN\n",
      "an DT\n",
      "approval NN\n",
      "possessing VBG\n",
      "given VBN\n",
      "the DT\n",
      "design NN\n",
      "of IN\n",
      "that DT\n",
      "trial NN\n",
      "given VBN\n",
      "the DT\n",
      "fact NN\n",
      "you PRP\n",
      "are VBP\n",
      "approved VBN\n",
      "for IN\n",
      "indication NN\n",
      "or CC\n",
      "does VBZ\n",
      "that IN\n",
      "include VB\n",
      "any DT\n",
      "regulatory JJ\n",
      "approval NN\n",
      "for IN\n",
      "the DT\n",
      "drug NN\n",
      "Thank NNP\n",
      "you.Okay NN\n",
      "I PRP\n",
      "am VBP\n",
      "going VBG\n",
      "to TO\n",
      "do VB\n",
      "the DT\n",
      "notice NN\n",
      "first RB\n",
      "We PRP\n",
      "at IN\n",
      "the DT\n",
      "moment NN\n",
      "understand NN\n",
      "that IN\n",
      "the DT\n",
      "Treasury NNP\n",
      "are VBP\n",
      "working VBG\n",
      "on IN\n",
      "formalizing VBG\n",
      "and CC\n",
      "regulating VBG\n",
      "the DT\n",
      "first JJ\n",
      "two CD\n",
      "notices NNS\n",
      "they PRP\n",
      "issued VBD\n",
      "which WDT\n",
      "are VBP\n",
      "not RB\n",
      "in IN\n",
      "many JJ\n",
      "ways NNS\n",
      "applicable JJ\n",
      "to TO\n",
      "our PRP$\n",
      "transaction NN\n",
      "as IN\n",
      "we PRP\n",
      "'re VBP\n",
      "at IN\n",
      "the DT\n",
      "below JJ\n",
      "50 CD\n",
      "% NN\n",
      "ownership.I NN\n",
      "really RB\n",
      "ca MD\n",
      "n't RB\n",
      "speculate VB\n",
      "if IN\n",
      "there EX\n",
      "is VBZ\n",
      "going VBG\n",
      "to TO\n",
      "be VB\n",
      "a DT\n",
      "third JJ\n",
      "notice NN\n",
      "or CC\n",
      "not RB\n",
      "We PRP\n",
      "feel VBP\n",
      "confident JJ\n",
      "the DT\n",
      "transaction NN\n",
      "is VBZ\n",
      "fully RB\n",
      "within IN\n",
      "the DT\n",
      "U.S. NNP\n",
      "law NN\n",
      "and CC\n",
      "fully RB\n",
      "within IN\n",
      "accepted JJ\n",
      "interpretation NN\n",
      "of IN\n",
      "that DT\n",
      "law NN\n",
      "and CC\n",
      "expect VBP\n",
      "the DT\n",
      "transaction NN\n",
      "to TO\n",
      "close VB\n",
      "in IN\n",
      "the DT\n",
      "second JJ\n",
      "half NN\n",
      "of IN\n",
      "next JJ\n",
      "year.With NN\n",
      "that IN\n",
      "I PRP\n",
      "'ll MD\n",
      "go VB\n",
      "to TO\n",
      "growth NN\n",
      "to TO\n",
      "Frank NNP\n",
      "and CC\n",
      "I PRP\n",
      "would MD\n",
      "ask VB\n",
      "Mikael NNP\n",
      "to TO\n",
      "talk VB\n",
      "about IN\n",
      "Palbociclib.On NNP\n",
      "China NNP\n",
      "for IN\n",
      "the DT\n",
      "quarter NN\n",
      "China NNP\n",
      "grew VBD\n",
      "10 CD\n",
      "% NN\n",
      "Full CD\n",
      "year NN\n",
      "China NNP\n",
      "grew VBD\n",
      "about RB\n",
      "10 CD\n",
      "% NN\n",
      "Nice JJ\n",
      "numbers NNS\n",
      "Somewhat RB\n",
      "moderated VBN\n",
      "from IN\n",
      "2014 CD\n",
      "In IN\n",
      "2014 CD\n",
      "China NNP\n",
      "grew VBD\n",
      "to TO\n",
      "about IN\n",
      "15 CD\n",
      "% NN\n",
      "So RB\n",
      "we PRP\n",
      "saw VBD\n",
      "some DT\n",
      "moderation NN\n",
      "in IN\n",
      "the DT\n",
      "growth NN\n",
      "in IN\n",
      "China.That NNP\n",
      "said VBD\n",
      "Andrew NNP\n",
      "we PRP\n",
      "remain VBP\n",
      "very RB\n",
      "bullish JJ\n",
      "on IN\n",
      "China NNP\n",
      "Has NNP\n",
      "an DT\n",
      "increasing VBG\n",
      "population NN\n",
      "increasing VBG\n",
      "personal JJ\n",
      "wealth NN\n",
      "government NN\n",
      "is VBZ\n",
      "committed VBN\n",
      "to TO\n",
      "healthcare VB\n",
      "We PRP\n",
      "see VBP\n",
      "increased JJ\n",
      "spending NN\n",
      "in IN\n",
      "the DT\n",
      "government NN\n",
      "and CC\n",
      "the DT\n",
      "GDP NNP\n",
      "rate NN\n",
      "is VBZ\n",
      "still RB\n",
      "very RB\n",
      "healthy JJ\n",
      "Not RB\n",
      "as RB\n",
      "high JJ\n",
      "as IN\n",
      "it PRP\n",
      "has VBZ\n",
      "been VBN\n",
      "the DT\n",
      "past JJ\n",
      "but CC\n",
      "still RB\n",
      "quite RB\n",
      "healthy JJ\n",
      "So RB\n",
      "we PRP\n",
      "remain VBP\n",
      "very RB\n",
      "bullish JJ\n",
      "on IN\n",
      "the DT\n",
      "China NNP\n",
      "market NN\n",
      "on IN\n",
      "going VBG\n",
      "forward RB\n",
      "basis.Yes NN\n",
      "Thank NNP\n",
      "you PRP\n",
      "Andrew NNP\n",
      "for IN\n",
      "a DT\n",
      "good JJ\n",
      "question NN\n",
      "here RB\n",
      "Two CD\n",
      "things NNS\n",
      "first RB\n",
      "I PRP\n",
      "want VBP\n",
      "to TO\n",
      "just RB\n",
      "to TO\n",
      "point VB\n",
      "out RP\n",
      "that IN\n",
      "Abemaciclib NNP\n",
      "is VBZ\n",
      "somewhat RB\n",
      "different JJ\n",
      "from IN\n",
      "Palbo NNP\n",
      "and CC\n",
      "Novartis NNP\n",
      "drug NN\n",
      "in IN\n",
      "that DT\n",
      "it PRP\n",
      "seems VBZ\n",
      "to TO\n",
      "be VB\n",
      "less RBR\n",
      "selective JJ\n",
      "and CC\n",
      "has VBZ\n",
      "a DT\n",
      "different JJ\n",
      "resident NN\n",
      "profile NN\n",
      "likely RB\n",
      "due JJ\n",
      "to TO\n",
      "hitting VBG\n",
      "multiple JJ\n",
      "CDKs NNP\n",
      "particularly RB\n",
      "been VBN\n",
      "reported VBN\n",
      "significant JJ\n",
      "GI NNP\n",
      "issues NNS\n",
      "So IN\n",
      "it PRP\n",
      "'s VBZ\n",
      "a DT\n",
      "different JJ\n",
      "profile NN\n",
      "and CC\n",
      "we PRP\n",
      "as IN\n",
      "Albert NNP\n",
      "very RB\n",
      "well RB\n",
      "pointed VBN\n",
      "out RP\n",
      "have VBP\n",
      "been VBN\n",
      "extremely RB\n",
      "pleased JJ\n",
      "with IN\n",
      "the DT\n",
      "favorable JJ\n",
      "profile NN\n",
      "that WDT\n",
      "allow VBP\n",
      "patients NNS\n",
      "to TO\n",
      "benefit VB\n",
      "from IN\n",
      "Ibrance NN\n",
      "with IN\n",
      "very RB\n",
      "good JJ\n",
      "reliability.Now NN\n",
      "you PRP\n",
      "asked VBD\n",
      "about IN\n",
      "this DT\n",
      "late JJ\n",
      "stage NN\n",
      "population NN\n",
      "studies NNS\n",
      "Abema NNP\n",
      "[ NNP\n",
      "ph NN\n",
      "] NN\n",
      "and CC\n",
      "how WRB\n",
      "that DT\n",
      "population NN\n",
      "in IN\n",
      "the DT\n",
      "future NN\n",
      "will MD\n",
      "evolve VB\n",
      "We PRP\n",
      "anticipate VBP\n",
      "as IN\n",
      "Ibrance NNP\n",
      "is VBZ\n",
      "having VBG\n",
      "a DT\n",
      "very RB\n",
      "nice JJ\n",
      "uptake NN\n",
      "in IN\n",
      "the DT\n",
      "marketplace NN\n",
      "in IN\n",
      "first JJ\n",
      "line NN\n",
      "metastatic NN\n",
      "and CC\n",
      "some DT\n",
      "also RB\n",
      "more RBR\n",
      "advanced JJ\n",
      "lines NNS\n",
      "and CC\n",
      "hopefully RB\n",
      "with IN\n",
      "Prevnar NNP\n",
      "3 CD\n",
      "approval NN\n",
      "Ibrance NNP\n",
      "is VBZ\n",
      "likely JJ\n",
      "to TO\n",
      "be VB\n",
      "used VBN\n",
      "in IN\n",
      "multiple JJ\n",
      "lines.Hence NN\n",
      "monotherapy NN\n",
      "with IN\n",
      "another DT\n",
      "CDK NNP\n",
      "will MD\n",
      "of IN\n",
      "course NN\n",
      "have VBP\n",
      "the DT\n",
      "potential NN\n",
      "to TO\n",
      "face VB\n",
      "patient JJ\n",
      "population NN\n",
      "that WDT\n",
      "have VBP\n",
      "seen VBN\n",
      "CDK NNP\n",
      "inhibitor NN\n",
      "and CC\n",
      "that DT\n",
      "'s VBZ\n",
      "why WRB\n",
      "we PRP\n",
      "are VBP\n",
      "developing VBG\n",
      "a DT\n",
      "strategy NN\n",
      "for IN\n",
      "how WRB\n",
      "we PRP\n",
      "can MD\n",
      "see VB\n",
      "patients NNS\n",
      "benefit VB\n",
      "from IN\n",
      "drug NN\n",
      "like IN\n",
      "Ibrance NNP\n",
      "at IN\n",
      "various JJ\n",
      "stages NNS\n",
      "with IN\n",
      "different JJ\n",
      "anti-hormonals NNS\n",
      "And CC\n",
      "we PRP\n",
      "are VBP\n",
      "also RB\n",
      "now RB\n",
      "studying VBG\n",
      "Ibrance NNP\n",
      "in IN\n",
      "triple JJ\n",
      "therapy NN\n",
      "So RB\n",
      "I PRP\n",
      "think VBP\n",
      "you PRP\n",
      "can MD\n",
      "see VB\n",
      "that IN\n",
      "multiple JJ\n",
      "drugs NNS\n",
      "is VBZ\n",
      "likely JJ\n",
      "to TO\n",
      "be VB\n",
      "the DT\n",
      "preferred JJ\n",
      "as IN\n",
      "patients NNS\n",
      "become VBP\n",
      "more JJR\n",
      "advanced.Hi JJ\n",
      "good JJ\n",
      "morning NN\n",
      "Just RB\n",
      "again RB\n",
      "on IN\n",
      "Biosimilars NNP\n",
      "front NN\n",
      "I PRP\n",
      "know VBP\n",
      "there RB\n",
      "has VBZ\n",
      "been VBN\n",
      "a DT\n",
      "couple NN\n",
      "of IN\n",
      "questions NNS\n",
      "but CC\n",
      "just RB\n",
      "a DT\n",
      "couple NN\n",
      "of IN\n",
      "more JJR\n",
      "if IN\n",
      "I PRP\n",
      "could MD\n",
      "One CD\n",
      "is VBZ\n",
      "specifically RB\n",
      "on IN\n",
      "Enbrel NNP\n",
      "and CC\n",
      "if IN\n",
      "you PRP\n",
      "can MD\n",
      "discuss VB\n",
      "in IN\n",
      "terms NNS\n",
      "of IN\n",
      "2016 CD\n",
      "how WRB\n",
      "you PRP\n",
      "are VBP\n",
      "viewing VBG\n",
      "the DT\n",
      "impact NN\n",
      "of IN\n",
      "Biosimiliars NNP\n",
      "to TO\n",
      "your PRP$\n",
      "performance NN\n",
      "for IN\n",
      "that DT\n",
      "product NN\n",
      "And CC\n",
      "then RB\n",
      "second JJ\n",
      "now RB\n",
      "that IN\n",
      "Hospira NNP\n",
      "has VBZ\n",
      "closed VBN\n",
      "I PRP\n",
      "am VBP\n",
      "just RB\n",
      "wondering NN\n",
      "I PRP\n",
      "guess VBP\n",
      "this DT\n",
      "is VBZ\n",
      "a DT\n",
      "question NN\n",
      "for IN\n",
      "John NNP\n",
      "or CC\n",
      "whoever WDT\n",
      "wants VBZ\n",
      "to TO\n",
      "jump VB\n",
      "in IN\n",
      "in IN\n",
      "terms NNS\n",
      "of IN\n",
      "the DT\n",
      "value NN\n",
      "having VBG\n",
      "a DT\n",
      "Biosimilar JJ\n",
      "business NN\n",
      "under IN\n",
      "the DT\n",
      "same JJ\n",
      "broad JJ\n",
      "umbrella NN\n",
      "as IN\n",
      "your PRP$\n",
      "innovative JJ\n",
      "business NN\n",
      "so IN\n",
      "you PRP\n",
      "can MD\n",
      "leverage VB\n",
      "that DT\n",
      "commercial JJ\n",
      "infrastructure NN\n",
      "areas NNS\n",
      "like IN\n",
      "oncology NN\n",
      "and CC\n",
      "autoimmune NN\n",
      "disorders NNS\n",
      "Is VBZ\n",
      "there EX\n",
      "any DT\n",
      "way NN\n",
      "sort NN\n",
      "of IN\n",
      "maybe RB\n",
      "make VB\n",
      "more JJR\n",
      "sense NN\n",
      "than IN\n",
      "to TO\n",
      "keep VB\n",
      "Pfizer NNP\n",
      "as IN\n",
      "a DT\n",
      "single JJ\n",
      "entity NN\n",
      "as IN\n",
      "opposed VBN\n",
      "to TO\n",
      "splitting VBG\n",
      "up RP\n",
      "and CC\n",
      "then RB\n",
      "needing VBG\n",
      "to TO\n",
      "rebuild VB\n",
      "the DT\n",
      "commercial JJ\n",
      "infrastructure NN\n",
      "for IN\n",
      "your PRP$\n",
      "Biosimilars NNS\n",
      "in IN\n",
      "those DT\n",
      "similar JJ\n",
      "areas NNS\n",
      "where WRB\n",
      "you PRP\n",
      "do VBP\n",
      "have VB\n",
      "innovative JJ\n",
      "products NNS\n",
      "Thanks.Sure NN\n",
      "So RB\n",
      "the DT\n",
      "first JJ\n",
      "Biosimilar NNP\n",
      "for IN\n",
      "Etanercept NNP\n",
      "has VBZ\n",
      "been VBN\n",
      "approved VBN\n",
      "in IN\n",
      "Europe NNP\n",
      "And CC\n",
      "we PRP\n",
      "'ve VBP\n",
      "watching VBG\n",
      "the DT\n",
      "situation NN\n",
      "very RB\n",
      "closely RB\n",
      "and CC\n",
      "evaluating VBG\n",
      "adoption NN\n",
      "of IN\n",
      "Biosimilars NNP\n",
      "across IN\n",
      "each DT\n",
      "of IN\n",
      "the DT\n",
      "countries NNS\n",
      "throughout IN\n",
      "Europe NNP\n",
      "for IN\n",
      "awhile RB\n",
      "now.Our JJ\n",
      "overall JJ\n",
      "expectation NN\n",
      "is VBZ\n",
      "that IN\n",
      "there EX\n",
      "will MD\n",
      "be VB\n",
      "somewhat RB\n",
      "modest JJ\n",
      "impact NN\n",
      "in IN\n",
      "2016 CD\n",
      "The DT\n",
      "Biosimilar NNP\n",
      "landscape NN\n",
      "is VBZ\n",
      "clearly RB\n",
      "still RB\n",
      "developing VBG\n",
      "There EX\n",
      "are VBP\n",
      "different JJ\n",
      "approaches NNS\n",
      "taken VBN\n",
      "by IN\n",
      "different JJ\n",
      "countries NNS\n",
      "And CC\n",
      "we PRP\n",
      "have VBP\n",
      "a DT\n",
      "very RB\n",
      "clear JJ\n",
      "detailed VBN\n",
      "roadmap NN\n",
      "for IN\n",
      "how WRB\n",
      "to TO\n",
      "address VB\n",
      "each DT\n",
      "of IN\n",
      "the DT\n",
      "dynamics NNS\n",
      "that WDT\n",
      "exist VBP\n",
      "in IN\n",
      "these DT\n",
      "different JJ\n",
      "countries.So NN\n",
      "we PRP\n",
      "are VBP\n",
      "fairly RB\n",
      "confident JJ\n",
      "that IN\n",
      "we PRP\n",
      "are VBP\n",
      "going VBG\n",
      "to TO\n",
      "continue VB\n",
      "to TO\n",
      "have VB\n",
      "a DT\n",
      "strong JJ\n",
      "Enbrel NN\n",
      "business NN\n",
      "throughout IN\n",
      "Europe NNP\n",
      "We PRP\n",
      "think VBP\n",
      "that IN\n",
      "the DT\n",
      "new JJ\n",
      "patients NNS\n",
      "would MD\n",
      "be VB\n",
      "probably RB\n",
      "most RBS\n",
      "at IN\n",
      "risk NN\n",
      "of IN\n",
      "being VBG\n",
      "exposed VBN\n",
      "to TO\n",
      "the DT\n",
      "Biosimilars NNP\n",
      "and CC\n",
      "hope NN\n",
      "that IN\n",
      "the DT\n",
      "availability NN\n",
      "of IN\n",
      "lower JJR\n",
      "cost NN\n",
      "biologics NNS\n",
      "will MD\n",
      "expand VB\n",
      "the DT\n",
      "market NN\n",
      "So RB\n",
      "overall JJ\n",
      "we PRP\n",
      "see VBP\n",
      "this DT\n",
      "as RB\n",
      "again RB\n",
      "a DT\n",
      "modest JJ\n",
      "impact NN\n",
      "to TO\n",
      "our PRP$\n",
      "business NN\n",
      "in IN\n",
      "the DT\n",
      "initial JJ\n",
      "period NN\n",
      "of IN\n",
      "time.And NN\n",
      "Vamil NNP\n",
      "maybe RB\n",
      "a DT\n",
      "very RB\n",
      "interesting JJ\n",
      "question NN\n",
      "on IN\n",
      "the DT\n",
      "connectivity NN\n",
      "between IN\n",
      "the DT\n",
      "Biosimilars NNP\n",
      "and CC\n",
      "the DT\n",
      "other JJ\n",
      "space NN\n",
      "I PRP\n",
      "would MD\n",
      "say VB\n",
      "that IN\n",
      "that DT\n",
      "would MD\n",
      "be VB\n",
      "taken VBN\n",
      "into IN\n",
      "account NN\n",
      "if IN\n",
      "there EX\n",
      "was VBD\n",
      "any DT\n",
      "such JJ\n",
      "linkage NN\n",
      "that WDT\n",
      "was VBD\n",
      "positive JJ\n",
      "in IN\n",
      "our PRP$\n",
      "TSAs NNP\n",
      "the DT\n",
      "setup NN\n",
      "the DT\n",
      "separate JJ\n",
      "companies NNS\n",
      "to TO\n",
      "ensure VB\n",
      "that DT\n",
      "that WDT\n",
      "as IN\n",
      "overall JJ\n",
      "we PRP\n",
      "maximize VBP\n",
      "value NN\n",
      "of IN\n",
      "that DT\n",
      "between IN\n",
      "both DT\n",
      "companies NNS\n",
      "in IN\n",
      "the DT\n",
      "contracts NNS\n",
      "we PRP\n",
      "would MD\n",
      "sign VB\n",
      "if IN\n",
      "we PRP\n",
      "decided VBD\n",
      "to TO\n",
      "split VB\n",
      "Thank NNP\n",
      "you.Couple NN\n",
      "of IN\n",
      "questions NNS\n",
      "First RB\n",
      "apologizes VBZ\n",
      "if IN\n",
      "I PRP\n",
      "missed VBD\n",
      "the DT\n",
      "explanation NN\n",
      "but CC\n",
      "the DT\n",
      "2016 CD\n",
      "guidance NN\n",
      "includes VBZ\n",
      "roughly RB\n",
      "an DT\n",
      "incremental JJ\n",
      "4 CD\n",
      "billion CD\n",
      "in IN\n",
      "revenue NN\n",
      "and CC\n",
      "0.08 CD\n",
      "in IN\n",
      "earnings NNS\n",
      "from IN\n",
      "Hospira NNP\n",
      "implying VBG\n",
      "down RP\n",
      "to TO\n",
      "significantly RB\n",
      "down RP\n",
      "underlying VBG\n",
      "sales NNS\n",
      "for IN\n",
      "the DT\n",
      "legacy NN\n",
      "Pfizer NNP\n",
      "and CC\n",
      "flattish VB\n",
      "to TO\n",
      "down VB\n",
      "EPS NNP\n",
      "and CC\n",
      "it PRP\n",
      "seems VBZ\n",
      "that IN\n",
      "generic JJ\n",
      "exposure NN\n",
      "in IN\n",
      "currency NN\n",
      "can MD\n",
      "not RB\n",
      "be VB\n",
      "the DT\n",
      "explanation NN\n",
      "because IN\n",
      "the DT\n",
      "predicted JJ\n",
      "4.6 CD\n",
      "billion CD\n",
      "hurdle NN\n",
      "in IN\n",
      "2016 CD\n",
      "from IN\n",
      "these DT\n",
      "factors NNS\n",
      "is VBZ\n",
      "well RB\n",
      "less JJR\n",
      "than IN\n",
      "the DT\n",
      "6 CD\n",
      "billion CD\n",
      "plus NNS\n",
      "predicted VBN\n",
      "in IN\n",
      "2015 CD\n",
      "at IN\n",
      "this DT\n",
      "time NN\n",
      "last JJ\n",
      "year.So NN\n",
      "actually RB\n",
      "the DT\n",
      "comparison NN\n",
      "on IN\n",
      "generic JJ\n",
      "exposure NN\n",
      "in IN\n",
      "currency NN\n",
      "is VBZ\n",
      "improving VBG\n",
      "and CC\n",
      "more JJR\n",
      "than IN\n",
      "offsets VBZ\n",
      "the DT\n",
      "year-over-year JJ\n",
      "increase NN\n",
      "in IN\n",
      "Prevnar NNP\n",
      "So RB\n",
      "any DT\n",
      "thoughts NNS\n",
      "on IN\n",
      "that DT\n",
      "would MD\n",
      "be VB\n",
      "appreciated.And JJ\n",
      "one CD\n",
      "more JJR\n",
      "how WRB\n",
      "should MD\n",
      "we PRP\n",
      "think VB\n",
      "about IN\n",
      "the DT\n",
      "long-term JJ\n",
      "outlook NN\n",
      "for IN\n",
      "Sutent NNP\n",
      "particularly RB\n",
      "given VBN\n",
      "the DT\n",
      "competition NN\n",
      "from IN\n",
      "immuno-oncology NN\n",
      "agent NN\n",
      "You PRP\n",
      "think VBP\n",
      "Sutent NNP\n",
      "will MD\n",
      "soon RB\n",
      "become VB\n",
      "a DT\n",
      "defining JJ\n",
      "asset NN\n",
      "or CC\n",
      "do VB\n",
      "you PRP\n",
      "see VB\n",
      "growth NN\n",
      "in IN\n",
      "the DT\n",
      "future NN\n",
      "Thanks.I NNP\n",
      "'ll MD\n",
      "ask VB\n",
      "Albert NNP\n",
      "to TO\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "talk VB\n",
      "about IN\n",
      "Sutent NNP\n",
      "and CC\n",
      "its PRP$\n",
      "possible JJ\n",
      "combinations NNS\n",
      "and CC\n",
      "the DT\n",
      "other JJ\n",
      "studies NNS\n",
      "we PRP\n",
      "have VBP\n",
      "already RB\n",
      "had VBN\n",
      "on IN\n",
      "Sutent NNP\n",
      "And CC\n",
      "then RB\n",
      "I PRP\n",
      "'ll MD\n",
      "ask VB\n",
      "Frank NNP\n",
      "to TO\n",
      "come VB\n",
      "back RB\n",
      "on IN\n",
      "your PRP$\n",
      "questions NNS\n",
      "about IN\n",
      "growth NN\n",
      "rates.We NN\n",
      "remain VBP\n",
      "very RB\n",
      "confident JJ\n",
      "in IN\n",
      "our PRP$\n",
      "position NN\n",
      "in IN\n",
      "the DT\n",
      "RCC NNP\n",
      "space NN\n",
      "and CC\n",
      "that DT\n",
      "includes VBZ\n",
      "both CC\n",
      "Sutent NNP\n",
      "and CC\n",
      "Inlyta NNP\n",
      "because IN\n",
      "they PRP\n",
      "are VBP\n",
      "very RB\n",
      "well RB\n",
      "known VBN\n",
      "by IN\n",
      "physicians NNS\n",
      "and CC\n",
      "other JJ\n",
      "stakeholders NNS\n",
      "The DT\n",
      "recent JJ\n",
      "approval NN\n",
      "in IN\n",
      "RCC NNP\n",
      "for IN\n",
      "immunotherapy NN\n",
      "but CC\n",
      "this DT\n",
      "does VBZ\n",
      "not RB\n",
      "affect VB\n",
      "Sutent NNP\n",
      "It PRP\n",
      "is VBZ\n",
      "in IN\n",
      "the DT\n",
      "second JJ\n",
      "line NN\n",
      "Sutent NN\n",
      "is VBZ\n",
      "used VBN\n",
      "primarily RB\n",
      "in IN\n",
      "first JJ\n",
      "line NN\n",
      "And CC\n",
      "s NN\n",
      "we PRP\n",
      "have VBP\n",
      "previously RB\n",
      "disclosed VBN\n",
      "we PRP\n",
      "are VBP\n",
      "studying VBG\n",
      "Inlyta NNP\n",
      "and CC\n",
      "Inlyta NNP\n",
      "plus CC\n",
      "other JJ\n",
      "PD-1 JJ\n",
      "inhibitors NNS\n",
      "pretty RB\n",
      "aggressively RB\n",
      "so IN\n",
      "that IN\n",
      "we PRP\n",
      "can MD\n",
      "achieve VB\n",
      "better JJR\n",
      "result NN\n",
      "in IN\n",
      "monotherapy NN\n",
      "in IN\n",
      "RCC NNP\n",
      "second JJ\n",
      "line.Yes NN\n",
      "Let VB\n",
      "'s POS\n",
      "see VB\n",
      "if IN\n",
      "I PRP\n",
      "can MD\n",
      "answer VB\n",
      "the DT\n",
      "question NN\n",
      "Just RB\n",
      "first RB\n",
      "we PRP\n",
      "do VBP\n",
      "n't RB\n",
      "give VB\n",
      "a DT\n",
      "specific JJ\n",
      "number NN\n",
      "for IN\n",
      "Hospira NNP\n",
      "revenues NNS\n",
      "for IN\n",
      "2016 CD\n",
      "But CC\n",
      "that DT\n",
      "said VBD\n",
      "I PRP\n",
      "believe VBP\n",
      "I PRP\n",
      "could MD\n",
      "still RB\n",
      "answer VB\n",
      "the DT\n",
      "question NN\n",
      "So RB\n",
      "the DT\n",
      "way NN\n",
      "I PRP\n",
      "think VBP\n",
      "about IN\n",
      "this DT\n",
      "is VBZ\n",
      "if IN\n",
      "you PRP\n",
      "enter VBP\n",
      "the DT\n",
      "midpoint NN\n",
      "of IN\n",
      "the DT\n",
      "guidance NN\n",
      "prior RB\n",
      "to TO\n",
      "foreign JJ\n",
      "exchange NN\n",
      "in IN\n",
      "Venezuela NNP\n",
      "which WDT\n",
      "is VBZ\n",
      "part NN\n",
      "of IN\n",
      "the DT\n",
      "basis NN\n",
      "of IN\n",
      "your PRP$\n",
      "question NN\n",
      "the DT\n",
      "midpoint NN\n",
      "for IN\n",
      "guidance NN\n",
      "would MD\n",
      "be VB\n",
      "52.3 CD\n",
      "just RB\n",
      "to TO\n",
      "use VB\n",
      "midpoint NN\n",
      "We PRP\n",
      "take VBP\n",
      "50.3 CD\n",
      "compare NN\n",
      "that WDT\n",
      "to TO\n",
      "the DT\n",
      "48.9 NNS\n",
      "that IN\n",
      "we PRP\n",
      "printed VBD\n",
      "in IN\n",
      "2015 CD\n",
      "are VBP\n",
      "all DT\n",
      "now RB\n",
      "at IN\n",
      "the DT\n",
      "same JJ\n",
      "foreign JJ\n",
      "exchange NN\n",
      "so RB\n",
      "clearly RB\n",
      "operational JJ\n",
      "That DT\n",
      "'s VBZ\n",
      "an DT\n",
      "increase NN\n",
      "of IN\n",
      "about IN\n",
      "3.5 CD\n",
      "billion CD\n",
      "We PRP\n",
      "said VBD\n",
      "Ian NNP\n",
      "said VBD\n",
      "when WRB\n",
      "he PRP\n",
      "answered VBD\n",
      "Jami NNP\n",
      "'s POS\n",
      "question NN\n",
      "that IN\n",
      "revenue NN\n",
      "excluding VBG\n",
      "Hospira NNP\n",
      "on IN\n",
      "a DT\n",
      "year-over-year JJ\n",
      "basis NN\n",
      "was VBD\n",
      "essentially RB\n",
      "flat JJ\n",
      "operationally RB\n",
      "while IN\n",
      "absorbing VBG\n",
      "2.3 CD\n",
      "billion CD\n",
      "in IN\n",
      "LOEs NNP\n",
      "for IN\n",
      "2016.The CD\n",
      "other JJ\n",
      "data NNS\n",
      "point NN\n",
      "I PRP\n",
      "think VBP\n",
      "to TO\n",
      "help VB\n",
      "you PRP\n",
      "answer VB\n",
      "the DT\n",
      "question NN\n",
      "is VBZ\n",
      "remember VB\n",
      "we PRP\n",
      "did VBD\n",
      "1.5 CD\n",
      "billion CD\n",
      "in IN\n",
      "Hospira NNP\n",
      "sales NNS\n",
      "this DT\n",
      "year NN\n",
      "So RB\n",
      "when WRB\n",
      "we PRP\n",
      "say VBP\n",
      "that IN\n",
      "the DT\n",
      "bulk NN\n",
      "of IN\n",
      "the DT\n",
      "growth NN\n",
      "is VBZ\n",
      "from IN\n",
      "Hospira NNP\n",
      "you PRP\n",
      "understand VBP\n",
      "it PRP\n",
      "'s VBZ\n",
      "incremental JJ\n",
      "growth NN\n",
      "on IN\n",
      "top NN\n",
      "of IN\n",
      "the DT\n",
      "1.5 CD\n",
      "billion CD\n",
      "that IN\n",
      "we PRP\n",
      "printed VBD\n",
      "in IN\n",
      "2015 CD\n",
      "So IN\n",
      "that DT\n",
      "'s VBZ\n",
      "how WRB\n",
      "I PRP\n",
      "think VBP\n",
      "that DT\n",
      "'s VBZ\n",
      "how WRB\n",
      "you PRP\n",
      "get VBP\n",
      "to TO\n",
      "numbers NNS\n",
      "we PRP\n",
      "said VBD\n",
      "and CC\n",
      "why WRB\n",
      "we PRP\n",
      "said VBD\n",
      "operationally RB\n",
      "the DT\n",
      "numbers NNS\n",
      "were VBD\n",
      "essentially RB\n",
      "flat JJ\n",
      "if IN\n",
      "you PRP\n",
      "left VBD\n",
      "Hospira NNP\n",
      "out IN\n",
      "of IN\n",
      "the DT\n",
      "equation.Hey NN\n",
      "guys NNS\n",
      "How WRB\n",
      "are VBP\n",
      "you PRP\n",
      "doing VBG\n",
      "Thanks NNS\n",
      "for IN\n",
      "being VBG\n",
      "so RB\n",
      "clear JJ\n",
      "on IN\n",
      "the DT\n",
      "communications NNS\n",
      "in IN\n",
      "the DT\n",
      "quarter NN\n",
      "I PRP\n",
      "have VBP\n",
      "one CD\n",
      "question NN\n",
      "that WDT\n",
      "'s VBZ\n",
      "been VBN\n",
      "danced VBN\n",
      "around IN\n",
      "but CC\n",
      "maybe RB\n",
      "let VB\n",
      "me PRP\n",
      "just RB\n",
      "ask VB\n",
      "you PRP\n",
      "it PRP\n",
      "again RB\n",
      "and CC\n",
      "hope VBP\n",
      "so RB\n",
      "I PRP\n",
      "wo MD\n",
      "n't RB\n",
      "annoy VB\n",
      "you PRP\n",
      "but CC\n",
      "I PRP\n",
      "'ll MD\n",
      "try VB\n",
      "again.So NN\n",
      "first RB\n",
      "is VBZ\n",
      "do VB\n",
      "you PRP\n",
      "believe VB\n",
      "that IN\n",
      "there EX\n",
      "is VBZ\n",
      "anything NN\n",
      "Ian NNP\n",
      "under IN\n",
      "the DT\n",
      "current JJ\n",
      "U.S. NNP\n",
      "statute NN\n",
      "that WDT\n",
      "would MD\n",
      "allow VB\n",
      "treasury NN\n",
      "to TO\n",
      "block VB\n",
      "and/or NNS\n",
      "materially RB\n",
      "delay VBP\n",
      "the DT\n",
      "closing NN\n",
      "of IN\n",
      "the DT\n",
      "AGN NNP\n",
      "deal NN\n",
      "So RB\n",
      "I PRP\n",
      "am VBP\n",
      "asking VBG\n",
      "you PRP\n",
      "if IN\n",
      "there EX\n",
      "will MD\n",
      "be VB\n",
      "third JJ\n",
      "proposed VBN\n",
      "notice NN\n",
      "I PRP\n",
      "am VBP\n",
      "asking VBG\n",
      "you PRP\n",
      "under IN\n",
      "the DT\n",
      "current JJ\n",
      "law NN\n",
      "are VBP\n",
      "you PRP\n",
      "very RB\n",
      "do VB\n",
      "you PRP\n",
      "remain VB\n",
      "I PRP\n",
      "guess JJ\n",
      "very RB\n",
      "comfortable JJ\n",
      "there EX\n",
      "is VBZ\n",
      "nothing NN\n",
      "that IN\n",
      "treasury NN\n",
      "legally RB\n",
      "could MD\n",
      "do VB\n",
      "to TO\n",
      "block VB\n",
      "the DT\n",
      "deal NN\n",
      "or CC\n",
      "to TO\n",
      "materially RB\n",
      "delay VB\n",
      "it PRP\n",
      "like IN\n",
      "in IN\n",
      "the DT\n",
      "2017 CD\n",
      "when WRB\n",
      "there EX\n",
      "will MD\n",
      "be VB\n",
      "a DT\n",
      "new JJ\n",
      "a DT\n",
      "congress NN\n",
      "and CC\n",
      "a DT\n",
      "new JJ\n",
      "president.And NN\n",
      "then RB\n",
      "I PRP\n",
      "would MD\n",
      "also RB\n",
      "just RB\n",
      "for IN\n",
      "Frank NNP\n",
      "perhaps RB\n",
      "just RB\n",
      "like IN\n",
      "you PRP\n",
      "talked VBD\n",
      "a DT\n",
      "little JJ\n",
      "about IN\n",
      "your PRP$\n",
      "leverage NN\n",
      "ratio NN\n",
      "if IN\n",
      "my PRP$\n",
      "math NN\n",
      "is VBZ\n",
      "right JJ\n",
      "the DT\n",
      "leverage NN\n",
      "ratio NN\n",
      "of IN\n",
      "the DT\n",
      "combined VBN\n",
      "company NN\n",
      "the DT\n",
      "NewCo NNP\n",
      "should MD\n",
      "closer VB\n",
      "to TO\n",
      "be VB\n",
      "around IN\n",
      "1 CD\n",
      "By IN\n",
      "my PRP$\n",
      "math NN\n",
      "you PRP\n",
      "could MD\n",
      "take VB\n",
      "that DT\n",
      "to TO\n",
      "maybe RB\n",
      "3 CD\n",
      "without IN\n",
      "affecting VBG\n",
      "credit NN\n",
      "ratings NNS\n",
      "in IN\n",
      "a DT\n",
      "big JJ\n",
      "way NN\n",
      "I PRP\n",
      "would MD\n",
      "like VB\n",
      "to TO\n",
      "hear VB\n",
      "that DT\n",
      "'s POS\n",
      "my PRP$\n",
      "math NN\n",
      "and CC\n",
      "I PRP\n",
      "am VBP\n",
      "not RB\n",
      "very RB\n",
      "good JJ\n",
      "at IN\n",
      "math NN\n",
      "so IN\n",
      "I PRP\n",
      "would MD\n",
      "love VB\n",
      "to TO\n",
      "hear VB\n",
      "your PRP$\n",
      "general JJ\n",
      "thoughts NNS\n",
      "around IN\n",
      "leverage NN\n",
      "ratio NN\n",
      "of IN\n",
      "the DT\n",
      "NewCo NNP\n",
      "where WRB\n",
      "you PRP\n",
      "might MD\n",
      "be VB\n",
      "willing JJ\n",
      "to TO\n",
      "take VB\n",
      "that DT\n",
      "should MD\n",
      "the DT\n",
      "deal NN\n",
      "close RB\n",
      "Thank NNP\n",
      "you.Thank NN\n",
      "you PRP\n",
      "Mark NNP\n",
      "And CC\n",
      "thank VB\n",
      "you PRP\n",
      "for IN\n",
      "the DT\n",
      "compliment NN\n",
      "on IN\n",
      "the DT\n",
      "clarity NN\n",
      "to TO\n",
      "communications NNS\n",
      "We PRP\n",
      "strive VBP\n",
      "to TO\n",
      "make VB\n",
      "them PRP\n",
      "clear JJ\n",
      "So RB\n",
      "on IN\n",
      "your PRP$\n",
      "question NN\n",
      "which WDT\n",
      "I PRP\n",
      "do VBP\n",
      "n't RB\n",
      "think VB\n",
      "on IN\n",
      "the DT\n",
      "current JJ\n",
      "law NN\n",
      "I PRP\n",
      "do VBP\n",
      "not RB\n",
      "believe VB\n",
      "there EX\n",
      "is VBZ\n",
      "any DT\n",
      "reason NN\n",
      "why WRB\n",
      "this DT\n",
      "deal NN\n",
      "will MD\n",
      "not RB\n",
      "close VB\n",
      "full JJ\n",
      "stop.Mark NN\n",
      "let VB\n",
      "me PRP\n",
      "run VB\n",
      "some DT\n",
      "numbers NNS\n",
      "So RB\n",
      "on IN\n",
      "leverage NN\n",
      "let VB\n",
      "me PRP\n",
      "run VB\n",
      "the DT\n",
      "Pfizer NNP\n",
      "numbers NNS\n",
      "based VBN\n",
      "on IN\n",
      "third JJ\n",
      "quarter NN\n",
      "We PRP\n",
      "have VBP\n",
      "n't RB\n",
      "issued VBN\n",
      "a DT\n",
      "balance NN\n",
      "sheet NN\n",
      "yet RB\n",
      "for IN\n",
      "the DT\n",
      "fourth JJ\n",
      "quarter NN\n",
      "We PRP\n",
      "will MD\n",
      "do VB\n",
      "that DT\n",
      "when WRB\n",
      "we PRP\n",
      "file VBP\n",
      "the DT\n",
      "K. NNP\n",
      "We PRP\n",
      "had VBD\n",
      "about IN\n",
      "37 CD\n",
      "billion CD\n",
      "of IN\n",
      "cash NN\n",
      "in IN\n",
      "investments NNS\n",
      "We PRP\n",
      "had VBD\n",
      "about IN\n",
      "39 CD\n",
      "billion CD\n",
      "of IN\n",
      "debt NN\n",
      "short JJ\n",
      "and CC\n",
      "long JJ\n",
      "term NN\n",
      "debt NN\n",
      "So RB\n",
      "to TO\n",
      "your PRP$\n",
      "point NN\n",
      "call NN\n",
      "that WDT\n",
      "one CD\n",
      "to TO\n",
      "one CD\n",
      "essentially RB\n",
      "and CC\n",
      "what WP\n",
      "we PRP\n",
      "said VBD\n",
      "when WRB\n",
      "we PRP\n",
      "announced VBD\n",
      "the DT\n",
      "Allergan NNP\n",
      "deal NN\n",
      "what WP\n",
      "I PRP\n",
      "said VBD\n",
      "was VBD\n",
      "we PRP\n",
      "could MD\n",
      "take VB\n",
      "the DT\n",
      "leverage NN\n",
      "ratio NN\n",
      "at IN\n",
      "yield NN\n",
      "point NN\n",
      "up RB\n",
      "to TO\n",
      "about IN\n",
      "2.5 CD\n",
      "to TO\n",
      "3.And CD\n",
      "then RB\n",
      "obviously RB\n",
      "once RB\n",
      "took VBD\n",
      "it PRP\n",
      "there RB\n",
      "we PRP\n",
      "would MD\n",
      "want VB\n",
      "to TO\n",
      "see VB\n",
      "what WP\n",
      "kind NN\n",
      "of IN\n",
      "rhythm NN\n",
      "that WDT\n",
      "created VBD\n",
      "relative JJ\n",
      "to TO\n",
      "the DT\n",
      "company NN\n",
      "the DT\n",
      "operation NN\n",
      "supporting VBG\n",
      "the DT\n",
      "company NN\n",
      "in IN\n",
      "that DT\n",
      "we PRP\n",
      "take VBP\n",
      "it PRP\n",
      "there RB\n",
      "but CC\n",
      "that IN\n",
      "we PRP\n",
      "still RB\n",
      "want VBP\n",
      "access NN\n",
      "to TO\n",
      "commercial JJ\n",
      "paper NN\n",
      "We PRP\n",
      "would MD\n",
      "be VB\n",
      "willing JJ\n",
      "take VB\n",
      "a DT\n",
      "one CD\n",
      "notch NN\n",
      "downgrade NN\n",
      "but CC\n",
      "we PRP\n",
      "would MD\n",
      "still RB\n",
      "want VB\n",
      "to TO\n",
      "have VB\n",
      "access NN\n",
      "to TO\n",
      "commercial JJ\n",
      "paper NN\n",
      "But CC\n",
      "in IN\n",
      "terms NNS\n",
      "of IN\n",
      "your PRP$\n",
      "math NN\n",
      "and CC\n",
      "your PRP$\n",
      "calculation NN\n",
      "2.5 CD\n",
      "to TO\n",
      "3 CD\n",
      "that DT\n",
      "'s VBZ\n",
      "right JJ\n",
      "That DT\n",
      "'s VBZ\n",
      "basically RB\n",
      "what WP\n",
      "I PRP\n",
      "talked VBD\n",
      "about IN\n",
      "when WRB\n",
      "we PRP\n",
      "announced VBD\n",
      "the DT\n",
      "Allergan NNP\n",
      "deal NN\n",
      "So RB\n",
      "your PRP$\n",
      "math NN\n",
      "was VBD\n",
      "good.Yes NN\n",
      "few JJ\n",
      "things NNS\n",
      "One CD\n",
      "is VBZ\n",
      "can MD\n",
      "you PRP\n",
      "tell VB\n",
      "us PRP\n",
      "what WP\n",
      "the DT\n",
      "key NN\n",
      "products NNS\n",
      "are VBP\n",
      "in IN\n",
      "Venezuela NNP\n",
      "if IN\n",
      "there EX\n",
      "are VBP\n",
      "any DT\n",
      "massive JJ\n",
      "ones NNS\n",
      "that IN\n",
      "we PRP\n",
      "need VBP\n",
      "to TO\n",
      "be VB\n",
      "hitting VBG\n",
      "the DT\n",
      "model NN\n",
      "on IN\n",
      "Second JJ\n",
      "Frank NNP\n",
      "maybe RB\n",
      "you PRP\n",
      "can MD\n",
      "go VB\n",
      "through IN\n",
      "some DT\n",
      "of IN\n",
      "the DT\n",
      "push-pulls NNS\n",
      "on IN\n",
      "SG NNP\n",
      "& CC\n",
      "A NNP\n",
      "and CC\n",
      "how WRB\n",
      "you PRP\n",
      "are VBP\n",
      "thinking VBG\n",
      "about IN\n",
      "the DT\n",
      "spending NN\n",
      "this DT\n",
      "year NN\n",
      "And CC\n",
      "then RB\n",
      "third JJ\n",
      "can MD\n",
      "you PRP\n",
      "just RB\n",
      "give VB\n",
      "us PRP\n",
      "an DT\n",
      "update NN\n",
      "on IN\n",
      "the DT\n",
      "IL-6 NNP\n",
      "Thanks.So NNP\n",
      "key NN\n",
      "products NNS\n",
      "I PRP\n",
      "do VBP\n",
      "n't RB\n",
      "think VB\n",
      "there EX\n",
      "'s VBZ\n",
      "any DT\n",
      "outstanding JJ\n",
      "product NN\n",
      "but CC\n",
      "the DT\n",
      "Enbrel NNP\n",
      "is VBZ\n",
      "the DT\n",
      "biggest JJS\n",
      "product NN\n",
      "that WDT\n",
      "contributes VBZ\n",
      "John NNP\n",
      "would MD\n",
      "you PRP\n",
      "want VB\n",
      "to TO\n",
      "add VB\n",
      "anything NN\n",
      "to TO\n",
      "that DT\n",
      "Yes UH\n",
      "I PRP\n",
      "think VBP\n",
      "the DT\n",
      "Enbrel NNP\n",
      "is VBZ\n",
      "the DT\n",
      "biggest JJS\n",
      "product NN\n",
      "I PRP\n",
      "think VBP\n",
      "in IN\n",
      "addition NN\n",
      "to TO\n",
      "that IN\n",
      "we PRP\n",
      "have VBP\n",
      "a DT\n",
      "portfolio NN\n",
      "of IN\n",
      "matured VBN\n",
      "established VBN\n",
      "product NN\n",
      "Lipitor NNP\n",
      "and CC\n",
      "Norvasc NNP\n",
      "would MD\n",
      "be VB\n",
      "other JJ\n",
      "key JJ\n",
      "products NNS\n",
      "for IN\n",
      "us PRP\n",
      "in IN\n",
      "Venezuela NNP\n",
      "So RB\n",
      "really RB\n",
      "just RB\n",
      "think VB\n",
      "about IN\n",
      "the DT\n",
      "basket NN\n",
      "of IN\n",
      "established VBN\n",
      "products NNS\n",
      "and CC\n",
      "the DT\n",
      "fit NN\n",
      "in IN\n",
      "that DT\n",
      "marketplace.So NN\n",
      "Marc NNP\n",
      "on IN\n",
      "SG NNP\n",
      "& CC\n",
      "A NNP\n",
      "let VB\n",
      "me PRP\n",
      "just RB\n",
      "talk VB\n",
      "to TO\n",
      "the DT\n",
      "quarter NN\n",
      "and CC\n",
      "then RB\n",
      "I PRP\n",
      "'ll MD\n",
      "talk VB\n",
      "to TO\n",
      "the DT\n",
      "rhythm NN\n",
      "of IN\n",
      "the DT\n",
      "numbers NNS\n",
      "So RB\n",
      "if IN\n",
      "you PRP\n",
      "look VBP\n",
      "at IN\n",
      "the DT\n",
      "quarter NN\n",
      "we PRP\n",
      "had VBD\n",
      "a DT\n",
      "big JJ\n",
      "spend NN\n",
      "in IN\n",
      "SG NNP\n",
      "& CC\n",
      "A NNP\n",
      "It PRP\n",
      "'s VBZ\n",
      "4.6 CD\n",
      "billion CD\n",
      "all DT\n",
      "in IN\n",
      "Three CD\n",
      "major JJ\n",
      "factors NNS\n",
      "there RB\n",
      "right RB\n",
      "one CD\n",
      "obviously RB\n",
      "the DT\n",
      "inclusion NN\n",
      "of IN\n",
      "Hospira NNP\n",
      "which WDT\n",
      "added VBD\n",
      "a DT\n",
      "couple NN\n",
      "of IN\n",
      "hundred CD\n",
      "million CD\n",
      "Two CD\n",
      "sequentially RB\n",
      "if IN\n",
      "you PRP\n",
      "think VBP\n",
      "about IN\n",
      "the DT\n",
      "fourth JJ\n",
      "quarter NN\n",
      "compared VBN\n",
      "to TO\n",
      "the DT\n",
      "third JJ\n",
      "quarter NN\n",
      "we PRP\n",
      "had VBD\n",
      "a DT\n",
      "lot NN\n",
      "more RBR\n",
      "selling JJ\n",
      "days NNS\n",
      "in IN\n",
      "the DT\n",
      "quarter NN\n",
      "So RB\n",
      "internationally RB\n",
      "we PRP\n",
      "had VBD\n",
      "six CD\n",
      "more JJR\n",
      "selling NN\n",
      "days NNS\n",
      "Domestically RB\n",
      "we PRP\n",
      "had VBD\n",
      "two CD\n",
      "more JJR\n",
      "selling NN\n",
      "days.So NN\n",
      "sequentially RB\n",
      "Q3 NNP\n",
      "of IN\n",
      "'15 NNP\n",
      "to TO\n",
      "Q4 NNP\n",
      "of IN\n",
      "'15 NNP\n",
      "we PRP\n",
      "had VBD\n",
      "more RBR\n",
      "selling JJ\n",
      "days NNS\n",
      "So RB\n",
      "obviously RB\n",
      "it PRP\n",
      "helps VBZ\n",
      "revenue NN\n",
      "but CC\n",
      "also RB\n",
      "increases VBZ\n",
      "the DT\n",
      "spend NN\n",
      "on IN\n",
      "our PRP$\n",
      "line NN\n",
      "items NNS\n",
      "And CC\n",
      "then RB\n",
      "we PRP\n",
      "had VBD\n",
      "obviously RB\n",
      "I PRP\n",
      "alluded VBD\n",
      "to TO\n",
      "in IN\n",
      "my PRP$\n",
      "comments NNS\n",
      "increased VBD\n",
      "promotional JJ\n",
      "spend NN\n",
      "in IN\n",
      "many JJ\n",
      "areas NNS\n",
      "of IN\n",
      "the DT\n",
      "business.Now NN\n",
      "if IN\n",
      "you PRP\n",
      "take VBP\n",
      "that IN\n",
      "4.6 CD\n",
      "and CC\n",
      "you PRP\n",
      "annualize VBP\n",
      "it PRP\n",
      "times VBZ\n",
      "2 CD\n",
      "is VBZ\n",
      "what WP\n",
      "9.2 CD\n",
      "times NNS\n",
      "2 CD\n",
      "is VBZ\n",
      "18.4 CD\n",
      "If IN\n",
      "you PRP\n",
      "look VBP\n",
      "at IN\n",
      "the DT\n",
      "guidance NN\n",
      "we PRP\n",
      "gave VBD\n",
      "for IN\n",
      "next JJ\n",
      "year NN\n",
      "on IN\n",
      "SI NNP\n",
      "& CC\n",
      "A NNP\n",
      "it PRP\n",
      "'s VBZ\n",
      "13.2 CD\n",
      "to TO\n",
      "14.2 CD\n",
      "billion CD\n",
      "So RB\n",
      "you PRP\n",
      "ca MD\n",
      "n't RB\n",
      "take VB\n",
      "that DT\n",
      "Q4 NNP\n",
      "number NN\n",
      "and CC\n",
      "annualize VB\n",
      "it PRP\n",
      "You PRP\n",
      "get VBP\n",
      "to TO\n",
      "a DT\n",
      "number NN\n",
      "that WDT\n",
      "'s VBZ\n",
      "nothing NN\n",
      "close RB\n",
      "to TO\n",
      "what WP\n",
      "our PRP$\n",
      "guidance NN\n",
      "is VBZ\n",
      "for IN\n",
      "2016 CD\n",
      "which WDT\n",
      "is VBZ\n",
      "a DT\n",
      "combination NN\n",
      "of IN\n",
      "Hospira NNP\n",
      "numbers NNS\n",
      "the DT\n",
      "selling NN\n",
      "days NNS\n",
      "and CC\n",
      "then RB\n",
      "the DT\n",
      "increased VBN\n",
      "spend NN\n",
      "in IN\n",
      "the DT\n",
      "quarter NN\n",
      "But CC\n",
      "we PRP\n",
      "look VBP\n",
      "at IN\n",
      "it PRP\n",
      "for IN\n",
      "next JJ\n",
      "year NN\n",
      "we PRP\n",
      "get VBP\n",
      "a DT\n",
      "number NN\n",
      "that WDT\n",
      "our PRP$\n",
      "annual JJ\n",
      "basis NN\n",
      "is VBZ\n",
      "significantly RB\n",
      "lower JJR\n",
      "than IN\n",
      "what WP\n",
      "that IN\n",
      "annualized JJ\n",
      "number NN\n",
      "would MD\n",
      "be.Yes VB\n",
      "Thank NNP\n",
      "you PRP\n",
      "for IN\n",
      "your PRP$\n",
      "question NN\n",
      "So IN\n",
      "we PRP\n",
      "tested VBD\n",
      "IL-6 NNP\n",
      "antibody NN\n",
      "in IN\n",
      "Lupus NNP\n",
      "and CC\n",
      "[ NNP\n",
      "indiscernible JJ\n",
      "] NN\n",
      "and CC\n",
      "while IN\n",
      "antibody NN\n",
      "did VBD\n",
      "show VB\n",
      "some DT\n",
      "activity NN\n",
      "we PRP\n",
      "found VBD\n",
      "that IN\n",
      "overall JJ\n",
      "profile NN\n",
      "did VBD\n",
      "not RB\n",
      "compete VB\n",
      "as RB\n",
      "well RB\n",
      "as IN\n",
      "many JJ\n",
      "other JJ\n",
      "real JJ\n",
      "interesting JJ\n",
      "immunology NN\n",
      "agents NNS\n",
      "and CC\n",
      "other JJ\n",
      "opportunities NNS\n",
      "we PRP\n",
      "have VBP\n",
      "in IN\n",
      "our PRP$\n",
      "very RB\n",
      "rich JJ\n",
      "pipeline NN\n",
      "of IN\n",
      "90 CD\n",
      "clinical JJ\n",
      "programs NNS\n",
      "So RB\n",
      "this DT\n",
      "is VBZ\n",
      "part NN\n",
      "of IN\n",
      "prudent JJ\n",
      "portfolio NN\n",
      "prioritization NN\n",
      "within IN\n",
      "Pfizer.Thanks NNP\n",
      "for IN\n",
      "taking VBG\n",
      "the DT\n",
      "questions NNS\n",
      "and CC\n",
      "for IN\n",
      "all PDT\n",
      "the DT\n",
      "clarity NN\n",
      "that IN\n",
      "you PRP\n",
      "'ve VBP\n",
      "given VBN\n",
      "on IN\n",
      "the DT\n",
      "'16 JJ\n",
      "guidance NN\n",
      "Ian NNP\n",
      "first JJ\n",
      "question NN\n",
      "on IN\n",
      "the DT\n",
      "timing NN\n",
      "around IN\n",
      "the DT\n",
      "breakup NN\n",
      "I PRP\n",
      "think VBP\n",
      "you PRP\n",
      "'ve VBP\n",
      "indicated VBN\n",
      "that IN\n",
      "integration NN\n",
      "of IN\n",
      "Allergan NNP\n",
      "is VBZ\n",
      "very RB\n",
      "important JJ\n",
      "You PRP\n",
      "'ve VBP\n",
      "also RB\n",
      "indicated VBN\n",
      "that IN\n",
      "you PRP\n",
      "had VBD\n",
      "time NN\n",
      "to TO\n",
      "look VB\n",
      "even RB\n",
      "deeper RBR\n",
      "into IN\n",
      "the DT\n",
      "Allergan NNP\n",
      "portfolio.As NN\n",
      "you PRP\n",
      "think VBP\n",
      "about IN\n",
      "integration NN\n",
      "can MD\n",
      "you PRP\n",
      "give VB\n",
      "us PRP\n",
      "some DT\n",
      "more RBR\n",
      "commentary JJ\n",
      "around IN\n",
      "how WRB\n",
      "you PRP\n",
      "are VBP\n",
      "thinking VBG\n",
      "about IN\n",
      "mapping VBG\n",
      "out RP\n",
      "integration NN\n",
      "Some DT\n",
      "look NN\n",
      "at IN\n",
      "Wyeth NNP\n",
      "and CC\n",
      "look NN\n",
      "at IN\n",
      "the DT\n",
      "massive JJ\n",
      "amount NN\n",
      "of IN\n",
      "synergies NNS\n",
      "that IN\n",
      "you PRP\n",
      "are VBP\n",
      "able JJ\n",
      "to TO\n",
      "extract VB\n",
      "out IN\n",
      "of IN\n",
      "Wyeth NNP\n",
      "transaction NN\n",
      "and CC\n",
      "are VBP\n",
      "somewhat RB\n",
      "puzzled JJ\n",
      "as IN\n",
      "to TO\n",
      "why WRB\n",
      "you PRP\n",
      "ca MD\n",
      "n't RB\n",
      "do VB\n",
      "that DT\n",
      "here RB\n",
      "So RB\n",
      "any DT\n",
      "commentary JJ\n",
      "around IN\n",
      "that DT\n",
      "Two CD\n",
      "additional JJ\n",
      "questions NNS\n",
      "one CD\n",
      "on IN\n",
      "CDK NNP\n",
      "4/6 CD\n",
      "this DT\n",
      "one CD\n",
      "is VBZ\n",
      "for IN\n",
      "Mikael NNP\n",
      "Mikael NNP\n",
      "when WRB\n",
      "you PRP\n",
      "look VBP\n",
      "at IN\n",
      "preclinical JJ\n",
      "models NNS\n",
      "is VBZ\n",
      "there RB\n",
      "any DT\n",
      "argument NN\n",
      "or CC\n",
      "hypothesis NN\n",
      "around IN\n",
      "a DT\n",
      "drug NN\n",
      "that WDT\n",
      "has VBZ\n",
      "to TO\n",
      "be VB\n",
      "given VBN\n",
      "intermittently RB\n",
      "that IN\n",
      "it PRP\n",
      "might MD\n",
      "have VB\n",
      "less JJR\n",
      "efficacy NN\n",
      "than IN\n",
      "one CD\n",
      "that WDT\n",
      "'s VBZ\n",
      "given VBN\n",
      "on IN\n",
      "a DT\n",
      "continuous JJ\n",
      "dosing NN\n",
      "And CC\n",
      "is VBZ\n",
      "that IN\n",
      "supported VBN\n",
      "by IN\n",
      "any DT\n",
      "preclinical JJ\n",
      "models NNS\n",
      "And CC\n",
      "then RB\n",
      "the DT\n",
      "last JJ\n",
      "question NN\n",
      "just RB\n",
      "has VBZ\n",
      "to TO\n",
      "do VB\n",
      "with IN\n",
      "Xeljanz NNP\n",
      "Obviously RB\n",
      "a DT\n",
      "very RB\n",
      "important JJ\n",
      "asset NN\n",
      "for IN\n",
      "you PRP\n",
      "not RB\n",
      "only RB\n",
      "in IN\n",
      "the DT\n",
      "U.S. NNP\n",
      "but CC\n",
      "on IN\n",
      "the DT\n",
      "EU NNP\n",
      "timing NN\n",
      "for IN\n",
      "filing NN\n",
      "I PRP\n",
      "think VBP\n",
      "you PRP\n",
      "indicated VBN\n",
      "you PRP\n",
      "wanted VBD\n",
      "to TO\n",
      "have VB\n",
      "that DT\n",
      "filed VBN\n",
      "before IN\n",
      "the DT\n",
      "end NN\n",
      "of IN\n",
      "the DT\n",
      "year NN\n",
      "Just RB\n",
      "any DT\n",
      "update NN\n",
      "on IN\n",
      "what WP\n",
      "Europe NNP\n",
      "is VBZ\n",
      "looking VBG\n",
      "for IN\n",
      "within IN\n",
      "that DT\n",
      "filing NN\n",
      "to TO\n",
      "secure VB\n",
      "approval NN\n",
      "in IN\n",
      "Europe NNP\n",
      "And CC\n",
      "then RB\n",
      "on IN\n",
      "psoriasis NN\n",
      "in IN\n",
      "the DT\n",
      "U.S. NNP\n",
      "any DT\n",
      "developments NNS\n",
      "there RB\n",
      "on IN\n",
      "the DT\n",
      "modified JJ\n",
      "release NN\n",
      "from IN\n",
      "a DT\n",
      "regulatory JJ\n",
      "standpoint NN\n",
      "and CC\n",
      "then RB\n",
      "obviously RB\n",
      "with IN\n",
      "Enbrel NNP\n",
      "seeing VBG\n",
      "generic JJ\n",
      "competition NN\n",
      "what WP\n",
      "have VBP\n",
      "you PRP\n",
      "done VBN\n",
      "with IN\n",
      "your PRP$\n",
      "infrastructure NN\n",
      "in IN\n",
      "Europe NNP\n",
      "to TO\n",
      "still RB\n",
      "keep VB\n",
      "some DT\n",
      "infrastructure NN\n",
      "in IN\n",
      "place NN\n",
      "to TO\n",
      "support VB\n",
      "Xeljanz NNP\n",
      "if IN\n",
      "and CC\n",
      "when WRB\n",
      "it PRP\n",
      "gets VBZ\n",
      "approved VBN\n",
      "Okay NNP\n",
      "So RB\n",
      "let VB\n",
      "me PRP\n",
      "just RB\n",
      "quickly RB\n",
      "the DT\n",
      "last JJ\n",
      "one CD\n",
      "first RB\n",
      "we PRP\n",
      "still RB\n",
      "have VBP\n",
      "very RB\n",
      "strong JJ\n",
      "expectations NNS\n",
      "from IN\n",
      "Enbrel NNP\n",
      "in IN\n",
      "Europe NNP\n",
      "as IN\n",
      "Geno NNP\n",
      "was VBD\n",
      "discussing VBG\n",
      "We PRP\n",
      "are VBP\n",
      "not RB\n",
      "removing VBG\n",
      "our PRP$\n",
      "support NN\n",
      "from IN\n",
      "Enbrel NNP\n",
      "So IN\n",
      "we PRP\n",
      "expect VBP\n",
      "to TO\n",
      "have VB\n",
      "full JJ\n",
      "support NN\n",
      "for IN\n",
      "Xeljanz NN\n",
      "when WRB\n",
      "it PRP\n",
      "launches VBZ\n",
      "in IN\n",
      "Europe NNP\n",
      "There EX\n",
      "was VBD\n",
      "a DT\n",
      "somewhat RB\n",
      "of IN\n",
      "a DT\n",
      "slippage NN\n",
      "from IN\n",
      "as IN\n",
      "you PRP\n",
      "say VBP\n",
      "the DT\n",
      "end NN\n",
      "of IN\n",
      "the DT\n",
      "year NN\n",
      "to TO\n",
      "the DT\n",
      "beginning NN\n",
      "of IN\n",
      "this DT\n",
      "year NN\n",
      "on IN\n",
      "the DT\n",
      "Xeljanz NNP\n",
      "application NN\n",
      "in IN\n",
      "Europe NNP\n",
      "We PRP\n",
      "wanted VBD\n",
      "to TO\n",
      "get VB\n",
      "it PRP\n",
      "right JJ\n",
      "and CC\n",
      "make VB\n",
      "sure JJ\n",
      "that IN\n",
      "it PRP\n",
      "was VBD\n",
      "in IN\n",
      "the DT\n",
      "best JJS\n",
      "shape NN\n",
      "we PRP\n",
      "could MD\n",
      "and CC\n",
      "these DT\n",
      "things NNS\n",
      "happened VBD\n",
      "So RB\n",
      "there EX\n",
      "was VBD\n",
      "a DT\n",
      "slight JJ\n",
      "slippage NN\n",
      "on IN\n",
      "time NN\n",
      "on IN\n",
      "that DT\n",
      "Mikael NNP\n",
      "do VBP\n",
      "you PRP\n",
      "want VB\n",
      "to TO\n",
      "deal VB\n",
      "with IN\n",
      "this DT\n",
      "hypothetical JJ\n",
      "on IN\n",
      "CDK NNP\n",
      "4/6 CD\n",
      "Yes UH\n",
      "thank VB\n",
      "you PRP\n",
      "for IN\n",
      "the DT\n",
      "questions NNS\n",
      "Of IN\n",
      "course NN\n",
      "always RB\n",
      "we PRP\n",
      "would MD\n",
      "caution VB\n",
      "you PRP\n",
      "can MD\n",
      "speculate VB\n",
      "on IN\n",
      "things NNS\n",
      "that WDT\n",
      "have VBP\n",
      "n't RB\n",
      "been VBN\n",
      "studied VBN\n",
      "in IN\n",
      "humans NNS\n",
      "in IN\n",
      "comparative JJ\n",
      "aspects NNS\n",
      "but CC\n",
      "you PRP\n",
      "know VBP\n",
      "we PRP\n",
      "think VBP\n",
      "it PRP\n",
      "'s VBZ\n",
      "important JJ\n",
      "to TO\n",
      "hit VB\n",
      "CDK NNP\n",
      "4/6 CD\n",
      "hard NN\n",
      "for IN\n",
      "breast NN\n",
      "cancer NN\n",
      "and CC\n",
      "when WRB\n",
      "you PRP\n",
      "do VBP\n",
      "that IN\n",
      "with IN\n",
      "high JJ\n",
      "doses NNS\n",
      "you PRP\n",
      "will MD\n",
      "get VB\n",
      "efficacy NN\n",
      "on IN\n",
      "the DT\n",
      "tumor NN\n",
      "but CC\n",
      "also RB\n",
      "see VB\n",
      "some DT\n",
      "neutropenia NNS\n",
      "and CC\n",
      "that DT\n",
      "'s VBZ\n",
      "we PRP\n",
      "why WRB\n",
      "chose VBD\n",
      "the DT\n",
      "intermittent NN\n",
      "schedules NNS\n",
      "Particularly RB\n",
      "it PRP\n",
      "seems VBZ\n",
      "very RB\n",
      "effective JJ\n",
      "for IN\n",
      "combination NN\n",
      "therapy NN\n",
      "with IN\n",
      "multiple JJ\n",
      "agents NNS\n",
      "such JJ\n",
      "as IN\n",
      "[ NNP\n",
      "indiscernible JJ\n",
      "] NN\n",
      "in IN\n",
      "breast NN\n",
      "cancer.For NN\n",
      "other JJ\n",
      "tumor NN\n",
      "types NNS\n",
      "we PRP\n",
      "may MD\n",
      "explore VB\n",
      "various JJ\n",
      "schedules NNS\n",
      "for IN\n",
      "various JJ\n",
      "combination NN\n",
      "of IN\n",
      "drugs NNS\n",
      "but CC\n",
      "for IN\n",
      "breast JJ\n",
      "cancer NN\n",
      "we PRP\n",
      "think VBP\n",
      "to TO\n",
      "show VB\n",
      "some DT\n",
      "schedule NN\n",
      "with IN\n",
      "the DT\n",
      "combinations NNS\n",
      "we PRP\n",
      "have VBP\n",
      "studied VBN\n",
      "is VBZ\n",
      "very RB\n",
      "effective JJ\n",
      "and CC\n",
      "works VBZ\n",
      "well.Thank NN\n",
      "you PRP\n",
      "Geno NNP\n",
      "you PRP\n",
      "want VBP\n",
      "to TO\n",
      "deal VB\n",
      "with IN\n",
      "the DT\n",
      "other JJ\n",
      "questions NNS\n",
      "that IN\n",
      "John NNP\n",
      "asked VBD\n",
      "on IN\n",
      "Xeljanz NNP\n",
      "Yes UH\n",
      "John NNP\n",
      "I PRP\n",
      "think VBP\n",
      "the DT\n",
      "question NN\n",
      "as IN\n",
      "Ian NNP\n",
      "had VBD\n",
      "already RB\n",
      "alluded VBN\n",
      "to TO\n",
      "we PRP\n",
      "are VBP\n",
      "now RB\n",
      "expecting VBG\n",
      "our PRP$\n",
      "filing NN\n",
      "to TO\n",
      "be VB\n",
      "in IN\n",
      "the DT\n",
      "first JJ\n",
      "quarter NN\n",
      "of IN\n",
      "this DT\n",
      "year NN\n",
      "We PRP\n",
      "'re VBP\n",
      "actually RB\n",
      "meeting VBG\n",
      "with IN\n",
      "[ NNP\n",
      "indiscernible JJ\n",
      "] NN\n",
      "at IN\n",
      "this DT\n",
      "point NN\n",
      "We PRP\n",
      "did VBD\n",
      "generate VB\n",
      "additional JJ\n",
      "data NNS\n",
      "on IN\n",
      "immune JJ\n",
      "function NN\n",
      "as IN\n",
      "a DT\n",
      "result NN\n",
      "of IN\n",
      "the DT\n",
      "discussions NNS\n",
      "that IN\n",
      "we PRP\n",
      "had VBD\n",
      "with IN\n",
      "the DT\n",
      "regulators NNS\n",
      "in IN\n",
      "the DT\n",
      "first JJ\n",
      "submission NN\n",
      "So IN\n",
      "we PRP\n",
      "feel VBP\n",
      "that IN\n",
      "we PRP\n",
      "have VBP\n",
      "a DT\n",
      "strong JJ\n",
      "package NN\n",
      "that IN\n",
      "we PRP\n",
      "have VBP\n",
      "responded VBN\n",
      "to TO\n",
      "the DT\n",
      "information NN\n",
      "requests VBZ\n",
      "that IN\n",
      "they PRP\n",
      "had VBD\n",
      "and CC\n",
      "we PRP\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "'re VBP\n",
      "just RB\n",
      "tidying VBG\n",
      "up RP\n",
      "the DT\n",
      "kind NN\n",
      "of IN\n",
      "last JJ\n",
      "few JJ\n",
      "details NNS\n",
      "and CC\n",
      "expect VBP\n",
      "to TO\n",
      "put VB\n",
      "that DT\n",
      "filing NN\n",
      "in IN\n",
      "imminently.So JJ\n",
      "psoriasis NN\n",
      "well RB\n",
      "as IN\n",
      "you PRP\n",
      "probably RB\n",
      "know VBP\n",
      "we PRP\n",
      "have VBP\n",
      "a DT\n",
      "we PRP\n",
      "received VBD\n",
      "a DT\n",
      "complete JJ\n",
      "response NN\n",
      "letter NN\n",
      "from IN\n",
      "the DT\n",
      "FDA NNP\n",
      "on IN\n",
      "psoriasis NN\n",
      "We PRP\n",
      "have VBP\n",
      "provided VBN\n",
      "a DT\n",
      "backgrounder NN\n",
      "to TO\n",
      "the DT\n",
      "FDA NNP\n",
      "and CC\n",
      "we PRP\n",
      "expect VBP\n",
      "to TO\n",
      "meet VB\n",
      "with IN\n",
      "them PRP\n",
      "also RB\n",
      "this DT\n",
      "quarter NN\n",
      "to TO\n",
      "follow-up NN\n",
      "on IN\n",
      "the DT\n",
      "components NNS\n",
      "of IN\n",
      "the DT\n",
      "complete JJ\n",
      "response NN\n",
      "letter NN\n",
      "and CC\n",
      "once RB\n",
      "we PRP\n",
      "know VBP\n",
      "in IN\n",
      "more JJR\n",
      "detail NN\n",
      "what WP\n",
      "their PRP$\n",
      "issues NNS\n",
      "and CC\n",
      "concerns NNS\n",
      "are VBP\n",
      "then RB\n",
      "we PRP\n",
      "'ll MD\n",
      "determine VB\n",
      "best JJS\n",
      "way NN\n",
      "forward RB\n",
      "from IN\n",
      "there.Yes NN\n",
      "So IN\n",
      "we PRP\n",
      "have VBP\n",
      "certainly RB\n",
      "announced VBN\n",
      "the DT\n",
      "deal NN\n",
      "more JJR\n",
      "than IN\n",
      "2 CD\n",
      "billion CD\n",
      "We PRP\n",
      "gave VBD\n",
      "you PRP\n",
      "the DT\n",
      "timing NN\n",
      "in IN\n",
      "terms NNS\n",
      "of IN\n",
      "when WRB\n",
      "we PRP\n",
      "would MD\n",
      "get VB\n",
      "that DT\n",
      "A DT\n",
      "couple NN\n",
      "of IN\n",
      "comments NNS\n",
      "John NNP\n",
      "to TO\n",
      "your PRP$\n",
      "question NN\n",
      "I PRP\n",
      "think VBP\n",
      "first JJ\n",
      "why WRB\n",
      "more JJR\n",
      "than IN\n",
      "2 CD\n",
      "billion CD\n",
      "why WRB\n",
      "not RB\n",
      "a DT\n",
      "higher JJR\n",
      "number NN\n",
      "I PRP\n",
      "think VBP\n",
      "these DT\n",
      "are VBP\n",
      "two CD\n",
      "companies NNS\n",
      "that WDT\n",
      "have VBP\n",
      "done VBN\n",
      "a DT\n",
      "lot NN\n",
      "on IN\n",
      "the DT\n",
      "cost NN\n",
      "reduction NN\n",
      "front NN\n",
      "significant JJ\n",
      "reductions NNS\n",
      "at IN\n",
      "both DT\n",
      "companies NNS\n",
      "I PRP\n",
      "think VBP\n",
      "efficiently RB\n",
      "run VBN\n",
      "companies NNS\n",
      "Two CD\n",
      "not RB\n",
      "a DT\n",
      "lot NN\n",
      "of IN\n",
      "therapeutic JJ\n",
      "area NN\n",
      "overlap NN\n",
      "which WDT\n",
      "is VBZ\n",
      "always RB\n",
      "seeing VBG\n",
      "a DT\n",
      "kind NN\n",
      "of IN\n",
      "a DT\n",
      "trigger NN\n",
      "for IN\n",
      "synergy NN\n",
      "opportunities NNS\n",
      "Third NNP\n",
      "if IN\n",
      "you PRP\n",
      "look VBP\n",
      "at IN\n",
      "the DT\n",
      "Allergan NNP\n",
      "cost NN\n",
      "of IN\n",
      "goods NNS\n",
      "sold VBN\n",
      "two-thirds NNS\n",
      "of IN\n",
      "that IN\n",
      "from IN\n",
      "my PRP$\n",
      "perspective NN\n",
      "from IN\n",
      "a DT\n",
      "synergy JJ\n",
      "perspective NN\n",
      "was VBD\n",
      "unaddressable JJ\n",
      "It PRP\n",
      "'s VBZ\n",
      "their PRP$\n",
      "end NN\n",
      "of IN\n",
      "business NN\n",
      "and CC\n",
      "then RB\n",
      "royalties NNS\n",
      "So RB\n",
      "really RB\n",
      "not RB\n",
      "a DT\n",
      "lot NN\n",
      "we PRP\n",
      "could MD\n",
      "do VB\n",
      "there RB\n",
      "but CC\n",
      "all PDT\n",
      "that DT\n",
      "said VBD\n",
      "and CC\n",
      "done VBN\n",
      "we PRP\n",
      "'re VBP\n",
      "working VBG\n",
      "now RB\n",
      "with IN\n",
      "the DT\n",
      "Allergan NNP\n",
      "teams NNS\n",
      "with IN\n",
      "Brent NNP\n",
      "with IN\n",
      "Bob NNP\n",
      "Steward NNP\n",
      "with IN\n",
      "Tessa NNP\n",
      "Ian NNP\n",
      "and CC\n",
      "myself PRP\n",
      "our PRP$\n",
      "leadership NN\n",
      "team NN\n",
      "here RB\n",
      "at IN\n",
      "Pfizer NNP\n",
      "we PRP\n",
      "'ve VBP\n",
      "already RB\n",
      "launched VBN\n",
      "a DT\n",
      "couple NN\n",
      "of IN\n",
      "operational JJ\n",
      "teams NNS\n",
      "and CC\n",
      "we PRP\n",
      "'re VBP\n",
      "starting VBG\n",
      "to TO\n",
      "dig VB\n",
      "into IN\n",
      "this DT\n",
      "in IN\n",
      "much RB\n",
      "more JJR\n",
      "detail NN\n",
      "If IN\n",
      "there EX\n",
      "is VBZ\n",
      "more JJR\n",
      "there RB\n",
      "please VB\n",
      "know VBP\n",
      "we PRP\n",
      "'re VBP\n",
      "going VBG\n",
      "to TO\n",
      "get VB\n",
      "it PRP\n",
      "and CC\n",
      "we PRP\n",
      "'ll MD\n",
      "tell VB\n",
      "you PRP\n",
      "about IN\n",
      "it PRP\n",
      "So RB\n",
      "I PRP\n",
      "think VBP\n",
      "on IN\n",
      "a DT\n",
      "synergy JJ\n",
      "front NN\n",
      "just RB\n",
      "more RBR\n",
      "to TO\n",
      "come.Yes VB\n",
      "And CC\n",
      "you PRP\n",
      "know VBP\n",
      "John NNP\n",
      "the DT\n",
      "process NN\n",
      "from IN\n",
      "this DT\n",
      "deal NN\n",
      "was VBD\n",
      "not RB\n",
      "huge JJ\n",
      "cost NN\n",
      "synergies NNS\n",
      "it PRP\n",
      "was VBD\n",
      "about IN\n",
      "driving VBG\n",
      "revenue NN\n",
      "growth NN\n",
      "in IN\n",
      "the DT\n",
      "innovative JJ\n",
      "business NN\n",
      "driving VBG\n",
      "reasonably RB\n",
      "young JJ\n",
      "portfolios NNS\n",
      "taking VBG\n",
      "the DT\n",
      "products NNS\n",
      "internationally RB\n",
      "and CC\n",
      "then RB\n",
      "getting VBG\n",
      "excellent JJ\n",
      "capital NN\n",
      "allocation NN\n",
      "over IN\n",
      "the DT\n",
      "world NN\n",
      "So IN\n",
      "we PRP\n",
      "will MD\n",
      "get VB\n",
      "the DT\n",
      "synergies NNS\n",
      "we PRP\n",
      "can MD\n",
      "get VB\n",
      "but CC\n",
      "our PRP$\n",
      "focus NN\n",
      "is VBZ\n",
      "on IN\n",
      "growth NN\n",
      "and CC\n",
      "a DT\n",
      "lot NN\n",
      "of IN\n",
      "the DT\n",
      "questions NNS\n",
      "on IN\n",
      "the DT\n",
      "call NN\n",
      "have VBP\n",
      "been VBN\n",
      "about IN\n",
      "growth NN\n",
      "So RB\n",
      "this DT\n",
      "is VBZ\n",
      "part NN\n",
      "of IN\n",
      "the DT\n",
      "solution NN\n",
      "to TO\n",
      "that DT\n",
      "and CC\n",
      "also RB\n",
      "really RB\n",
      "a DT\n",
      "good JJ\n",
      "capital NN\n",
      "allocation.Thank NN\n",
      "you PRP\n",
      "If IN\n",
      "I PRP\n",
      "could MD\n",
      "go VB\n",
      "back RB\n",
      "to TO\n",
      "the DT\n",
      "revenue NN\n",
      "guidance NN\n",
      "the DT\n",
      "midpoint NN\n",
      "is VBZ\n",
      "about IN\n",
      "2.5 CD\n",
      "billion CD\n",
      "below IN\n",
      "consensus NN\n",
      "you PRP\n",
      "flagged VBD\n",
      "FX NNP\n",
      "was VBD\n",
      "a DT\n",
      "major JJ\n",
      "headwind NN\n",
      "I PRP\n",
      "know VBP\n",
      "that IN\n",
      "we PRP\n",
      "spend VBP\n",
      "a DT\n",
      "lot NN\n",
      "of IN\n",
      "time NN\n",
      "trying VBG\n",
      "to TO\n",
      "incorporate VB\n",
      "FX NNP\n",
      "and CC\n",
      "I PRP\n",
      "imagine VBP\n",
      "consensus NN\n",
      "does VBZ\n",
      "too RB\n",
      "yet CC\n",
      "that DT\n",
      "'s VBZ\n",
      "still RB\n",
      "a DT\n",
      "very RB\n",
      "big JJ\n",
      "delta NN\n",
      "So RB\n",
      "my PRP$\n",
      "question NN\n",
      "on IN\n",
      "this DT\n",
      "is VBZ\n",
      "when WRB\n",
      "you PRP\n",
      "look VBP\n",
      "at IN\n",
      "analyst NN\n",
      "models NNS\n",
      "are VBP\n",
      "there RB\n",
      "particular JJ\n",
      "revenue NN\n",
      "line NN\n",
      "items NNS\n",
      "for IN\n",
      "products NNS\n",
      "or CC\n",
      "divisions NNS\n",
      "where WRB\n",
      "you PRP\n",
      "think VBP\n",
      "consensus NN\n",
      "is VBZ\n",
      "too RB\n",
      "high JJ\n",
      "unrelated JJ\n",
      "to TO\n",
      "foreign JJ\n",
      "exchange NN\n",
      "Second JJ\n",
      "question NN\n",
      "you PRP\n",
      "mentioned VBD\n",
      "the DT\n",
      "4-1BB JJ\n",
      "with IN\n",
      "Merck NNP\n",
      "and CC\n",
      "I PRP\n",
      "'m VBP\n",
      "showing VBG\n",
      "foundation NN\n",
      "data NNS\n",
      "with IN\n",
      "Keytruda NNP\n",
      "That DT\n",
      "'s VBZ\n",
      "Phase NNP\n",
      "I PRP\n",
      "data VBP\n",
      "so RB\n",
      "as IN\n",
      "such JJ\n",
      "I PRP\n",
      "'m VBP\n",
      "blinded JJ\n",
      "I PRP\n",
      "'m VBP\n",
      "wondering VBG\n",
      "if IN\n",
      "you PRP\n",
      "can MD\n",
      "give VB\n",
      "us PRP\n",
      "a DT\n",
      "preview NN\n",
      "of IN\n",
      "the DT\n",
      "tumor NN\n",
      "types NNS\n",
      "here RB\n",
      "you PRP\n",
      "think VBP\n",
      "are VBP\n",
      "most RBS\n",
      "promising JJ\n",
      "and CC\n",
      "also RB\n",
      "any DT\n",
      "preliminary JJ\n",
      "safety NN\n",
      "findings NNS\n",
      "And CC\n",
      "then RB\n",
      "last JJ\n",
      "pipeline NN\n",
      "question NN\n",
      "last JJ\n",
      "year NN\n",
      "you PRP\n",
      "mentioned VBD\n",
      "having VBG\n",
      "an DT\n",
      "oral JJ\n",
      "PCSK9 NNP\n",
      "approaching VBG\n",
      "human JJ\n",
      "development NN\n",
      "and CC\n",
      "I PRP\n",
      "'m VBP\n",
      "wondering VBG\n",
      "if IN\n",
      "that DT\n",
      "is VBZ\n",
      "now RB\n",
      "in IN\n",
      "the DT\n",
      "clinic NN\n",
      "when WRB\n",
      "I PRP\n",
      "look VBP\n",
      "at IN\n",
      "your PRP$\n",
      "pipeline NN\n",
      "chart NN\n",
      "I PRP\n",
      "see VBP\n",
      "a DT\n",
      "new JJ\n",
      "compound NN\n",
      "has VBZ\n",
      "been VBN\n",
      "advanced VBN\n",
      "on IN\n",
      "the DT\n",
      "Phase NNP\n",
      "I PRP\n",
      "Okay NNP\n",
      "Frank NNP\n",
      "if IN\n",
      "you PRP\n",
      "could MD\n",
      "deal VB\n",
      "with IN\n",
      "the DT\n",
      "first JJ\n",
      "question NN\n",
      "and CC\n",
      "Mikael NNP\n",
      "will MD\n",
      "have VB\n",
      "remaining VBG\n",
      "two.Sure NN\n",
      "So RB\n",
      "Tim NNP\n",
      "let VB\n",
      "me PRP\n",
      "run VB\n",
      "the DT\n",
      "numbers NNS\n",
      "in IN\n",
      "then RB\n",
      "I PRP\n",
      "'ll MD\n",
      "answer VB\n",
      "the DT\n",
      "questions NNS\n",
      "So RB\n",
      "your PRP$\n",
      "numbers NNS\n",
      "are VBP\n",
      "right JJ\n",
      "So RB\n",
      "consensus JJ\n",
      "numbers NNS\n",
      "give VBP\n",
      "or CC\n",
      "take VB\n",
      "on IN\n",
      "revenue NN\n",
      "for IN\n",
      "2016 CD\n",
      "about IN\n",
      "52.4 CD\n",
      "billion CD\n",
      "the DT\n",
      "midpoint NN\n",
      "of IN\n",
      "all DT\n",
      "guidance NN\n",
      "50 CD\n",
      "billion CD\n",
      "the DT\n",
      "net JJ\n",
      "there EX\n",
      "is VBZ\n",
      "roughly RB\n",
      "2.5 CD\n",
      "billion CD\n",
      "that IN\n",
      "you PRP\n",
      "alluded VBD\n",
      "to TO\n",
      "just RB\n",
      "to TO\n",
      "kind NN\n",
      "of IN\n",
      "nail NN\n",
      "the DT\n",
      "numbers.I JJ\n",
      "think VBP\n",
      "two CD\n",
      "major JJ\n",
      "pieces NNS\n",
      "in IN\n",
      "terms NNS\n",
      "of IN\n",
      "the DT\n",
      "GAAP NNP\n",
      "one CD\n",
      "is VBZ\n",
      "clearly RB\n",
      "the DT\n",
      "Venezuela NNP\n",
      "adjustment NN\n",
      "we PRP\n",
      "made VBD\n",
      "in IN\n",
      "2016 CD\n",
      "would MD\n",
      "n't RB\n",
      "have VB\n",
      "been VBN\n",
      "at IN\n",
      "the DT\n",
      "52.4 CD\n",
      "So IN\n",
      "that DT\n",
      "'s VBZ\n",
      "an DT\n",
      "800 CD\n",
      "million CD\n",
      "adjustment NN\n",
      "That DT\n",
      "would MD\n",
      "take VB\n",
      "a DT\n",
      "52.4 CD\n",
      "to TO\n",
      "51.6 CD\n",
      "and CC\n",
      "then RB\n",
      "I PRP\n",
      "think VBP\n",
      "when WRB\n",
      "you PRP\n",
      "look VBP\n",
      "at IN\n",
      "the DT\n",
      "line NN\n",
      "items NNS\n",
      "I PRP\n",
      "think VBP\n",
      "the DT\n",
      "big JJ\n",
      "difference NN\n",
      "[ NNP\n",
      "technical JJ\n",
      "difficulty NN\n",
      "] NN\n",
      "if IN\n",
      "you PRP\n",
      "ask VBP\n",
      "me PRP\n",
      "to TO\n",
      "point VB\n",
      "out RP\n",
      "one CD\n",
      "single JJ\n",
      "place NN\n",
      "it PRP\n",
      "'s VBZ\n",
      "Prevnar NNP\n",
      "13 CD\n",
      "Significant JJ\n",
      "results NNS\n",
      "and CC\n",
      "the DT\n",
      "growth NN\n",
      "expectations NNS\n",
      "in IN\n",
      "Prevnar NNP\n",
      "13 CD\n",
      "'16 POS\n",
      "versus IN\n",
      "our PRP$\n",
      "modeling NN\n",
      "for IN\n",
      "'16 WP\n",
      "where WRB\n",
      "I PRP\n",
      "said VBD\n",
      "in IN\n",
      "my PRP$\n",
      "comments NNS\n",
      "and CC\n",
      "Albert NNP\n",
      "punctuated VBD\n",
      "in IN\n",
      "some DT\n",
      "of IN\n",
      "his PRP$\n",
      "detailed JJ\n",
      "remarks NNS\n",
      "about IN\n",
      "we PRP\n",
      "'re VBP\n",
      "expecting VBG\n",
      "that DT\n",
      "to TO\n",
      "be VB\n",
      "essentially RB\n",
      "comparable JJ\n",
      "to TO\n",
      "2015 CD\n",
      "levels NNS\n",
      "Those DT\n",
      "are VBP\n",
      "the DT\n",
      "two CD\n",
      "things NNS\n",
      "that IN\n",
      "I PRP\n",
      "would MD\n",
      "point VB\n",
      "out RP\n",
      "that DT\n",
      "will MD\n",
      "make VB\n",
      "up RP\n",
      "the DT\n",
      "majority NN\n",
      "big JJ\n",
      "piece NN\n",
      "of IN\n",
      "the DT\n",
      "difference NN\n",
      "in IN\n",
      "terms NNS\n",
      "of IN\n",
      "your PRP$\n",
      "2.5 CD\n",
      "billion.So NN\n",
      "thank NN\n",
      "you PRP\n",
      "for IN\n",
      "asking VBG\n",
      "about IN\n",
      "4-1BB JJ\n",
      "and CC\n",
      "as IN\n",
      "you PRP\n",
      "know VBP\n",
      "we PRP\n",
      "believe VBP\n",
      "that IN\n",
      "the DT\n",
      "combination NN\n",
      "therapy NN\n",
      "moved VBD\n",
      "immuno-oncology JJ\n",
      "feel NN\n",
      "to TO\n",
      "the DT\n",
      "next JJ\n",
      "level NN\n",
      "We PRP\n",
      "are VBP\n",
      "very RB\n",
      "pleased JJ\n",
      "with IN\n",
      "the DT\n",
      "4-1BB JJ\n",
      "one CD\n",
      "of IN\n",
      "tumor NN\n",
      "antibody NN\n",
      "that IN\n",
      "we PRP\n",
      "have VBP\n",
      "We PRP\n",
      "have VBP\n",
      "started VBN\n",
      "eating VBG\n",
      "combination NN\n",
      "with IN\n",
      "Rituximab NNP\n",
      "in IN\n",
      "lymphoma NN\n",
      "and CC\n",
      "with IN\n",
      "PD-1 NNP\n",
      "Keytruda NNP\n",
      "in IN\n",
      "a DT\n",
      "small JJ\n",
      "study NN\n",
      "across IN\n",
      "various JJ\n",
      "tumor NN\n",
      "types NNS\n",
      "and CC\n",
      "have VBP\n",
      "also RB\n",
      "initiated VBN\n",
      "combination NN\n",
      "study NN\n",
      "with IN\n",
      "Avelumab.The NNP\n",
      "4-1BB JJ\n",
      "antibody NN\n",
      "the DT\n",
      "Pfizer NNP\n",
      "antibody NN\n",
      "shows VBZ\n",
      "very RB\n",
      "good JJ\n",
      "tolerability NN\n",
      "when WRB\n",
      "combined VBN\n",
      "with IN\n",
      "other JJ\n",
      "biological JJ\n",
      "agents NNS\n",
      "and CC\n",
      "it PRP\n",
      "'s VBZ\n",
      "clinical JJ\n",
      "performance NN\n",
      "suggest NN\n",
      "also RB\n",
      "very RB\n",
      "interesting JJ\n",
      "favorable JJ\n",
      "clinical JJ\n",
      "activity NN\n",
      "on IN\n",
      "top NN\n",
      "of IN\n",
      "other JJ\n",
      "biologicals NNS\n",
      "such JJ\n",
      "as IN\n",
      "Rituximab NNP\n",
      "and CC\n",
      "PD-1 NNP\n",
      "Keytruda NNP\n",
      "We PRP\n",
      "will MD\n",
      "share NN\n",
      "the DT\n",
      "date NN\n",
      "from IN\n",
      "this DT\n",
      "first JJ\n",
      "cohort NN\n",
      "this DT\n",
      "year NN\n",
      "likely RB\n",
      "at IN\n",
      "ASCO NNP\n",
      "We PRP\n",
      "are VBP\n",
      "quite RB\n",
      "excited JJ\n",
      "about IN\n",
      "4-1BB JJ\n",
      "and CC\n",
      "also RB\n",
      "OX40 NNP\n",
      "that WDT\n",
      "'s VBZ\n",
      "in IN\n",
      "our PRP$\n",
      "pipeline NN\n",
      "and CC\n",
      "you PRP\n",
      "will MD\n",
      "see VB\n",
      "4-1BB JJ\n",
      "Avelumab NNP\n",
      "data NNS\n",
      "likely RB\n",
      "late RB\n",
      "this DT\n",
      "year NN\n",
      "as RB\n",
      "well RB\n",
      "OX40 NNP\n",
      "monodata NN\n",
      "and CC\n",
      "early RB\n",
      "next JJ\n",
      "year NN\n",
      "several JJ\n",
      "doublets NNS\n",
      "and CC\n",
      "triplets NNS\n",
      "which WDT\n",
      "makes VBZ\n",
      "me PRP\n",
      "very RB\n",
      "enthusiastic JJ\n",
      "as IN\n",
      "I PRP\n",
      "look VBP\n",
      "forward RB\n",
      "how WRB\n",
      "we PRP\n",
      "advanced VBD\n",
      "the DT\n",
      "strategy NN\n",
      "of IN\n",
      "combinations NNS\n",
      "therapy.We WDT\n",
      "have VBP\n",
      "an DT\n",
      "oral JJ\n",
      "PCSK9 NNP\n",
      "in IN\n",
      "Phase NNP\n",
      "I PRP\n",
      "It PRP\n",
      "'s VBZ\n",
      "too RB\n",
      "early JJ\n",
      "to TO\n",
      "have VB\n",
      "any DT\n",
      "definitive JJ\n",
      "interpretation NN\n",
      "of IN\n",
      "that DT\n",
      "data NN\n",
      "and CC\n",
      "we PRP\n",
      "also RB\n",
      "have VBP\n",
      "a DT\n",
      "PCSK9 NNP\n",
      "vaccine NN\n",
      "in IN\n",
      "late JJ\n",
      "preclinical JJ\n",
      "development.Oh NN\n",
      "thanks NNS\n",
      "I PRP\n",
      "have VBP\n",
      "a DT\n",
      "couple NN\n",
      "of IN\n",
      "questions NNS\n",
      "for IN\n",
      "Mikael NNP\n",
      "just RB\n",
      "on IN\n",
      "Ibrance NNP\n",
      "can MD\n",
      "you PRP\n",
      "flag VB\n",
      "any DT\n",
      "upcoming JJ\n",
      "data NNS\n",
      "for IN\n",
      "tumor NN\n",
      "types NNS\n",
      "outside IN\n",
      "of IN\n",
      "breast NN\n",
      "cancer NN\n",
      "that IN\n",
      "we PRP\n",
      "should MD\n",
      "look VB\n",
      "out RP\n",
      "for IN\n",
      "Also RB\n",
      "can MD\n",
      "you PRP\n",
      "update VB\n",
      "on IN\n",
      "how WRB\n",
      "well RB\n",
      "the DT\n",
      "Adjuvant NNP\n",
      "breast NN\n",
      "cancer NN\n",
      "studies NNS\n",
      "are VBP\n",
      "enrolling VBG\n",
      "Thanks.Yes NNP\n",
      "I PRP\n",
      "could MD\n",
      "say VB\n",
      "a DT\n",
      "few JJ\n",
      "words NNS\n",
      "so RB\n",
      "as IN\n",
      "Albert NNP\n",
      "alluded VBD\n",
      "to TO\n",
      "there EX\n",
      "is VBZ\n",
      "a DT\n",
      "large JJ\n",
      "number NN\n",
      "of IN\n",
      "Ibrance NNP\n",
      "study NN\n",
      "the DT\n",
      "great JJ\n",
      "majority NN\n",
      "by IN\n",
      "investing VBG\n",
      "in IN\n",
      "initiative JJ\n",
      "research NN\n",
      "So IN\n",
      "we PRP\n",
      "will MD\n",
      "have VB\n",
      "to TO\n",
      "see VB\n",
      "as IN\n",
      "these DT\n",
      "studies NNS\n",
      "result VBP\n",
      "report NN\n",
      "emerging NN\n",
      "I PRP\n",
      "can MD\n",
      "say VB\n",
      "that IN\n",
      "we PRP\n",
      "also RB\n",
      "have VBP\n",
      "sponsor-led JJ\n",
      "studies NNS\n",
      "outside IN\n",
      "breasts NNS\n",
      "that WDT\n",
      "includes VBZ\n",
      "pancreatic JJ\n",
      "cancer NN\n",
      "and CC\n",
      "head NN\n",
      "and CC\n",
      "neck NN\n",
      "and CC\n",
      "we PRP\n",
      "'re VBP\n",
      "also RB\n",
      "looking VBG\n",
      "at IN\n",
      "triple JJ\n",
      "therapy NN\n",
      "in IN\n",
      "breast NN\n",
      "cancer NN\n",
      "I PRP\n",
      "remain VBP\n",
      "optimistic JJ\n",
      "and CC\n",
      "excited VBD\n",
      "about IN\n",
      "Ibrance NNP\n",
      "performance NN\n",
      "and CC\n",
      "think VBP\n",
      "we PRP\n",
      "will MD\n",
      "see VB\n",
      "interesting JJ\n",
      "datasets NNS\n",
      "coming VBG\n",
      "from IN\n",
      "several JJ\n",
      "of IN\n",
      "these DT\n",
      "new JJ\n",
      "tumor NN\n",
      "types.Yes NN\n",
      "actually RB\n",
      "I PRP\n",
      "can MD\n",
      "only RB\n",
      "add VB\n",
      "here RB\n",
      "But CC\n",
      "likely RB\n",
      "the DT\n",
      "Mantel NNP\n",
      "cell NN\n",
      "lymphoma NN\n",
      "and CC\n",
      "the DT\n",
      "neck NN\n",
      "we PRP\n",
      "may MD\n",
      "see VB\n",
      "data NNS\n",
      "even RB\n",
      "this DT\n",
      "year NN\n",
      "And CC\n",
      "then RB\n",
      "many JJ\n",
      "of IN\n",
      "the DT\n",
      "areas NNS\n",
      "that WDT\n",
      "Mikael NNP\n",
      "discussed VBD\n",
      "including VBG\n",
      "small-cell-lung JJ\n",
      "we PRP\n",
      "may MD\n",
      "see VB\n",
      "next JJ\n",
      "year.Good NN\n",
      "morning NN\n",
      "guys NNS\n",
      "And CC\n",
      "thanks NNS\n",
      "for IN\n",
      "taking VBG\n",
      "my PRP$\n",
      "question NN\n",
      "just RB\n",
      "a DT\n",
      "couple NN\n",
      "of IN\n",
      "quick JJ\n",
      "ones NNS\n",
      "On IN\n",
      "Bevacizumab NNP\n",
      "given VBN\n",
      "Pfizer NNP\n",
      "'s POS\n",
      "experience NN\n",
      "in IN\n",
      "cardiovascular NN\n",
      "I PRP\n",
      "was VBD\n",
      "just RB\n",
      "curious JJ\n",
      "what WP\n",
      "your PRP$\n",
      "thoughts NNS\n",
      "on IN\n",
      "the DT\n",
      "demand NN\n",
      "trends NNS\n",
      "were VBD\n",
      "looking VBG\n",
      "peripherally RB\n",
      "at IN\n",
      "the DT\n",
      "PCSK9 NNP\n",
      "class NN\n",
      "today NN\n",
      "I PRP\n",
      "know VBP\n",
      "a DT\n",
      "lot NN\n",
      "looking VBG\n",
      "forward RB\n",
      "depends VBZ\n",
      "on IN\n",
      "outcomes NNS\n",
      "data NNS\n",
      "but CC\n",
      "just RB\n",
      "curious JJ\n",
      "about IN\n",
      "whether IN\n",
      "there EX\n",
      "'s VBZ\n",
      "a DT\n",
      "tipping JJ\n",
      "point NN\n",
      "and CC\n",
      "the DT\n",
      "position NN\n",
      "adoption.And NN\n",
      "then RB\n",
      "just RB\n",
      "on IN\n",
      "Biosimilars NNS\n",
      "in IN\n",
      "the DT\n",
      "U.S. NNP\n",
      "just RB\n",
      "wanted VBN\n",
      "to TO\n",
      "get VB\n",
      "you PRP\n",
      "guys NNS\n",
      "to TO\n",
      "view VB\n",
      "on IN\n",
      "where WRB\n",
      "you PRP\n",
      "think VBP\n",
      "the DT\n",
      "FDA NNP\n",
      "is VBZ\n",
      "with IN\n",
      "respect NN\n",
      "to TO\n",
      "extrapolation NN\n",
      "when WRB\n",
      "we PRP\n",
      "'re VBP\n",
      "looking VBG\n",
      "at IN\n",
      "the DT\n",
      "upcoming JJ\n",
      "senior JJ\n",
      "panel NN\n",
      "next JJ\n",
      "week NN\n",
      "Thanks.Yes NNP\n",
      "I PRP\n",
      "mean VBP\n",
      "I PRP\n",
      "think VBP\n",
      "I PRP\n",
      "would MD\n",
      "just RB\n",
      "reinforce VB\n",
      "the DT\n",
      "comment NN\n",
      "that IN\n",
      "you PRP\n",
      "made VBD\n",
      "I PRP\n",
      "mean VBP\n",
      "it PRP\n",
      "'s VBZ\n",
      "been VBN\n",
      "our PRP$\n",
      "contention NN\n",
      "all DT\n",
      "along IN\n",
      "that DT\n",
      "this DT\n",
      "class NN\n",
      "becomes VBZ\n",
      "a DT\n",
      "real JJ\n",
      "class NN\n",
      "in IN\n",
      "managing VBG\n",
      "these DT\n",
      "patients NNS\n",
      "with IN\n",
      "the DT\n",
      "cardiovascular JJ\n",
      "outcome NN\n",
      "data NNS\n",
      "that IN\n",
      "we PRP\n",
      "'ll MD\n",
      "be VB\n",
      "seeing VBG\n",
      "either DT\n",
      "late RB\n",
      "this DT\n",
      "year NN\n",
      "or CC\n",
      "starting VBG\n",
      "next JJ\n",
      "year NN\n",
      "Our PRP$\n",
      "program NN\n",
      "is VBZ\n",
      "advancing VBG\n",
      "nicely RB\n",
      "We PRP\n",
      "have VBP\n",
      "as IN\n",
      "you PRP\n",
      "know VBP\n",
      "two CD\n",
      "cardiovascular JJ\n",
      "trials NNS\n",
      "And CC\n",
      "the DT\n",
      "SPIRE-2 NNP\n",
      "trial NN\n",
      "which WDT\n",
      "is VBZ\n",
      "in IN\n",
      "the DT\n",
      "high-risk JJ\n",
      "patient NN\n",
      "population NN\n",
      "we PRP\n",
      "'ve VBP\n",
      "now RB\n",
      "reached VBN\n",
      "the DT\n",
      "point NN\n",
      "where WRB\n",
      "we PRP\n",
      "'ve VBP\n",
      "discontinued VBN\n",
      "screening NN\n",
      "We PRP\n",
      "'re VBP\n",
      "almost RB\n",
      "completely RB\n",
      "enrolled VBN\n",
      "And CC\n",
      "that DT\n",
      "trial NN\n",
      "is VBZ\n",
      "moving VBG\n",
      "along RB\n",
      "very RB\n",
      "rapidly RB\n",
      "And CC\n",
      "the DT\n",
      "SPIRE-1 NNP\n",
      "trial NN\n",
      "will MD\n",
      "be VB\n",
      "completely RB\n",
      "enrolled VBN\n",
      "by IN\n",
      "the DT\n",
      "end NN\n",
      "of IN\n",
      "this DT\n",
      "year NN\n",
      "or CC\n",
      "early JJ\n",
      "next JJ\n",
      "year.So NN\n",
      "we PRP\n",
      "'re VBP\n",
      "looking VBG\n",
      "forward RB\n",
      "to TO\n",
      "these DT\n",
      "data NNS\n",
      "and CC\n",
      "the DT\n",
      "impact NN\n",
      "that IN\n",
      "we PRP\n",
      "think VBP\n",
      "they PRP\n",
      "'re VBP\n",
      "going VBG\n",
      "to TO\n",
      "have VB\n",
      "on IN\n",
      "the DT\n",
      "marketplace.So NN\n",
      "on IN\n",
      "the DT\n",
      "Inflectra NNP\n",
      "AdCom NNP\n",
      "as IN\n",
      "you PRP\n",
      "know VBP\n",
      "it PRP\n",
      "'s VBZ\n",
      "scheduled VBN\n",
      "for IN\n",
      "February NNP\n",
      "9 CD\n",
      "next JJ\n",
      "week NN\n",
      "I PRP\n",
      "think VBP\n",
      "it PRP\n",
      "would MD\n",
      "probably RB\n",
      "be VB\n",
      "premature JJ\n",
      "to TO\n",
      "speculate VB\n",
      "on IN\n",
      "the DT\n",
      "view NN\n",
      "that IN\n",
      "the DT\n",
      "FDA NNP\n",
      "will MD\n",
      "take VB\n",
      "We PRP\n",
      "certainly RB\n",
      "think VBP\n",
      "that IN\n",
      "this DT\n",
      "will MD\n",
      "be VB\n",
      "extremely RB\n",
      "informative JJ\n",
      "as IN\n",
      "to TO\n",
      "the DT\n",
      "FDA NNP\n",
      "'s POS\n",
      "views NNS\n",
      "and CC\n",
      "perspectives NNS\n",
      "on IN\n",
      "extrapolation NN\n",
      "I PRP\n",
      "think VBP\n",
      "obviously RB\n",
      "their PRP$\n",
      "product NN\n",
      "is VBZ\n",
      "being VBG\n",
      "filed VBN\n",
      "by IN\n",
      "Xeljanz NN\n",
      "So RB\n",
      "specific JJ\n",
      "questions NNS\n",
      "about IN\n",
      "the DT\n",
      "AdCom NNP\n",
      "really RB\n",
      "should MD\n",
      "be VB\n",
      "directed VBN\n",
      "to TO\n",
      "Xeljanz VB\n",
      "but CC\n",
      "I PRP\n",
      "would MD\n",
      "say VB\n",
      "is VBZ\n",
      "that IN\n",
      "while IN\n",
      "we PRP\n",
      "obviously RB\n",
      "await VBP\n",
      "the DT\n",
      "resolution NN\n",
      "of IN\n",
      "the DT\n",
      "advisory JJ\n",
      "committee NN\n",
      "and CC\n",
      "certain JJ\n",
      "other JJ\n",
      "factors NNS\n",
      "We PRP\n",
      "'re VBP\n",
      "certainly RB\n",
      "moving VBG\n",
      "ahead RB\n",
      "with IN\n",
      "the DT\n",
      "preparation NN\n",
      "for IN\n",
      "launch JJ\n",
      "plans NNS\n",
      "in IN\n",
      "2016.Yes CD\n",
      "thanks NNS\n",
      "very RB\n",
      "much RB\n",
      "I PRP\n",
      "have VBP\n",
      "three CD\n",
      "questions NNS\n",
      "First RB\n",
      "Ian NNP\n",
      "besides IN\n",
      "the DT\n",
      "likelihood NN\n",
      "of IN\n",
      "closing NN\n",
      "what WP\n",
      "do VBP\n",
      "think VB\n",
      "investors NNS\n",
      "most RBS\n",
      "under-appreciate JJ\n",
      "about IN\n",
      "the DT\n",
      "Allergan NNP\n",
      "merger NN\n",
      "Second JJ\n",
      "I PRP\n",
      "guess VBP\n",
      "these DT\n",
      "are VBP\n",
      "two CD\n",
      "financial JJ\n",
      "questions NNS\n",
      "One CD\n",
      "is VBZ\n",
      "with IN\n",
      "respect NN\n",
      "to TO\n",
      "Enbrel NNP\n",
      "ex-U.S. NN\n",
      "Could NNP\n",
      "you PRP\n",
      "just RB\n",
      "give VB\n",
      "us PRP\n",
      "a DT\n",
      "sense NN\n",
      "for IN\n",
      "the DT\n",
      "percentage NN\n",
      "of IN\n",
      "revenue NN\n",
      "that WDT\n",
      "is VBZ\n",
      "in IN\n",
      "countries NNS\n",
      "where WRB\n",
      "Biosimilars NNS\n",
      "are VBP\n",
      "launching VBG\n",
      "in IN\n",
      "2016 CD\n",
      "so IN\n",
      "that IN\n",
      "we PRP\n",
      "have VBP\n",
      "a DT\n",
      "sense NN\n",
      "for IN\n",
      "the DT\n",
      "percentage NN\n",
      "of IN\n",
      "Enbrel NNP\n",
      "revenue NN\n",
      "that WDT\n",
      "'s VBZ\n",
      "exposed VBN\n",
      "to TO\n",
      "Biosimilar NNP\n",
      "threat NN\n",
      "And CC\n",
      "then RB\n",
      "finally RB\n",
      "Frank NNP\n",
      "if IN\n",
      "you PRP\n",
      "could MD\n",
      "just RB\n",
      "run VB\n",
      "through IN\n",
      "the DT\n",
      "cash NN\n",
      "flow NN\n",
      "outlook NN\n",
      "for IN\n",
      "2016 CD\n",
      "the DT\n",
      "operating NN\n",
      "cash NN\n",
      "flow NN\n",
      "and CC\n",
      "then RB\n",
      "the DT\n",
      "planned VBN\n",
      "use NN\n",
      "of IN\n",
      "funds NNS\n",
      "Thank NNP\n",
      "you.David NN\n",
      "again RB\n",
      "on IN\n",
      "your PRP$\n",
      "question NN\n",
      "on IN\n",
      "Allergan NNP\n",
      "our PRP$\n",
      "interactions NNS\n",
      "with IN\n",
      "the DT\n",
      "shareholders NNS\n",
      "both DT\n",
      "sell JJ\n",
      "side NN\n",
      "and CC\n",
      "buy VB\n",
      "side NN\n",
      "have VBP\n",
      "been VBN\n",
      "very RB\n",
      "positive JJ\n",
      "I PRP\n",
      "do VBP\n",
      "n't RB\n",
      "think VB\n",
      "in IN\n",
      "reality NN\n",
      "there EX\n",
      "'s VBZ\n",
      "anything NN\n",
      "underappreciated JJ\n",
      "other JJ\n",
      "than IN\n",
      "the DT\n",
      "Street NNP\n",
      "'s POS\n",
      "perception NN\n",
      "of IN\n",
      "risk NN\n",
      "around IN\n",
      "the DT\n",
      "close NN\n",
      "I PRP\n",
      "would MD\n",
      "direct VB\n",
      "you PRP\n",
      "back RB\n",
      "of IN\n",
      "course NN\n",
      "to TO\n",
      "the DT\n",
      "excitement NN\n",
      "I PRP\n",
      "have VBP\n",
      "about IN\n",
      "the DT\n",
      "products NNS\n",
      "that WDT\n",
      "Allergan VBP\n",
      "have VBP\n",
      "that IN\n",
      "they PRP\n",
      "just RB\n",
      "launched VBD\n",
      "about IN\n",
      "their PRP$\n",
      "phase NN\n",
      "III NNP\n",
      "products NNS\n",
      "both DT\n",
      "in IN\n",
      "depression NN\n",
      "and CC\n",
      "in IN\n",
      "diabetic JJ\n",
      "gastroparesis NN\n",
      "And CC\n",
      "they PRP\n",
      "just RB\n",
      "got VBD\n",
      "breakthrough JJ\n",
      "status NN\n",
      "so RB\n",
      "and CC\n",
      "the DT\n",
      "combination NN\n",
      "of IN\n",
      "our PRP$\n",
      "information NN\n",
      "knowledge NN\n",
      "and CC\n",
      "RTAs NNP\n",
      "with IN\n",
      "Xeljanz NNP\n",
      "around IN\n",
      "their PRP$\n",
      "area NN\n",
      "Our PRP$\n",
      "jacks NNS\n",
      "around IN\n",
      "their PRP$\n",
      "expertise NN\n",
      "net JJ\n",
      "area NN\n",
      "I PRP\n",
      "think VBP\n",
      "perhaps RB\n",
      "the DT\n",
      "Street NNP\n",
      "is VBZ\n",
      "just RB\n",
      "is VBZ\n",
      "right JJ\n",
      "now RB\n",
      "hung VBP\n",
      "up RP\n",
      "on IN\n",
      "this DT\n",
      "close JJ\n",
      "issue NN\n",
      "So RB\n",
      "bio JJ\n",
      "John NNP\n",
      "Yes UH\n",
      "David NNP\n",
      "on IN\n",
      "the DT\n",
      "question NN\n",
      "regarding VBG\n",
      "percentage NN\n",
      "of IN\n",
      "Enbrel NNP\n",
      "business NN\n",
      "potentially RB\n",
      "exposed VBN\n",
      "to TO\n",
      "Biosimilar NNP\n",
      "competition NN\n",
      "I PRP\n",
      "do VBP\n",
      "n't RB\n",
      "have VB\n",
      "a DT\n",
      "figure NN\n",
      "on IN\n",
      "the DT\n",
      "top NN\n",
      "of IN\n",
      "my PRP$\n",
      "head NN\n",
      "I PRP\n",
      "would MD\n",
      "say VB\n",
      "more JJR\n",
      "than IN\n",
      "50 CD\n",
      "% NN\n",
      "of IN\n",
      "the DT\n",
      "ex-U.S. JJ\n",
      "business NN\n",
      "would MD\n",
      "be VB\n",
      "in IN\n",
      "the DT\n",
      "European NNP\n",
      "Union NNP\n",
      "where WRB\n",
      "we PRP\n",
      "expect VBP\n",
      "to TO\n",
      "see VB\n",
      "biosimilars NNS\n",
      "We PRP\n",
      "wo MD\n",
      "n't RB\n",
      "we PRP\n",
      "'re VBP\n",
      "not RB\n",
      "expecting VBG\n",
      "to TO\n",
      "see VB\n",
      "it PRP\n",
      "in IN\n",
      "Japan NNP\n",
      "Australia NNP\n",
      "and CC\n",
      "several JJ\n",
      "of IN\n",
      "the DT\n",
      "Latin JJ\n",
      "American JJ\n",
      "countries NNS\n",
      "But CC\n",
      "I PRP\n",
      "would MD\n",
      "say VB\n",
      "it PRP\n",
      "'s VBZ\n",
      "more JJR\n",
      "than IN\n",
      "50 CD\n",
      "% NN\n",
      "of IN\n",
      "the DT\n",
      "business.And NN\n",
      "then RB\n",
      "the DT\n",
      "last JJ\n",
      "question NN\n",
      "was VBD\n",
      "on IN\n",
      "'16 IN\n",
      "operating NN\n",
      "cash NN\n",
      "flow NN\n",
      "The DT\n",
      "way NN\n",
      "I PRP\n",
      "'ll MD\n",
      "answer VB\n",
      "this DT\n",
      "David NNP\n",
      "is VBZ\n",
      "if IN\n",
      "you PRP\n",
      "look VBP\n",
      "at IN\n",
      "our PRP$\n",
      "operating NN\n",
      "cash NN\n",
      "flow NN\n",
      "through IN\n",
      "three CD\n",
      "quarters NNS\n",
      "it PRP\n",
      "was VBD\n",
      "about RB\n",
      "10 CD\n",
      "billion CD\n",
      "We PRP\n",
      "expect VBP\n",
      "the DT\n",
      "fourth JJ\n",
      "quarter NN\n",
      "to TO\n",
      "be VB\n",
      "healthy JJ\n",
      "in IN\n",
      "terms NNS\n",
      "of IN\n",
      "the DT\n",
      "operating NN\n",
      "cash NN\n",
      "flow NN\n",
      "for IN\n",
      "the DT\n",
      "year NN\n",
      "And CC\n",
      "then RB\n",
      "obviously RB\n",
      "2016 CD\n",
      "we PRP\n",
      "expect VBP\n",
      "we PRP\n",
      "want VBP\n",
      "to TO\n",
      "obviously RB\n",
      "continue VB\n",
      "to TO\n",
      "grow VB\n",
      "that IN\n",
      "operating NN\n",
      "cash NN\n",
      "flow NN\n",
      "number NN\n",
      "And CC\n",
      "then RB\n",
      "in IN\n",
      "terms NNS\n",
      "of IN\n",
      "the DT\n",
      "uses NNS\n",
      "from IN\n",
      "my PRP$\n",
      "perspective NN\n",
      "the DT\n",
      "uses NNS\n",
      "of IN\n",
      "how WRB\n",
      "we PRP\n",
      "deploy VBP\n",
      "our PRP$\n",
      "capital NN\n",
      "have VBP\n",
      "n't RB\n",
      "changed VBN\n",
      "obviously RB\n",
      "investing VBG\n",
      "in IN\n",
      "our PRP$\n",
      "business NN\n",
      "returning VBG\n",
      "capital NN\n",
      "to TO\n",
      "shareholders NNS\n",
      "I PRP\n",
      "mentioned VBD\n",
      "in IN\n",
      "my PRP$\n",
      "remarks NNS\n",
      "we PRP\n",
      "returned VBD\n",
      "13.1 CD\n",
      "billion CD\n",
      "to TO\n",
      "our PRP$\n",
      "shareholders NNS\n",
      "in IN\n",
      "2015 CD\n",
      "through IN\n",
      "a DT\n",
      "combination NN\n",
      "of IN\n",
      "dividends NNS\n",
      "and CC\n",
      "share NN\n",
      "buybacks NNS\n",
      "and CC\n",
      "obviously RB\n",
      "looking VBG\n",
      "at IN\n",
      "some DT\n",
      "bolt-on JJ\n",
      "acquisitions NNS\n",
      "if IN\n",
      "those DT\n",
      "make VBP\n",
      "sense NN\n",
      "So RB\n",
      "but CC\n",
      "no DT\n",
      "change NN\n",
      "It PRP\n",
      "would MD\n",
      "be VB\n",
      "how WRB\n",
      "I PRP\n",
      "'d MD\n",
      "answer VB\n",
      "the DT\n",
      "question NN\n",
      "on IN\n",
      "capital NN\n",
      "allocation.Thanks NNS\n",
      "also RB\n",
      "a DT\n",
      "three-parter NN\n",
      "First NNP\n",
      "Frank NNP\n",
      "what WP\n",
      "level NN\n",
      "of IN\n",
      "detail NN\n",
      "should MD\n",
      "we PRP\n",
      "expect VB\n",
      "in IN\n",
      "the DT\n",
      "proxy NN\n",
      "in IN\n",
      "terms NNS\n",
      "of IN\n",
      "your PRP$\n",
      "long-term JJ\n",
      "projections NNS\n",
      "similar JJ\n",
      "to TO\n",
      "the DT\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Pfizer NNP\n",
      "Wyeth NNP\n",
      "documents NNS\n",
      "or CC\n",
      "any DT\n",
      "difference NN\n",
      "and CC\n",
      "any DT\n",
      "caveats NNS\n",
      "you PRP\n",
      "'d MD\n",
      "like VB\n",
      "to TO\n",
      "order NN\n",
      "to TO\n",
      "let VB\n",
      "us PRP\n",
      "know VB\n",
      "about IN\n",
      "before RB\n",
      "folks NNS\n",
      "start VBP\n",
      "slapping VBG\n",
      "accretion NN\n",
      "percentages NNS\n",
      "on IN\n",
      "those DT\n",
      "numbers NNS\n",
      "Secondly RB\n",
      "going VBG\n",
      "back RB\n",
      "to TO\n",
      "something NN\n",
      "you PRP\n",
      "said VBD\n",
      "earlier RBR\n",
      "Taking VBG\n",
      "your PRP$\n",
      "leverage NN\n",
      "to TO\n",
      "two-and-a-half NN\n",
      "to TO\n",
      "three CD\n",
      "times NNS\n",
      "for IN\n",
      "Newco NNP\n",
      "and CC\n",
      "if IN\n",
      "you PRP\n",
      "were VBD\n",
      "to TO\n",
      "apply VB\n",
      "that DT\n",
      "capital NN\n",
      "to TO\n",
      "buybacks NNS\n",
      "that WDT\n",
      "would MD\n",
      "create VB\n",
      "EPS NNP\n",
      "accretion NN\n",
      "that WDT\n",
      "'s VBZ\n",
      "far RB\n",
      "beyond IN\n",
      "what WP\n",
      "you PRP\n",
      "'ve VBP\n",
      "suggested VBN\n",
      "So RB\n",
      "just RB\n",
      "would MD\n",
      "like VB\n",
      "your PRP$\n",
      "thoughts NNS\n",
      "on IN\n",
      "what WP\n",
      "you PRP\n",
      "'d MD\n",
      "be VB\n",
      "doing VBG\n",
      "with IN\n",
      "that DT\n",
      "leverage NN\n",
      "or CC\n",
      "is VBZ\n",
      "that DT\n",
      "just RB\n",
      "kind NN\n",
      "of IN\n",
      "a DT\n",
      "hypothetical.And JJ\n",
      "third JJ\n",
      "for IN\n",
      "John NNP\n",
      "do VBP\n",
      "you PRP\n",
      "still RB\n",
      "see VB\n",
      "the DT\n",
      "benefit NN\n",
      "of IN\n",
      "the DT\n",
      "Hospira NNP\n",
      "device NN\n",
      "business NN\n",
      "alongside IN\n",
      "the DT\n",
      "drug NN\n",
      "business NN\n",
      "as IN\n",
      "you PRP\n",
      "originally RB\n",
      "thought VBN\n",
      "Thank NNP\n",
      "you.Yes NN\n",
      "sure JJ\n",
      "I PRP\n",
      "think VBP\n",
      "we PRP\n",
      "would MD\n",
      "say VB\n",
      "that IN\n",
      "in IN\n",
      "the DT\n",
      "Hospira NNP\n",
      "infusion NN\n",
      "systems NNS\n",
      "business NN\n",
      "which WDT\n",
      "comprises VBZ\n",
      "pumps NNS\n",
      "consumables NNS\n",
      "large JJ\n",
      "volume NN\n",
      "solutions NNS\n",
      "We PRP\n",
      "believe VBP\n",
      "we PRP\n",
      "acquired VBD\n",
      "a DT\n",
      "very RB\n",
      "valuable JJ\n",
      "asset NN\n",
      "It PRP\n",
      "provides VBZ\n",
      "novel JJ\n",
      "capabilities NNS\n",
      "in IN\n",
      "an DT\n",
      "adjacent JJ\n",
      "area NN\n",
      "And CC\n",
      "that DT\n",
      "adds VBZ\n",
      "significant JJ\n",
      "value NN\n",
      "to TO\n",
      "customers NNS\n",
      "and CC\n",
      "their PRP$\n",
      "patients NNS\n",
      "And CC\n",
      "we PRP\n",
      "are VBP\n",
      "committed VBN\n",
      "to TO\n",
      "ensuring VBG\n",
      "its PRP$\n",
      "success NN\n",
      "in IN\n",
      "the DT\n",
      "short JJ\n",
      "medium NN\n",
      "and CC\n",
      "longer JJR\n",
      "term.So NN\n",
      "I PRP\n",
      "think VBP\n",
      "on IN\n",
      "level NN\n",
      "of IN\n",
      "detail NN\n",
      "we PRP\n",
      "'ll MD\n",
      "be VB\n",
      "providing VBG\n",
      "revenue NN\n",
      "details NNS\n",
      "EPS NNP\n",
      "details NNS\n",
      "It PRP\n",
      "would MD\n",
      "be VB\n",
      "directed VBN\n",
      "out RP\n",
      "I PRP\n",
      "believe VBP\n",
      "it PRP\n",
      "'s VBZ\n",
      "several JJ\n",
      "years NNS\n",
      "five CD\n",
      "years NNS\n",
      "So RB\n",
      "there EX\n",
      "'ll MD\n",
      "be VB\n",
      "information NN\n",
      "out IN\n",
      "there RB\n",
      "relative JJ\n",
      "to TO\n",
      "projections NNS\n",
      "on IN\n",
      "the DT\n",
      "company NN\n",
      "on IN\n",
      "the DT\n",
      "leverage NN\n",
      "number NN\n",
      "the DT\n",
      "2.5 CD\n",
      "to TO\n",
      "3 CD\n",
      "in IN\n",
      "my PRP$\n",
      "mind NN\n",
      "that DT\n",
      "'s VBZ\n",
      "what WP\n",
      "'s VBZ\n",
      "possible JJ\n",
      "In IN\n",
      "terms NNS\n",
      "of IN\n",
      "what WP\n",
      "we PRP\n",
      "did VBD\n",
      "on IN\n",
      "buybacks NNS\n",
      "we PRP\n",
      "tried VBD\n",
      "to TO\n",
      "provide VB\n",
      "information NN\n",
      "when WRB\n",
      "we PRP\n",
      "announced VBD\n",
      "the DT\n",
      "deal NN\n",
      "to TO\n",
      "give VB\n",
      "you PRP\n",
      "all PDT\n",
      "the DT\n",
      "data NN\n",
      "you PRP\n",
      "needed VBN\n",
      "So RB\n",
      "that IN\n",
      "when WRB\n",
      "you PRP\n",
      "connected VBD\n",
      "the DT\n",
      "dots NNS\n",
      "you PRP\n",
      "could MD\n",
      "model VB\n",
      "what WP\n",
      "at IN\n",
      "buyback NN\n",
      "numbers NNS\n",
      "would MD\n",
      "be VB\n",
      "right.So VB\n",
      "we PRP\n",
      "started VBD\n",
      "out RP\n",
      "with IN\n",
      "the DT\n",
      "accretion NN\n",
      "dilution NN\n",
      "We PRP\n",
      "said VBD\n",
      "neutral JJ\n",
      "in IN\n",
      "year NN\n",
      "one CD\n",
      "modestly RB\n",
      "accretive VBP\n",
      "in IN\n",
      "year NN\n",
      "one CD\n",
      "more JJR\n",
      "than IN\n",
      "10 CD\n",
      "% NN\n",
      "in IN\n",
      "year NN\n",
      "three CD\n",
      "and CC\n",
      "then RB\n",
      "high JJ\n",
      "teens NNS\n",
      "in IN\n",
      "year NN\n",
      "four CD\n",
      "We PRP\n",
      "gave VBD\n",
      "what WP\n",
      "the DT\n",
      "beginning NN\n",
      "share NN\n",
      "count JJ\n",
      "number NN\n",
      "of IN\n",
      "the DT\n",
      "combined VBN\n",
      "company NN\n",
      "would MD\n",
      "be VB\n",
      "It PRP\n",
      "was VBD\n",
      "10.6 CD\n",
      "billion CD\n",
      "shares NNS\n",
      "We PRP\n",
      "said VBD\n",
      "we PRP\n",
      "'d MD\n",
      "have VB\n",
      "5.5 CD\n",
      "billion CD\n",
      "and CC\n",
      "Allergan NNP\n",
      "would MD\n",
      "have VB\n",
      "4.7 CD\n",
      "billion CD\n",
      "And CC\n",
      "then RB\n",
      "we PRP\n",
      "gave VBD\n",
      "the DT\n",
      "tax NN\n",
      "rate NN\n",
      "which WDT\n",
      "was VBD\n",
      "17 CD\n",
      "% NN\n",
      "to TO\n",
      "18 CD\n",
      "% NN\n",
      "So RB\n",
      "with IN\n",
      "those DT\n",
      "data NNS\n",
      "points NNS\n",
      "we PRP\n",
      "felt VBD\n",
      "we PRP\n",
      "provided VBD\n",
      "the DT\n",
      "information NN\n",
      "that IN\n",
      "you PRP\n",
      "needed VBD\n",
      "in IN\n",
      "order NN\n",
      "to TO\n",
      "model VB\n",
      "what WP\n",
      "the DT\n",
      "buybacks NNS\n",
      "would MD\n",
      "be VB\n",
      "And CC\n",
      "then RB\n",
      "just RB\n",
      "to TO\n",
      "the DT\n",
      "two-and-a-half NN\n",
      "to TO\n",
      "three CD\n",
      "now RB\n",
      "clearly RB\n",
      "there EX\n",
      "could MD\n",
      "be VB\n",
      "some DT\n",
      "extra JJ\n",
      "juice NN\n",
      "if IN\n",
      "we PRP\n",
      "took VBD\n",
      "the DT\n",
      "leverage NN\n",
      "ratio VBD\n",
      "up RB\n",
      "to TO\n",
      "that DT\n",
      "level.Great NN\n",
      "thanks NNS\n",
      "just RB\n",
      "two CD\n",
      "quick JJ\n",
      "ones NNS\n",
      "here RB\n",
      "First NNP\n",
      "just RB\n",
      "more RBR\n",
      "broadly RB\n",
      "on IN\n",
      "emerging VBG\n",
      "markets NNS\n",
      "can MD\n",
      "you PRP\n",
      "talk VB\n",
      "about IN\n",
      "the DT\n",
      "growth NN\n",
      "outlook NN\n",
      "here RB\n",
      "maybe RB\n",
      "beyond IN\n",
      "China NNP\n",
      "just RB\n",
      "given VBN\n",
      "the DT\n",
      "current JJ\n",
      "economic JJ\n",
      "environment NN\n",
      "we PRP\n",
      "'re VBP\n",
      "seeing VBG\n",
      "Has NNP\n",
      "there RB\n",
      "been VBN\n",
      "any DT\n",
      "change NN\n",
      "in IN\n",
      "your PRP$\n",
      "growth NN\n",
      "expectations NNS\n",
      "there RB\n",
      "And CC\n",
      "then RB\n",
      "the DT\n",
      "second JJ\n",
      "question NN\n",
      "for IN\n",
      "Ian NNP\n",
      "I PRP\n",
      "know VBP\n",
      "you PRP\n",
      "'ve VBP\n",
      "obviously RB\n",
      "had VBD\n",
      "a DT\n",
      "very RB\n",
      "large JJ\n",
      "deal NN\n",
      "pending VBG\n",
      "right RB\n",
      "now RB\n",
      "But CC\n",
      "how WRB\n",
      "are VBP\n",
      "you PRP\n",
      "thinking VBG\n",
      "of IN\n",
      "business NN\n",
      "development NN\n",
      "given VBN\n",
      "the DT\n",
      "recent JJ\n",
      "volatility NN\n",
      "and CC\n",
      "kind NN\n",
      "of IN\n",
      "valuation NN\n",
      "reset NN\n",
      "we PRP\n",
      "see VBP\n",
      "in IN\n",
      "the DT\n",
      "market NN\n",
      "I PRP\n",
      "guess VBP\n",
      "what WP\n",
      "'s VBZ\n",
      "the DT\n",
      "size NN\n",
      "and CC\n",
      "scope NN\n",
      "of IN\n",
      "assets NNS\n",
      "that IN\n",
      "you PRP\n",
      "could MD\n",
      "be VB\n",
      "interested JJ\n",
      "at IN\n",
      "this DT\n",
      "point NN\n",
      "given VBN\n",
      "the DT\n",
      "upcoming JJ\n",
      "Allergan NNP\n",
      "transaction NN\n",
      "And CC\n",
      "maybe VB\n",
      "how WRB\n",
      "quickly RB\n",
      "post VB\n",
      "the DT\n",
      "Allergan NNP\n",
      "transaction NN\n",
      "could MD\n",
      "this DT\n",
      "company NN\n",
      "start VB\n",
      "considering VBG\n",
      "larger JJR\n",
      "deals NNS\n",
      "if IN\n",
      "there EX\n",
      "was VBD\n",
      "an DT\n",
      "attractive JJ\n",
      "opportunity NN\n",
      "in IN\n",
      "the DT\n",
      "market.Yes NN\n",
      "sure JJ\n",
      "So RB\n",
      "I PRP\n",
      "mean VBP\n",
      "I PRP\n",
      "think VBP\n",
      "as IN\n",
      "we PRP\n",
      "always RB\n",
      "say VBP\n",
      "Chris NNP\n",
      "on IN\n",
      "the DT\n",
      "emerging VBG\n",
      "markets NNS\n",
      "We PRP\n",
      "'re VBP\n",
      "always RB\n",
      "going VBG\n",
      "to TO\n",
      "see VB\n",
      "courses NNS\n",
      "and CC\n",
      "course NN\n",
      "of IN\n",
      "volatility NN\n",
      "But CC\n",
      "at IN\n",
      "the DT\n",
      "same JJ\n",
      "time NN\n",
      "we PRP\n",
      "continue VBP\n",
      "to TO\n",
      "expect VB\n",
      "to TO\n",
      "see VB\n",
      "growth NN\n",
      "numbers NNS\n",
      "in IN\n",
      "the DT\n",
      "mid-single JJ\n",
      "digit NN\n",
      "mid NN\n",
      "to TO\n",
      "high JJ\n",
      "single-digit JJ\n",
      "range NN\n",
      "Frank NNP\n",
      "'s POS\n",
      "already RB\n",
      "talked VBN\n",
      "about IN\n",
      "China NNP\n",
      "We PRP\n",
      "continue VBP\n",
      "to TO\n",
      "be VB\n",
      "very RB\n",
      "positive JJ\n",
      "about IN\n",
      "the DT\n",
      "prospects NNS\n",
      "in IN\n",
      "the DT\n",
      "short JJ\n",
      "medium NN\n",
      "and CC\n",
      "longer JJR\n",
      "term NN\n",
      "in IN\n",
      "China NNP\n",
      "It PRP\n",
      "'s VBZ\n",
      "obviously RB\n",
      "not RB\n",
      "just RB\n",
      "the DT\n",
      "world NN\n",
      "'s POS\n",
      "largest JJS\n",
      "country NN\n",
      "with IN\n",
      "1.3 CD\n",
      "1.4 CD\n",
      "billion CD\n",
      "population NN\n",
      "but CC\n",
      "we PRP\n",
      "continue VBP\n",
      "to TO\n",
      "see VB\n",
      "a DT\n",
      "strong JJ\n",
      "government NN\n",
      "commitment NN\n",
      "to TO\n",
      "expanding VBG\n",
      "access NN\n",
      "to TO\n",
      "to TO\n",
      "quality NN\n",
      "healthcare NN\n",
      "We PRP\n",
      "are VBP\n",
      "very RB\n",
      "encouraged VBN\n",
      "by IN\n",
      "steps NNS\n",
      "that IN\n",
      "we PRP\n",
      "see VBP\n",
      "the DT\n",
      "government NN\n",
      "taking VBG\n",
      "in IN\n",
      "the DT\n",
      "regulatory JJ\n",
      "environment NN\n",
      "to TO\n",
      "really RB\n",
      "enhance VB\n",
      "quality NN\n",
      "standards NNS\n",
      "in IN\n",
      "the DT\n",
      "marketplace.And NN\n",
      "whilst NN\n",
      "there EX\n",
      "are VBP\n",
      "few JJ\n",
      "headwinds NNS\n",
      "GDP NNP\n",
      "growth NN\n",
      "is VBZ\n",
      "slowly RB\n",
      "but CC\n",
      "still RB\n",
      "positive JJ\n",
      "still RB\n",
      "mid JJ\n",
      "single-digit JJ\n",
      "percentage NN\n",
      "We PRP\n",
      "are VBP\n",
      "seeing VBG\n",
      "some DT\n",
      "pressure NN\n",
      "on IN\n",
      "pricing NN\n",
      "But CC\n",
      "overall JJ\n",
      "when WRB\n",
      "you PRP\n",
      "put VBP\n",
      "all DT\n",
      "of IN\n",
      "those DT\n",
      "factors NNS\n",
      "together RB\n",
      "we PRP\n",
      "can MD\n",
      "continue VB\n",
      "to TO\n",
      "see VB\n",
      "China NNP\n",
      "being VBG\n",
      "a DT\n",
      "very RB\n",
      "positive JJ\n",
      "growth NN\n",
      "driver.Thank NN\n",
      "you PRP\n",
      "John NNP\n",
      "On IN\n",
      "BD NNP\n",
      "Chris NNP\n",
      "we PRP\n",
      "see VBP\n",
      "we PRP\n",
      "would MD\n",
      "be VB\n",
      "more RBR\n",
      "focused JJ\n",
      "to TO\n",
      "smaller JJR\n",
      "deals NNS\n",
      "than IN\n",
      "larger JJR\n",
      "deals NNS\n",
      "right RB\n",
      "now RB\n",
      "But CC\n",
      "once RB\n",
      "we PRP\n",
      "close VBP\n",
      "we PRP\n",
      "'ll MD\n",
      "look VB\n",
      "at IN\n",
      "the DT\n",
      "opportunities NNS\n",
      "And CC\n",
      "we PRP\n",
      "know VBP\n",
      "we PRP\n",
      "still RB\n",
      "have VBP\n",
      "substantial JJ\n",
      "flexibility NN\n",
      "and CC\n",
      "of IN\n",
      "course NN\n",
      "it PRP\n",
      "will MD\n",
      "be VB\n",
      "measured VBN\n",
      "against IN\n",
      "the DT\n",
      "alternative JJ\n",
      "usage NN\n",
      "of IN\n",
      "that DT\n",
      "cash NN\n",
      "which WDT\n",
      "right RB\n",
      "now RB\n",
      "are VBP\n",
      "scheduled VBN\n",
      "for IN\n",
      "buybacks NNS\n",
      "and CC\n",
      "the DT\n",
      "accretion NN\n",
      "equation NN\n",
      "So IN\n",
      "we PRP\n",
      "'ll MD\n",
      "make VB\n",
      "the DT\n",
      "decisions NNS\n",
      "that IN\n",
      "we PRP\n",
      "believe VBP\n",
      "are VBP\n",
      "best JJS\n",
      "for IN\n",
      "shareholders NNS\n",
      "and CC\n",
      "we PRP\n",
      "will MD\n",
      "take VB\n",
      "it PRP\n",
      "into IN\n",
      "account NN\n",
      "the DT\n",
      "what WP\n",
      "the DT\n",
      "asset NN\n",
      "priced VBN\n",
      "at IN\n",
      "the DT\n",
      "time NN\n",
      "when WRB\n",
      "we PRP\n",
      "close.And VBP\n",
      "Chris NNP\n",
      "the DT\n",
      "only JJ\n",
      "thing NN\n",
      "I PRP\n",
      "would MD\n",
      "add VB\n",
      "is VBZ\n",
      "we PRP\n",
      "Pfizer-standalone JJ\n",
      "today NN\n",
      "generate VBP\n",
      "a DT\n",
      "lot NN\n",
      "of IN\n",
      "operating NN\n",
      "cash NN\n",
      "flow NN\n",
      "The DT\n",
      "combine JJ\n",
      "new JJ\n",
      "company NN\n",
      "we PRP\n",
      "said VBD\n",
      "by IN\n",
      "2018 CD\n",
      "would MD\n",
      "be VB\n",
      "generating VBG\n",
      "in IN\n",
      "excess NN\n",
      "of IN\n",
      "25 CD\n",
      "billion CD\n",
      "a DT\n",
      "year NN\n",
      "in IN\n",
      "operating NN\n",
      "cash NN\n",
      "flow NN\n",
      "So RB\n",
      "new JJ\n",
      "company NN\n",
      "will MD\n",
      "generate VB\n",
      "significant JJ\n",
      "amounts NNS\n",
      "of IN\n",
      "operating NN\n",
      "cash NN\n",
      "flow NN\n",
      "Thank NNP\n",
      "you.Hi NN\n",
      "it PRP\n",
      "'s VBZ\n",
      "Manoj NNP\n",
      "Thanks NNS\n",
      "for IN\n",
      "taking VBG\n",
      "the DT\n",
      "question NN\n",
      "A DT\n",
      "couple NN\n",
      "on IN\n",
      "the DT\n",
      "pending VBG\n",
      "Allergan NNP\n",
      "transaction NN\n",
      "and CC\n",
      "one CD\n",
      "on IN\n",
      "next JJ\n",
      "Tuesday NNP\n",
      "on IN\n",
      "Allergan NNP\n",
      "one CD\n",
      "I PRP\n",
      "guess VBP\n",
      "if IN\n",
      "maybe RB\n",
      "just RB\n",
      "if IN\n",
      "you PRP\n",
      "can MD\n",
      "highlight VB\n",
      "what WP\n",
      "are VBP\n",
      "some DT\n",
      "of IN\n",
      "the DT\n",
      "levers NNS\n",
      "that WDT\n",
      "would MD\n",
      "dictate VB\n",
      "whether IN\n",
      "the DT\n",
      "deal NN\n",
      "would MD\n",
      "close VB\n",
      "in IN\n",
      "early JJ\n",
      "second JJ\n",
      "half NN\n",
      "of IN\n",
      "'16 CD\n",
      "versus NN\n",
      "later RB\n",
      "in IN\n",
      "the DT\n",
      "second JJ\n",
      "half NN\n",
      "Two CD\n",
      "is VBZ\n",
      "for IN\n",
      "Frank NNP\n",
      "on IN\n",
      "the DT\n",
      "2 CD\n",
      "billion CD\n",
      "synergy NNS\n",
      "number NN\n",
      "if IN\n",
      "you PRP\n",
      "can MD\n",
      "just RB\n",
      "quantify VB\n",
      "as IN\n",
      "we PRP\n",
      "fine-tune VBP\n",
      "our PRP$\n",
      "pro JJ\n",
      "forma NN\n",
      "model NN\n",
      "if IN\n",
      "that DT\n",
      "'s VBZ\n",
      "a DT\n",
      "gross JJ\n",
      "number NN\n",
      "or CC\n",
      "an DT\n",
      "net JJ\n",
      "number NN\n",
      "Okay NNP\n",
      "On IN\n",
      "the DT\n",
      "lever NN\n",
      "Doug NNP\n",
      "Lankler NNP\n",
      "would MD\n",
      "you PRP\n",
      "indicate VB\n",
      "what WP\n",
      "you PRP\n",
      "see VBP\n",
      "the DT\n",
      "levers NNS\n",
      "are VBP\n",
      "for IN\n",
      "the DT\n",
      "close NN\n",
      "Sure NNP\n",
      "So RB\n",
      "Manoj NNP\n",
      "we PRP\n",
      "'re VBP\n",
      "working VBG\n",
      "closely RB\n",
      "with IN\n",
      "regulators NNS\n",
      "We PRP\n",
      "are VBP\n",
      "pleased JJ\n",
      "with IN\n",
      "the DT\n",
      "profits NNS\n",
      "that IN\n",
      "we PRP\n",
      "are VBP\n",
      "making VBG\n",
      "We PRP\n",
      "like VBP\n",
      "the DT\n",
      "standpoint NN\n",
      "from IN\n",
      "the DT\n",
      "complementary JJ\n",
      "nature NN\n",
      "of IN\n",
      "the DT\n",
      "businesses NNS\n",
      "And CC\n",
      "as IN\n",
      "a DT\n",
      "result NN\n",
      "we PRP\n",
      "continue VBP\n",
      "to TO\n",
      "expect VB\n",
      "to TO\n",
      "close VB\n",
      "the DT\n",
      "transaction NN\n",
      "during IN\n",
      "the DT\n",
      "second JJ\n",
      "half.Right NN\n",
      "Yes UH\n",
      "you PRP\n",
      "asked VBD\n",
      "whether IN\n",
      "it PRP\n",
      "was VBD\n",
      "gross JJ\n",
      "or CC\n",
      "net JJ\n",
      "And CC\n",
      "the DT\n",
      "answer NN\n",
      "is VBZ\n",
      "it PRP\n",
      "'s VBZ\n",
      "a DT\n",
      "net JJ\n",
      "number.Ladies NNS\n",
      "and CC\n",
      "gentlemen NNS\n",
      "this DT\n",
      "does VBZ\n",
      "conclude VB\n",
      "today NN\n",
      "'s POS\n",
      "fourth JJ\n",
      "quarter NN\n",
      "2015 CD\n",
      "earnings NNS\n",
      "conference NN\n",
      "call NN\n",
      "Thank NNP\n",
      "you PRP\n",
      "for IN\n",
      "participating VBG\n",
      "You PRP\n",
      "may MD\n",
      "now RB\n",
      "disconnect VB\n"
     ]
    }
   ],
   "source": [
    "from textblob import TextBlob\n",
    "blob = TextBlob(x[0])\n",
    "for word, pos in blob.tags:\n",
    "            print(word, pos)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "df1=pd.read_excel('FutureSentences_output600.xlsx',sheet_name=2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{55429,\n",
       " 55541,\n",
       " 55628,\n",
       " 55645,\n",
       " 55709,\n",
       " 55830,\n",
       " 55913,\n",
       " 55986,\n",
       " 56097,\n",
       " 56100,\n",
       " 56220,\n",
       " 56336,\n",
       " 56785,\n",
       " 57321,\n",
       " 59298,\n",
       " 59364,\n",
       " 59423,\n",
       " 59607,\n",
       " 59638,\n",
       " 59642,\n",
       " 59810,\n",
       " 59824,\n",
       " 59941,\n",
       " 59953,\n",
       " 60337,\n",
       " 60746,\n",
       " 61021,\n",
       " 63043,\n",
       " 63081,\n",
       " 63132,\n",
       " 63316,\n",
       " 63347,\n",
       " 63457,\n",
       " 63542,\n",
       " 63552,\n",
       " 63704,\n",
       " 63728,\n",
       " 64015,\n",
       " 64108,\n",
       " 64624,\n",
       " 64918,\n",
       " 65053,\n",
       " 66908,\n",
       " 66936,\n",
       " 67050,\n",
       " 67258,\n",
       " 67268,\n",
       " 67288,\n",
       " 67376,\n",
       " 67384,\n",
       " 67495,\n",
       " 67676,\n",
       " 67828,\n",
       " 68176,\n",
       " 68814,\n",
       " 68903,\n",
       " 70670,\n",
       " 70816,\n",
       " 70859,\n",
       " 70861,\n",
       " 71038,\n",
       " 71052,\n",
       " 71064,\n",
       " 71145,\n",
       " 71147,\n",
       " 71158,\n",
       " 71234,\n",
       " 71320,\n",
       " 71407,\n",
       " 72284,\n",
       " 72656,\n",
       " 74254,\n",
       " 74305,\n",
       " 74364,\n",
       " 74581,\n",
       " 74598,\n",
       " 74706,\n",
       " 74777,\n",
       " 74923,\n",
       " 74997,\n",
       " 75037,\n",
       " 75107,\n",
       " 75437,\n",
       " 75509,\n",
       " 75802,\n",
       " 76651,\n",
       " 77932,\n",
       " 78039,\n",
       " 78069,\n",
       " 78243,\n",
       " 78249,\n",
       " 78413,\n",
       " 78444,\n",
       " 78675,\n",
       " 78749,\n",
       " 78834,\n",
       " 78845,\n",
       " 79178,\n",
       " 79237,\n",
       " 79437,\n",
       " 79516,\n",
       " 81564,\n",
       " 81616,\n",
       " 81659,\n",
       " 81822,\n",
       " 81969,\n",
       " 82001,\n",
       " 82005,\n",
       " 82168,\n",
       " 82237,\n",
       " 82410,\n",
       " 82677,\n",
       " 82945,\n",
       " 83126,\n",
       " 83200,\n",
       " 83240,\n",
       " 85189,\n",
       " 85318,\n",
       " 85385,\n",
       " 85421,\n",
       " 85440,\n",
       " 85464,\n",
       " 85576,\n",
       " 85647,\n",
       " 85653,\n",
       " 85783,\n",
       " 85810,\n",
       " 86134,\n",
       " 86242,\n",
       " 88750,\n",
       " 88790,\n",
       " 88832,\n",
       " 89006,\n",
       " 89021,\n",
       " 89125,\n",
       " 89167,\n",
       " 89396,\n",
       " 89431,\n",
       " 89446,\n",
       " 89584,\n",
       " 89827,\n",
       " 89869,\n",
       " 90135,\n",
       " 91215,\n",
       " 91859,\n",
       " 92429,\n",
       " 92484,\n",
       " 92535,\n",
       " 92810,\n",
       " 92819,\n",
       " 92839,\n",
       " 93032,\n",
       " 93116,\n",
       " 93128,\n",
       " 93270,\n",
       " 93415,\n",
       " 93534,\n",
       " 93594,\n",
       " 93874,\n",
       " 93934,\n",
       " 96406,\n",
       " 96447,\n",
       " 96502,\n",
       " 96671,\n",
       " 96780,\n",
       " 96781,\n",
       " 96848,\n",
       " 96856,\n",
       " 96958,\n",
       " 97081,\n",
       " 97398,\n",
       " 97873,\n",
       " 97909,\n",
       " 98019,\n",
       " 98038,\n",
       " 100354,\n",
       " 100437,\n",
       " 100497,\n",
       " 100502,\n",
       " 150650,\n",
       " 150673,\n",
       " 150684,\n",
       " 150694,\n",
       " 150756,\n",
       " 150761,\n",
       " 150786,\n",
       " 150799,\n",
       " 150801,\n",
       " 150803,\n",
       " 150812,\n",
       " 150819,\n",
       " 150831,\n",
       " 150846,\n",
       " 150929,\n",
       " 150937,\n",
       " 150946,\n",
       " 150953,\n",
       " 150961,\n",
       " 150967,\n",
       " 151107,\n",
       " 151125,\n",
       " 151175,\n",
       " 151192,\n",
       " 151201,\n",
       " 151230,\n",
       " 151261,\n",
       " 151264,\n",
       " 151343,\n",
       " 151382,\n",
       " 151385,\n",
       " 151393,\n",
       " 151407,\n",
       " 151576,\n",
       " 151669,\n",
       " 151670,\n",
       " 151683,\n",
       " 151698,\n",
       " 151707,\n",
       " 151708,\n",
       " 151726,\n",
       " 151962,\n",
       " 151970,\n",
       " 152039,\n",
       " 152083,\n",
       " 152104,\n",
       " 152138,\n",
       " 152309,\n",
       " 152412,\n",
       " 152434,\n",
       " 152489,\n",
       " 152491,\n",
       " 152631,\n",
       " 152647,\n",
       " 152655,\n",
       " 152673,\n",
       " 152675,\n",
       " 152681,\n",
       " 152718,\n",
       " 152897,\n",
       " 152922,\n",
       " 152934,\n",
       " 152944,\n",
       " 152960,\n",
       " 152987,\n",
       " 153128,\n",
       " 153184,\n",
       " 153193,\n",
       " 153210,\n",
       " 153558,\n",
       " 153580,\n",
       " 153680,\n",
       " 153718,\n",
       " 153754,\n",
       " 160587,\n",
       " 161057,\n",
       " 161127,\n",
       " 161271,\n",
       " 161310,\n",
       " 161341,\n",
       " 161579,\n",
       " 161708,\n",
       " 162044,\n",
       " 162209,\n",
       " 162639,\n",
       " 163031,\n",
       " 163141,\n",
       " 163522,\n",
       " 163894,\n",
       " 163936,\n",
       " 164208,\n",
       " 164216,\n",
       " 164388,\n",
       " 164440,\n",
       " 165707,\n",
       " 165999,\n",
       " 166522,\n",
       " 167595,\n",
       " 167693,\n",
       " 167885,\n",
       " 168175,\n",
       " 168271,\n",
       " 168292,\n",
       " 168433,\n",
       " 168617,\n",
       " 169372,\n",
       " 169644,\n",
       " 169894,\n",
       " 170455,\n",
       " 170644,\n",
       " 170752,\n",
       " 170931,\n",
       " 171023,\n",
       " 171111,\n",
       " 171922,\n",
       " 173179,\n",
       " 173216,\n",
       " 173379,\n",
       " 173529,\n",
       " 173658,\n",
       " 174010,\n",
       " 174266,\n",
       " 174612,\n",
       " 174712,\n",
       " 174917,\n",
       " 175135,\n",
       " 175321,\n",
       " 175406,\n",
       " 175501,\n",
       " 176136,\n",
       " 176186,\n",
       " 178416,\n",
       " 178713,\n",
       " 178891,\n",
       " 178959,\n",
       " 179309,\n",
       " 179325,\n",
       " 179583,\n",
       " 179625,\n",
       " 179771,\n",
       " 179911,\n",
       " 181067,\n",
       " 181415,\n",
       " 181909,\n",
       " 182275,\n",
       " 182465,\n",
       " 182855,\n",
       " 183147,\n",
       " 183704,\n",
       " 184025,\n",
       " 184247,\n",
       " 184423,\n",
       " 184917,\n",
       " 185006,\n",
       " 185731,\n",
       " 185751,\n",
       " 185980,\n",
       " 186390,\n",
       " 186759,\n",
       " 186795,\n",
       " 187027,\n",
       " 187226,\n",
       " 187811,\n",
       " 188184,\n",
       " 188928,\n",
       " 189014,\n",
       " 189330,\n",
       " 190088,\n",
       " 190251,\n",
       " 190292,\n",
       " 191102,\n",
       " 191166,\n",
       " 192207,\n",
       " 192367,\n",
       " 192496,\n",
       " 192757,\n",
       " 192817,\n",
       " 192912,\n",
       " 193280,\n",
       " 193536,\n",
       " 193728,\n",
       " 193901,\n",
       " 194215,\n",
       " 194444,\n",
       " 195190,\n",
       " 195395,\n",
       " 195561,\n",
       " 195642,\n",
       " 195782,\n",
       " 195929,\n",
       " 196160,\n",
       " 197270,\n",
       " 197501,\n",
       " 197672,\n",
       " 198538,\n",
       " 198716,\n",
       " 199768,\n",
       " 200994,\n",
       " 201274,\n",
       " 201477,\n",
       " 201618,\n",
       " 202307,\n",
       " 202503,\n",
       " 203745,\n",
       " 204156,\n",
       " 204836,\n",
       " 205607,\n",
       " 205842,\n",
       " 205914,\n",
       " 206055,\n",
       " 206186,\n",
       " 206483,\n",
       " 206705,\n",
       " 207320,\n",
       " 207472,\n",
       " 210448,\n",
       " 210955,\n",
       " 212244,\n",
       " 212454,\n",
       " 212606,\n",
       " 213441,\n",
       " 213620,\n",
       " 214024,\n",
       " 214655,\n",
       " 214911,\n",
       " 216108,\n",
       " 216449,\n",
       " 216465,\n",
       " 217084,\n",
       " 217576,\n",
       " 219168,\n",
       " 219440,\n",
       " 219635,\n",
       " 219938,\n",
       " 220225,\n",
       " 220457,\n",
       " 220635,\n",
       " 221200,\n",
       " 222378,\n",
       " 223118,\n",
       " 223140,\n",
       " 224343,\n",
       " 224373,\n",
       " 248514,\n",
       " 250658,\n",
       " 255842,\n",
       " 257951,\n",
       " 261508,\n",
       " 266856,\n",
       " 275145,\n",
       " 416415,\n",
       " 417026,\n",
       " 417251,\n",
       " 444629,\n",
       " 445374,\n",
       " 445535,\n",
       " 445657,\n",
       " 446532,\n",
       " 446877,\n",
       " 446913,\n",
       " 447210,\n",
       " 447317,\n",
       " 447701,\n",
       " 447743,\n",
       " 447929,\n",
       " 448122,\n",
       " 451097,\n",
       " 452141,\n",
       " 453490,\n",
       " 454110,\n",
       " 467636,\n",
       " 467661,\n",
       " 467666,\n",
       " 467672,\n",
       " 467674,\n",
       " 467688,\n",
       " 467690,\n",
       " 467702,\n",
       " 467703,\n",
       " 467722,\n",
       " 467724,\n",
       " 467727,\n",
       " 467729,\n",
       " 467732,\n",
       " 467733,\n",
       " 467737,\n",
       " 467738,\n",
       " 467739,\n",
       " 467740,\n",
       " 467741,\n",
       " 467747,\n",
       " 467762,\n",
       " 467794,\n",
       " 467816,\n",
       " 467826,\n",
       " 467829,\n",
       " 467839,\n",
       " 484090,\n",
       " 484580,\n",
       " 484598,\n",
       " 484701,\n",
       " 484703,\n",
       " 484705,\n",
       " 485289,\n",
       " 485290,\n",
       " 486298,\n",
       " 486406,\n",
       " 486407,\n",
       " 486623,\n",
       " 486819,\n",
       " 488553,\n",
       " 488577,\n",
       " 490947,\n",
       " 491726,\n",
       " 491736,\n",
       " 491839,\n",
       " 493963,\n",
       " 494044,\n",
       " 494056,\n",
       " 494453,\n",
       " 494512,\n",
       " 494540,\n",
       " 494543,\n",
       " 494547,\n",
       " 494557,\n",
       " 494598,\n",
       " 494675,\n",
       " 494732,\n",
       " 494830,\n",
       " 494838,\n",
       " 494956,\n",
       " 495073,\n",
       " 495213,\n",
       " 495292,\n",
       " 495330,\n",
       " 495458,\n",
       " 495610,\n",
       " 495678,\n",
       " 496429,\n",
       " 497160,\n",
       " 497606,\n",
       " 497708,\n",
       " 497873,\n",
       " 498149,\n",
       " 498216,\n",
       " 499548,\n",
       " 499751,\n",
       " 503472,\n",
       " 503648,\n",
       " 503650,\n",
       " 503655,\n",
       " 504362,\n",
       " 504409,\n",
       " 504448,\n",
       " 504697,\n",
       " 504720,\n",
       " 504767,\n",
       " 504773,\n",
       " 504795,\n",
       " 504833,\n",
       " 504946,\n",
       " 504949,\n",
       " 504989,\n",
       " 505375,\n",
       " 505501,\n",
       " 511633,\n",
       " 512719,\n",
       " 512724,\n",
       " 513358,\n",
       " 527444,\n",
       " 527653,\n",
       " 543059,\n",
       " 543324,\n",
       " 544311,\n",
       " 544343,\n",
       " 625267,\n",
       " 625278,\n",
       " 625562,\n",
       " 626500,\n",
       " 627444,\n",
       " 634109,\n",
       " 641434,\n",
       " 641608,\n",
       " 642236,\n",
       " 646179,\n",
       " 646284,\n",
       " 646802,\n",
       " 647986,\n",
       " 648575,\n",
       " 653397,\n",
       " 653853,\n",
       " 657678,\n",
       " 659925,\n",
       " 661866,\n",
       " 662007,\n",
       " 662022,\n",
       " 662545,\n",
       " 662607,\n",
       " 663011,\n",
       " 663850,\n",
       " 665852,\n",
       " 666846,\n",
       " 668622,\n",
       " 672711,\n",
       " 677240,\n",
       " 677249,\n",
       " 677365}"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "set(df1['ECNo'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "v=[]\n",
    "for i in df1[df1['ECNo']==55429]['Sentence']:\n",
    "    v.append(i)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"But with reference to my earlier comments on redeploying balance sheet, a portion of this reduction will likely reverse in the near future.Do you intend to keep lending to the oil and gas companies as they run into problems?These deposits that we're talking about that have the high basis are valuable deposits with valuable clients for us and we want to be competitive and pay fair rates.A lot of concerns we're going to get into some type of broader deterioration of which your numbers showed no signs of heading towards --what are you looking for?Operator\\nYour next question -- \\nMarianne Lake\\nSo based on that with the obvious caveat of what happens with oil prices and energy over the course of the near future, yes, we would still expect our charge-offs to be relatively low.You've said that you don't want to be an outlier, so you're whittling that down.At that point it becomes increasingly compelling to want to look at the margin for what you could do to get within the bucket and so that is what we did in the fourth quarter is spend time really focusing on getting to that achievable boundary which we thought at that point its was.It's also the case that when you get the entire business and company attuned to the sense of urgency and desire to want to be increasingly efficient in this way, that at the margin in our 100 different things little benefits accrue.Just want to get a better sense as to what methodology are you employing in terms of thinking about a management buffer and all the different binding constraints that you have to manage to day-to-day and thinking about through the cycle target that you guys would like to manage to.But we do intend to continue to gather deposits and extend loans and portfolio loans as well.Do you think the competitive environment has hit a plateau and on co-brands are there any kind of large upcoming repricing events and is there any bigger than a bread box size you can give on, Marianne?\""
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "''.join(v)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [],
   "source": [
    "import spacy\n",
    "nlp=spacy.load('en_core_web_sm')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [],
   "source": [
    "from wordcloud import WordCloud, STOPWORDS, ImageColorGenerator"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [],
   "source": [
    "f=nlp(''.join(v))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "UsageError: Line magic function `%` not found.\n"
     ]
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "% matplotlib inline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "stopwords = set(STOPWORDS)\n",
    "wordcloud = WordCloud(stopwords=stopwords, background_color=\"white\",max_words=20).generate(str(f))\n",
    "\n",
    "# Display the generated image:\n",
    "# the matplotlib way:\n",
    "plt.imshow(wordcloud, interpolation='bilinear')\n",
    "plt.axis(\"off\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [],
   "source": [
    "from gensim.summarization.summarizer import summarize"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [],
   "source": [
    "d=nlp(x[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Good day everyone, and welcome to Pfizer's Fourth Quarter 2015 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Mr. Chuck Triano, Senior Vice President of Investor Relations. Please go ahead, sir.Good morning, and thanks for joining us today to review Pfizer's fourth quarter and full year 2015 performance, as well as 2016 financial guidance.I am joined here today as usual by our Chairman and CEO, Ian Read; Frank D'Amelio, our CFO; Mikael Dolsten, President of Worldwide Research and Development; Albert Bourla, President of Vaccines, Oncology and Consumer; Geno Germano, President of Global Innovative Pharma; John Young, President of Established Pharma; and Doug Lankler, General Counsel.The slides that will be presented on this call can be viewed on our homepage, pfizer.com by clicking on the link for Pfizer Quarterly Corporate Performance Fourth Quarter 2015, which is located in the For Investors Section in the lower right hand corner of the page.Before we start, I'd like to remind you that our discussion during the call will include forward-looking statements and that actual results could differ materially from those projected in the statements. Factor that could cause actual results to differ are discussed in Pfizer's 2014 Annual Report on Form 10-K, as well as on our reports in Forms 10-Q and 8-K.Discussions during the call will also include certain financial measures that were not prepared in accordance with Generally Accepted Accounting Principles. Reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in Pfizer's current report on Form 8-K dated today.Also, today's call is not intended to, and does not constitute an offer to sell or the solicitation of an offer to subscribe for, or buy securities of Pfizer or Allergan.We will now make prepared remarks and then we will move to a question-and-answer session. With that, I'll now turn the call over to Ian Read. Ian?Thank you Chuck, and good morning everyone. We finished 2015 with strong financial and operational performance. For the full year, we exceeded our 2015 revenue guidance and met the top-end of our adjusted diluted EPS guidance. Excuse me; and we achieved our first year of operational revenue growth in five years.Frank will take you through the numbers. Before he does, I have a few brief comments about what is driving our performance, some thoughts regarding where we expect to see pipeline advancements during the year, and I will close with a few comments about Allergan.Throughout the year and especially in the fourth quarter, our business executed flawlessly despite a challenging operational environment. We ended 2015 with solid momentum in both developed and emerging markets.Specifically in developed markets, during the year we gained incremental market penetration driven by continued success of products that are early in their life cycles, including Prevnar 13 adults, Ibrance, Eliquis, Xeljanz, and we still saw steady growth from key inline products in 2015, specifically Lyrica in markets where it remains patent protected.And during the year in emerging markets we saw operational revenue growth primarily due to the performance of Prevnar, Lipitor, and Enbrel, as well as from the addition of legacy Hospira products. The integration of the Hospira business into Pfizer Global Established pharma businesses is on track, and we look forward to this business being an attractive potential growth driver. This acquisition is indeed proving to be an excellent strategic fit, and we are seeing the expected value contribution to our GAAP business that we anticipated.Frank will speak to our 2016 guidance in a moment. We expect to deliver operational revenue growth in 2016. Our key growth drivers will continue to be Ibrance, Eliquis, and Xeljanz. And we believe that Prevnar adult global revenues will be comparable to the strong results we achieved in 2015. Additionally, we believe our near-term pipeline will help accelerate this ongoing growth forward.In looking at the year ahead, we expect our businesses will continue to execute well. They are competitively positioned to win their markets and are performing strongly against their competitors' set.Regarding the pipeline, we anticipate advancing many of our Phase III programs during the year. For Bococizumab, we reported today that the first of our six Phase III efficacy studies achieved its primary endpoint, and we expect readouts of the remaining five Bococizumab lipid-lowering studies [technical difficulty] during 2016.For [indiscernible], this year, we and our partners Merck will begin to deliver results from our comprehensive Phase III clinical program. In 2016, the alliance expects to submit applications to regulatory approval in the U.S. for both monotherapy and two fixed dose combination tablets using data from eight clinical trials.For Dacomitinib, we expect results in the second half of the year for a Phase III study in first-line EGFR mutant non-small-cell lung cancer, and we'll discuss our regulatory strategy with the FDA. So Xeljanz in the first half of this year we expect top line results for our Phase III program in psoriatic arthritis. We believe Xeljanz can potentially fill a significant unmet need in the psoriatic arthritis when non-biologic DMARDS do not have proven success, and where there are currently few alternatives for patients who have inadequate responses to anti-TNF therapy.In addition, in the first half of the year we anticipate the decisions from the FDA for a once-a-day daily Xeljanz formulation for rheumatoid arthritis, and we remain on track to re-file our application for RA in the EU.For Ibrance, we expect to see the top line PALOMA-2 study results in first-line advanced breast cancer in combination with letrozole, and we have an April PDUFA date for second and third-line treatment for advanced breast cancer based on the PALOMA-3 data. We could also see a regulatory decision for Ibrance in the E.U. by year end.Additionally, in the oncology business, we have a PDUFA date this year in the U.S. with Xalkori in ROS 1 non-small-cell lung cancer, and we expect to file for approval of Inotuzumab for acute lymphoblastic leukemia in the U.S. And in immuno-oncology we now have a broad portfolio of compounds that we believe has the potential to support the development of a strong, deep competitive market position. We now have five immuno-oncology assets in the clinic, and expect to have up to 10 in the clinic by the end of 2016. As a result of our partnership with Merck KGaA, as of the end of 2015, we had 28 ongoing clinical development programs for Avelumab, with seven of them being pivotal registrational studies.We anticipate some of these studies will give us potential registrations in areas like Merkel cell, ovarian, bladder, gastric, and lung cancer. Of these seven studies, we expect to present data in Merkel cell this year, and to see data from the other tumor types in the following two years. And we continue to believe that the winners in this space will be those that have a breadth of portfolio assets to support rational combinations. We have a range of assets to combine with Avelumab when compared to other companies' assets, and we have already initiated six combination studies with Avelumab.In 2016, we expect to see data from 4-1BB in combination with Keytruda and in combination with Avelumab in various tumors, 4-1BB in combination with Rituximab in lymphoma, a combination of Lorlatinib, our next generation ALK inhibitor with Avelumab and ALK-positive non-small-cell lung cancer, and data from [indiscernible] with Avelumab in renal cell carcinoma. Finally, we may see data from OX40 as a single agent this year. Taking of all of this into account, we believe we are well on our way to being a leading player in this space.And now a few comments about our proposed combination with Allergan. We're excited about bringing two great companies together that have a strong strategic fit. The transaction is about acceleration growth potential in our innovative businesses and strengthening our established business, and more efficiently allocating our capital around the world. We are confident that we are taking appropriate steps so that we can achieve the key milestones needed to complete the transaction and continue to expect close in the second half of 2016.Since the announcement, we have been working closely with Brent Saunders and his team at Allergan, and have been delighted by the engagement and rapport that is occurring. We see a number of potential opportunities after closing as we continue to learn more about each other's portfolio. For example, we see complementarity in information in gastroenterology, and we have a -- when we will have a broader presence in cardiovascular disease with Eliquis and Bystolic.In neuroscience, Allergan's work in Alzheimer's, schizophrenia, and major depressive orders will be highly complementary to Pfizer's promising early work in such areas as Parkinson's, Alzheimer's, and Duchenne muscular dystrophy.When you look at over the next few years we expect both companies will continue -- contribute, sorry, several potential new drugs to launch. We'll also continue to be excited about the international potential. And by coming together, we are enhancing category leadership throughout our complementary inline portfolio, and a combined pipeline with great late-stage and mid-stage assets across each of our key therapeutic areas. Both companies bring a great deal of scientific and product expertise to the provost combination and a shared philosophy in our approach to research and development.Upon the close of the transaction, the combined company will be an influential player in the industry with a competitive product portfolio with several leadership positions, robust pipeline, compelling capital structure, and financial position, and aligned cultures that are based on ownership and entrepreneurial spirit creating shareholder value and meeting patients' needs. This combination is about investing in our business. It's about accelerating our existing strategy, while preserving our options as putting the company into an innovative business and an established business. If we determine that is the best way to unlock the most value for our shareholders.By the end of the current quarter our integration teams will be fully engaged, and we anticipate announcing post-closing leadership positions. Throughout the year we will continue to keep you updated on our progress. In summary, we're looking at a year ahead we have a sound strategy, and a strong business. Our outlook and financial guidance for the year takes into the account the benefit of anticipated positive organic growth from key products, as well as the impact from foreign exchange. We have a solid portfolio of market-leading inline products, a healthy pipeline. We expect to further strengthen the growth potential of the business with the pending addition of Allergan. We will continue to have the means by which we can create value for our shareholders and bring innovative medicines to patients by producing expected top line growth, progressing key pipeline assets, pursuing strategic business development, and returning capital to shareholders through dividends and buybacks.Now I'll turn it over to Frank for additional details on the quarter and our 2016 financial guidance.Thanks, Ian. Good day everyone. As always, the charts that we're viewing today are included in our webcast. As a reminder, because we completed the acquisition of Hospira on September 3, 2015, Pfizer's full year financial results for the year ended December 31, 2015 include four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations.Financial results for the fourth quarter 2015 include three months of legacy Hospira Global operations. By comparison, financial results for full year and fourth quarter 2014 do not include any contribution from legacy Hospira operations.Now, moving on to the financials; fourth quarter 2015 reported revenues were approximately $14 billion, and reflect year-over-year operational growth of 1.9 billion or 14%, mainly driven by the addition of legacy Hospira operations. The continued strong performance of products that are early in their lifecycles such as Prevnar 13 adult, Ibrance, Eliquis, and Xeljanz, Lyrica primarily in the U.S. and 5% operational growth in emerging markets, mainly from legacy Hospira operations, Prevnar 13, and certain other products.Reported revenues continued to be unfavorably impacted by foreign exchange of 934 million or 7%. Excluding the inclusion of legacy Hospira operations of 1.2 billion, the negative impact of foreign exchange and to a much lesser extent the inclusion of 35 million of revenues associated with vaccines acquired from Baxter, Pfizer-standalone achieved operational growth of 646 million or 5% while at the same time absorbing a 720 million negative operational impact from product losses of exclusivity.Fourth quarter adjusted diluted EPS was $0.53 versus $0.54 in the year ago quarter. The decrease is primarily due to an aggregate operational increase and adjusted cost of sales, adjusted SI&A expenses, and adjusted R&D expenses or 1.8 billion or 21%, $0.07 due to foreign exchange and the continued product losses of exclusivity in certain geographies. These were partially offset by revenue growth of certain new, in-line, and acquired products, lower effective tax rate, and few diluted weighted average shares outstanding which declined by 125 million shares versus the year ago quarter due to our share repurchase program which includes the impact of $5 billion accelerated share repurchase agreement executed in February 2015 and completed in July.Reported diluted EPS was $0.10 compared with $0.19 in the year ago quarter due to the previously mentioned factors and the unfavorable impact of foreign currency losses related to Venezuela, increased purchase accounting adjustments, acquisition related cost, restructuring charges, and asset impairment charges versus the prior year quarter, and non-recurring charges related to pension settlements, which were partially offset by the non-recurrence of a charge associated with the global strategic alliance formed with Merck KGaA in November 2014 to jointly develop and commercialize Avelumab, lower charges for certain legal matters, and a lower effective tax rate.Foreign exchange negatively impacted fourth quarter reported revenues by approximately $934 million or 7% and positively impacted adjusted cost of sales, adjusted SI&A expenses and adjusted R&D expenses in the aggregate by $435 million or 5%. As a result, foreign exchange negatively impacted fourth quarter adjusted diluted EPS by approximately $0.07 compared with the year ago quarter.Now, moving on to the financial highlights of our business segments; in the fourth quarter, Global Innovative Pharmaceutical revenues increased 10% operational year-over-year due to the strong performance of recently launched products including Eliquis globally and Xeljanz in the U.S. and the strong performance of Lyrica in the U.S. and Japan.Income before taxes increased 17% operationally due to the increase of revenues and a 5% operational decrease in cost of sales. Cost of sales as a percentage of revenue decreased 1.7 percentage points operationally because of low royalty expenses and increased alliance revenues with no associated cost of sales.IBT was unfavorably impacted by a 4% operational increase and SI&A expenses as a result of additional investment in Eliquis, Xeljanz, and Chantix, and 11% operational increase in R&D reflecting investments in our late-stage pipeline primarily for Bococizumab and Tanezumab.Fourth quarter VOC revenues increased 38% operationally, reflecting operational revenue growth in each business. Global vaccine revenues grew 53% operationally driven by 102% increase of Prevnar 13 U.S. revenues to the strong uptake among adults.Global oncology revenues grew 61% operationally driven by Ibrance in the U.S. and to a lesser extent by Sutent and Xalkori globally. And consumer healthcare revenues grew 4% operationally due to Nexium 24HR in the U.S.Income before taxes increased 33% operationally, mainly due to increased revenues and associated improvement in gross margin, which were partially offset by a 66% operational increase and SI&A expenses as a result of higher promotional expenses in the U.S. for newly launched consumer healthcare products, Ibrance, and Prevnar 13 adult. And the 46% operational increase in R&D expenses due to increased cost associated with oncology oncology programs, primarily our alliance with Merck KGaA and Ibrance.Fourth quarter, Global Established Pharmaceutical revenues increased 5% operationally, mainly due to the previously mentioned inclusion of legacy Hospira revenues contributing $1.2 billion, which was partially offset by loss of exclusivity and generic competition for Celebrex in the U.S. and certain other developed markets, Lyrica in most developed markets in Europe and Zyvox in the U.S.Emerging market revenues were flat operationally, which reflected the positive impact of the inclusion of legacy Hospira operations and continued strong growth in China offset by declines in certain markets in the Middle East.Income before taxes declined 12% operationally reflecting the unfavorable impact of a 4.7 percentage point operational increase in cost of sales as a percentage of revenues due to the inclusion of Hospira operations and the impact of losses of exclusivity, a 24% operational increase in SI&A expenses driven in part by the addition of Hospira operations and the 53% operational increase in R&D expenses due to increased legacy Hospira development programs.We exceeded the top of our guidance range of expectations for 2015 reported revenues by approximately $400 million. Adjusted cost of sales as a percentage of revenues was 18.5% versus 18.7% at the low-end of our guidance range due to increased Alliance revenues and sales volumes, and we exceeded our expectation for our effective tax rate on adjusted income as a result of the favorable change in our jurisdictional mix of earnings.We met our expectations for adjusted R&D expenses and achieved the top-end of our adjusted diluted EPS. Adjusted SI&A expenses are $14.3 billion, or higher than our guidance range due to increased expenses for recently launched products such as Prevnar 13 adult and Ibrance, other inline products, and certain Consumer Healthcare brands.We recorded adjusted other income of $409 million versus our expectation of approximately $500 million. Finally, reported diluted EPS was a $1.24 versus our expected range of a $1.37 to a $1.43, mainly as a result of increased purchase accounting adjustments, acquisition-related costs and restructuring charges primarily related to the acquisition of Hospira, the negative impact of foreign currency losses related to Venezuela, and non-recurring charges related to pension settlements.Now I'd like to walk you through the 2016 guidance ranges for reported revenues, reported diluted EPS, and adjusted diluted EPS relative to our 2015 actual results. First, it's important to note that our 2016 financial guidance excludes the impact of our pending combination with Allergan.Our 2016 reported revenue guidance range reflects anticipated strong growth of certain new inline and acquired product that is partially offset by an anticipated $2.3 billion negative impact due to continuing product losses of exclusivity. I want to point out that that would be in this range and consistent with our previous comments we expect full year Prevnar 13 adult global revenues to be comparable with its full year 2015 global revenue level.We expect adverse changes in foreign exchange based on mid-January 2016 rates relative to the U.S. dollar compared with actual foreign exchange rates in 2015 to have an additional $2.3 billion negative impact on the reported revenues, including an estimated $800 million negative currency impact related to Venezuela. Consequently, we expect 2016 reported revenues to be in the range of $49 billion to $51 billion.Reported diluted EPS and adjusted diluted EPS guidance also include the negative impact from product losses of exclusivity, as well as an expected $0.09 negative impact from foreign exchange rates and the $0.07 negative currency impact related to Venezuela. As a result, we expect reported diluted EPS to be in the range of a $1.54 to a $1.67, and adjusted diluted EPS to be in the range $2.20 to $2.30.In addition, I want to remind everyone that guidance ranges for both reported and adjusted diluted EPS incorporate $5 billion of anticipated share repurchases in 2016, which consists of our previously announced intention to execute a $5 billion accelerated share repurchase program in the first half of 2016. These repurchases are expected to more than offset the potential dilution related to employee compensation programs.In summary, to exclude anticipated foreign exchange impacts, including the negative currency impact related to Venezuela, full year 2016 revenue and adjusted EPS guidance midpoints are 7% and 10% greater than actual full year 2015 levels respectively. The remaining elements of our 2016 financial guidance are set forth on this chart.Now moving on to key takeaways, we had a very strong financial performance in 2015 and we achieved operational revenue growth every quarter, including 14% operational growth in the fourth quarter. For the full year 2015, we achieved 6% operational revenue growth that was mainly driven by new products that are early in their lifecycles and we achieved this growth despite a 3.2 billion negative impact from product losses of exclusivity.Our full year 2016 reported revenue guidance range of 49 billion to 51 billion absorbs a 4.6 billion combined negative impact of product losses of exclusivity, adverse changes in foreign exchange rates, and the negative currency impact related to Venezuela. And the adjusted diluted EPS guidance range includes an anticipated $0.16 negative impact from foreign exchange, including Venezuela.We announced our proposed combination with Allergan, and continue to expect the transaction to close the second half of 2016. And we continue to create shareholder value through prudent capital allocation. In 2015, we returned $13.1 billion to our shareholders through dividends and share repurchases. And we expect to execute a $5 billion accelerated share repurchase program in the first half of 2016. Finally, we remain committed to delivering attractive shareholder returns in 2016, and beyond.[Operator Instructions] Your first question comes from Colin Bristow from Bank of America.Good morning, and congrats on the solid finish for the year. So a couple of product-specific questions if I may, on the Prevnar franchise, you've posted strong 4Q numbers. Could you just talk about your expectations for the trajectory going forward? On Ibrance there's been a lot of discussion around [indiscernible], and the potential there for a threat to Ibrance. What's your view here?And then just lastly on Biosimilars, can you update us on the status of your Biosimilar candidates, and when we should expect any data readouts? Thanks.Thank you, Colin. I'll ask Albert to manage the Prevnar and Ibrance, and then pass it over to John for Biosimilars.Thank you very much for the question, Colin. Let me provide some insight to help you understand the situation moving forward. In the U.S., obviously we have done an excellent job with the catch-up opportunity. We have achieved 86% markets there, 92% at retailers. We have 90% awareness of the recommendation at healthcare practitioner. And as a result, over the 45 million adults eligible at the time of recommendation for vaccination, we have already captured about a third [ph] of them.Now while many adults remain, this cohort is more difficult to capture, as the low-hanging fruit is gone. It will require more innovative strategies that we all have in place, but even if we assume a similar or higher penetration rate this year, it will be on a much smaller pool of adults. However, we expect this will be mitigated by Europe, which has a very different growth profile. Even with prices lower than U.S., the demographics are very favorable, with much larger eligible population, and who have already received pneumonia in our label in 2015, and we are working to obtain broad recommendations, and following that reimbursement from the authorities.Now this will be phased likely over a two-years window period, because in Europe this is done country-by-country, and sometimes region-by-region within the same country. But all in all, we expect very strong growth in Europe next year.Now let me move on Ibrance, and your question about competition or particularly [indiscernible] drug. Look, [indiscernible] drug, while in the same class, is for any [ph] indication. The refractory patient population, what we have received breakthrough designation, is a very small population with few options available. In fact the average refractory patient undergoes seven lines of treatment. So it's -- they are in high-mid.Now speaking generally on competition, there is only limited clinical data on the public domain, and we need to see more efficacy and safety data to make comparisons. What I can tell you is about our strategic position. We are the only company with a registered product in U.S., and six other countries, and an accepted filing in Europe, where we may obtain registration as early as next year. We have very good clinical experience with the product. Ibrance has been prescribed by 5,000 physicians in more than 20,000 patients. And so far feedback is very positive, particularly on patients' quality of life.We are having a very heavy clinical program. We have two pivotal studies in first-line metastatic breast cancer, two studies in recurrent metastatic breast cancer, and three in early breast cancer, PENELOPE-B, PALLAS, and PEARL [ph]. Ibrance is part of 88 investigational initiated trials, approximately 50 in breast cancer and 38 in other tumor types. So as you can see, we are investing heavily to stay ahead of the competition.Thank you, Albert. I think just on Ibrance, you mentioned next year for Europe, you meant this year, late this year we may be able to get registrationâ€¦Okay. So thanks for the question on Biosimilars, Colin. So I think we're obviously very excited to being able to bring together the combination of Hospira's current inline biosimiliars which are already in the market. So we have three assets, as you know, which are already in the market in Europe, Nivestim, Retacrit, and Inflectra. And to bring that together along with the legacy Pfizer monoclonal antibody pipeline, plus some additional assets that Hospira have. So in total, when you look at the pipeline, we have nine distinct biosimilar molecules in different stages of development. Infliximab, outside of the E.U., Adalimumab, Trastuzumab, Bevacizumab, Rituximab, Pegfilgrastim, Ranibizumab, Denosumab, and Ustekinumab.So overall we have a very strong pipeline. A number of those assets are in Phase III, late-phase development. And the first dataset there you'd be seeing from our Phase III studies would come from the legacy Pfizer Infliximab program where we would expect to produce data from our Phase III towards the end of this year.Jami? Okay, Jami. We may come back to Jami if she's -- if we can correct the technical issues. If not, let's go to Alex.Good morning and thank you for taking the questions. Frank, your gross margin for 2016 is better than we expected, considering you're integrating a lower margin business in Hospira and losing exclusivity on some high-margin products. Can you help us understand what's driving that, and how we should think about -- and should we expect traditional margin expansion going forward, given that your Innovative business is growing at a faster rate?And then on Hospira's contribution this quarter, it doesn't seem to reflect much revenue synergies. Obviously it's too early, but how should we think about Hospira's contribution next year and possible revenue synergies going forward? Thank you.So Alex, on the gross margin, let me run the numbers and then I'll answer the question. So we ended the full year at 18.5% in terms of cost of sale. So I'll do the cost of sale. The reciprocal obviously is gross margin. We got it for next year across the sales number of 21% to 22%. So if you take the midpoint of that 21 to 22, just to make the math easy, that's 21.5% from our 18.5%. That's a 3%, 300 basis point increase in our cost of sales as a percentage of revenues. By the way, that's being driven by a few factors, but one of which clearly is Hospira.In terms of -- I think your question, which was why wasn't even more, I think the answer is our ongoing productivity and cost reduction initiatives. When you think about our factories, our manufacturing capabilities, we really manage that from a cost perspective. First of all, we focus that on quality, service, and cost. If you think about that as a triangle, quality is at the top of the triangle. But there's four major buckets, right? There's the number of facilities, there's the numerous quality initiatives we have within each facility. There's the purchasing that we can get from a leverage perspective, and then finally, there's the center cost that resides outside of the factories. We manage all four of those very aggressively to basically -- to manage our cost structure in manufacturing, but that gives you a feel for what the numbers were, and why they are what they are.So thanks, Alex. So obviously, again, we are very excited by the opportunities afforded us by the combination of our two businesses. And I think I've talked about biosimilars already, and the opportunities we see in that marketplace. So let me just touch briefly on sterile injectables. Obviously it's a very -- it's a large, it's a growing market. It's somewhere between $50 billion to $70 billion currently globally, and one of the sort of features of that market is it's very concentrated, particularly in the U.S., but also in a few ex-U.S. markets, such as Western Europe, and particularly China.So, one of the things that we are very focused on is going to be revenue synergy. We obviously have a strong commercial presence in China, and also in the hospital segment in developed Europe and emerging Europe. So essentially the lag time since September when we closed this transaction we've been focused really on making sure that we have our blocking and tackling in place to be very systematic with our highest value molecules that really sort of meet market needs most appropriately. To be very focused on registering and brining those molecules to market.So in the biggest opportunity that we have in China, that is going to take time, as you are very well aware. Drug lag in China is a significant issue, but we're very encouraged by the progress that the CFDA are making to accelerate access to important new medicines in China. But that will take time. But we do see opportunities both in the short-term, as well as medium and long-term to deliver significant growth ex-U.S. through the sterile injectable business and the combination of Hospira's portfolio into our commercial footprint.Thank you. Sorry about that. Don't really know what happened on my end, but anyway, just a few questions. Frank, can you tell us what the Venezuela revenues are? I guess we are in consensus, we're surprised by the size of the hit; can you all hear me?Okay, sorry about that. Anyway, so Frank, if you could just provide more color on Venezuela? And why such a big hit?And then Ian, just a couple of questions for you, just back on this whole breakup thesis and the timing, I think investors initially were disappointed by the timing that you laid out at the time that you were announcing Allergan deal. I think you said you would make a decision by the end of 2018. I just want to put out there that the stock has pulled back quite a bit since you announced the Allergan deal, and I would think despite clearly the market is excited about this, but I would think that that would -- that the difference in -- even growing gap in valuation between where your stock is in an SOTP should help you to accelerate your decision to move in that direction, and if you could just comment on that please.And then just, thirdly, on revenue growth. I mean, clearly there have been tons of pushes and pulls in your numbers, mostly currency, and patent expirations. Can you remind us when you expect, and this excludes the acquisition from Allergan, but when you expect your reported revenue growth -- or just talk about operationally revenue growth, when we should start to see a positive inflection point, because it has, when I look at my models, revenues have been in decline for many years and some of that's divestitures, and spins, but really since 2013, we've had revenues sort of flat to down. When is that going to change, and what's going to drive that change, just talking from Pfizer's standpoint? Thanks very much.Let me just do the revenue growth first. Well, you know, as I said, '15 was the first year when we saw revenue growth; '16, we expect it to be around operationally narrow. We expect it to be Hospira and Allergan, we expect it to be flat and that's because we had a huge growth from adult vaccine in '15, and we'll hold that franchise. We won't grow it again. We'll have good growth from our inline products and our newly launched products, but we'll still deal with a couple of billion of LOEs. So I think you can begin to see, as we launch -- as we begin to get more traction with more clinical trial in Ibrance as we begin to see the launch, as we begin to see our next wave of products get approved, you'll see us returning to a very robust growth. But obviously, Jami, one of the reasons for doing the Allergan deal was in fact to ensure that we had robust growth in our innovative business. So we're aware of that issue.Now this is the breakup timing. Number one, I point out that while the stock is down, I don't think it's specifically down more than a DRG. In fact I think it's roughly the same as a DRG, and in fact, given the our pressure that one would expect in a stock, I'm actually -- well, never like to see the stock go down. It certainly was expected to come under pressure from the odd community.Now the breakup timing is an issue of -- we are focused on integrating this company and the two companies together, and we have laid out the full questions that we need to answer. And I think shareholder would want those questions answered. So, can we run the businesses successfully insider Pfizer? And we bought Hospira. You are seeing the sterile injectables. You have got the Biosimilars. You're beginning to see if you strip out the LOEs and stabilization of the core business, which we expect to return to growth, but that being said, we can run it well inside Pfizer. Can it be run better outside Pfizer? Is there trade value and can we unlock trade value in tax efficient manner? And these are the very serious questions. These are very large companies. And I think that by innovating we will be well positioned to make that decision in the best interest of our shareholders. And frankly, don't particularly see a way of short-circuiting that just because of the amount of work that has to be done and integration and getting the transaction of Allergan right. I do understand your wish for more speedy decision, but I think we are taking the right approach for shareholder value here.So, Jami, the Venezuela revenues for -- I'll call it initially projected for 2016 were about $800 million, roughly the same size as 2015. If you look at the adjustments, we took -- we changed the exchange rate from 6.3 Bolivar to a dollar to 200 Bolivar to dollar. We went to the SIMADI rate for Venezuela. That change in the translation is what causes the adjustment that we made for 2016, and we thought that the timing of that adjustment was appropriate, given oil prices, given what's going on in Venezuela economically, given the dollars that are coming out of Venezuela, we thought the timing for this was appropriate. But it's really the 6.3 to 200 to the dollar conversion that's really causing the adjustment to 2016.Now, Jami, ongoing, when Venezuela passes through this crisis and they re-establish a normal economy, we would expect Venezuela to grow back to be in the -- between 200 and 400 million a year. So the actual delta medium-term is for the 400 million between what was an overvalued currency.Hi. Three questions please, two of them of very short. Firstly, perhaps you could just outline sequential growth for China, say, [technical difficulty] last quarter? Second, do you anticipate extra notice from Treasury on conversion, and obviously [technical difficulty] how restricted do you see any measures to impact the Allergan transaction? And then finally, just returning to [indiscernible], the patients in the ongoing Phase 2 trial, which accelerates approval that have not seen Palbociclib in early line of therapy, is that an approval possessing given the design of that trial, given the fact you are approved for indication or does that include any regulatory approval for the drug? Thank you.Okay. I am going to do the notice first. We at the moment understand that the Treasury are working on formalizing and regulating the first two notices they issued, which are not in many ways applicable to our transaction as we're at the below 50% ownership.I really can't speculate if there is going to be a third notice or not. We feel confident the transaction is fully within the U.S. law and fully within accepted interpretation of that law and expect the transaction to close in the second half of next year.With that, I'll go to growth to Frank, and I would ask Mikael to talk about Palbociclib.On China, for the quarter, China grew 10%. Full year, China grew about 10%. Nice numbers. Somewhat moderated from 2014. In 2014, China grew to about 15%. So, we saw some moderation in the growth in China.That said, Andrew, we remain very bullish on China. Has an increasing population, increasing personal wealth, government is committed to healthcare. We see increased spending in the government and the GDP rate is still very healthy. Not as high as it has been the past, but still quite healthy. So, we remain very bullish on the China market on going forward basis.Yes. Thank you, Andrew, for a good question here. Two things; first, I want to just to point out that Abemaciclib is somewhat different from Palbo and Novartis drug in that it seems to be less selective and has a different resident profile likely due to hitting multiple CDKs particularly been reported significant GI issues. So it's a different profile, and we, as Albert very well pointed out, have been extremely pleased with the favorable profile that allow patients to benefit from Ibrance with very good reliability.Now you asked about this late stage population studies Abema [ph], and how that population in the future will evolve. We anticipate as Ibrance is having a very nice uptake in the marketplace in first line metastatic and some also more advanced lines, and hopefully with Prevnar 3 approval, Ibrance is likely to be used in multiple lines.Hence, monotherapy with another CDK will of course have the potential to face patient population that have seen CDK inhibitor, and that's why we are developing a strategy for how we can see patients benefit from drug like Ibrance at various stages with different anti-hormonals. And we are also now studying Ibrance in triple therapy. So I think you can see that multiple drugs is likely to be the preferred as patients become more advanced.Hi, good morning. Just again on Biosimilars front, I know there has been a couple of questions, but just a couple of more if I could. One is specifically on Enbrel, and if you can discuss in terms of 2016 how you are viewing the impact of Biosimiliars to your performance for that product?And then second, now that Hospira has closed, I am just wondering, I guess this is a question for John or whoever wants to jump in, in terms of the value having a Biosimilar business under the same broad umbrella as your innovative business so you can leverage that commercial infrastructure areas like oncology and autoimmune disorders. Is there any way sort of maybe make more sense than to keep Pfizer as a single entity as opposed to splitting up and then needing to rebuild the commercial infrastructure for your Biosimilars in those similar areas where you do have innovative products? Thanks.Sure. So, the first Biosimilar for Etanercept has been approved in Europe. And we've watching the situation very closely and evaluating adoption of Biosimilars across each of the countries throughout Europe for awhile now.Our overall expectation is that there will be somewhat modest impact in 2016. The Biosimilar landscape is clearly still developing. There are different approaches taken by different countries. And we have a very clear detailed roadmap for how to address each of the dynamics that exist in these different countries.So we are fairly confident that we are going to continue to have a strong Enbrel business throughout Europe. We think that the new patients would be probably most at risk of being exposed to the Biosimilars and hope that the availability of lower cost biologics will expand the market. So overall, we see this as again a modest impact to our business in the initial period of time.And Vamil, maybe a very interesting question on the connectivity between the Biosimilars and the other space. I would say that that would be taken into account if there was any such linkage that was positive in our TSAs, the setup the separate companies to ensure that that as overall we maximize value of that between both companies in the contracts we would sign if we decided to split. Thank you.Couple of questions. First, apologizes if I missed the explanation, but the 2016 guidance includes roughly an incremental 4 billion in revenue and $0.08 in earnings from Hospira implying down to significantly down underlying sales for the legacy Pfizer and flattish to down EPS, and it seems that generic exposure in currency cannot be the explanation because the predicted 4.6 billion hurdle in 2016 from these factors is well less than the 6 billion plus predicted in 2015 at this time last year.So actually the comparison on generic exposure in currency is improving and more than offsets the year-over-year increase in Prevnar. So, any thoughts on that would be appreciated.And one more, how should we think about the long-term outlook for Sutent particularly given the competition from immuno-oncology agent. You think Sutent will soon become a defining asset or do you see growth in the future? Thanks.I'll ask Albert to talk about Sutent and its possible combinations and the other studies we have already had on Sutent. And then, I'll ask Frank to come back on your questions about growth rates.We remain very confident in our position in the RCC space and that includes both, Sutent and Inlyta, because they are very well known by physicians and other stakeholders. The recent approval in RCC for immunotherapy but this does not affect Sutent. It is in the second line. Sutent is used primarily in first line. And s we have previously disclosed we are studying Inlyta, and Inlyta plus other PD-1 inhibitors pretty aggressively so that we can achieve better result in monotherapy in RCC second line.Yes. Let's see if I can answer the question. Just first, we don't give a specific number for Hospira revenues for 2016. But that said, I believe I could still answer the question. So, the way I think about this is if you enter the midpoint of the guidance prior to foreign exchange in Venezuela, which is part of the basis of your question, the midpoint for guidance would be 52.3 just to use midpoint. We take 50.3 compare that to the 48.9 that we printed in 2015 are all now at the same foreign exchange, so, clearly operational. That's an increase of about $3.5 billion. We said -- Ian said when he answered Jami's question that revenue excluding Hospira on a year-over-year basis was essentially flat operationally while absorbing 2.3 billion in LOEs for 2016.The other data point I think to help you answer the question is, remember, we did 1.5 billion in Hospira sales this year. So, when we say that the bulk of the growth is from Hospira, you understand it's incremental growth on top of the 1.5 billion that we printed in 2015. So that's how I think -- that's how you get to numbers we said and why we said operationally the numbers were essentially flat if you left Hospira out of the equation.Hey, guys. How are you doing? Thanks for being so clear on the communications in the quarter. I have one question that's been danced around but maybe let me just ask you it again and hope so I won't annoy you, but I'll try again.So first is do you believe that there is anything, Ian, under the current U.S. statute that would allow treasury to block and/or materially delay the closing of the AGN deal? So I am asking you if there will be third proposed notice. I am asking you under the current law, are you very -- do you remain I guess very comfortable there is nothing that treasury legally could do to block the deal or to materially delay it like in the 2017 when there will be a new a congress and a new president.And then I would also just for Frank perhaps just like you talked a little about your leverage ratio, if my math is right, the leverage ratio of the combined company the NewCo should closer to be around 1? By my math, you could take that to maybe 3 without affecting credit ratings in a big way, I would like to hear -- that's my math and I am not very good at math, so I would love to hear your general thoughts around leverage ratio of the NewCo where you might be willing to take that should the deal close. Thank you.Thank you, Mark. And thank you for the compliment on the clarity to communications. We strive to make them clear. So on your question which I don't think on the current law, I do not believe there is any reason why this deal will not close; full stop.Mark, let me run some numbers. So on leverage let me run the Pfizer numbers based on third quarter. We haven't issued a balance sheet yet for the fourth quarter. We will do that when we file the K. We had about 37 billion of cash in investments. We had about 39 billion of debt, short and long term debt. So to your point call that one to one essentially, and what we said when we announced the Allergan deal, what I said was we could take the leverage ratio at yield point up to about 2.5 to 3.And then, obviously, once took it there, we would want to see what kind of rhythm that created relative to the company, the operation supporting the company in that we take it there, but that we still want access to commercial paper. We would be willing take a one notch downgrade but we would still want to have access to commercial paper. But in terms of your math and your calculation 2.5 to 3, that's right. That's basically what I talked about when we announced the Allergan deal. So, your math was good.Yes, few things. One is can you tell us what the key products are in Venezuela, if there are any massive ones that we need to be hitting the model on? Second, Frank, maybe you can go through some of the push-pulls on SG&A and how you are thinking about the spending this year? And then, third, can you just give us an update on the IL-6? Thanks.So key products, I don't think there's any outstanding product, but the Enbrel is the biggest product that contributes. John, would you want to add anything to that?Yes, I think the Enbrel is the biggest product. I think in addition to that we have a portfolio of matured established product, Lipitor and Norvasc would be other key products for us in Venezuela. So really just think about the basket of established products and the fit in that marketplace.So, Marc, on SG&A, let me just talk to the quarter and then I'll talk to the rhythm of the numbers. So if you look at the quarter, we had a big spend in SG&A. It's 4.6 billion all in. Three major factors there, right, one, obviously the inclusion of Hospira, which added a couple of hundred million. Two, sequentially, if you think about the fourth quarter compared to the third quarter, we had a lot more selling days in the quarter. So, internationally, we had six more selling days. Domestically, we had two more selling days.So, sequentially, Q3 of '15 to Q4 of '15, we had more selling days. So obviously it helps revenue, but also increases the spend on our line items. And then, we had obviously I alluded to in my comments increased promotional spend in many areas of the business.Now, if you take that 4.6 and you annualize it, times 2 is what? 9.2 times 2 is 18.4. If you look at the guidance we gave for next year on SI&A, it's 13.2 to 14.2 billion. So you can't take that Q4 number and annualize it. You get to a number that's nothing close to what our guidance is for 2016, which is a combination of Hospira numbers, the selling days, and then the increased spend in the quarter. But we look at it for next year, we get a number that our annual basis is significantly lower than what that annualized number would be.Yes. Thank you for your question. So we tested IL-6 antibody in Lupus and [indiscernible], and while antibody did show some activity, we found that overall profile did not compete as well as many other real interesting immunology agents and other opportunities we have in our very rich pipeline of 90 clinical programs. So this is part of prudent portfolio prioritization within Pfizer.Thanks for taking the questions and for all the clarity that you've given on the '16 guidance. Ian, first question on the timing around the breakup, I think you've indicated that integration of Allergan is very important. You've also indicated that you had time to look even deeper into the Allergan portfolio.As you think about integration, can you give us some more commentary around how you are thinking about mapping out integration? Some look at Wyeth and look at the massive amount of synergies that you are able to extract out of Wyeth transaction and are somewhat puzzled as to why you can't do that here. So, any commentary around that?Two additional questions; one on CDK 4/6, this one is for Mikael. Mikael, when you look at preclinical models, is there any argument or hypothesis around a drug that has to be given intermittently that it might have less efficacy than one that's given on a continuous dosing? And is that supported by any preclinical models?And then, the last question just has to do with Xeljanz. Obviously, a very important asset for you not only in the U.S. but on the EU timing for filing, I think you indicated you wanted to have that filed before the end of the year. Just any update on what Europe is looking for within that filing to secure approval in Europe?And then, on psoriasis in the U.S., any developments there on the modified release from a regulatory standpoint and then obviously with Enbrel seeing generic competition what have you done with your infrastructure in Europe to still keep some infrastructure in place to support Xeljanz if and when it gets approved?Okay. So let me just -- quickly the last one first, we still have very strong expectations from Enbrel in Europe as Geno was discussing. We are not removing our support from Enbrel. So we expect to have full support for Xeljanz when it launches in Europe. There was a somewhat of a slippage from -- as you say, the end of the year to the beginning of this year on the Xeljanz application in Europe. We wanted to get it right and make sure that it was in the best shape we could, and these things happened. So there was a slight slippage on time on that. Mikael, do you want to deal with this hypothetical on CDK 4/6?Yes, thank you for the questions. Of course, always we would caution you can speculate on things that haven't been studied in humans in comparative aspects, but you know, we think it's important to hit CDK 4/6 hard for breast cancer, and when you do that with high doses you will get efficacy on the tumor, but also see some neutropenia and that's we why chose the intermittent schedules. Particularly it seems very effective for combination therapy with multiple agents such as [indiscernible] in breast cancer.For other tumor types, we may explore various schedules for various combination of drugs, but for breast cancer we think to show some schedule with the combinations we have studied is very effective and works well.Thank you. Geno, you want to deal with the other questions that John asked on Xeljanz?Yes. John, I think the question -- as Ian had already alluded to, we are now expecting our filing to be in the first quarter of this year. We're actually meeting with [indiscernible] at this point. We did generate additional data on immune function as a result of the discussions that we had with the regulators in the first submission. So we feel that we have a strong package that we have responded to the information requests that they had, and we're just tidying up the kind of last few details and expect to put that filing in imminently.So psoriasis -- well, as you probably know we have a -- we received a complete response letter from the FDA on psoriasis. We have provided a backgrounder to the FDA, and we expect to meet with them also this quarter to follow-up on the components of the complete response letter, and once we know in more detail what their issues and concerns are, then we'll determine best way forward from there.Yes. So we have certainly announced the deal more than $2 billion. We gave you the timing in terms of when we would get that. A couple of comments, John, to your question, I think first why more than $2 billion, why not a higher number? I think these are two companies that have done a lot on the cost reduction front; significant reductions at both companies, I think efficiently run companies. Two, not a lot of therapeutic area overlap, which is always seeing a kind of a trigger for synergy opportunities. Third, if you look at the Allergan cost of goods sold, two-thirds of that from my perspective, from a synergy perspective was unaddressable. It's their end of business and then royalties. So really not a lot we could do there, but all that said and done, we're working now with the Allergan teams with Brent, with Bob Steward, with Tessa. Ian and myself, our leadership team here at Pfizer, we've already launched a couple of operational teams, and we're starting to dig into this in much more detail. If there is more there, please know we're going to get it, and we'll tell you about it. So I think on a synergy front just more to come.Yes. And you know, John, the process from this deal was not huge cost synergies, it was about driving revenue growth in the innovative business, driving reasonably young portfolios, taking the products internationally, and then getting excellent capital allocation over the world. So we will get the synergies we can get, but our focus is on growth, and a lot of the questions on the call have been about growth. So this is part of the solution to that, and also really a good capital allocation.Thank you. If I could go back to the revenue guidance, the midpoint is about $2.5 billion below consensus, you flagged FX was a major headwind. I know that we spend a lot of time trying to incorporate FX, and I imagine consensus does too, yet that's still a very big delta. So my question on this is when you look at analyst models, are there particular revenue line items for products or divisions where you think consensus is too high unrelated to foreign exchange?Second question, you mentioned the 4-1BB with Merck, and I'm showing foundation data with Keytruda. That's Phase I data, so as such I'm blinded -- I'm wondering if you can give us a preview of the tumor types here you think are most promising and also any preliminary safety findings?And then last pipeline question, last year you mentioned having an oral PCSK9 approaching human development, and I'm wondering if that is now in the clinic when I look at your pipeline chart I see a new compound has been advanced on the Phase I?Okay. Frank, if you could deal with the first question, and Mikael will have remaining two.Sure. So Tim, let me run the numbers in, then I'll answer the questions. So your numbers are right. So consensus numbers give or take on revenue for 2016 about 52.4 billion the midpoint of all guidance $50 billion, the net there is roughly 2.5 billion that you alluded to, just to kind of nail the numbers.I think two major pieces in terms of the GAAP; one is, clearly the Venezuela adjustment we made in 2016 wouldn't have been at the 52.4. So that's an $800 million adjustment. That would take a 52.4 to 51.6, and then I think when you look at the line items, I think the big difference [technical difficulty] if you ask me to point out one single place, it's Prevnar 13. Significant results, and the growth expectations in Prevnar 13 -- '16 versus our modeling for '16 where I said in my comments, and Albert punctuated in some of his detailed remarks about we're expecting that to be essentially comparable to 2015 levels. Those are the two things that I would point out that will make up the majority big piece of the difference in terms of your 2.5 billion.So thank you for asking about 4-1BB, and as you know, we believe that the combination therapy moved immuno-oncology feel to the next level. We are very pleased with the 4-1BB, one of tumor antibody that we have. We have started eating combination with Rituximab in lymphoma and with PD-1 Keytruda in a small study across various tumor types, and have also initiated combination study with Avelumab.The 4-1BB antibody, the Pfizer antibody shows very good tolerability when combined with other biological agents, and it's clinical performance suggest also very interesting favorable clinical activity on top of other biologicals, such as Rituximab and PD-1 Keytruda. We will share the date from this first cohort this year likely at ASCO. We are quite excited about 4-1BB and also OX40 that's in our pipeline, and you will see 4-1BB Avelumab data likely late this year as well OX40 monodata, and early next year several doublets and triplets, which makes me very enthusiastic as I look forward how we advanced the strategy of combinations therapy.We have an oral PCSK9 in Phase I. It's too early to have any definitive interpretation of that data, and we also have a PCSK9 vaccine in late preclinical development.Oh, thanks. I have a couple of questions for Mikael, just on Ibrance, can you flag any upcoming data for tumor types outside of breast cancer that we should look out for? Also, can you update on how well the Adjuvant breast cancer studies are enrolling? Thanks.Yes. I could say a few words, so as Albert alluded to, there is a large number of Ibrance study, the great majority by investing in initiative research. So we will have to see as these studies result report emerging. I can say that we also have sponsor-led studies outside breasts, that includes pancreatic cancer, and head and neck, and we're also looking at triple therapy in breast cancer. I remain optimistic and excited about Ibrance performance, and think we will see interesting datasets coming from several of these new tumor types.Yes, actually I can only add here. But likely the Mantel cell lymphoma, and the neck we may see data even this year. And then many of the areas that Mikael discussed, including small-cell-lung, we may see next year.Good morning guys. And thanks for taking my question, just a couple of quick ones. On Bevacizumab, given Pfizer's experience in cardiovascular I was just curious what your thoughts on the demand trends were, looking peripherally at the PCSK9 class today. I know a lot looking forward depends on outcomes data, but just curious about whether there's a tipping point, and the position adoption.And then just on Biosimilars in the U.S., just wanted to get you guys to view on where you think the FDA is with respect to extrapolation when we're looking at the upcoming senior panel next week. Thanks.Yes, I mean I think I would just reinforce the comment that you made. I mean, it's been our contention all along that this class becomes a real class in managing these patients with the cardiovascular outcome data, that we'll be seeing either late this year or starting next year. Our program is advancing nicely. We have, as you know, two cardiovascular trials. And the SPIRE-2 trial, which is in the high-risk patient population, we've now reached the point where we've discontinued screening. We're almost completely enrolled. And that trial is moving along very rapidly. And the SPIRE-1 trial will be completely enrolled by the end of this year or early next year.So we're looking forward to these data, and the impact that we think they're going to have on the marketplace.So, on the Inflectra AdCom, as you know it's scheduled for February 9, next week. I think it would probably be premature to speculate on the view that the FDA will take. We certainly think that this will be extremely informative as to the FDA's views and perspectives on extrapolation. I think obviously their product is being filed by Xeljanz. So specific questions about the AdCom really should be directed to Xeljanz, but I would say is that while we obviously await the resolution of the advisory committee and certain other factors. We're certainly moving ahead with the preparation for launch plans in 2016.Yes, thanks very much. I have three questions. First, Ian, besides the likelihood of closing, what do think investors most under-appreciate about the Allergan merger? Second, I guess these are two financial questions. One is with respect to Enbrel ex-U.S. Could you just give us a sense for the percentage of revenue that is in countries where Biosimilars are launching in 2016, so that we have a sense for the percentage of Enbrel revenue that's exposed to Biosimilar threat?And then finally, Frank, if you could just run through the cash flow outlook for 2016, the operating cash flow, and then the planned use of funds. Thank you.David, again on your question on Allergan, our interactions with the shareholders, both sell side and buy side have been very positive. I don't think in reality there's anything underappreciated, other than the Street's perception of risk around the close. I would direct you back of course to the excitement I have about the products that Allergan have that they just launched, about their phase III products, both in depression, and in diabetic gastroparesis. And they just got breakthrough status, so -- and the combination of our information knowledge and RTAs with Xeljanz around their area. Our jacks around their expertise net area. I think perhaps the Street is just -- is right now hung up on this close issue. So bio, John?Yes, David on the question regarding percentage of Enbrel business potentially exposed to Biosimilar competition, I don't have a figure on the top of my head. I would say more than 50% of the ex-U.S. business would be in the European Union, where we expect to see biosimilars. We won't -- we're not expecting to see it in Japan, Australia, and several of the Latin American countries. But I would say it's more than 50% of the business.And then the last question was on '16 operating cash flow. The way I'll answer this David, is if you look at our operating cash flow through three quarters, it was about $10 billion. We expect the fourth quarter to be healthy in terms of the operating cash flow for the year. And then obviously 2016, we expect -- we want to obviously continue to grow that operating cash flow number. And then in terms of the uses, from my perspective, the uses of how we deploy our capital haven't changed, obviously investing in our business, returning capital to shareholders. I mentioned in my remarks we returned 13.1 billion to our shareholders in 2015 through a combination of dividends and share buybacks, and obviously looking at some bolt-on acquisitions if those make sense. So -- but no change. It would be how I'd answer the question on capital allocation.Thanks, also a three-parter. First Frank, what level of detail should we expect in the proxy in terms of your long-term projections, similar to the Pfizer Wyeth documents or any difference and any caveats you'd like to order to let us know about before folks start slapping accretion percentages on those numbers?Secondly, going back to something you said earlier. Taking your leverage to two-and-a-half to three times for Newco, and if you were to apply that capital to buybacks that would create EPS accretion that's far beyond what you've suggested. So just would like your thoughts on what you'd be doing with that leverage or is that just kind of a hypothetical.And third, for John, do you still see the benefit of the Hospira device business alongside the drug business as you originally thought? Thank you.Yes, sure. I think we would say that in the Hospira infusion systems business, which comprises pumps, consumables, large volume solutions. We believe we acquired a very valuable asset. It provides novel capabilities in an adjacent area. And that adds significant value to customers, and their patients. And we are committed to ensuring its success in the short, medium, and longer term.So I think on level of detail, we'll be providing revenue details, EPS details. It would be directed out, I believe, it's several years, five years. So there'll be information out there relative to projections on the company; on the leverage number, the 2.5 to 3, in my mind that's what's possible. In terms of what we did on buybacks, we tried to provide information when we announced the deal to give you all the data you needed. So that when you connected the dots you could model what at buyback numbers would be, right.So we started out with the accretion dilution. We said neutral in year one, modestly accretive in year one, more than 10% in year three, and then high teens in year four. We gave what the beginning share count number of the combined company would be. It was 10.6 billion shares. We said we'd have 5.5 billion, and Allergan would have 4.7 billion. And then we gave the tax rate, which was 17% to 18%. So with those data points, we felt we provided the information that you needed in order to model what the buybacks would be. And then just to the two-and-a-half to three, now clearly there could be some extra juice if we took the leverage ratio up to that level.Great, thanks, just two quick ones here. First, just more broadly on emerging markets, can you talk about the growth outlook here maybe beyond China, just given the current economic environment we're seeing? Has there been any change in your growth expectations there?And then the second question for Ian. I know you've obviously had a very large deal pending right now. But how are you thinking of business development given the recent volatility and kind of valuation reset we see in the market. I guess what's the size and scope of assets that you could be interested at this point, given the upcoming Allergan transaction. And maybe how quickly post the Allergan transaction could this company start considering larger deals if there was an attractive opportunity in the market.Yes, sure. So I mean, I think as we always say, Chris, on the emerging markets. We're always going to see courses and course of volatility. But at the same time we continue to expect to see growth numbers in the mid-single digit mid to high single-digit range. Frank's already talked about China. We continue to be very positive about the prospects in the short, medium, and longer term in China. It's obviously not just the world's largest country, with 1.3, 1.4 billion population, but we continue to see a strong government commitment to expanding access to to quality healthcare. We are very encouraged by steps that we see the government taking in the regulatory environment to really enhance quality standards in the marketplace.And whilst there are few headwinds, GDP growth is slowly but still positive, still mid single-digit percentage. We are seeing some pressure on pricing. But overall when you put all of those factors together, we can continue to see China being a very positive growth driver.Thank you, John. On BD, Chris, we see we would be more focused to smaller deals than larger deals right now. But once we close, we'll look at the opportunities. And we know we still have substantial flexibility and of course it will be measured against the alternative usage of that cash which right now are scheduled for buybacks and the accretion equation. So we'll make the decisions that we believe are best for shareholders and we will take it into account the -- what the asset priced at the time when we close.And Chris, the only thing I would add is we, Pfizer-standalone today generate a lot of operating cash flow. The combine new company we said by 2018 would be generating in excess of $25 billion a year in operating cash flow. So, new company will generate significant amounts of operating cash flow. Thank you.Hi, it's Manoj. Thanks for taking the question. A couple on the pending Allergan transaction and one on next Tuesday, on Allergan, one, I guess if maybe just if you can highlight, what are some of the levers that would dictate whether the deal would close in early second half of '16 versus later in the second half?Two is, for Frank, on the $2 billion synergy number if you can just quantify as we fine-tune our pro forma model, if that's a gross number or an net number?Okay. On the lever, Doug Lankler, would you indicate what you see the levers are for the close?Sure. So, Manoj, we're working closely with regulators. We are pleased with the profits that we are making. We like the standpoint from the complementary nature of the businesses. And as a result, we continue to expect to close the transaction during the second half.Right. Yes, you asked whether it was gross or net. And the answer is it's a net number.Ladies and gentlemen, this does conclude today's fourth quarter 2015 earnings conference call. Thank you for participating. You may now disconnect."
      ]
     },
     "execution_count": 76,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "d"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Please go ahead, sir.Good morning, and thanks for joining us today to review Pfizer's fourth quarter and full year 2015 performance, as well as 2016 financial guidance.I am joined here today as usual by our Chairman and CEO, Ian Read; Frank D'Amelio, our CFO; Mikael Dolsten, President of Worldwide Research and Development; Albert Bourla, President of Vaccines, Oncology and Consumer; Geno Germano, President of Global Innovative Pharma; John Young, President of Established Pharma; and Doug Lankler, General Counsel.The slides that will be presented on this call can be viewed on our homepage, pfizer.com by clicking on the link for Pfizer Quarterly Corporate Performance Fourth Quarter 2015, which is located in the For Investors Section in the lower right hand corner of the page.Before we start, I'd like to remind you that our discussion during the call will include forward-looking statements and that actual results could differ materially from those projected in the statements.\n",
      "We ended 2015 with solid momentum in both developed and emerging markets.Specifically in developed markets, during the year we gained incremental market penetration driven by continued success of products that are early in their life cycles, including Prevnar 13 adults, Ibrance, Eliquis, Xeljanz, and we still saw steady growth from key inline products in 2015, specifically Lyrica in markets where it remains patent protected.And during the year in emerging markets we saw operational revenue growth primarily due to the performance of Prevnar, Lipitor, and Enbrel, as well as from the addition of legacy Hospira products.\n",
      "We believe Xeljanz can potentially fill a significant unmet need in the psoriatic arthritis when non-biologic DMARDS do not have proven success, and where there are currently few alternatives for patients who have inadequate responses to anti-TNF therapy.In addition, in the first half of the year we anticipate the decisions from the FDA for a once-a-day daily Xeljanz formulation for rheumatoid arthritis, and we remain on track to re-file our application for RA in the EU.For Ibrance, we expect to see the top line PALOMA-2 study results in first-line advanced breast cancer in combination with letrozole, and we have an April PDUFA date for second and third-line treatment for advanced breast cancer based on the PALOMA-3 data.\n",
      "We could also see a regulatory decision for Ibrance in the E.U. by year end.Additionally, in the oncology business, we have a PDUFA date this year in the U.S. with Xalkori in ROS 1 non-small-cell lung cancer, and we expect to file for approval of Inotuzumab for acute lymphoblastic leukemia in the U.S. And in immuno-oncology we now have a broad portfolio of compounds that we believe has the potential to support the development of a strong, deep competitive market position.\n",
      "We will continue to have the means by which we can create value for our shareholders and bring innovative medicines to patients by producing expected top line growth, progressing key pipeline assets, pursuing strategic business development, and returning capital to shareholders through dividends and buybacks.Now I'll turn it over to Frank for additional details on the quarter and our 2016 financial guidance.Thanks, Ian. Good day everyone.\n",
      "Excluding the inclusion of legacy Hospira operations of 1.2 billion, the negative impact of foreign exchange and to a much lesser extent the inclusion of 35 million of revenues associated with vaccines acquired from Baxter, Pfizer-standalone achieved operational growth of 646 million or 5% while at the same time absorbing a 720 million negative operational impact from product losses of exclusivity.Fourth quarter adjusted diluted EPS was $0.53 versus $0.54 in the year ago quarter.\n",
      "These were partially offset by revenue growth of certain new, in-line, and acquired products, lower effective tax rate, and few diluted weighted average shares outstanding which declined by 125 million shares versus the year ago quarter due to our share repurchase program which includes the impact of $5 billion accelerated share repurchase agreement executed in February 2015 and completed in July.Reported diluted EPS was $0.10 compared with $0.19 in the year ago quarter due to the previously mentioned factors and the unfavorable impact of foreign currency losses related to Venezuela, increased purchase accounting adjustments, acquisition related cost, restructuring charges, and asset impairment charges versus the prior year quarter, and non-recurring charges related to pension settlements, which were partially offset by the non-recurrence of a charge associated with the global strategic alliance formed with Merck KGaA in November 2014 to jointly develop and commercialize Avelumab, lower charges for certain legal matters, and a lower effective tax rate.Foreign exchange negatively impacted fourth quarter reported revenues by approximately $934 million or 7% and positively impacted adjusted cost of sales, adjusted SI&A expenses and adjusted R&D expenses in the aggregate by $435 million or 5%.\n",
      "And the 46% operational increase in R&D expenses due to increased cost associated with oncology oncology programs, primarily our alliance with Merck KGaA and Ibrance.Fourth quarter, Global Established Pharmaceutical revenues increased 5% operationally, mainly due to the previously mentioned inclusion of legacy Hospira revenues contributing $1.2 billion, which was partially offset by loss of exclusivity and generic competition for Celebrex in the U.S. and certain other developed markets, Lyrica in most developed markets in Europe and Zyvox in the U.S.Emerging market revenues were flat operationally, which reflected the positive impact of the inclusion of legacy Hospira operations and continued strong growth in China offset by declines in certain markets in the Middle East.Income before taxes declined 12% operationally reflecting the unfavorable impact of a 4.7 percentage point operational increase in cost of sales as a percentage of revenues due to the inclusion of Hospira operations and the impact of losses of exclusivity, a 24% operational increase in SI&A expenses driven in part by the addition of Hospira operations and the 53% operational increase in R&D expenses due to increased legacy Hospira development programs.We exceeded the top of our guidance range of expectations for 2015 reported revenues by approximately $400 million.\n"
     ]
    }
   ],
   "source": [
    "print(summarize(str(d),word_count=1000))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "stopwords = set(STOPWORDS)\n",
    "wordcloud = WordCloud(stopwords=stopwords, background_color=\"white\",max_words=20).generate(x[0])\n",
    "\n",
    "# Display the generated image:\n",
    "# the matplotlib way:\n",
    "plt.imshow(wordcloud, interpolation='bilinear')\n",
    "plt.axis(\"off\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "stopwords = set(STOPWORDS)\n",
    "wordcloud = WordCloud(stopwords=stopwords, background_color=\"white\",max_words=20).generate(str(d))\n",
    "\n",
    "# Display the generated image:\n",
    "# the matplotlib way:\n",
    "plt.imshow(wordcloud, interpolation='bilinear')\n",
    "plt.axis(\"off\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "stopwords = set(STOPWORDS)\n",
    "wordcloud = WordCloud(stopwords=stopwords, background_color=\"white\",max_words=20).generate(summarize(str(d)))\n",
    "\n",
    "# Display the generated image:\n",
    "# the matplotlib way:\n",
    "plt.imshow(wordcloud, interpolation='bilinear')\n",
    "plt.axis(\"off\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
